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3Abstract
This thesis investigates in depth the phenomenon of biobanking from an 
anthropological and socio-legal approach. In recent years there has been an ever-
tighter alliance formed between discoveries in life sciences and capital accumulation. 
The rapid advances in genomics introduce a new form of capital in the development of 
technoscience. In order to find biomarkers for genetic association studies in the 
susceptibility of common complex diseases, the generation of large-scale population 
resources is deemed to be an important step to support the development of genomics 
which now transforms its imagery from informatics to therapeutics. Biobanks -
collections of human biological materials linked through genetic information - have 
attracted considerable attention across the globe. These global assemblages of capital 
and vital politics have led to innovative institutions and arrangements in fields of 
technoscience and ethics. Though biobanking is an apparently global phenomenon, 
diverse political innovations and ethical configurations emerge from the specific social 
and cultural milieux, in which its establishment and operation are situated. This thesis 
uses recent developments of a longitudinal population-based research resource in 
Taiwan as a specific instance to analyse the delicate entanglement between politics, 
capital and life sciences. It explores not only the legal and ethical issues posed by 
biobanks, such as consent, privacy and property, but also the political and economic 
aspects of the biobanks that are embedded in the broader global bio-economies. This 
emphasis, focusing on the way in which biovalue is produced, politico-scientific 
decisions are made and ethical configurations are framed, allows an opportunity to 
reassess law and ethics, capital and politics, as well as the role of the state and its 
populations in this new form of biotechnology. 
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9Chapter 1 Introduction
1. 1 A Political Economy of Biobanks
1.1.1 The Production of Biovalue
In recent years there has been an ever-tighter alliance formed between discoveries in life 
sciences and capital accumulation. The rapid advances in genomics introduce a new type 
of capital in the development of technoscience. In his book Biocapital, Kaushik Sunder 
Rajan studies the entanglement between scientific and economic growth by examining 
the co-production of the life sciences and political economy.1 The term ‘biocapital’ has 
been used to analyse the constitutive facts of biopolitics in processes of global capitalism 
that lay the ground for the market frameworks within which genomics emerge.2
Biocapital, according to Sunder Rajan, refers to sets of systems and practices related to 
the production and exchange of biovalue on the global stage. Compared to other 
traditional arenas of accumulation under global capitalism, such as industrial and 
commercial capital, biocapital derived from advances in genomics remains relatively 
juvenile. The discovery of the molecular structure of DNA - the double helix - in 1953 was 
only a few decades ago and the application of this idea to genetic engineering had not yet 
been fully developed until the early 80s. 
Since the announcement of the working draft sequence of the human genome in June 
2000, the rapid development of population genomics has brought the new form of capital 
and socio-politics into the terrain of the life sciences. After the initial attempts to 
sequence and map human genomes, scientific enquiries propel further analysis of genetic 
variation between individuals and populations. In order to find biomarkers for genetic 
association studies in the susceptibility of common complex diseases, the generation of
large-scale population-based research resources is deemed to be a preliminary but 
important step to support the development of genomics which now transforms its 
imagery from informatics to therapeutics.3 The scientific shift to postgenomics opens up 
                                                     
1 Kaushik Sunder Rajan, Biocapital: The Constitution of Postgenomic Life (Duke University Press, 2006). P. 4
2 Ibid., pp 33-34
3 Kaushik Sunder Rajan, "Two Tales of Genomics: Capital, Epistemology, and Global Constitutions of the 
Biomedical Subject," in Reframing Rights: Bioconstitutionalism in the Genetic Age, ed. Sheila Jasanoff (MIT 
Press, 2011). P. 198
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the opportunity for further development of personalised medicine so that diagnostic and 
therapeutic tools based on genomics could be tailored to individual genetic profiles.4 On 
the other hand, this aspiration to consumer genomics influences the development of 
pharmacogenomics which aims to tailor prescriptions based on individual genetic 
variation in drug response in order to optimise drug therapies by ensuring maximum 
efficacy with minimal side effects.
Biobanks - collections of human biological materials linked through genetic information -
have therefore attracted considerable attention across the globe. Following the mapping 
of genetic variation which made it easier to link genes and disease, biobanks have been 
recognised by many scientists and geneticists as the next logical step to translate 
genomics knowledge into clinical applications. Many countries have joined in this
emerging global trend to set up their own large-scale population biobanks to support the 
application of genomics research. With the goal of capitalising on a state’s genetic 
resources, biobanking turns into a new technique for a state to incorporate the biological 
existence of its population into a series of political and economic concerns. The dual 
investment in public health and economic growth characterises biobanks as both 
generators of pioneering scientific knowledge and a new technique for the advancement 
of the health and wealth of modern states, which may now take its stewardship
responsibility for generating technologies of government by rearranging its resources in 
the name of collective security and the public good.
This thesis examines how the initiative and practice of biobanking is shaped through its 
entanglement with political economy and how theoretical engagement with biocapital 
and biopolitics may contribute in a meaningful way to reassess the role of bioethics and 
the notion of the individual and the collective within the context of biobanking. The thesis 
uses recent developments of a longitudinal population-based research resource in Taiwan 
as a specific instance to analyse the delicate entanglement between politics, capital and 
life sciences. It demonstrates how bioethical configurations may have failed to challenge 
the influence of global capitalism when they are positioned within the context of Taiwan’s 
biocapital formation. It further analyses the relations between the state and the people 
and how the notion of citizenship may assist in turning population into resources when 
                                                     
4 Ibid. 
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the state has transformed its role from a steward to an investor in global bioeconomic 
competition.
The French philosopher Michel Foucault had argued that modern sovereign power is 
manifested in the management of life by a set of procedures and mechanisms through 
which human beings become the object of political strategy.5 Unlike classical sovereignty, 
which was characterised by its power to ‘take life or let live’, the modern operation of 
biopower emphasises taking charge of life and turns modern politics into an innovative
apparatus for the administration of the life of each and all.6 For Foucault, the genealogy
of the modern welfare state can be traced back to various state strategies invented in 
eighteenth-century Europe as a means to govern the naturalness of the population such 
as birth, disease and mortality. These strategies should not be understood separately, 
according to Foucault, from the development of statistics as the technique for numerical 
calculability of subjects and the emergence of risk calculation on which modern states 
relied to manage their administration of demographics and to measure the economy for 
prosperous continuity.7 From this Foucauldian perspective, the welfare state may be 
viewed as an innovative political form of mutual risk pooling.8 It emphasises the 
individual’s relation to the collective by the state’s intervention with techniques to protect 
the life of each and all through redistributing national wealth to its citizens in exchange 
for a reciprocal obligation on citizens to render their lives to the governance of the state.9
Like genomics, national population biobanks have become prolific sites at which scientific
knowledge and its derived value and hope are closely entangled. Biobanks act vigorously 
as assemblages of vital politics and capitalism on the global stage. On the one hand, 
biobanking demonstrates modern states’ stewardship responsibility to address the 
wellbeing of their populations by managing diseases and improving health. On the other 
hand, however, biobanking is a technique for states to increase their competitiveness in 
the global bio-economy. As Sunder Rajan recognises, biotechnologies such as genomics 
                                                     
5 Michel Foucault, The History of Sexuality, Vol. 1: An Introduction (Penguin, 1981). pp 137-139
6 Nikolas Rose, "The Politics of Life Itself," Theory, Culture, & Society 18, no. 6 (2001). pp 1-2
7 Graham Burchell et al., The Foucault Effect : Studies in Governmentality ; with Two Lectures by and an 
Interview with Michel Foucault (Chicago: University of Chicago Press, 1991).
8 Melinda. Cooper, Life as Surplus : Biotechnology and Capitalism in the Neoliberal Era (Seattle: University 
of Washington Press, 2008). P. 7
9 Ibid., P. 8
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have transformed life into a calculable market unit; biobanks set up a similar strategic 
terrain on which states may operate as agents and investors negotiating in global
markets.10 By studying modes and relations of production in biotechnologies, Sunder 
Rajan turns to Karl Marx’s Capital as a supplement to Foucault’s conceptions of biopower 
and biopolitics. In doing so, Foucault’s influential notions of knowledge and power may be 
reconceptualised in the context of market forces.11
For Marx, capital is not a thing but a social relation between persons that was established 
through industrial capitalist production and exchange by the instrumentality of things. 
Compared to industrial capital, surplus value generated from merchant’s (commercial) 
capital has a speculative nature as it is mainly created through the circulation of capital 
rather than relying on production. Emerging as a result of the rapid technoscientific 
changes in the life sciences, biocapital involves the production and circulation of capital 
and commodities which are composed of human biological materials and genomic 
information.12 As political theorist Melina Cooper has argued, life science technologies 
and neoliberalism share a commonality in their ambition to overcome limitations on 
growth associated with the decay of industrial production and as a result, they both need 
to rely on finding new resources through a speculative reinvention of the future in order 
to create surplus value.13 By analysing the link between biocapital and the drug 
development value chain, Sunder Rajan suggests that biotech and pharmaceutical
industries represent two distinct forms of capital.14 Biotechnologies, like industrial capital, 
focus more on upstream drug discovery and production; pharmaceutical industries, on 
the other hand, are more like speculative commercial capital, regulating the distribution 
of commodities and capital flows by deciding whether to invest in upstream technologies
in the process of drug development.15
Furthermore, the rapid development of biotech and pharmaceutical industries in the field 
of genomics has transformed populations into fertile sources of biotech innovation and 
                                                     
10 Supra note 6, P. 34
11 Supra note 7, P. 194
12 Supra note 6, P. 17 
13 Melinda. Cooper, Life as Surplus : Biotechnology and Capitalism in the Neoliberal Era (Seattle: University 
of Washington Press, 2008). P. 11
14 Supra note 6, P. 21
15 Ibid., pp 23-24
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biocapital accumulation. In order to constitute a prospective cohort for facilitating the 
study of multiple diseases, it requires very large numbers of participant enrolment to give 
ongoing access to donated samples and prospective health information for at least 20 to 
30 years. Compared to small tissue and genetic information collections, a large-scale 
population biobank is characterised by the specific goal of providing long-term access to 
information, such as participants’ lifestyle and health records. As a result, a national 
biobank may provide the statistical power necessary to identify gene-environment risk 
factors for common complex diseases.16
In a recent study discussing the economic aspects of biobanks, Catherine Waldby and 
Robert Mitchell point out that a population contributes a significant portion of the ‘clinical 
labour’ required for the creation of biovalue through the establishment of population 
biobanks, and that participation in biobanks’activities has been conceptualised as ‘gift’
rather than a form of embodied labour work that produces economic value.17 The 
population is nurtured as a resource so the value it generates can be added through a 
process of biobanking by the technicians who collect and process samples. In this context, 
national populations may be viewed as ‘economically productive participants’, as their 
enrolment into biobanking is expected to bring a commercial potential for states.18 As 
Waldby and Mitchell rightly observe, even though populations’participation in biobanks 
is often under civic discourses of public good, their enrolment is, in fact, formulated in 
profitable way and is closely linked to the creation of biovalue that demonstrates the 
economic aspect of population biobanks.19
The notion of biovalue here denotes how the productivity of living entities may be 
produced as a valuable resource useful for human projects.20 As it has been argued that 
the production of biovalue is associated with the development of bio-economies, modern 
articulations of citizenship have been reconfigured with neoliberal techniques by viewing 
the constitution of a population as a living resource for satisfying a state’s economic 
                                                     
16 Ibid., P. 2
17 Robert Mitchell and Catherine Waldby, "National Biobanks: Clinical Labor, Risk Production, and the 
Creation of Biovalue," Science Technology Human Values 35, no. 3 (2010). P. 7
18 Ibid., P. 13
19 Ibid.
20 Cathy Waldby and Robert Mitchell, Tissue Economies: Blood, Organs, and Cell Lines in Late Capitalism 
(Duke: Duke University Press, 2006).
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demands.21 New debates over what it means to be a citizen in the postgenomics era is 
gradually being framed by interrelationships between biopolitics, neoliberal logics and 
governmentality. The traditional elements constituting citizenship such as sovereignty, 
rights and entitlements have been linked to techniques of optimisation adopted by the 
state. This includes not only technologies of subjectivity, as anthropologist Aihwa Ong 
argues, such as techniques of capital accumulation and optimisation of health regimes, 
but also technologies of subjection, so national populations may be governed for optimal 
productivity through citizenship projects and practices that engage market forces.22 In 
addition, as contemporary sovereignty providing the territoriality of citizenship has 
embedded in the territoriality of global capitalism,23 the articulation of civil rights, 
benefits and obligations in the age of postgenomics is inevitably influenced by forces set 
into motion by global technoscience and global markets. 
Moreover, even though an important aim for population biobanks is to improve public 
health (so biobanks may be viewed as national projects for achieving a public good), these 
biobanks have been associated with various types of biocapital formation generated 
mainly by the genomic and pharmaceutical industries.24 As Sunder Rajan has recognised, 
the distinction between public and private is blurred when most pharmaceutical 
industries are consumers rather than generators of genomic data in the public domain. 
When a state itself starts acting analogously to a biotech company to conduct upstream 
research and development in the drug production process, 25 population biobanks 
produce and reproduce a similar entanglement between public and private in terms of 
the allocation of resources in health regimes and the mobilisation of potential participants
from the perspective of citizenship. As preserving citizens and enhancing the biovalue 
produced from them extends the stewardship responsibilities of the state, the notion of 
biovalue has also been expanded from economic and political meanings, such as 
enhancement of health and wealth, to an ethical endeavour. In the process of 
transforming national citizens into a potential resource for the production and 
accumulation of health and wealth, the conception of citizenship helps generate clinical 
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labour in the context of biobanks which can produce both long-term benefits to public 
health and short-term incentives to intellectual property rights as well as their derived 
commercial profits.
Nikolas Rose and Carlos Novas have used the term biological citizenship to illustrate how 
national citizenship projects may form contemporary citizens as not only individuals with 
entitlements to national healthcare and welfare but also potential generators of biovalue 
for the development of the state.26 Traditionally, the notion of citizenship presupposes an 
individual’s particular awareness of rights and duties of the self and its relations with 
others that forms the moral attributes of a community. Contemporary biological citizens, 
according to Rose and Novas, have also learned to use life - the very fundamental desires 
of survival - to negotiate the practices of health policies and regulation as well as the 
population’s economic and social inclusion.27 In other words, a new form of ethics which 
makes life into a marketable asset for the political economy of hope has taken shape and 
become a desirable good in order to facilitate the production of clinical labour by which 
citizens are being built up as both consumers for the products of genomics and subjects of 
autonomy and responsibility.28
By emphasising the safeguard of individual autonomy, for instance, ethical discourses 
such as informed consent and privacy have been placed in the forefront for the creation 
and operation of biobanks. These bioethical mechanisms may be viewed as techniques of 
ethical formation for the management of the individual and the collective from the 
perspective of governmentality and biopolitics. According to Foucault, governmentality is 
an array of technologies proposed by governing authorities to regulate individuals’
decisions and choices so the governed subjects may act out of their own will in 
accordance with authoritative criteria.29 Similarly, the mechanism of informed consent 
acts as advanced liberal rule to construct populations as ‘empowered citizens’ who are 
able to make rational choices based on given information with regard to their 
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participation in biobanks.30 As a result, these bioethical mechanisms should not be 
treated simply as politically neutral premises; rather, their practices and trajectories need 
to be understood when the bioethical arrangements are re-embedded in the political 
economy structure in which biobanks were born and operate. 
From a political economy perspective, neoliberal logics of economic growth stimulate 
states to take biobanking as a technoscientific approach to find niches in global
competitiveness and to restore national pride. For these states, biobanking is not only a 
biotech innovation to improve public health and the quality of life but also the 
materialisation of expanding national aspirations in global competition. In addition, even 
though biobanking appears as a global phenomenon and its initiative is closely linked with 
the flow of global capital, it reflects diverse political innovation and ethical configuration 
when its establishment and operation are situated in specific social and cultural milieux. 
Characterised as heterogeneous and contingent, these national biobanks have revealed 
different civic epistemologies in various localities. As Stephen Collier and Aihwa Ong
argue, even though technoscience and ethics may have global forms and qualities, they 
shape novel values of individual and collective existence and reconstitute the classic 
abstractions such as economy, society and culture when they are articulated in specific 
situations. 31 Anthropologist Michael Fischer has also suggested a recombinant 
anthropology of science and technology is moving into public futures that call for 
engagement across cultural difference on the global stage.32 According to Fischer, the 
public future refers to an emergent phenomenon in the context of cosmopolitics in which 
articulations about politics, new knowledge and ethics can be generated and assembled in 
culturally and socially contested sites.33
1.1.2 Biobanking in Taiwan
In April 2005, the Taiwanese government launched a Biomedical Technology Island Plan in 
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which a large-scale population biobank was proposed as a governmental project to 
upgrade Taiwan’s bio-economies and to support health and medical research in Taiwan. 
From the 1960s to the 1980s, Taiwan fitted well into the model of a capitalist 
developmental state described by Chalmers Johnson. By analysing Japan’s postwar 
economic reconstruction, Johnson argued that the rapid economic recovery in Japan was 
exemplary in a state-guided market economy that was characterised by the state’s leading 
role in overall economic development and the closer collaboration between the public 
and private sectors.34 The Japanese experience was taken up as a model to be widely 
replicated by the newly industrialising states of East Asia, such as Taiwan, South Korea, 
Singapore and Hong Kong, the so-called semi-peripheral parts of an interconnected global 
economy compared to the established core economies in North America and Western 
Europe during the 60s to 70s.35 Unlike liberal policies and laissez-faire capitalism, a 
developmental state relies on a strong state apparatus to take on developmental
functions so it is mainly based on technocratic macroeconomic planning to lead the 
state’s industrialisation drive. In a nutshell, a key quality that makes a state developmental
is that it relies on state agencies rather than market forces to determine the optimal 
allocation of resources.36  
Strong state autonomy supported by competent bureaucratic technocrats provided state 
capacities not only to design and implement developmental policy but also to penetrate 
markets and mobilise society. From the 60s to 80s, the combination of domestic capacity 
and external environment provided Taiwan with opportunities to emulate the Japanese 
model and direct the course of its economic development. Having retreated from 
mainland China to Taiwan after the defeat of the Chinese civil war in 1949, the 
Kuomintang (KMT, Nationalist) government had remained a single-party state in Taiwan 
until the lifting of martial law in 1987. Consensus on developmentalism demonstrated the 
regime’s survival imperatives as a response to the security threat from mainland China as 
well as the KMT’s initial military plan to ‘recover the mainland’by constructing its base on 
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the island. Furthermore, Taiwan’s particular geopolitical location - proximate to China, 
right at the intersection of Southeast Asia and East Asia - and its anti-communist political 
stance made it a crucial element in the United States’containment strategy during the 
Cold War Era.37 Even though the cold war ended a few decades ago, the rise of China and 
India as new powers in Asia has influenced the international division of labour that also 
impacts on Taiwan’s developmental strategies. 
The rapid growth of newly industrialised economies depended mainly on resource 
accumulation, especially that of capital. Taiwan’s industrial development leading to capital 
aggregation was mainly attributable to the contributions of its small and medium-sized 
enterprises (SMEs), which had been greatly supported by the state due to their flexibility 
in product lines, which allowed these enterprises to quickly adapt skills and imitate 
products of many innovative entrepreneurs.38 In contrast with South Korea, which 
borrowed from the Japanese zaibatsu to form a highly conglomerated industrial structure
composed of large-scale corporations (Chaebol), Taiwan’s economic development was 
based on the state’s cooperation with and support of vigorous SMEs, which were mainly 
export-oriented and more flexible than large enterprises in adjusting to changing world 
market conditions.39 In Taiwan, the share of the large conglomerates in overall economic 
production is relatively smaller than that in Korea and Japan and such conglomerates
were mostly concentrated in the state-owned enterprises (SOE), such as the China Steel 
Corporation and the China Petroleum Corporation.40 Robert Wade has therefore pointed 
out that the function of state intervention in Taiwan was not to encourage domestic firms 
to maximise their long-run profitability; rather, it was for the state to control and manage 
the composition of national investment so that an integrated but flexible structure for 
production could be established.41
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Another factor was the evolution of a more market-friendly environment and institutional 
framework in order to increase competitiveness by cutting transaction costs and 
enhancing the process of capital accumulation. Due to the relatively limited size of its 
domestic market for sustained growth, Taiwan did not adopt an inward-oriented strategy
in its overall development. Its import-substitution phase lasted for a short period in the 
1950s before its transition to a phase of export promotion (1962-80) followed by a new 
phase of development characterised by a science and technology orientation since the 
early 80s.42 At the beginning of the 1960s, export expansion became an essential factor 
contributing to domestic agricultural and manufacturing growth that shaped a closer 
nexus between exports and the growth of domestic productivity in Taiwan’s development 
history. 43 Since the 80s, Taiwan’s exports have gone through another structural
adjustment, moving from a labour-intensive industrial structure to a capital- and 
technology-intensive one that increasingly replaces exports of non-durable consumer 
goods with final products such as electronic machinery and machine tools, etc.44
Due to the deepening of global economic integration, Taiwan has faced increasing
challenges for its developmental strategies since the country became exposed to 
globalisation in the early 1990s. Considering that Taiwan’s economic growth from the 60s 
to 80s was mainly based on export expansion underpinned by cheap labour costs, the 
increases to the general minimum wage in the early 90s raised a serious question for 
Taiwan’s labour-intensive industrial structure when it faced the increasing loss of price 
competitiveness to other developing countries with abundant supplies of low-cost labour. 
Some Taiwanese enterprises started to move production lines to mainland China for 
export competition and since 1993, China has become the biggest recipient of Taiwan’s 
outward foreign direct investment (FDI)45, leading to the shrinking of its domestic 
manufacturing base and employment opportunities in Taiwan. Given the threat of global 
competition and the rise in the unemployment rate, the Taiwanese government saw that 
it would need to adjust the industrial structure by upgrading Taiwan’s manufacturing 
economy to a knowledge-based one, developing sectors such as information technology 
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(IT) and biotechnologies which generally require a more sophisticated labour force so that 
the country could maintain its comparative advantages under the trend of globalisation. 
On the other hand, in domestic politics, Taiwan experienced its democratic transition 
after the mid-1980s with the legitimising of a newly-formed opposition party - the 
Democratic Progressive Party (DPP) - in 1986 and the lifting of martial law a year later in 
1987. Following the full election of the Legislative Yuan (Parliament) in 1992 and then the 
first direct presidential election in 1996, Taiwan has peacefully transitioned from a 
one-party political system to an electoral democracy. Democratisation undermines the 
constituent elements of a developmental state, which relies on a strong, autonomous 
state apparatus to deliberately intervene in overall economic decisions. In 2000, the DPP 
marginally won the presidential election due to a substantial split inside the KMT, and 
during its two-term, eight-year administration from 2000 to 2008, biotechnology and 
pharmaceutical industry had been treated by the government as the flagship industry for 
Taiwan’s next stage of economic transition. In addition, democratic political competition 
has triggered welfare state construction in Taiwan as a response to electoral promises 
delivered by both parties. 
By contrast with Western welfare states which view welfare expenditures, such as 
healthcare, pensions and public health policy, as a growing burden on economic growth, 
especially in the context of an integrated world economy as the states need to raise 
production costs via higher taxes for social welfare, the welfare state system in Taiwan has 
been established and incorporated in the state’s overall strategy of economic 
development.46 In other words, social and public health policies in Taiwan have been 
instrumentalised to promote economic growth that subordinates the policies to economic 
efficiency in order to maintain the state’s developmental credentials.47 In this context, 
the role of the state becomes complicated. Even though it needs to take a stewardship 
responsibility to ensure its citizens’rights and entitlements, as an actor and investor in 
global markets, the state relies on its population to produce resources and generate 
surplus value for the state’s long-term sustainability and perpetual growth through the 
revenue it can draw from the economy of which it is steward. 
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Biobanking blurs the traditional distinction between concepts of citizens and population 
by generating a collective mode of biovalue from subjected population through discourses 
of common good based on the notion of citizenship. As a new type of biovalue generator, 
it manifests a novel form of biopolitics in Taiwan when biobanking is re-embedded in the 
specific context of biocapital formation in which the future of life science research is being 
rerouted towards economic applications. What is at issue here is the extension of the 
speculative logic of capital into genomics research and personalised medicine so the 
classic growth cycles of production, reproduction and capital accumulation is rejuvenated
by introducing the “biological turn” in the neoliberal era.48 In so doing, the state may 
facilitate a neoliberal rationale to capitalise not only its own population but also the 
intrinsic value of the welfare state, such as collective wellbeing, social justice and 
redistribution. As Melinda Cooper argues, neoliberalism projects its strategy of capital 
accumulation into a speculative future by “installing speculation at the very core of 
production”.49 Population biobanks materialise this kind of rationale in the life sciences 
by producing a prospective life surplus50 in biotech application in the hope of overcoming 
the limits to growth associated with industrial production. 
Despite rapid economic growth from the 60s to 80s, Taiwan’s developmental strategy 
confronted a series of challenges of domestic democratic transition and global 
competition. As a result, establishing a population biobank may be viewed as a response 
not only to an economic downturn but also to the increasing demand for forming a 
welfare state in Taiwan. The idea of setting up a population biobank has been particularly
welcomed and supported by biotech and pharmaceutical industries in the island as they 
will be the major beneficiaries from using the data of the biobank. As the ultimate goal of 
biobanking in Taiwan is for the development of personalised medicine, considering that 
Taiwan’s overall population is dominated by Han Chinese, if Taiwan could take an 
advanced position in pharmaceutical design for Han Chinese genes, it would bring the 
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country tremendous commercial benefits for drug invention specifically targeting Han 
Chinese around the world. 
In addition, as an important function of a large-scale population biobank is to discover 
gene-environment risk factors by searching biomarkers, such as single nucleotide 
polymorphisms (SNPs) or haplotype (a set of SNPs), across the complete set of human 
genome for identifying affected genetic association in DNA sequences, the biobanks 
create a distinctive form of biocapital grounded in the identification of risk categories that 
opens up a market for DNA-based risk factor diagnostic devices and products. These 
lucrative commodities allow individuals to realise their susceptibility to certain diseases 
given the presence of certain conditions and environmental exposures. Without
continued access to a biobank which can provide stored biospecimens and genetic 
information that remains traceable to the particular individuals, the biovalue generated 
would not have been possible.51 However, when more and more emphasis has been 
placed on the function of the biobank to produce and reproduce biovalue than on its duty 
of redistribution of wealth, biobanking in Taiwan has become a specific strategy of 
neoliberal life politics by reconfiguring the very meaning of life. 
1.2 Research Approach
1.2.1 An Anthropological and Socio-Legal Approach
This thesis adopts anthropological and socio-legal approaches. It attempts to present 
research findings which combine empirical and theoretical viewpoints. Compared to 
traditionally doctrinal methods undertaken in studying law and relevant legal phenomena, 
carrying out research in law from a humanistic and social scientific standpoint is still 
relatively new in legal scholarship. However, rather than viewing law as a system of rules 
and doctrines, law may also be understood as a reflexive social institution so it requires a 
special research method besides those already developed by mainstream legal research. 
In their paper discussing the study of law in society in Britain in the mid-70s, English 
scholars Wiles and Campbell made a methodological distinction between the approaches
taken by socio-legal studies and the sociology of law. For them, the so-called socio-legal 
studies seemed to focus more on employing social sciences as a research tool than 
adapting it in a theoretical way for substantive analysis of law, so sociology in this sense 
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was treated as a technique for data collection.52 Nevertheless, the further development 
of socio-legal studies since then has put this stereotypical distinction into question. Not 
limiting methods to empirical research, contemporary socio-legal research is captured in a 
more recent attempt to employ interdisciplinary perspectives to challenge classical 
doctrinal studies of law.53 In so doing, a legal system may no longer be taken for granted 
as the way it appears; nor are the existing legal norms, rules or definitions the system 
encompasses. Rather, the legal system needs to be comprehended thoroughly under the 
wider political-economic and social structures within which it forms and operates, so the 
system itself and its purpose may be challenged from an exogenous standpoint.54
To a certain extent, this kind of research concern is not unfamiliar to social 
anthropologists who seek to keep themselves exogenous from their research subjects so a 
space and liberty can be created to generate new insights in the substantive contents of 
their research topics. An anthropological perspective can provide a holistic and contextual
analysis of law that draws attention to the effects of political economy and social 
conditions within which law become a set of relations. Such a perspective, according to 
Anne Griffiths, generates an alternative vision of law from formalist legal discourses by 
incorporating views of “law as process” in the study of what constitutes a legal domain.55
In addition, as the anthropological approach adopts an actor-oriented perspective, it 
supplements conventional legal doctrines and sources, such as cases and rules, with 
subtle and essential elements, for instances, class, ethnicities, gender and power relations 
which are often missing in the traditional study of legal system.56 As it has been argued 
that individuals are located within kin and social networks to which they belong, an 
anthropological approach helps situate law in relations to agencies and their situated 
networks that opens up for a more sophisticated analysis of law with regard to how it may 
be reconfigured through social processes that frame its constitution and transformation 
over time.57
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The empirical data collected from qualitative research methods such as interviewing, 
focus group and observation in this research has been used to constitute theoretical sides 
of the thesis. In other words, research findings derived from empirical data have been 
situated in relations to debates in the existing literature. In doing so, the thesis aims to 
show that socio-legal studies may not only address the effects of law in society but also 
the constitution of law itself. However, due to the nature of this research, the 
anthropological approach involved here does not refer to a long period of fieldwork and 
participatory observation anthropologists rely on to produce their ethnographic 
knowledge. Rather, it is constituted of several short-term fieldtrips encompassing
observation and interviewing carried out during a three-year period from 2008 to 2011. In 
anthropological methodology, a long period of fieldwork (at least a year) provides 
researchers an opportunity to observe the annual cycle of important behaviour and 
events emerging from the fieldwork setting. However, compared to most anthropological 
research design which focuses more on a specific territory or area, rather than a research
problem itself, the research method adopted here is a deliberate choice to reflect the 
difference between the nature of this research and traditional anthropological study. In 
addition, in terms of building up theories, the anthropological approach here refers to an 
exploration of the rich literature of ethnographies including concerns, conceptions and 
narratives that have been produced and reproduced by social anthropologists.
With an attempt to reconcile structure and agency, French anthropologist Pierre 
Bourdieu argued that the system of the legal universe, like the social universe, is 
constituted by the dual spaces of social structures and mental structures.58 The former 
refers to objective systems of position such as the system of distribution of resources, 
whereas the latter concerns the subjective systems of dispositions of the agents. By 
putting the agents back to the legal system, law may be viewed not merely as a matter of 
techniques but as symbolic power systems which are constituted by economic and 
cultural capital in relation to the reproduction of the power of the state and the 
economy.59 An anthropological approach reflects the symbolic structures presented in 
the legal field, so rather than focusing on its formal characteristics, this thesis plans to 
                                                     




explore the vision of law from its constitution, trajectory, power structures and its 
relations with social conditions and political economy. 
1.2.2 Empirical Viewpoints 
The central empirical questions in this thesis relate mainly to formulating ways to observe 
how biobanking operates within the context of Taiwan. As the pararegulatory and ethical 
regime with regard to biobanking in Taiwan may be traced to a diverse set of social and 
economic processes, the scope of this empirical research includes studying the biobank’s 
initiatives, research designs, institutional coordination, agencies, sample collections, 
confronted ethical dilemmas and governance frameworks, as well as Taiwanese 
aborigines’participation in the biobank, such as their concerns about stigmatisation, their 
political and economic rights and their perception about the implementation of the 
so-called ‘group consent’. The biobanking project in Taiwan was still in its very early 
development from 2008 to 2011 and therefore it was very difficult to ascertain precisely 
the future evolution of the biobank. As a pilot study project, the biobank’s operation 
fluctuated because of compromises of various different interests of the involved actors
and agencies - the government, scientists, social scientists, the Institutional Review Board
(IRB), the Ethics and Governance Council (EGC), potential participants, human rights 
organisations and biotech industries. The trajectory of the project demonstrated a 
mixture of aspirations and anxieties about health and economics which provided a 
valuable opportunity to observe the dynamics of the emergence of the biobank within 
the Taiwanese context.
Since the aim of the study is to investigate in depth the practice of biobanking in Taiwan, 
this research adopts multi- qualitative research methods such as semi-structured
interviews, participant observation and a focus group. In order to ensure that the whole 
image of the biobanking may be faithfully presented, a purposive sampling strategy was 
taken which means that in the research design, the interviewees were not randomly 
chosen but purposely covered a broad range of actors who had constituted the 
biobanking phenomenon in Taiwan one way or another. For example, they included 
scientists who were responsible for the research design and the preliminary operation of 
the pilot study of the Taiwan Biobank project; geneticists and epidemiologists engaged 
with research on population genomics; medical doctors and pathologists collecting
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various types of small-scale biobanks; legislators, scholars and governmental officials who 
had once been involved in the enactment of the recently passed Human Biobank 
Management Act, human rights advocates opposed to the pilot study project, members of 
the original Ethics and Governance Council of the biobank, ordinary Taiwanese aborigines 
and aboriginal medical doctors for their responses to the inclusion of Taiwanese 
aborigines into the original biobanking research design. 
In order to identify and approach participants, a snowball sampling was adopted for the 
recruitment of potential respondents. It means that extended interviewees were mainly 
refereed by existing study subjects who were requested to provide the names of the 
people to whom they were acquainted that might be relevant to this research project. 
The initial contacts at the start of this snowballing strategy were identified biobank 
stakeholders such as the PIs of the Taiwan Biobank and the relevant ELSI people who were 
involved in the design of the governance framework of the biobank. The samples of 
respondents were then expanded when the information flow about research targets
increased throughout the target group. Semi-structured interviews were chosen in data 
collection so a fairly open framework allowed for both focused and flexible 
communication for giving and receiving information. The interview process started with 
general and open-ended questions prepared beforehand but the majority of the 
subsequent questions were created during the interviews that enabled both respondents 
and the researcher to probe further. The formulated questions phrased ahead of time 
allowed interviewees to express their experiences, opinions and attitudes toward the 
biobanking project. The interviews took place between April of 2008 and January 2011. 
Among the total of 23 interviews, 21 were audio-recorded with the permission of the 
respondents and were then transcribed verbatim. Each of the interviews were carried out 
face-to-face lasting for about one to two hours so plenty of time was allowed to discuss 
issues and topics that were particularly important to the respondents. In order to keep 
updated the development of the project, some respondents were also invited to have 
second or third interviews during the period of the data collection. 
The observational participation referred to observed recruitment, sample collection and 
short interviews and discussions with research nurses who were involved in the forefront 
operation of the pilot study of the biobank at sample collection sites. In addition, a focus 
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group with ordinary aborigines (six Taroko youth with ages of 23-30) was carried out in 
Taipei in January 2010. The main purpose for choosing a focus group for data collection 
was to spot issues that might concern aboriginal people about biobanking once they were 
included in the population biobank project. In the beginning of the focus group research, 
each of the participants was given a test about their knowledge of biobanks. After the 
knowledge test, the formal discussion began. The discussion covered four big topics about 
biobank dilemmas – privacy and data exchange, informed consent, commercialisation and 
benefit sharing, and law. Each dilemma was briefly explained and was followed by several 
detailed questions for further discussion. Each participant was then given a red and a 
green card in order to answer some of the detailed questions. Raising the red card means 
they don’t agree, and the green card means they agree. After the participants showed 
their cards to some yes/ no questions, they were asked to explain the reasons to their 
answers. 
The deliberative decision to use this focus group and a snowballing sampling strategy in 
in-depth interviews unavoidably introduces a range of methodological limitations. A 
common concern is about the issue of representative and the researcher’s interpretive 
judgments made about the data collected from the interviews. However, as described 
above, the main reason for carrying out the focus group is for the purpose of 
“issue-spotting”. As a result, the research findings should not be further interpreted as 
the general perception of the Taroko group or the Taiwanese aborigines in general. Nor 
may the research results be taken to represent the general public’s perception about the 
biobank plan in Taiwan. The same concerns may also challenge the issue of generalisation 
from interpreting research results derived from snowballing samples that may be 
relatively limited in size. Nevertheless, the main purpose for carrying out interviews in this 
research is to explore the practice of the biobanking within the Taiwanese context. 
Though the research findings may form a basis for theorising the development of the 
biobank in Taiwan, the researcher makes no claims to generalise what had been observed 
from the Taiwanese biobanking phenomenon as a regular pattern existing elsewhere 
around the world.  
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This thesis plans to present its findings as a modest attempt to combine empirical and 
theoretical viewpoints.60 The further analysis of the research findings in the subsequent 
chapters seeks to engage with both theoretical frameworks and empirical examples. For 
instance, empirical evidence will be used to discuss the issues of the biobank initiative 
drawn out in Chapter 3 and complement the background information of the biobank 
governance discussed in Chapter 4. In Chapter 5, empirical data will be used as a way to 
challenge existing bioethical discourses about informed consent and provide a 
supplement for further discussions about group consent within the Taiwanese context. 
This research followed the ethics code of the LSE Research Ethics Policy issued in 2008 and 
the general ethical guidelines in the conduct of anthropological research. Participants in 
the interviews were given a description of the project and the background of the 
researcher when they were initially contacted by email requesting their willingness to 
take part in the research. The respondents who showed their interest in joining in the 
research were then given more information verbally about the purpose of this study and 
the way to deal with the collected data. All respondents were given the opportunity to 
withdraw their participation at any time during the research period. Except for the PIs of 
the Taiwan Biobank and some prominent scientists whose opinions about biobanking in 
Taiwan had been published and who also agreed to disclose their identities, all other 
respondents have been anonymised and have been labelled according to their occupation 
or ethnic categories.  
1.2.3 Theoretical Perspectives 
The on-going biobanking project may be viewed as an ideal prism to reflect the dynamic 
and complex entanglement of the life sciences, politics and capital as it brings together in 
one site a number of the essential assemblages that have constituted Taiwan’s modernity 
(and postmodernity). What is at stake for this thesis is therefore to locate Taiwan’s 
                                                     
60 Prior to this research, there had been no studies that have analysed biobanking from a theoretical 
engagement with political economy and combined this with empirical analysis within the field of Taiwan. 
Even though there have been studies that have focused on biobanks in particular and combined empirical 
and theoretical analysis, these studies had been conducted on biobanks in the UK or within Europe. The 
most recent one is a study about the interplay between law and practice in biobank governance in the UK. 
The study draws from theoretical perspective on regulation and combined this with empirical analysis to 
understand the view of researchers in the field of biobanking. See, Kaye, Jane, Susan M C Gibbons, 
Catherine Heeney, Michael Parker, and Andrew Smart. Governing Biobanks : Understanding the Interplay 
between Law and Practice Oxford: Hart Publishing, 2012.
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biobanking practices in a broader context of political economy as it helps illustrate the 
specific national aspiration and neoliberal reasons that propel the country to join in the 
global biobanking trend (See Chapter 2 and 3). In other words, rather than simply 
proposing a legal analysis of legal and ethical issues about biobank governance, the thesis 
attempts to explore how regulatory and ethical configurations related to the biobanking 
practice in Taiwan have come into being when the issues are re-embedded in the broader 
context to reflect Taiwan’s geopolitics, ethnicities, and its socio-economic reality (Chapter 
3, 4, and 5). 
In Chapter 4, the thesis argues that the ethics involved in the biobank project in Taiwan 
entails a wider politics of organisation, decision-making and accountability in democratic
societies to political subjects self-organised as citizens. As a result, the ethics involved in 
the discussion are not limited to the narrow bioethics and codified norms for biomedical 
practices on which most lawyers and ethicists focus. Rather, they involve wider political 
innovation and joint decision-making of potential research that also demonstrates why 
democratic transition in Taiwan has challenged the traditional technocrat decision model 
so a technocrat-based policy now needs to go through scrutiny from society in order to 
obtain its own legitimacy. In addition, analysing biobanking from the perspective of 
biopolitics, in Chapter 5 and 6, this thesis illustrates how bioethical configurations such as 
consent and privacy may be regarded as a technique of governance in Taiwan while taking 
into account the emergence of modern welfare states in which the state’s intervention to
redress social problems for national wellbeing becomes a legitimate technique of
governance “at a distance.”61
The original plan to include Taiwanese aborigines in the biobank project in Taiwan 
highlights an inner tension between the interests of the individual and the collective. This 
thesis further demonstrates how such a contrast may have been extended from a general 
discussion on the conflicting interests of individual rights and common good to a more 
specific consideration of the inclusion of minority populations in the biobank project 
within the Taiwanese context (paragraph 5.3). The possibility of the inclusion of 
Taiwanese aborigines in the biobank project triggers questions about stigmatisation and 
the implementation of consent at a collective level. This thesis shows that even though 
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group consent is necessary to safeguard the interests of minority populations in 
biobanking, its implementation concerns group identification, representation, and how to 
reach consensus by joint decision making, all of which involve deeper political 
implications with regard to the recognition of aboriginal status and its related economic 
and social inclusion (paragraph 5.3.1). By placing ethical governance frameworks and 
group consent in the broader political and social context of Taiwan, the thesis has linked 
the relation between bioethics and accountabilities in a democratic society.   
The influence of modernity along with the transitional role the state plays make Taiwan a
distinctive case for reflecting on the distinction between public and private in the context 
of biobanks (paragraph 6.3). In order to mitigate the inner tension between the interests 
in biobanks between the individual rights and the benefits of the collective, this thesis 
adopts the principle of the moral economy developed by social anthropologist Marcel 
Mauss whose perceptions of the morality of exchange based on the gift relationship in a 
total society provides insights into the justification of redistributive exchange and
reciprocal altruism (paragraph 6.2). Since the increasing association of global capital and 
life sciences gradually transforms human tissue and genetic data into commodities whose 
value can be created by exchange, a moral economy of biobanks is proposed in this thesis 
as an ideology to acknowledge the importance of the recognition of participants’
co-production of biovalue in the market economy (paragraph 6.1 and 6.2). 
For Mauss, gifts are deemed to be a mode of exchange that helps establish the bonds of
reciprocity between givers and recipients. The grand cycles of exchanges observed by 
Mauss constitute the whole society that maps all the obligations between its members 
whose permanent commitments articulate the dominant institutions. As the main
purpose behind Mauss’s concept of gift-exchange was to support social democratic 
redistribution, a new form of ethic has been created when individuals are organized as 
collective subjects to produce mutual interests based on their positive obligations to the 
greater totality. By referring to Mauss, this thesis further argues that the legitimacy of 
biobanks may be consolidated by treating both participants and the whole society as 
stakeholders in a greater totality in which they are parts of a division of labour.
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1.3 Overview of Chapters 
This thesis contains five substantive chapters that move from the macro to the micro. 
Chapter 2 and 3 are based on macro analysis of biobanking as a global phenomenon in 
the postgenomics era. They aim to illustrate the development of genomics, the notion 
and rise of biobanks in cosmopolitical technoscience and the driving forces and symbolic 
implications for the formation of biocapital and ethical configuration within the context of
Taiwan. Chapter 4 discusses the political-scientific decision to establish the population
biobank in Taiwan. It analyses the biobank’s initiatives, agencies, ethical puzzles and the 
dilemmas with regard to the complicated framework of ethical governance for the 
biobank’s pilot study. Chapter 5 and 6 are micro analyses of key legal and ethical issues 
about biobank governance, such as consent, privacy, property and benefit sharing. Rather 
than focusing on legal and ethical analysis, these bioethical configurations are deployed in 
a broader context of Taiwan’s biopolitics and biocapital formation.
This section provides an overview of the remaining chapters of the thesis. Chapter 2
conceptualises biobanks by introducing their notions, forms and driving forces. It asks
what a biobank is and how biobanks have become a phenomenon across the globe in 
recent years. It then introduces the cases of the national biobank projects in Iceland, the 
United Kingdom, Estonia and Tonga to analyse different factors leading to or impeding the 
establishment of these biobanks as well as their entanglement with global capital and 
local politics. Biobanks provide a useful resource for scientists to study the causes of 
common complex diseases and to translate biomedical research into diagnostic and 
therapeutic applications through pharmacogenomics and personalised medicine. The 
successful completion of the Human Genome Project was an important scientific 
breakthrough as it makes possible the study of human genome, namely the entirety of 
human hereditary information. The term “genomics” refers to this kind of study so its 
focus was no longer on single genes or its disorders but on interactions of those genes 
with each other and with the environment as well. However, the information from the 
genome project mainly shows the structure and function of the complete set of human 
genes. As it is generally believed that every individual has his or her unique genome, 
further scientific efforts have moved into studying genetic variants by comparing the 
genetic sequences of different populations and individuals.
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Biobanks as a new research tool and supporting technology can facilitate the study of 
genetic variation across whole populations. In recent years, many countries have joined 
in the global trend to set up their population biobanks to support the application of 
genomics research with the goal of capitalizing on the states’ untouched genetic 
resources.62 Even though medical and commercial incentives seem to be promising and 
scientists are largely convinced that biobanks offers a powerful technology for mining the 
riches of the human genome, the success and failure of a biobank, as this chapter 
demonstrates, depends largely on how willing people are to continue contributing their 
tissue samples and personal health information and how this newly invented 
infrastructure can sustain its operation for a longer period of time.
Chapter 3 discusses the deployment of biotechnologies in Taiwan’s biocapital formation 
and examines the social and symbolic effects of biobanking in Taiwanese political 
economy and geopolitical analysis. Technology and capital are two crucial elements to 
demonstrate a biotech revolution in Asian modernity. In order to transform Taiwan from a 
manufacturing economy to a knowledge based economy, the government has identified 
biotechnologies as a useful tool to produce value. Biotech echoes the government’s
neoliberal rationale of value accumulation and how it plans to position Taiwan in the map 
of global capitalism. As the rise of China and India as two emerging economic powers has 
changed the international division of labour in the world system, it urges Taiwan to 
recapitalise its geopolitical location in the regions. In addition, Taiwan’s withdrawal from 
the United Nations has prevented it from participating in the international system. This 
chapter illustrates how the official exclusion from the international stage has driven 
Taiwan to experience a series of domestic political transformation from an authoritarian
state to a transitional democracy. This questions the idea of Taiwan as a developmental
state and influences Taiwanese civic epistemologies toward technocratic policies which 
have faced increasing challenges from an emerging social sphere of different opinions and 
voices. 
This chapter also argues that Taiwanese DNA has become a symbol of showing Taiwan’s 
anxiety about being excluded from the international health management system and its 
eagerness to return to the global stage by promoting its biotech capacity. In addition, the 
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state’s developmental strategy to use biotech to upgrade its economy and enhance its 
international visibility has attracted global venture capital and pharmaceutical companies 
to establish partnership with Taiwanese local biotech industry. This chapter further 
explores the influence of the private sector in the formation of Taiwan’s biocapital. It 
illustrates the enthusiasm of the government of Taiwan to encourage private start-ups to 
play a leading role in transmitting innovative technologies and in bringing inward 
investment for Taiwan to be reconnected to the global trend of biotech development. 
Through mechanisms such as technology transfer and research collaborations, regulatory
infrastructures and capacity building have gradually blurred the distinctions between 
public and private. 
As the government of Taiwan identifies biobanks as a new form of biotech for Taiwan’s 
common good and future citizens, ethical configurations have emerged in Taiwan’s 
biopolitical narratives that illustrate the ambiguous and paradoxical role the state plays in 
biobank practices. Since the biobank project is intertwined with Taiwan’s governmentality 
and the formation of Taiwan’s bioeconomy, the chapter argues that it is not appropriate
to treat the project as simply a scientific research plan; rather, the biobank should be 
viewed as a public policy and social enterprise which needs to be fully scrutinised by the 
public. In the end, this chapter argues that current ethical configurations with regard to 
biobank governance in Taiwan may not be thoroughly responsive to the commercial 
challenges for the biobank. Approaching the issue of biobank governance from a 
bioethical viewpoint may ignore the influence of global capitalism on the activities of 
biobanks. 
Chapter 4 explores the politics of science and technology behind the biobanking story in 
Taiwan by analysing the initiatives, agencies, ethical puzzles, and the complexities of the 
governance framework of the biobank pilot study. Taiwan Biobank is designed as a 
prospective cohort study which plans to collect about 200,000 blood samples and 
personal health information from voluntary Taiwanese participants aged 30-70. The pilot 
study was proposed by the Department of Health as a sub-project under the scheme of 
the Biomedical Technology Island Plan, which aims at building Taiwan into a centre of 
genomics research and clinical trials in Asia. Given several strengths of biobanking in 
Taiwan, establishing a large-scale population biobank becomes a beneficial idea for some 
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supporting scientists, industries and the government in order to secure Taiwan’s niche in 
the global bioeconomy for biomedical and pharmaceutical innovations. However, the 
biobank pilot study has staggered along the way in its early development. Much criticism 
of the project comes from human rights groups and some social scientists who 
questioned the transparency and trust in the project. 
This chapter studies how biomedical issues have become bioethical problems by linking 
the relation between bioethics and accountability in Taiwan’s modern democracy. By 
extending discussions from bioethics to a broader politics of decision-making among the 
public, this chapter analyses the trajectories of the biobank project by asking how the 
innovative framework of the dual-track governance operated by the Institutional Review
Board (IRB) and the Ethics and Governance Council (EGC) made the supervision of the 
biobank project prolonged and complex. In addition, this chapter studies the mutual 
interaction between science and society in Taiwan’s biobanking reality. By introducing the 
notion of “co-production” of Sheila Jasanoff, this chapter demonstrates how the existing 
political and cultural structures in Taiwanese society may feed back into the production of 
scientific knowledge in a process of legislative formation by social mobilisation and 
political narratives. In addition, through the prism of technocrat governance, this chapter 
observes the deeper relationships among politics, S&T policy formation, and the emerging 
civil society and public sphere in Taiwan. It argues that the inclusion of public engagement 
in biobanking in Taiwan may legitimise the biobank project, which was formed on the 
basis of the technocrat-decision model. However, when both science and society seek to 
reach a consensus (if any) about the project, they need to be aware of the limit of rational 
communication given the information asymmetry among the variety of actors and 
agencies involved in the biobank. 
Chapter 5 critically examines the role of consent in biobanking in Taiwan. By studying how 
consent has been conceptualised and positioned in the forefront of Taiwanese biobank 
governance, this chapter argues that the mechanism of consent has been constructed not 
only as a matter of ethics but also as a legal endeavour for the establishment of the 
biobank. In so doing, consent was instrumentalised by the state as a technology of power 
to legitimise various agendas in the politics of life. This chapter argues that by setting 
aside other essential issues in the context of biobanking, such as access and ownership, 
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the consent mechanism may satisfy the general expectation of ‘good ethics’ at the 
expense of substantive deliberation of the rearrangement of rights and benefits related to 
biobanks. It demonstrates that an overemphasis on consent has meant that biobank 
governance in Taiwan has failed to challenge the neoliberal rationality that focuses on 
individual autonomy but leaves the underprivileged on an unequal footing in the 
development of modern life sciences. 
In addition, as the potential risks of genetic research are normally of a collective nature, 
biobank governance opens up an arena of power reconfiguration between the individual 
and the collective. The original idea of involving Taiwanese aborigines in the population 
biobank questions the rationale of individual consent that overlooks the significance of 
collective involvement in decision making in aboriginal cultures. This chapter presents 
empirical findings in response to questions related to Taiwanese aboriginal involvement in 
the practice of group consent, such as how to identify a group (by whom and by what 
criteria) as well as who may legitimately represent the group to give consent. In Taiwan, 
as the status of aborigines and its associated rights and entitlements are embedded in law, 
genetic information could be used to challenge an existing aboriginal status or prevent a 
group from asserting its legal claims to be recognised as aborigine. This chapter suggests 
that rather than viewing consent as a contract or an event, consent should be regarded as 
a process of reciprocal exchange so that research subjects, especially when they belong to 
minority populations, can have a certain amount of bargaining power to decide how their 
samples and the derived information will be processed and interpreted.
Chapter 6 focuses on issues concerning property, privacy and commodification in the 
context of biobanks. The development of genomics and modern biotechnologies has 
given rise to serious debates regarding property as human tissue and genetic information 
have been transformed into useful resources of biovalue. This chapter explores the 
circumstances and conditions by which human tissue may be viewed as commodities for 
exchange. By adopting anthropological theories developed by Karl Polanyi, the chapter
argues that while considering the exposure of nature to a market economy, human tissue 
and genetic materials have been deemed to be fictitious commodities as they are not 
produced for sale but regarded as commodities for exchange in order to organize the 
market system. Such commodification of bodies has formed a new discourse in scientific 
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and biotech development by creating a space for the speedy flow of technologies and 
capital across the globe. In addition, by analysing the John Moore case, this chapter
criticizes the adequacy of using consent and privacy to replace property as it neglects the 
limits on these ethical arrangements in terms of empowering research subjects by 
providing them continuing control over their samples and data stored in biobanks. 
This chapter also examines the notion of the gift relationship proposed respectively by 
anthropologist Marcel Mauss and sociologist Richard Titmuss. Even though altruistic 
gift-giving developed by Titmuss has been favourably adopted as a policy model to 
govern the relationship of researchers and research subjects, such a free gift model, as 
the chapter points out, implies a tendency to avoid the recognition of participants as 
stakeholders and the rearrangement of entitlements for a share of profits related to 
biobanks. In contrast, for Mauss, gifts are not given for free but deemed to be a mode of 
exchange that helps establish the bonds of reciprocity between givers and recipients. This 
chapter argues that Mauss’s moral economy of redistribution based on gift circles, which 
focuses mainly on the larger collective benefits, provides a justification to mitigate the 
tension between an ethic of individual rights and a utilitarianism which prioritises the 
public good and the interests of the community at large. In addition, in the total social 
phenomenon constituted by the gift-exchange, a new form of ethic may be created in 
which individuals are organized as collective subjects to produce mutual interests based 
on their positive obligations to the greater community. This chapter suggests that in order 
to form a trust relationship in biobanking, the moral ideal of an alliance of participants
and the biobank (and its commercial extensions) needs to be acknowledged with 
reference to their joint interest and their co-dependent relations in a greater totality in 
which they are parts of a division of labour. 
In addition, this chapter challenges the legal mechanisms focusing on personal data 
protection in biobanks which have switched the issue of property to a concern with
privacy. By analysing the Source Informatics case, this chapter distinguishes the notion of 
confidentiality from privacy and illustrates how the narrow conception of privacy being 
adopted in Taiwanese biobank governance has mistakenly suggested that so long as the 
samples and data are anonymised and encoded, privacy would no longer be an issue of 
concern. In addition, through a discussion of Foucault’s theories on surveillance and 
37
governmentality, this chapter argues that the boundary between the private and public is 
subject to negotiation, especially when the individuals are viewed as autonomous agents 
whose choices and freedom have real effects on the greater interests of community. As 
biobanking is a project involving groups, the discussion of privacy and its public interest 
defence needs to reconsider how this technique of governance may have influenced the
scope of privacy. 
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Chapter 2 Biobanking as a Global Phenomenon: the Co-Production of Life 
Sciences and Capitalism
Introduction
A recent TIME magazine article featured biobanks as one of the “10 Ideas Changing the 
World Right Now.”1 In the article, biobanks were introduced as an “organic bank account” 
to safeguard people’s most valuable assets. Rather than depositing money in a personal 
bank account, it is a repository for people to put in their biomaterials - blood, tissue 
samples and DNA - in order to earn medical interest some later day in the form of new 
knowledge and therapies for diseases.2 As most complex diseases and cancers that affect 
large populations are typically caused by a combination of genetic and environmental 
factors rather than by individual genes, scientists generally recognise that studying the 
population genome, namely the entirety of a person’s genes across whole populations, is 
necessary to fully understand the complex and subtle interaction between the incidence 
of disease, genes and environment.3 This kind of population studies in genomics requires 
large sample sizes with high-quality tissue samples and it has fuelled the drive for the 
establishment of large-scale population biobanks.4 Even though the collection and 
storage of human tissue samples for medical research has a decades-long history, 
biobanks as a sophisticated new technology can facilitate continuous collection of 
samples and linkage with associated epidemiological, clinical and research data.5
In recent years, the idea of creating biobanks has become a global phenomenon. Many 
countries in the West, such as Iceland, Britain, Norway, Sweden, Estonia, Canada and the 
United States, either already have or are building national biobanks in response to the 
demands of science and commerce.6 In East Asia, Biobank Japan was launched in 2003 
with initial three-year funding of about USD 200 million from the Japanese government 
and it has collected more than 200,000 blood samples and medical records from over 
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2 Ibid.
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170,000 patients in three years.7In China, the first population biobank was launched in 
Guangzhou - capital of Guangdong Province in southern China - in 2004. Even though it is 
not a national biobank and has only collected samples from Guangzhou, it aims to create 
profiles for 50,000 people in four to five years.8 In South East Asia, the Singapore 
government approved a grant of USD 8.7 million in 2002 to set up the facility over three 
years for the establishment of the Singapore Bio-Bank. Located at the research centre 
Biopolis, Singapore Bio-Bank was then the region’s first national biobank and it gave 
scientists and researchers free access to samples and data critical in studying diseases.9
Inspired by the cases of Iceland and the United Kingdom, the government of Taiwan has 
been heading up an effort to establish its own population biobank.
In addition, some transnational infrastructures have also been established to respond to 
this global biobanking phenomenon. For instance, the Public Population Project in 
Genomics (P³G) was founded in 2003. Headquartered in Montreal, Canada, P³G is a 
non-for-profit international consortium aiming to build a network for sharing and 
harmonization of infrastructures, research methods and governance framework for the 
population genomics community across the globe. 10 One important goal of the 
consortium is to optimize the benefits of collaborative research for the interests of all 
affected biobank stakeholders, including not only scientists and research sponsors but 
also research participants and their communities. In 2005, the consortium created its 
platform website - P³G Observatory - to facilitate comparison and sharing of information 
between studies. The Observatory provides an overview of biobanking activities around 
the world covering information about operational procedures for sample collection and 
storage conditions.11 In Europe, a pan-European Biobanking and Biomolecular Resources 
Research Infrastructure (BBMRI) finished a 28 month’s preparatory phrase in January 
2011.12 Funded by the European Commission (EC), the BBMRI has grown to a 53-member 
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consortium in less than two-and-half year’s time. Its scientific partners cover more than 
30 countries, including 280 associated organizations, most of which are biobanks of 
various types.13 This federated network aims to provide a sustainable legal and financial 
conceptual framework to benefit European research in life sciences and increase the 
scientific efficacy of biomedical research in Europe.14
However, will biobanking really change the world? Even though medical and commercial 
incentives seem to be promising and scientists are largely convinced that biobanks offers 
a powerful technology for mining the riches of the human genome, the success and 
failure of a biobank depends largely on how willing people are to continue contributing 
their tissue samples and genetic information. In addition, how this newly invented 
infrastructure can sustain its operation for a longer period of time remains questionable. 
In November 2009, deCODE Genetics, the operator of the Health Sector Database in 
Iceland, filed for bankruptcy protection and announced the sale of its drug discovery and 
development subsidiary, which includes its population genetics resources.15 In Asia, the 
Singapore government announced the decision to close its national biobank in June 2011, 
about only a decade after the establishment of the Singapore Bio-Bank, much less than 
the time required for biomedical research to bear fruit. Though the biobank was 
recognised as a significant resource for the country’s biomedical research community, the 
operation of the biobank cost around USD 1 million a year and its capacity to process 
about 10,000 samples had been deemed to be under-utilised.16 After the closure of the 
biobank, the new challenge the Singapore government faces is how to find appropriate 
solutions to deal with the precious 230,000 samples (about 1.2 million vials) stored in the 
biobank when other similar facilities in the country are reaching their maximum 
capacities.17
Although biobanks have potential to transform the ways we see the development of 
disease, biobanking initiatives should not be seen as limited to only a scientific inquiry. 
Rather, they need to be embedded in a broader context of political economy. This 
chapter explains how biobanking has become a phenomenon across the globe. It first 
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introduces the rise, notions and norms of biobanks. It then analyses several biobanking 
cases around the world - Iceland, the United Kingdom, Estonia and Tonga - in order to 
better understand how biobanks have become global assemblages of life sciences and 
capitalism. 
2.1 What is a Biobank?
Even though certain shared characteristics of biobanks may be identified, there is no 
consensus about what constitutes the term “biobank” in the current literature. Different 
names have been given to describe a collection of human biomaterials, such as “genetic 
databases,”18 “biospecimen repositories,”19 and “tissue banks,”20 etc. For instance, an 
earlier working definition given by Mats Hasson describes a biobank as “collections of 
human biological material within the health care system and the medical sciences.”21Such 
a definition, however, ignores the fact that information linkage is the key feature of 
biobanks by which they can be distinguished from a collection of biospecimens, such as a 
tissue bank, which stores tissue samples only, without collecting and banking associated 
genealogical and personal health data. In the recent OECD Guidelines on Human Biobanks 
and Genetic Research Databases (HBGRD) (2009), biobanks are viewed as “structured 
resources that can be used for the purpose of genetic research, and which include: a) 
human biological materials and/or information generated from their analysis; and b) 
extensive associated information.”22 It has been recognised by the OECD that even 
though the Guidelines were intended to be applied as broadly as possible, they may not 
be fully applicable to all kinds of human biobanks, given their diversity of purpose and 
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operation, especially for those established for non-research purposes, such as for 
diagnostic, therapeutic, treatment or forensic uses, etc.23
According to the Best Practices for Biospecimen Resources (2007) published by the US 
National Cancer Institute, which has headed up an effort to establish the first national 
biobank - the cancer Human Biobank (caHUB) - in the United States, a “biospecimen 
resource” is defined as “a collection of human specimens and associated data for research 
purposes, the physical structure where the collection is stored, and all relevant processes 
and policies.”24 Even though the Institute uses a different term to refer to the collection 
of human samples and genetic data, the definition it uses is similar to that used to define 
a biobank. In addition, in the earlier report published by the OECD on Creation and 
Governance of Human Genetic Research Databases (2006), the term “genetic databases” 
rather than “biobanks” was used to cover the same type of collections described by the 
OECD in its later Guidelines on Human Biobanks and Genetic Research Databases 
(HBGRDs) published in 2009. According to the earlier report, human genetic research 
databases (HGRDs) are described as databases containing “data, information and 
biological samples from populations” that are used to contribute to scientific 
understanding of the complex multi-factorial basis of diseases.25
The wide use of “biobank” to cover all types of collections of human specimens and 
associated data creates difficulties as the different types of collections with different 
structures and purposes may raise different technological, ethical and legal 
considerations. 26 According to the OECD Guidelines, the extent and types of 
consultations about the establishment of human biobanks need to take into consideration 
the biobanks’ nature, purpose and scope as the greater the breadth of targeted 
participants, the more extensive the tissue samples and data to be collected that may 
cause risks involved in sharing the samples and data.27 Even though a number of 
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significant variables, such as size, scale and nature will influence a range of biobank 
activities, including recruitment, practices of consent and governance arrangements, etc, 
human biobanks typically share a number of common features.28 For instance, they 
usually involve unspecified research in the future so they have an ongoing and
open-ended nature that challenges the traditional practice of informed consent. 
Furthermore, in order to link collected biospecimens with phenotypic data, the banked 
samples and data need to remain potentially re-identifiable by biobank custodians even 
though the data may have been anonymised, and because it is not possible to make the 
samples and data completely de-identified, appropriate mechanisms need to be set for 
data management to minimise the risk of individuals being identified.29 In addition, as 
the biobanks are more concerned with the public benefit for future generations than with 
the individual benefit of participants themselves, they have a common good focus and as 
a result, their governance needs to call for balancing individual and collective interests. 
Beyond these shared features, however, a number of significant variables may further 
categorise human biobanks by their size and scale, participants’ health status, the scope 
of potential research, the extent to which data linkage is possible, the nature of the 
collection and business models and founding sources, etc.30 For instance, in terms of 
biobanks’ differences in size, they can be distinguished between large-scale and 
smaller-scale collections. While the former are being established at regional, national or 
international levels to support large-scale longitudinal genetic research, the latter are 
generally small-scale collections restricted to particular population groups and particular 
research projects.31 Besides, a biobank may target healthy people by collecting samples 
and data from a healthy population or target those with a specific disease to establish a 
diseased-oriented biobank. Most current large-scale population biobanks collect samples 
from healthy people; the biobanking projects in Iceland, the United Kingdom, Estonia, 
mainland China and Taiwan 32 are all biobanks of this type. An example of a 
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disease-oriented biobank may be found in Biobank Japan, which mainly collects samples 
and data from diseased individuals for medical research covering a total of forty-six 
diseases.33 In terms of the scope of potential research, a biobank may be limited to a 
particular field of research with a particular disease or it may be intended for unlimited or 
multi-disease research that may be unspecified at the time of data collection for the 
biobank.34
In addition, as for the nature of the collection, biobanks can be distinguished between a 
purely prospective collection and an integration of a pre-existing collection or a 
combination of both. In terms of the extent to which data linkage is possible, types of 
biobanks may be categorised depending on the coding system or anonymization 
procedures the biobank uses for its data protection. If funding sources and business 
models are taken into account, the categorization may be further refined into distinctions 
between public or private, commercial or non-commercial biobanks. Different types of 
biobanks require different governance frameworks for issues regarding consent and 
privacy. For instance, whether a biobank is commercially oriented may have a significant 
influence on people’s willingness to participate, as the business model of profit 
maximization may not be accepted by a participant who might otherwise like to 
contribute her or his samples to a public and non-commercial biobank. Biobanks may also 
be distinguished from other collections of biospecimens created for research purposes or 
for other purposes but also used for research even though the boundaries between the 
biobanks and these kinds of collections may not be easily drawn.35 For instance, the 
genetic research database used for the HapMap Project stored de-identified genetic 
information compiled from multiple donors. Even though the samples and cell lines used 
by the project could be identified as coming from one of the four populations taking part 
in the study, they were not linked to any individual participant. This is very different from 
a biobank in which re-identification and data linkage are necessary. Making these 
distinctions helps to clarify the term biobank. When it is used in this thesis, it refers to 
large collections of human biological materials that may be linked with personal and 
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health information for use in health and medical research as in the definition given by the 
OECD. 
2.2 Why Biobanking? 
2.2.1 Human Population Genomics
Biobanks provide an important resource to scientific research in two main areas. One is to 
find out the interaction between genetic factors underlying common complex diseases 
and the environment. The other is to translate biomedical research into diagnostic and 
therapeutic applications through pharmacogenomics to achieve personalised medicine 
and improve public health. Since the announcement of the completion of the Human 
Genome Project (HGP) in2003, the creation of large-scale biobanks for population studies 
in genomics has expanded rapidly.The HGP was an international scientific collaborative 
program aiming to understand and map the entirety of human genes. Launched in 1990, 
the project involved 18 countries, headed by the United States, the United Kingdom, 
Germany, France, mainland China and Japan but mainly funded by the National Institute 
of Health (NIH) in the US and the Wellcome Trust in the UK.36 The successful completion 
of the project was an important scientific breakthrough. Prior to the HGP, scientists 
studied genes and their roles in inheritance in order to realise how certain inherited 
disorders were passed down from one generation to another. The information coming 
from the HGP makes possible the study of human genome, namely the entirety of human 
hereditary information. The term “genomics” refers to this kind of study so the focus of 
genomics was no longer on single genes or its disorders but on interactions of those genes 
with each other and with the environment as well.37 Scientists have gradually recognised 
that cancers and several common diseases, such as asthma, diabetes and heart disease, 
are complex diseases because they are caused by a combination of genetic variants and 
environmental factors rather than by individual genes.38 The study of genomics is 
therefore expected to open up opportunities for new therapies and diagnostic methods 
for some complex diseases.
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The completed human sequence means that about 20,500 human genes can now be 
identified by determining their orders and mapping their locations.39 However, the data 
announced by the HGP represents the combination of genomes of projects participants, 
rather than the individual’s genome. In other words, such information mainly shows the 
structure and function of the complete set of human genes that does not represent the 
exact sequence of the entirety of every individual’s genes.40As it is generally believed that 
every individual has his or her unique genome, the data published by the HGP makes 
possible further efforts in identifying differences among individuals. For instance, the 
HapMap project started to focus on identifying genetic similarities and differences in 
human beings. The project was another effort of multi-country collaboration, starting 
officially with a meeting from October 2002 and lasting for about three years.41 Its 
primary goal was to identify genetic variants by comparing the genetic sequences of 
different individuals so researchers can use this freely available information to find genes 
involved in diseases and individual responses to medications and environmental factors.42
The HapMap project consisting of scientists, funding agencies, public and private 
organisations from six countries— Canada, China, Japan, Nigeria, the United Kingdom and
the United States— gathered genetic information from populations with Asian, African 
and European ancestry.43In genomics, the term “HapMap” is a catalog of common genetic 
variants that is used to describe what these variants are, their locations in the DNA in 
human cells and how they are distributed within and among various populations across 
the world.44 Even though the HapMap project claimed that their purposes was not to 
identify disease-related genes directly but to provide a tool for researchers to link genetic 
variants to the incidence of diseases for new methods of diagnosis and treatment, the 
project had raised concerns about connections established between particular genetic 
variants and specific illnesses.45
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Existing in a human cell, the DNA contains long chains of four chemical building blocks 
that can be abbreviated by their first English letters— A, T, C and G— strung together in 
23 pairs of chromosomes.46 The information contained in these genetic sequences 
influence people’s physical traits and our bodies’ responses to substances encountered in 
the environment. However, it has also been recognised that the genetic sequences of 
different people are remarkably similar, comparing the chromosomes of two different 
individuals, the difference of genetic sequences of the two people occurring only about 
one in every 1,200 bases.47 Therefore, for geneticists, the most common type of genetic 
variation they can find out is differences in individual bases which are known as SNPs—
single nucleotide polymorphisms.48 SNPs can be used as markers to locate and identify 
genes in DNA sequences. For instance, even though an affected gene is known to 
increase the risk of suffering from a certain disease, researchers still need to find out 
where that gene is located in our chromosomes for the purpose of treatment. A way to 
locate genes is to compare the SNPs in people who have this disease with the SNPs of 
those who do not (the controls). If a particular SNP is found more frequently among the 
diseased group, then that SNP can be used to locate the gene involved in the disease.49
As it is extremely expensive to test all of the common SNPs in an individual’s 
chromosomes, the HapMap project aims to identify the basis for a large fraction of the 
genetic diversity in the human species and provides researchers with this resource to 
discover the genetic variants involved in disease and individual response to therapies.50
A basic assumption behind the HapMap project is that medical treatment could be 
customised based on individual’s genetic makeup. So more knowledge about genomics, 
namely understanding of the interactions between genes and the environment, could 
help researchers to find better ways to cure and prevent disease. The samples gathered 
for the HapMap project came from a total of 270 people of multiple populations.51 With 
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51 According to the HapMap project, 30 sets of samples were from the Yoruba people of Ibadan, Nigeria. 
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ancestry by the Centre d'Etude du Polymorphisme Humain (CEPH). More information about which 
population were being sampled in the HapMap project, see: 
http://hapmap.ncbi.nlm.nih.gov/hapmappopulations.html.en (Last visit: 10 March 2012)
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samples from more than one population, researchers worldwide can have opportunities 
to access the genetic contributions to diseases that are prevalent in different populations. 
The blood samples provided for the project had been converted into cell lines for making 
DNA. Even though these samples and cell lines cannot be linked to any individuals, they 
can certainly be identified as coming from one of the four populations participating in the 
project. As a result, it raised ethical issues concerning stigmatisation with conducting 
genetic research in named populations.
In order to address these ethical issues, the HapMap project incorporated the 
consideration of bioethics into its samples collection. For instance, all samples were 
anonymous, no medical and phenotype information were collected and no individual 
personal information can be linked to any samples.52 Besides, the project collected more 
samples from each population than they were used so no any particular person’s DNA 
can be identified by knowing whether it was included in the study or not.53 However, 
even though the infringement of individual privacy seemed to be minimal, as each sample 
was identified as coming from a particular population, the HapMap project raised new 
ethical issues about stigmatization and discrimination in a collective level. For instance, a 
research finding may show that a genetic variant associated with an incidence of a 
disease is more frequent in one population than another. But this finding may be 
interpreted incorrectly to indicate that each individual in this higher risk group has a 
higher-than-average risk of the disease, even though the higher risk may apply only to 
those who have the genetic variant, whether they are members of the group or not.54
In addition, genetic findings might also be misinterpreted to suggest that constructed 
biological category such as “race” is precise and meaningful.55 Being aware of this ethical 
issue associated particularly with genetic study, the HapMap project made an 
announcement on its official website that the information emerging from the project was 
helping to illustrate that common perceptions about race are “loosely connected to 
biological ancestry” but largely from social and cultural interactions.56 In fact, genetic 
findings could undermine established cultural or religious traditions set up from groups’ 
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firm beliefs about their lineage or conflict with the methods the groups have developed 
to determine their membership, so such findings also have significant implications on 
legal or political status of a group and its members. To address these concerns, the 
HapMap project initiated a process of community engagement before seeking individual 
consent from each of its participants. Though the engagement process varied from 
country to country, it provided an opportunity for community members to discuss the 
issues raised by the project and then fedback their input into research designs about how 
to collect samples and what information should be covered in the consent form.57 In 
most cases, the process is involved a combination of several forms of consultation, such 
as focus group discussions, community meetings, public surveys and interviews on 
individual basis.58
This community engagement process helped create a more transparent climate in which 
trust could be developed between researchers and participants by not only informing the 
participants about the nature and goals of the project but also for researchers to 
understand and respond to participants’ concerns. In addition, a special agency -
Community Advisory Group (CAG) - was established in each participant community to 
function as a liaison between the community participating in the project and the Coriell 
Institute in New Jersey, in which samples will be stored.59 The Coriell Institute was 
required to distribute quarterly report and periodic newsletters about how samples were 
being used to the Community Asvisory Group in each participating community. Unlike 
other population biobank studies, as the HapMap did not collect medical data and no 
personal identifiers were included with samples, it is not possible for researchers to 
re-contact individual participants to obtain their re-consent for each new study and the 
participants would not be able to withdraw from the project based on the same reason. 
However, it is possible for an entire community to withdraw their samples from the 
repository if they wished to do so after careful discussion and consultation with 
researchers.60 As the purpose of the HapMap project was mainly to improve health of all 
people, no commercial products and drugs would be developed as part of the project, 
however other studies can still use the information produced from the HapMap to find 
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genetic variants involved in diseases and then translate such findings into diagnostic and 
therapeutic products.61
2.2.2 Personalised Medicine and Pharmacogenomics
The idea of customisation of medical treatment has been further developed by the 
advancement of the study of genetics. It leads to a new field - personalized medicine - in 
healthcare, namely all medical decisions and treatment, including preventive and 
therapeutic care being tailored to adapt to each individual’s particular genetic makeup. In 
the past, medical care was unable to take into account individual’s genetic variability as it 
has centered on standards of care based on epidemiological studies of large cohorts. 
Traditionally, clinical diagnosis and treatment was mainly based on patients’ symptoms 
and their medical and family history so the medical treatment was reactive rather than 
prospective. In other words, medication in clinics started only after the symptoms 
appeared. Recent advances in genomics introduced a new way to know certain diseases, 
especially the functions of genes and its impact on the development of complex diseases. 
The HapMap project has laid the groundwork for the further understanding of the 
similarities and differences of genetic makeup between individuals and it made possible 
for the application of the new tool, GWAS - Genome-Wide Association Studies - to 
examine how genome may affect a person’s susceptibility to diseases. 
A genome-wide association study is a new method for scientists to strategically search 
genetic markers that involves rapidly scanning SNPs across the complete set of human 
genomes to find genetic variations associated with a particular disease.62 The purpose of 
this tool is to efficiently identify genetic associations so researchers can use the 
information to better detect, treat or even prevent the disease.63 The potential impact of 
medical care from the studies could be significant, especially for the development of 
personalized medicine as the studies have been recognised as particularly useful in 
searching genetic variations that contribute to common, complex diseases.64 The studies 
are expected to benefit health management when it widely applies to medical care with 
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other innovative technologies, so health professionals can provide individual with 
information about their susceptibility of developing certain diseases or even tailor 
prevention programs to them according to their genetic makeup.65 In addition, in 
therapy, the information produced from the GWAS is expected to be used to select most 
likely effective treatments with less likely adverse reactions. Since 2005, the application 
of the GWAS has been reported to successfully identify genetic variations that are 
associated with prostate cancer, type 2 diabetes and heart disorders, etc.66
The recent advancement in the study of genetics has greatly influenced pharmaceutical 
development. For example, a new field – pharmacogenomics - has been developed to 
study the impact of genetic variations on the response to medications. The primary goal 
of such study is to tailor drug therapy for the increase of the efficacy and safety of 
medications. For instance, the chemotherapy drug Purinethol was recommended by the 
Food and Drug Administration (FDA) in the United States to carry out drug testing before 
its use as some patients with acute lymphoblastic leukemia had been reported to have 
problems with processing this drug that can cause severe side effects unless the standard 
dose is adjusted to adapt to the patients’ genetic makeup.67 In fact, the systematic 
collection of samples has been closely linked to the study of pharmacogenomics. Many 
large multinational pharmaceutical companies have made considerable investment in this 
area by sponsoring clinical drug trials or building extensive biobanks to support 
genomic-based research.
In addition to studying an individual’s response to particular drugs, pharmacogenomics 
may also examine genetic variations among populations, namely to see how different 
drugs might affect different racial or ethnic groups.68 Biobanks as a new research tool 
and supporting technology can facilitate the study of genetic variation across whole 
populations. In recent years, many countries have joined in the global trend to set up 
their population biobanks to support the application of genomics research with the goal 
of capitalizing on the states’ untouched genetic resources.69 Biobanks as a substantial 
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facility could turn a society into a promising region for gene hunting, drug testing and 
health management. Following the HGP’s completion of human genome sequence in 
2003, the HapMap’s mapping human genetic variation in 2005 and the rise of the 
genome-wide association studies which makes it easier to link genes and disease, 
biobanking has been recognised by some geneticists and pharmaceutical industries as the 
next logical step to translate genetic data into clinical applications.70 According to 
interview material published by Nature magazine in April 2008, a statistical geneticist has 
pointed out that they “found more genes for complex disease in 2007 than in the entire 
history of the field.”71 The discovery boom not only demonstrated a revolution in gene 
hunting but also produced a great amount of useful genomic data and information.
2.3 The Rise and Fall of Biobanks
2.3.1 The Icelandic Health Sector Database
Iceland was the first country in the world to initiate a national biobank for population 
genetics research. The idea of biobanking was proposed by deCODE Genetics, a US 
incorporated private company founded in 1996 with its headquarters located in Reykjavik. 
Describing itself as a “global leader in analysing and understanding the human genome,” 
deCODE aims to conduct population genetics research to discover genetic risk factors of 
common diseases and develop technologies for DNA-based tests and personal genome 
scans.72 Its business includes providing services of sequencing and genotyping analysis to 
research institutes and licensing its intellectual property, analytical tools and tests to 
partner companies. 73 Its recent product, deCODEme provides individuals with a 
comprehensive genome scan by analysing one million genetic variants to explore genetic 
risks for health investment.74 The product can now be purchased on-line for under USD 
1,000. 
                                                     
70 Ibid.
71 Ibid., according to Lon Cardon, a statistical geneticist and the newly appointed leader of the genetics 
division at GlaxoSmithKline (GSK).
72 Garðar Árnason, "Icelandic Biobank: A Report for Genbenefit" (2007).Information available at 
http://www.uclan.ac.uk/schools/school_of_health/research_projects/files/health_genbenefit_icelandic_cas
e.pdf (Last visit: 27 February 2012)




From 1996-98 deCODE actively negotiated with the Icelandic government to set up an 
Icelandic Health Sector Database (HSD) to collect medical records from the entire 
Icelandic population. The aim was to establish a population database for the entire nation 
and for data linkage with databases containing complete Icelandic genealogies. Unlike 
most genealogical data already computerised and accessible in the public domain, 
medical records in Iceland had been confidentially kept in regional hospitals and health 
care centres. Therefore, in order to establish the HSD, it needed to have a legitimate basis 
for the hospitals and centres to transfer their medical records to this health database. 
After successful negotiation, deCODE Genetics obtained support from the Icelandic Prime 
Minister, David Oddsson, to establish the database. On 17 December 1998, the Icelandic 
parliament passed the Act on a Health Sector Database permitting the establishment of 
the health database by a vote of 38 to 23.75
Furthermore, the Act also granted an exclusive operating license to deCODE for the 
management of the HSD for 12 years. An agreement set between the deCODE and the 
Icelandic Ministry of Health was that the company would pay the government its 6% 
profits up to the amount equivalent to the annual fee (about 800,000 EUR) for securing 
the position as a monopoly licensee.76 In addition to the arrangement of monopoly 
control, the Act adopted presumed consent as an arrangement for the HSD to efficiently 
collect patients’ medical data from hospitals and clinical centres around the nation. 
According to the Act, the hospitals and clinical centres were presumably to have obtained 
consent from their patients so they could negotiate with deCODE directly to decide 
whether or not to transfer their clinical data into the HSD. If individual patients did not 
want their records to be included in the HSD, they needed to follow a separate opt-out 
procedure within six months, namely before mid-June 1999 as stipulated by the Act. 
Many concerns arose about consent, privacy and confidentiality. For a country of a small 
population (about 275,000 people), it remained questionable whether coding and 
competence of computer security of the HSD was sufficient to protect the privacy of 
individuals and families. Furthermore, an anxiety emerged with the ambition of deCODE 
to use Iceland’s population to create a commercial laboratory. Such an attempt worried 
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those who treated genealogies and genetics as cultural elements constituting Icelandic 
personal and national identity.77 For that reason, debates about patients’ rights appeared 
in society especially with regard to issues about confidentiality, ownership and 
commodification of clinical data. For the medical profession, maintaining confidentiality of 
patients’ clinical records was their legal and professional responsibility. As a result, most 
of Icelandic physicians refused to submit their records to the HSD unless requested by 
patients. Furthermore, based on the right to opt out, about 11,000 Icelanders had opted 
out from the HSD by mid-June 1999 so their data would not be included in the health 
database before the HSD was formed.78
However, despite the opt-out option, this concession was ethically inadequate as it was 
not yet clear whether patients would have a right to withdraw their already entered data 
from the HSD after the database was created. In addition, according to the Act, only 
adults, namely those who were over 18 by mid-June 1999, could have legal rights to opt 
out; as a result, data of deaths would have been automatically included in the HSD, 
leaving children and the dead as the two categories without adequate privacy 
protection.79 In 2003, an Icelandic Supreme Court’s decision on the case Guðmundsdóttir 
v. the State of Iceland (No.151/2003) rendered the Act unconstitutional based on the 1st
paragraph of article 73 of the Icelandic Constitution about the freedom from interference 
with privacy.80 The case was filed by Ms. Guðmundsdóttir against the Icelandic Ministry 
of Health in February 2000 to exclude her deceased father’s clinical record from the HSD. 
The Reykjavik District Court first dismissed the case on the ground that Ms. 
Guðmundsdóttir did not have legal standing to file the lawsuit as the legislation only 
conferred the right to opt out on adult individuals rather than extending the right to their 
family members. The Supreme Court’s decision granted Ms. Guðmundsdóttir a personal 
interest in the case on the grounds that the one-way encryption system of the HSD could 
not ensure data anonymity.81 Furthermore, the nature of genetic data concerned not 
only the individuals from which they are derived but also descendants and family 
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members of the individuals.82 After the legislation was struck down by the Supreme 
Court, the probability of resuming the establishment of the HSD declined dramatically. 
Even though deCODE Genetics has continued operating its business since then, without 
support from Icelanders, the idea of building a centralised health database for population 
genetics research turned out to be futile. On 24 November 2008, a press release 
announced that the company was removed from the NASDAQ Biotechnology Index and a 
year later, deCODE Genetics filed for bankruptcy in the US with debts of $313.9 million.83
2.3.2. The UK Biobank
The UK biobank is a prospective cohort project aiming to recruit 500,000 British 
participants aged 40-69 to form a genetic database for a wide range of medical research 
uses. As a national research resource, the biobank was funded by the Wellcome Trust, 
Britain’s largest public charity sponsoring biomedical research84 and the UK government 
through agencies of the Department of Health, the Medical Research Council (MRC), and 
the Scottish Executive and the Northwest Regional Development Agency.85 In 2003, the 
biobank was incorporated and registered as a charity in England and Wales; about 61 
million GBP had been secured for its initial phase for recruitment and assessment.86
Recruitment started in April 2007, about eight years after the idea of the biobank was 
initiated, and it was scheduled to reach the final goal of recruiting 500,000 participants by 
August 2010.87
Even though the biobank was registered as a charitable company, its link with 
commercialisation was not invisible. In fact, the earliest initiative of setting up the 
biobank for linking to electronic medical records retained by the NHS can be traced back 
to 1999 when Sir George Poste proposed the idea to ministers to discuss.88 Poste then 
worked for a global pharmaceutical company - SmithKline Beecham - ,89 a firm later 
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merged with Glaxo Wellcome, another healthcare company to form Glaxo SmithKline
(GSK)90, a global drug firm with business focusing on invention and marketing of 
medications. In April 1999, Poste published an article in Science as co-author noting the 
potential use of NHS electronic medical data to link with DNA samples for exploring the 
association between genes and disease.91 Considering the decode controversy about 
commercialisation of medical records, Poste proposed an idea of a “public-private 
partnership (PPP)” as a model for the creation and management of the biobank.92 In May 
1999, the Wellcome Trust organised a workshop to discuss the possibility of creating the 
UK Population Biomedical Collection, a national DNA database for Britain. In the same 
year, the Wellcome Trust and the Medical Research Council agreed in principle to co-fund 
the project and later, in January 2000, the MRC called for proposals for establishing a large 
genetic database as a national resource accessible to biomedical researchers in the UK.93
Learning from the Icelandic lesson, in order to have adequate social legitimacy to ensure 
the biobank’s success in Britain, the funding agencies have carried out a series of public 
engagement activities since the early stage of the project. The first public consultation 
began in 200094 and it has continued as the project develops as a way to receive updated 
feedback and obtain trust from the public. In addition, in order to increase public 
confidence, the project upholds the principle of openness and transparency. It has made 
accessible the information about the management of the biobank online such as minutes 
of meetings, reviewers’reports on the protocol, etc. Even though several methods to 
generate public engagement have been adopted, for instance, focus groups, panel 
discussion and surveys, criticism remains especially with regard to the lack of serious 
debate in society about the scientific aims and approaches of the biobank and the 
inadequate legal safeguards to prevent genetic discrimination and protect personal 
genetic information.95 For instance, GeneWatch, a pressure group in the UK, has 
challenged the necessity to build a national DNA database like this and called for more 
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democratic mechanisms to be involved in the biobank project, especially more debates 
about the research design and agenda.96 Furthermore, despite public involvement in 
every stage, the engagement has been criticised as an “upstream” ethics,97 namely the 
public is entitled to have their voices heard on the existing arrangement of the biobank so 
the obstacles to the project can be smoothed. However, the public cannot really control 
the direction of the project throughout its development or even stop it when there is a 
need to do so. 
In addition, in order to ensure the biobank acts for the public good, an independent 
committee - the Ethics and Governance Council (EGC) - has been set up by the Wellcome 
Trust and the MRC since November 2004 in order to monitor the biobank management 
and keep the use of the biobank resource under review.98 One of the important functions 
of the EGC is to advise the biobank on the interests of donors and the public in general 
based on the Ethics and Governance Framework (EGF) under which the biobank operates. 
The framework acting as an ethical standard for the operation of the biobank was drafted 
in 2003 by the biobank founders with the advice of the Interim Advisory Group consisting 
of multidisciplinary experts. It is expected that the Ethics and Governance Framework can 
be evolved throughout the development of the project. The latest version which is the 
third draft of the EGF agreed by the ethical committee and the Board of Directors of the 
biobank was published in October 2007.99
In the framework, the ethical standards are discussed according to the three relationships 
associated with the biobank - relationship with participants, relationship with research 
users, and relationship with society.100 The first category covers issues about recruitment, 
namely consent and confidentiality with regard to participants’ enrolment in the biobank 
project. The second category focuses on stewardship of and research access to data and
samples. In addition to stipulations regarding decisions on access and use, the section 
also covers principles on sharing of data and findings as well as licences for specific use. 
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The last category emphasises the management and accountability of the biobank. Besides 
the internal governance arrangements such as the Board of Directors, the Ethics and 
Governance Council, the Steering Committee and International Scientific Advisory Board, 
the framework lists the plan for external governance that includes an ethics approval 
review by relevant ethics committees and compliance with the Research Governance 
Framework for Health and Social Care in England and the corresponding frameworks in 
Wales and Scotland.101 More to the point, this section acknowledges the principle of 
benefit sharing by requesting dissemination of new knowledge produced from research to 
benefit public health not only in the UK but also in the rest of world.102 As the biobank is 
positioned as a common resource, in order to ensure it is not improperly exploited by non 
bona fide users, terms of access and intellectual property procedures are separately 
developed and expected to be embodied in legal agreements that are compliant with the 
project’s aims and purposes.103
However, despite the ethical framework stating clearly that the biobank does not expect 
itself to lead to significant income returns from patentable inventions, it does not exclude 
the opportunities that the biotech and pharmaceutical industries may use the biobank 
resource for inventions that make a profit. According to the governance framework, 
commercial companies are allowed access to the biobank so long as their research 
application falls within the biobank purposes.104 Such arrangement of access has been 
criticised; even though the internal ethical committee was set up as a guardian of the 
biobank to review the uses of data, it has no veto power over such decisions as the power 
to decide on types of research belongs to the Board of Directors.105 Furthermore, 
although the Ethics and Governance Council and all interested parties including 
participants and members of the public may propose amendments to the governance 
framework, whether to adopt such advice on revisions still rests with the Board of 
Directors. The board, acting as company directors and charity trustees, includes one 
member from the scientific committee but no members from the ethical committee.106
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Besides the anxiety about commercialisation, a further concern is about how to safeguard 
privacy without compromising freedom of research. Even though the data are collected 
for the biobank with the consent of participants, it is not clear whether such consent 
would be extended later on to allow the linkage between electronic medical records 
retained in the NHS and the genetic data of the biobank. The UK government’s recent 
forced withdrawal of the data sharing provisions from the Coroners and Justice Bill 2009 
reflected the worries from the public that the government would allow personal data to 
be shared with third parties, including police and private companies, without proper 
consent.107 Clause 152 of the Coroners and Justice Bill 2009 obviates privacy protection 
of individuals by inserting a new section 50A into the Data Protection Act 1998 that 
confers designated authority, which is further defined in 50A (2) as an order-making 
power to share information consisting of or including personal data.108 The Clause 152 
initiative came from a review of the Data Protection Act proposed by Dr. Mark Walport, 
Director of the Wellcome Trust, to remove unnecessary legal barriers on data sharing for 
creating new mechanisms that enable population-based research.109 However, many 
concerns that patients’ personal data would be misused and inappropriately disclosed to 
third parties triggered a campaign organised by more than 30 groups110 to stop the 
legislation, including the British Medical Association (BMA), Royal College of Psychiatrists 
and British Computer Society.111 The abandonment of Clause 152 illustrated the influence 
of British public opinion giving an abstract concept like privacy a concrete meaning in its 
implementation in reality. It also shows that the creation of biobanks needs to obtain its 
legitimacy from society. Questions such as what constitutes personal data and how it may 
be used in an ethically and legally acceptable way would be a question to be decided by 
the public. 
2.3.3 The Estonian Genome Project 
The Republic of Estonia, lying on the eastern shores of the Baltic Sea and bordered to the 
north by the Gulf of Finland, is one of the Baltic Rim countries of the northwestern part of 
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East Europe. Estonia has a population of 1.34 million. According to Andres Metspalu, the 
main initiator of the Estonian Genome Project (EGP), Estonians are representative of all 
Caucasian populations in Europe.112 Whereas the Icelandic Health Sector Database 
focused on the homogeneity of the Icelandic population, scientists in Estonia stressed the 
heterogeneity of Estonians as representative of the European gene pool as a whole. The 
main idea of the genome project was to set up a national gene bank in Estonia so the 
research carried out on the basis of the Gene Bank can be generalised for other 
Europeans. This was expected to not only improve Estonian health care but also bring an 
enormous benefit from the development of personalised medicine in the future. In 
addition, the genome project aimed to support the further development of existing 
biotechnology industries in the country. Compared to its Baltic neighbours, Estonia’s 
economy has grown rapidly after the country’s independence from the Soviet Union in 
1991. The country is listed as an advanced economy by international organisations and it 
has the highest GDP among former Soviet republics and the lowest ratio of government 
debt to GDP among EU countries at the end of 2010.113
The planning of the Estonian Genome Project began in March 1999. It was mainly 
developed by the Estonian Genome Foundation (EGF), a private and non-profit 
organisation founded by a group of scientists to support Estonia’s genetic research. In 
December 2000, the Estonian Parliament passed the Human Genes Research Act laying 
out ethical and security principles for the establishment and use of the Gene Bank, which 
aimed to be established during a period of five years and to collect blood samples of up to 
1 million Estonian people, with 70-80% of the participants being included during the first 
three years.114 In order to coordinate and govern the genome project, a non-profit 
institution - the Estonian Genome Project Foundation (EGPF) - was established under the 
Ministry of Social Affairs in March 2001.115 In the same year, the EGPF founded a private 
Estonian based company EGeen Ltd to form the public-private partnership between the 
foundation and the company in order to finance and commercialise the results of the 
Estonian Genome Project. As the foundation acted not only as a privacy shelter but also 
the owner of the Gene Bank, it granted EGeen a 25 years’ exclusive commercial licence 
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access to the EGP in return for EGeen’s annual payment of about 300,000 Euros to the 
EGPF and an unlimited annual profit payment of 0.5% as well as 3% of the turnover 
depending on the financial success of the EGeen Ltd.116
The EGPF and its exclusive commercial licensee EGeen Ltd, in turn, founded another 
private company EGeen International Inc (EGI Inc) registered in the United States to 
enable the involvement of private funding from international venture capital firms and 
private individuals without many regulatory restrictions.117 However, this public-private 
funding set-up lasted only for three years from 2001 until late 2004 when the contract 
between the EGeen Ltd and the EGP terminated. In fact, the contradiction between the 
EGP and the EGI Inc started from an early stage when the EGI Inc was reported to be 
dissatisfied with the way the samples were gathered by the EGI Inc and would prefer to 
have a significantly narrower approach to the Gene Bank to focus on a few specific 
diseases, so that marketable results could be delivered much sooner, which would add 
more incentives for private capital to invest in the project.118 Both EGPF and EGeen Ltd 
were reluctant to change the method of sample gathering from a broader 
population-based one to a narrower disease-based one, and since the contract was 
terminated, foreign capital flows underpinning the EGP had also stopped. Even though, 
from a scientific perspective, it is still arguable whether sample gathering on a broader 
basis would produce better scientific results in medical research, EGI Inc as venture capital 
seemed to be more interested in the short-term financial returns than the long-term 
research results and their impact on public health in general. During the contractual 
period from 2001 to 2004, EGI Inc totally financed the EGP with 4.3 million Euros while 
the funding from the public sector was little over 60 thousand Euros in 2001 for initiating 
the project and a few thousand Euros for covering the operation cost of the EGP for 
maintaining the DNA samples after the contract was terminated.119 The termination of 
the contract also meant that EGeen Ltd was no longer obligated to finance the genome 
project which had collected about 10,000 samples from Estonian participants.120
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The activity of the EGP was frozen from 2004 to 2007. During this period, several political 
debates about the future of the EGP emerged but the only related on-going substantial 
project was cooperation with Latvia about cancer prevention measures that enabled the 
EGP to collect 5,000 additional samples by the end of 2006.121 In 2007, the Estonian 
Parliament passed the Amendment of the Human Genes Research Act that provided a 
legitimate basis for the EGP to continue as a structural unit of the University of Tartu, the 
oldest public university in Estonia. The EGC was turned back into a public-funded scientific 
venture with direct funding from the state budget. In 2007, according to the State Budget 
Law, the government of Estonia financed the EGP with around 1.15 million Euros and later, 
about 7.7 million Euros of public funding was guaranteed for the years 2007-2009.122 The 
EGP had collected 13,500 samples in 2007 and expected to continue its collection to 
100,000 samples for the Gene Bank by 2010.123 The case of the EGP demonstrated that in 
the public-private partnership, when different expectations about the research benefits
occurred, the collaboration was threatened to be brought to breakdown, and that added 
many uncertainties in the development of the project. In addition, like the Icelandic 
Health Sector Database, the exclusive commercial licence created a monopoly for the use 
of scientific results that could have a potentially severe impact on the overall scientific 
and innovative environment for the country’s long-term scientific and biotech 
development. 
In order to create public support, the genome project was presented to the public by 
discourses associating with ‘Estonia’s return to Europe’ and framed as the ‘Estonian Nokia’ 
by means of technoscience and innovation to demonstrate the quality of Estonian 
biomedical development.124 Even though the passage of special legislation for the 
establishment of the Gene Bank may be viewed as a deliberate effort to create legitimacy 
for the Gene bank and mediate between science and society, it has been argued that the 
heavy involvement of private funding in the early phases of the EGP had not yet been fully 
disclosed to the public nor had it been seriously discussed in the Estonian Parliament in 
the enactment process of the Human Genes Research Act.125 According to the Act, 
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participants had the right to decide whether they would like to be informed of their 
genetic data and personalised information, but samples and data collected are the 
property of the Gene Bank.126 In addition, a special Ethics Committee composed of 
appointed members from the Supervisory Board of the EGP was legitimised by the Act, 
according to which the committee played a decisive role in evaluating the pertinence of 
the establishment of the Gene Bank and assisted in ensuring the protection of privacy and 
other rights related to research subjects in biobanking. Even though a coherent 
governance structure seemed to be created for the establishment of the EGP, the Estonian 
case illustrated that a feasible business model plays a key role, one as important as a legal 
and ethical framework for the sustainability of a biobank.
2.3.4 The Case of Tonga
The Kingdom of Tonga is an archipelago state in the South Pacific Ocean, comprising 176 
islands, about 36 of which are inhabited.127 The state has a population of 101,000 who 
are mainly descendants of Polynesians who inhabited the islands thousands of years 
ago.128 In November 2000, an Australian-based biotech company, Autogen, informed the 
Australian Stock Exchange (ASX) that it had reached an agreement with Tonga’s Ministry 
of Health to establish its own private genetic database with the population of Tonga to 
study the genes behind common diseases, such as obesity, diabetes, certain cancers and 
cardiovascular diseases. 129 According to Greg Collier, director of research and 
development of Autogen, Tonga offered a powerful resource for identifying genes 
associated with common diseases to develop disease-specific drugs as it was still 
relatively homogeneous in its genetic background.130 Under the terms of the agreement, 
Autogen would have exclusive access to the database even though samples and data 
gathered for the database remained the property of Tonga. In return for access to the 
exclusive use rights, Autogen agreed to provide annual research funding to the Ministry of 
Health in Tonga and net royalties on revenues derived from discoveries which were 
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commercialised.131Autogen would also give Tonga pharmaceutical drugs free of charge 
that were produced based on the Tonga database.132
In fact, the database project was an alliance between Autogen and a subsidiary of Merck, 
the German pharmaceutical giant, which held a 15% stake in Autogen and funded a 
six-year research project at the International Diabetes Institute located in Melbourne to 
discover genes associated with obesity and to develop new drugs for a potentially 
lucrative market as well as the diagnostic tests to predict the susceptibility of the 
disease.133 Merck was the major manufacturer of metformin, the top selling drug for the 
treatment of Type 2 diabetes, which produced sales of around 1.3 billion USD per year.134
The Melbourne-based Institute had a database established over decades which stores 
blood samples coming from many places across the world, such as Europe, China, India, 
Melanesia and Polynesia.135Autogen was also reported as a biotech company with good 
political connections as its chairman and managing director, Joseph Gutnick, was a leading 
businessman from the Australian Jewish Community and, according to media reports, a 
confidant of former prime minister of Israel, Benjamin Netanyahu, who had attended a 
forum on biotech hosted by Autogen in August 2001.136
Autogen’s agreement faced strong opposition from church and human rights groups in 
Tonga and this stalled the Tonga database project. According to Lopeti Senituli, director of 
the Tonga Human Rights and Democracy Movement, the main reason they opposed the 
Tonga proposal was because that there was no public discussion either through the media 
or in Tonga’s Legislative Assembly on the agreement.137 In addition, the Tonga National 
Council of Churches held a consultation conference on bioethics in March 2001 bringing 
together church and community leaders from the Pacific region that resolved to oppose 
conversion of life forms into corporate property through patent monopolies as it is 
“counter-productive to the interests of the people of the Pacific.”138 The consultation also 
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recognised that the ideal way to address common diseases, such as obesity and diabetes, 
was through education to change people’s dietary habits and lifestyles. Even though 
Autogen stated that it would follow the procedure of prior informed consent for its 
sample collection and the project would not involve the whole population in Tonga, such 
a statement, according to the churches, neglected the family-centred values in Tonga’s 
cultural norms and that blood samples donated from individuals would also reflect the 
extended kinship and group’s genetic makeup.139 In addition, it had been reported that 
the statements on ethics contained in the Autogen agreement were “unacceptably vague”; 
nor did they have enforcement mechanisms. 140 The economic benefits from the 
agreement were also argued to be heavily weighted in favour of Autogen, as the promised 
royalties from any invented drugs and new therapies were conditional on Autogen’s 
future revenues, but the agreement could immediately attract capital for Autogen from 
global pharmaceutical conglomerates.141
Stung by the regional opposition, the Minister of Health in Tonga denied having signed 
the agreement with Autogen and the company also stressed that it had no immediate 
interest in carrying out research in Tonga. Rather, it would put more resources into 
studying the Tasmanian population in Australia.142 However, human rights groups in 
Tonga were still concerned whether Autogen would really retreat from Tonga as the 
company had not removed its reference to the state from its website; nor had the 
Australian Stock Exchange been informed of the withdrawal of this Tonga project.143 For 
these opposition groups, the secretly negotiated agreement between Tonga and Autogen 
demonstrated that the state was prepared to cooperate with foreign commercial interests 
to sell its own resources, including the genes and genetic information of Tongan people, 
so they were concerned that other biotech and pharmaceutical companies would also 
follow Autogen’s footsteps to exploit their genetic resources and therefore it was 
necessary to advocate a more accountable government in Tonga, the Pacific’s only 
remaining monarchy.144
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The opposition groups urged the Tongan government to reconsider what Autogen offered, 
given that existing international intellectual property frameworks favoured those with the 
technology and capital but what Tongan provided was the raw materials - blood. On the 
company’s website, Autogen had already claimed 35 genes related to obesity and 
diabetes which were in different phases of patent protection. 145For Autogen, the alliance 
with the Tonga government continued the company’s growth as a world-class biotech 
enterprise, especially in the field of gene discovery, by complementing the unique 
samples from Tonga.146 In addition, the groups also called on the Tonga government to 
put in place national regulations to review any proposal like the one of Autogen before it 
could be seriously considered for Tonga. On 13 February 2002, the Tonga government 
approved the establishment of the National Health Ethics and Research Committee to 
take charge of this supervision role.147
Conclusion 
This chapter explains the notion, norms and driving forces of biobanks and introduces the 
cases of biobanks in Iceland, the UK, Estonia and Tonga to illustrate various reasons 
behind the rise and fall of biobanks and the entanglement between life sciences, politics 
and capitalism. In order to support genomics research and to capitalize on states’ genetic 
resources, many countries have joined in the global trend to set up their own national 
biobanks. Following the completion of the human genome sequence and the mapping of 
human genetic variation, biobanks have been recognised by supporting geneticists, 
governments and pharmaceutical industries as the next logical step to translate genetic 
data into clinical applications.
The four cases have illustrated that the lack of public cooperation may finally lead to great 
controversy and even failure of biobank projects. It also shows that commercialisation 
and the arrangements for consent and privacy influence the legitimacy of the 
establishment of a biobank. Since every agency involved in the creation and operation of 
biobanks comes with different expectations and interests, for instance, freedom of 
                                                     




research for scientists, protection of personal rights for participants, improvement of 
public health and the growth of bioeconomy for the states, it is essential to guarantee a 
procedure which is ethically acceptable and can create enough space for adequate public 
engagement in order to reach a balance among these different and sometimes conflicting 
interests. The cases also show that how the development of life sciences has been closely 
connected to global capital and how capital needs to be seriously considered in biobank 
governance. In Taiwan, even though its population biobank is still in an early phase of 
development, the idea of biobanks has been introduced as an international trend to 
follow that ignores various essential elements in the successful establishment and 
operation of a biobank. These examples may provide a valuable point of reference to 
Taiwan for its biobanking project and for the sustainability of a healthy biobank. 
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Chapter 3 Taiwan in the Global Bio-Economies: Biocapital Formation, 
Taiwanese DNA and Ethical Configuration
Introduction 
Since 1982, Taiwan’s government has identified the potential of biotechnology and 
systematically schemed for several large-scale programs in order to upgrade the country’s 
capacity from a manufacturing economy to a knowledge-based economy using knowledge 
resources such as technology and know-how as a tool to produce value. In addition, the 
neoliberal rationale of value accumulation dominates the state’s overall development 
policy that echoes the government’s recent ambitious plan to propose Taiwan as a “global 
operations centre.”1 By continually respecting market logics, the government is fully 
aware that in terms of better use of production factors such as capital, technology, land 
and manpower, Taiwan needs to find its own edge, especially compared to other Asian 
countries, in global competitiveness. Considering nearly 23 million people, which is 
equivalent to twice the population of Shanghai in 20102, living in a land area of 
approximately 36,000 square kilometres, two thirds of which is mountains, the 
government recognises that in order to lead the country to build its own niche on the 
global stage, it should make the most of capital and technology, since these two factors, 
compared to limited manpower and limited land resources, are relative advantages for 
Taiwan’s long-term development. 
As a distinct feature of modernity, technology has been viewed by some scholars and 
anthropologists in the field of Science and Technology Studies as a useful indicator to 
understand the process of modernisation and to interpret and reconstruct the notion of 
modernity in different regions. It can illuminate, for example, how technology has been 
projected by individual countries as a valued tool for their transformation from the 
pre-modern to the modern era. The term “modernity” thus captures a sense of 
revolutionary change when it entangles with the idea of technology. A parallel attempt 
can be found in Asian Biotech, a recent collection of several ethnographic studies on 
biotech innovations in Asia. In the book, Aihwa Ong used the term “biotech revolution” to 
introduce how Asian states make biotechnologies a “mechanism of regeneration” to 
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create a new form of knowledge, ethical configurations and value generation.3 She 
proposed that a biotech modernity seems to have emerged in some Asian regions that 
demonstrated the endeavours of Asian countries to catch up with the West when 
biotechnologies articulated not only the scientific imagination but also the nationalist 
aspirations of these modern states.4 As Charis Thompson shows in her ethnographic
studies of stem cell research in South Korea and Singapore, the hope of building a modern 
nation turns biotechnologies into state-led enterprises that are allied to the milieu of 
postcolonialism in the region in order for the former occupied countries to restore 
national identity and a competitive niche on the global stage.5  
Similarly, Michael Fischer identifies convergence across diversities by deploying 
development of science and technology in a global context in which he points out that “a 
cosmopolitical technoscientific world”6 is emerging and it is becoming ever more “diverse, 
distributed and dependent on a heterogeneity.”7 Even though for the global context, such 
as connections, networks, the flowing of expertise, materials, capital and technologies 
may be transnational, he argues that the grounded ethnographic concerns are mainly 
local and it is because of the local inputs to global assemblages8, a space has been created 
to realise the reconfiguration of social and ethical norms, politics and regulation in this 
technoscientific world. 9 Indeed, the contribution of local knowledge enriches the 
cosmopolitical world by creating a space for recognition and comparison. According to 
Ong and Fischer, such a space is an ethical terrain for which different civic 
epistemologies10 and their entangled frames on the issues of new technologies in the life 
sciences can be better understood and represented. 
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By the same token, locating a pragmatic case study under the context of cosmopolitical 
technoscience may enliven ethical and legal discussions of practical issues for biobanks. 
As a result, before directly moving into discussions with regard to ethical configurations 
on biobanking practices in Taiwan, the chapter first contextualises the role of 
biotechnologies in Taiwan’s bioeconomy in order to realise the state’s strategies in 
shaping its own niche according to the logics of cosmopolitics that is formed by both 
geopolitics and global capitalism. It then locates ethical practices with regard to 
commercialisation into the map so the issues may be addressed not only from the single 
viewpoint of biobank governance but also from a broader framework that hopes to 
contribute to a better understanding of a more dynamic and intricate entanglement with 
Taiwan’s sovereign reasons, biocapital formation, technoscientific imagination and 
collaboration of public and private entities based on which the ethical configurations 
emerge.
3.1 Biotech Aspirations and Neoliberal Logics
Taiwan’s genomics study has been embedded in the broader context of the development 
of biotechnology in Taiwan. The rationale behind it is to use this innovative scientific 
research to foster industrial applications by developing new technologies and medicines. 
Associating life sciences with engineering, biotechnology is a cross-disciplinary field 
addressing research on applied biology. The scope of biotech applications is vast including 
genetic engineering as one of its modern uses. Taiwan’s biotechnology development can 
be traced back to 1982 when the government first listed biotech as one of the eight key 
technologies to promote for Taiwan’s industry. 11 Two years later, the Ministry of 
Economic Affairs (MOEA) established the Development Centre for Biotechnology (DCB) to 
further assist in biotech research and encourage its applications. 12 Since then, 
biotechnology has been prioritised and placed at the centre of the state’s high-tech 
development plan.
For nearly 30 years, the government nurtured the biotech industry by launching national 
programmes and forming institutes to provide an amicable environment for attracting 
foreign investment. For instance, an advisory committee for promoting biotechnology 
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industry was set up under the Executive Yuan (the cabinet) in 1995. In the same year, the 
cabinet approved the “Promotion Plan for the Biotechnology Industry,” which is a road 
map document listing the nation’s development guidelines, goals, growth targets and 
needs to be revised biannually to meet the industry update.13 The plan allows the 
government to promote the biotech industry and provides bureaucratic bodies with a 
clearer direction about their action tasks. At the same time, the private sector can also 
benefit by having a better idea about the state’s prospective development strategies. 
According to the recent amendment to the guideline, the government planned to attract 
USD 4.5 billion as new investment in local pharmaceutical and biomedical companies by 
2010.14
Like many other East Asian countries, Taiwan faced the new development challenges 
brought by globalisation during the 1990s. Advance in the Internet and information
technology enhanced the division of labour across the globe. Outsourcing became a 
feasible way for firms and companies worldwide to reduce costs emerged in the process 
of manufacturing and distribution. This new economic pattern diminished the original 
competitive advantages of cheap labour costs in dragon countries and put more pressure 
on these East Asian newly industrialising economies to upgrade their local industries.15 At 
the same time, as the average product cycle had been shortened due to the overall 
market reduction, the competitive pressure from innovation and R&D became fiercer in 
the high-tech industries. 16 Developing location-specific advantages, such as human 
capital and science and technology policies, has become critical for Taiwan to transform 
itself from original equipment manufacturer (OEM) suppliers to own-brand manufacture 
(OBM).17 However, the process Taiwan relied on to upgrade its economy in the age of 
globalisation was more adaptive than revolutionary and the evolution of the state’s 
industrial policy apparatus had been understood as a path-dependent development, 
namely learning by doing.18
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3.1.1 The Developmental State and Its New Challenges
Chalmers Johnson has used the term “developmental state” to characterise fast-growing 
economies in East Asia that had followed Japan’s post-war state-led growth strategy.19
The developmental state model can be understood as an alternative capitalism, 
contrasting to the dominant model of laissez-faire capitalism. The four little dragons -
Taiwan, Hong Kong, Singapore and South Korea - were categorised by Johnson as core 
examples of the developmental state for their fast track economic growth from the 1960s 
through the 1980s.20 A developmental state can be primarily characterised by its high 
degree of state autonomy and the state’s penetration into the economy based on the idea 
of developmentalism. In this model, the state usually steers the industrialisation drive in 
order to take on developmental functions. Compared to a regulatory state, such as the 
United States, which governs the economy through regulatory agencies’enforcement of 
rules, a developmental state relies on governance through technocrats. As bureaucratic 
governmental elites are not elected officials, they are usually less subject to interest 
groups’ lobbying. It renders the technocrats more freedom and space to plan the 
economy for the state’s long-term interest without being interrupted by short-term 
political forces.
Policies formed in these developmental states usually reflect technocrats’consensus on 
developmentalism so high economic performance can be used as a way to consolidate the 
legitimacy of the governing regime. Even though local elections were instituted early in 
the 1950s, Taiwan was mainly a one party regime governed by the K.M.T. (Kuomintang, 
Nationalist) party so no genuine opposition was allowed to exist and this rendered society 
relatively inert and weak.21 The KMT’s defeat in the Chinese Civil War made the party 
more aware of the issue of class antagonism after it retreated to Taiwan in 1949. The 
party’s state-building process started from a sweeping land reform, which was already 
envisioned but failed to be implemented on the mainland until later. The influence of the 
landowners was largely curtailed after the reform so it could not form a powerful social 
group to challenge the regime. In addition, a highly penetrative state operated by the 
K.M.T was gradually established by forming networks with local factions and taking over 
                                                     
19 Chalmers Johnson, Miti and the Japanese Miracle : The Growth of Industrial Policy, 1925-1975 (Stanford 
University Press, 1982).
20 Ibid.
21 Yu-Shan Wu, "Taiwan's Developmental State: After the Economic and Political Turmoil”," Asian Survey 47, 
no. 6 (2007). P. 980
73
associations of farmers and fishermen, and the organisations representing labour and 
commerce became more state transmission belts than autonomous agencies representing 
social interests.22
Strong state autonomy is a precondition for implementing industrial policy. However, 
because the developmental state is also a modern mercantilist state, it relies on a world 
market for export expansion. In fact, the state’s capacity to export and accumulate foreign 
exchange reserves is usually taken as an important measure to evaluate its economic 
performance. As a result, technocrats need to correctly evaluate the strength of the state 
and then direct national resources to locate world market niches for locally designed 
industries. Since the 1980s, the rapid expansion of the information technology industry
has fuelled Taiwan’s export drive. This demonstrates that Taiwan’s industrial policy set 
during the 60s to 80s had been successfully linking domestic strengths with world market 
niches.23 However, the domestic democratisation in the late 80s has greatly changed the 
original structures that buttressed Taiwan’s developmental state. The impact of 
democratisation on the autonomy of the state was noticeable. Since the Parliament
(Legislative Yuan) election of 1992 and Taiwan’s first presidential election of 1996, the 
state’s developmental policies have been gradually transitioned to its electoral 
democracy.24 Even though many industrial policies are still formed through the consensus 
of technocrats, these policies need to face supervision from an emerging society and to 
satisfy various social interests.
On the other hand, globalisation has brought new challenges to Taiwan’s developmental 
state model. As the income level and labour cost of domestic economies rises, Taiwan 
needs to upgrade its industry in order to maintain its export competitiveness.25 However, 
which direction the country plans to move is no longer just a decision for technocrats. 
Rather, the allocation of national resources is now greatly influenced by the global market 
and global capitalism. Besides, Taiwan’s past experiences of following international trends 
for its industrial development may not be useful anymore. As the state has gradually 
reached manufacturing maturity, it now faces similar challenges as its forerunners, such 
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as Japan and other established core economies in North America and Western Europe, in 
designing its path ahead. As a result, in the 1990s, Taiwan faced the problem of 
designating the country’s future strategic industries. It then chose biotechnology as a 
major strategic policy for upgrading Taiwan’s economy.
Due to the government’s concentration on the development of high-tech industry, since 
the late 80s onward, Taiwan has successfully transformed itself from a traditional 
manufacturing state to a knowledge-based economy. The strong state-driven approach to 
economic growth may be found primarily in various strategic policies offering investment 
incentives, such as tax benefits, R&D subsidies and grants programmes, low interest 
preferential loans,26industrial park rent discounts (zero rent for the first two years), stock 
listing, and joint investment from the National Development Fund (NDF), etc.27 The 
National Development Fund is an investment scheme proposed by the Executive Yuan to 
encourage the private sector in Taiwan to take part in R&D and the biotech Venture 
Capital business. Announced in 2001, more than USD 0.62 billion of the development 
fund has been set aside for investment in the biotech industry.28 Even though the 
government still focuses on how much it will spend to promote industry development, it 
ignores the fact that the big environment of political economy has changed. Before the 
90s, Taiwan’s knowledge-based economy primarily concentrated on information 
technology (IT). Biotechnology did not become a strategic industry for Taiwan until the 
late 1990s. After the Democratic Progressive Party (DPP) won the presidential election in 
March 2000, in its eight years’administration, biotechnology had been regarded as the 
flagship industry for Taiwan’s future economic development. Nonetheless, because of the 
structural changes in the international market influenced by globalisation and the nature 
of the biotech industry, this strategic policy has proved problematic in its implementation 
in Taiwan.
Unlike manufacturing or previous strategic industries developed in Taiwan such as IT and 
microelectronics, biotechnology is a highly innovation-driven industry that relies heavily 
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on R&D and a long-term investment. For instance, it usually takes more than a decade 
from the innovation of a drug to the completion of several stages of clinical trials before 
the drug can be permitted for sale in the market. In order to thrive in the biotech industry, 
the government needs to provide long-term prospective plan and support rather than 
relying on traditional short-term incentives such as tax breaks and loans to motivate 
investors. Since the late 90s, the original structure supporting Taiwan’s developmental 
state has greatly changed. The autonomy of the state is increasingly limited so rather than 
penetrating into the economy as in the 60s to 80s, the state has gradually lost its capacity 
to exercise control over the market, which has been influenced by globalisation and the 
ideology of neoliberalism. 
3.1.2 Infrastructures
Since the early 90s, the pharmaceutical industries prioritise the government’s 
development agenda. Influenced by global ageing and the rise of living standards in the 
Asia Pacific region, the business opportunities of the drugs and disease-finding 
technologies has grown rapidly as a promising market prospect. In 1993, the Academia 
Sinica set up the Institute of Biomedical Science (IBMS) for fostering basic biomedical 
research. The institute later became the major executive body for the biobank project in 
Taiwan. Two years later, the Department of Health formed the National Health Research 
Institute (NHRI), a non-profit public foundation which aims at enhancement of innovative 
research in biomedical science and improvement of healthcare in Taiwan. In 1996, the 
Biotechnology & Pharmaceutical Industries Program Office was founded under the 
Ministry of Economic Affairs in order to assist promoting Taiwan as “an Asia-Pacific 
bio-manufacturing centre.”29 Later, the Department of Health set up the Centre for Drug 
Evaluation (CDE) and started to implement the Good Clinical Practice (GCP) which 
provides rules and standards for clinical trials in Taiwan.30
In addition, the government also established several science-based industrial parks. The 
coalition of the parks forms the four major “Bio Clusters” around the country. Among 
them, the cluster in Northern Taiwan mainly focuses on the biopharmaceutical industry, 
medical and clinical-trial related services.31 The investment incentives provided by the 
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industrial parks attract global and domestic biotechnology companies starting their 
enterprises in Taiwan and investing in several gene-related technologies and products, 
such as biochips, bioinformatics, new drug invention, gene diagnosis and gene therapy, 
etc.32 In terms of human resources, according to a recent governmental report, in 2008, 
there were 168 life science-related academic departments set up in Taiwan; about 8,000 
among 36,352 university graduates had a life science related background.33 In addition, 
the government launched plans for recruiting overseas Taiwanese high tech professionals 
returning back home to upgrade domestic industries and enhance international 
cooperation. A guideline prescribed by the Ministry of Economic Affairs listed the 
definition of high tech personnel, who are further classified in three detailed categories
(Levels I, II, III) based on their qualifications, academic and practical experience.34
Several laws and regulations are also enacted to help provide a friendly environment for 
biotech invention. For instance, a Statute for the Development of Biotechnology New 
Drug Industry was announced in 2007 and will be in force until the end of 2021. During 
these 15 years, the statute is expected to upgrade new domestic drug companies, to make 
them more capable of competing with their international counterparts. 35 The
government’s commitment to the protection of intellectual property rights, such as 
emphasising the implementation and enforcement of related laws and regulations, is 
expected to gain investment for Taiwan in biotech and pharmaceutical industry.36 This 
series of government actions aims to give Taiwan an edge over its competitors in the Asia 
Pacific region. With the dense Han Chinese population and a strategic geopolitical 
location - proximity to China, as a transportation hub of Northeast and Southeast Asia -
the government introduces Taiwan as an ideal “springboard” to tapping the Asian market, 
especially the greatest one in mainland China for biotechnology investment.37 However, 
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up to this point, Taiwan’s biotech industry is still in its very early development. All the 
efforts have only led to a small percentage of world biotech production. The slow 
development of biotech in Taiwan not only demonstrates the difficulty in implementing 
this strategic policy in Taiwan but also Taiwan’s gradual transformation from a 
developmental capitalist state to a neoliberal economy.
3.1.3 A Political Economy of the Human Genome Race
The idea of biobanking was regarded by the government as a way to equip Taiwan with a 
substantial niche in international biotech competition. When considering a long-term 
investment, the government hopes to look for a plan that can be positioned at the 
forefront but also satisfying domestic requirements so that Taiwan may distinguish itself 
with its own uniqueness. The project of the population biobank fits well into this 
consideration. In fact, before the emergence of the idea of biobanking, Taiwan already 
had a good start in genomics research. Due to its international political status, Taiwan was 
not able to be formally invited to join the Human Genome Project (HGP), which was 
initiated as a cross-national cooperation that the People’s Republic of China (P.R.C.) has 
been a consortium member state. However, in September 1999, when one of the 
cooperative labs based at Stanford University planned to withdraw itself from the ongoing 
sequencing work due to the heavy workload but unsatisfied progress, it started looking
for other research labs to carry on its task. The Rong-Yang Team, a genome research lab 
from Taiwan, seized this opportunity.
Set up by a group of researchers and medical geneticists from Veterans General Hospital 
and National Yang Ming University, the Rong-Yang Team is a publicly-funded joint venture 
based in Taipei. In early 2000, roughly about six months before the draft sequencing 
report was announced by the HGP, the Rong-Yang Team was informally invited to replace 
the Stanford lab and took part in this international cooperation for the task of sequencing
one part of human chromosome 4.38 In fact, what lay behind this opportunity is a 
personal relationship between the two leading scientists in charge of their research labs in 
Taipei and Palo Alto, respectively. Unlike other participators in the HGP project as formal 
consortium members, the Rong-Yang Team’s participation in the HGP is significant but 
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invisible.39 Chomsome 4 has around 200 million base pairs of which the Rong-Yang Team 
focused on sequencing a segment of around 10 million bases.40 The team successfully 
completed its task, locating over 200 genes from the bases about six weeks in advance of 
its original timetable, though it has not received due international recognition for its work 
on the HGP.41
Even though the Rong-Yang Team did not benefit much from international cooperation, its 
efforts demonstrated its capability. As gene sequencing is a tangled and repetitious 
process, it requires extreme precision to sort out useful information from a huge volume 
of repetitive data produced in the sequencing process. The scientist who was in charge of 
the sequencing work claimed that the Rong-Yang Team repeated each step ten times in 
the sequencing process for each base, so for every 100 bases sequenced by the team, 
there was only 3-5 breaks in the data, compared with a figure of 10-20 breaks sequenced 
in the United States.42 The contribution of the Rong-Yang Team to the HGP was about 3% 
of its total data that had ranked Taiwan seventh in the world in terms of its capability of 
gene sequencing and put it on a par with the contributions from other HGP consortium
member states, such as Germany and mainland China.43 Even though the data produced 
from the HGP is required to be registered internationally so it can be used as a common 
resource worldwide, subsequent discoveries of newly located genes and their association
with diseases may be privatised as the subjects of the intellectual property for patent. It 
makes biomedical research and biotechnology prospective fields of immense commercial 
opportunities. 
Despite the accomplishments made by the Rong-Yang Team, the participating scientists 
started to be concerned that the pace of research in Taiwan was slowing down and that it 
might already be losing out in the race for genomics research. A leading scientist of the 
team published an article in the China Times calling for more attention by the government 
to Taiwan’s genomics research.44 The article pointed out that the major difficulty Taiwan 
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faced with its genomics study was not due to the insufficiency of research resources but 
due to the lack of a coherent government plan. Even though the government has 
developed many strategic policies to improve Taiwan’s biotech environment, most of the 
schemes are simply task-oriented so the budgets allocated for them are only for a limited 
period of 3-5 years, not enough for basic biomedical research. In addition, because Taiwan 
was not a member of the HGP, it had limited opportunities to cooperate with other 
international consortium states. Even though the government recognised the importance 
and the necessity of developing genomics study, it did not fully realise that the timing for 
such development was extremely urgent for Taiwan as many other countries had already 
prepared well to join in this genome race.45
It is estimated that the cost of the Human Genome Project for the sequencing draft 
was at least USD 300 million. Currently the biggest project supported by the 
Taiwanese government - the Advanced Plan for Genomics Medicine and Health -
started as late as 1998 was under a budget of only NTD100 million each year. For the 
past two years, the total money the government putting into the genome sequencing 
was about USD 2 million or so. To put it simply, the effort that the government put 
into this area was too little and the speed was too slow.46 (China Times, 15 May 
2000)
The article further mentioned that even though mainland China started its race of 
genome sequencing in 1999, a few years later than Taiwan, it had equipped itself with 
over 40 cutting-edge capillary electrophoresis sequencing machines one year later in 2000
while Taiwan only had one. It showed that Taiwan was losing its original strength which 
had been built up with great efforts over the past few years.47 Scientists in Taiwan hoped 
the government would pay more attention to basic scientific research as it is a field 
demanding a long-term investment but cannot easily find a short-term return. For the 
supporting scientists, the completion of the DNA sequence has made personal genomics 
study a prospective field. However, what concerned them is the fierce competition with 
their counterparts worldwide, especially the competitive pressure caused by mainland 
China. After all, time is the most essential element in distinguishing success or failure in 





the field of genomics research.48 For instance, Shen Cheng-Yang, a professorial research 
fellow at the Institute of Biomedical Science at the Academia Sinica, Taiwan, and a 
co-principal investigator for the biobank project, mentioned his concerns on the 
cross-strait genomics race:
What I observed from mainland China is that it has already started its sample collection for a 
population biobank. If the Taiwan Biobank finally fails, it will be a big loss for Taiwan..
(because) the cost of obtaining the most suitable medicine for the Taiwanese people will be 
much higher and it also means that we still need to buy medicine designed by the Western 
clinics. If the biobank in China is successful and the medicine invented from its research is 
allowed to be patented, then Taiwan of course can use such medicine but it is not invented in 
particular for Taiwanese people and it is a pity because Taiwan is more advanced than the 
Mainland in biomedical research in terms of our experience and we have computerised our 
national population’s household registration data and health insurance data. ” (Interview 
with Shen Chen-Yang, Taipei, 2010)
The fundamental issue needs to be addressed is perhaps what kind of role Taiwan could 
play in the field of biomedical research and biotech industry in the context of global 
bio-economy. For scientists, they hoped that the government can realise Taiwan was 
dropping behind in their particular fields so related authorities can come up with a plan 
for catching up. Even though relying on government funding is an important factor for 
scientists to achieve a breakthrough, it had also been suggested that the current approach
taken by the National Science Council (NSC) - mainly providing funding for researchers 
freely carrying out their individual projects - was not an ideal strategy to support basic 
science and biotech development for Taiwan. 49 Rather, scientists hoped that the 
government could consolidate resources to concentrate on one particular area of research
and set up a clearer goal for long-term biomedical development. In addition, unlike the 
development pattern in some other countries in which investment from the industry and 
joint ventures have played an important role in biotech development, Taiwanese industry 
is rather conservative as most of them are still small-and-medium-sizes enterprises (SMEs), 
which cannot afford hugely investing in R&D.
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For government, the potential commercial interests the biobank would bring to Taiwan 
are tremendous. Taking into account that 98% of the Taiwanese population has Han 
Chinese ancestry, it is hoped that in the future, the research findings from the biobank 
can be applied to the great population of Chinese around the world. As one purpose of 
the establishment of the biobank is for reaching the goal of personalised medicine, if 
Taiwan can seize this opportunity to have an advanced position in pharmaceutical design 
for Han Chinese genes, enormous commercial returns will be expected. In the pilot study
proposal, it is also stated that the biobank can be used as a necessary “shortcut” for 
pharmaceutical and biotech companies to enter the market for medications in mainland 
China and for the development of pharmaceutics designed for Chinese people. 50
Furthermore, the biobank is expected to be able to attract funding and technology from 
multinational pharmaceutical companies that can make Taiwan’s biotech industries 
prominent in cross-strait competition and also create a tremendous business 
opportunity.51 A consultant for the biobank pilot study has mentioned that because the 
ethnic groups in Taiwan come from various areas of mainland China, the country can 
position itself as the centre for Han Chinese gene study in the world.52 In order not to 
lose this astonishing potential market, setting up a population-based biobank for Taiwan 
has been prioritised by the government in its biotech development plan.
3.2 Biocapital formation in Technoscientific Cosmopolitics
3.2.1 Geopolitical Reasons
The State has played an active role in shaping and promoting Taiwan’s biotech 
development. In the past 30 years, it adopted many strategies to make Taiwan an 
important destination for overseas investors. In addition to the endeavors made in 
building capacity and improving regulatory and human resource infrastructure as 
discussed earlier, the government proactively capitalises on Taiwan’s geographical 
location. Official reports and introductory brochures for investment in Taiwan emphasise
Taiwan’s geographic advantages: “Taiwan is located at the hub (or “heart”) of the 
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Asia-Pacific region.”53 Adjacent geographically to several large economic entities of the 
world, such as Japan (north), China (west), India and the Association of Southeast Asian 
Nations (south), the government’s strategy is to promote Taiwan as an ideal logistics 
centre for investors to make use of abundant production resources and marketplace in 
the region.54
Beyond the economic sense, however, Taiwan’s location has another significant layer of 
meaning. During the Cold War Era, Taiwan was a crucial element in the United States’
containment policy. In order to build a protective shield to maintain peace in the Pacific 
with a minimum military effort and expense, the US strategic frontier was to extend its 
power control to a chain of islands off the shores of mainland Asia so the prior allies could 
dominate air power in the region to prevent hostile aggression in the Pacific basin.55 In 
this strategy, Taiwan was viewed by the US as a critical element of this arc-shaped island 
chain as it is located at the very centre of the defensive perimeter. General MacArthur 
had compared Taiwan to an “unsinkable aircraft carrier and submarine tender”
considering that it was easier for the US air force to take off from Taiwan to the adjacent 
friendly segments of the island chain, ie., Okinawa and the Philippines, than from any 
point in continental Asia.56
Although the Cold War ended in the early 90s after the Soviet Union collapsed, the spirit 
of the cold war seems to have revived as a result of the rise of China and India. The two 
emerging major powers in Asia challenge the US dominant status during the post-Cold 
War period. Geo-strategic policies appear again in Eurasia and the Asia Pacific, although 
the new form of containment may not be simply reduced to the ideological confrontation 
of the Cold War. In his book, The Grand Chessboard, the former US national security 
advisor Zbigniev Brzezinski analysed the importance of Eurasia as a geopolitical axis. In his 
analysis, this biggest continent of the world covers two thirds of world’s population and 
75% of energy resources, including nuclear power, so a power that dominates the region 
can control the majority of economic production and initiatives.57 Interestingly, when the 
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Obama administration sought to improve US relationships with countries in Eurasia by 
taking a new Afghanistan-oriented foreign policy, China at the same time emphasises its 
cooperation with the region, for example, launching the China-Eurasia Expo 2011, a 
platform established for multi-field exchange and cooperation between China and 
Eurasia.58  
Another instance of power balance can be illustrated by China’s recent decision to tighten 
the long-term partnership with Pakistan by selling it two nuclear reactors.59 Such a 
decision was deciphered broadly as a counterweight to the cooperation between the US 
and India as the two formed a civilian nuclear deal which was approved by the US 
Congress under the Bush administration in 2008. 60 Certainly, “a new policy of 
containment”61 may not be an ideal view to see the dynamics of the emerging power in 
“the Modern World System,” in the language of Immanuel Wallerstein.62 However, the 
rise of China and India has influenced the international division of labour that inevitably
impacts on Taiwan’s economic strategies and its development policy on biotech 
industries.  
3.2.2 Mine for Gold on the East Side of the World
The release of the initial working draft sequence by both the Human Genome Project 
(HGP) and Celera Genomics has opened up various opportunities for genomic research
and the development of biotech industries. Scientists are optimistic that the data 
produced from the human genome sequence will provide new insights into inherited 
disease that may lead to innovative methods of disease prevention and genetic therapies. 
At the same time, international pharmaceutical companies and biotech venture capitals 
have also sought to explore the commercial potential of inventing new drugs. Some of 
them have tried to establish partnerships with East Asian biotech companies in order to 
expand their business maps and to mine genetic gold in the Asian region. For example, 
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Celera Genomics announced in January 2000 its acquisition of a 47.5% equity in Shanghai 
GeneCore Bio Technologies Co., Ltd. which was formerly held by Axys Pharmaceuticals.63
Shanghai GeneCore is a genomics service company selling products of DNA sequencing, 
mutation detection, nucleotide synthesis and bioinformatics analysis.64 Celera hopes the 
acquisition can help expand its genomic information globally as Shanghai GeneCore has 
established a large customer base in China and has collaborations with several Chinese 
government agencies.65 For Celera, building a partnership in China means it would have 
access to an abundant resources of genetic diversity located in the region. On the other 
hand, for GeneCore, using the information and software capability provided from Celera is 
expected to have a significant impact on its genomics research pace. Both parties 
anticipate having certain benefits from the collaboration. 
In Taiwan, there is a similar but slightly different story. A new Taiwanese genomics 
company - Vita Genomics, Inc. - was launched and opened its office in Taipei in March 
2001. The company aims to study the patterns of single-nucleotide polymorphisms (SNPs, 
pronounced snip)66 among East Asians and hopes to find the genes related to diseases 
common among people in the region so it would have new insights into drug responses in 
East Asian populations. In order to reach the goal, the company’s first step is to compile a 
database that includes disease-relevant SNPs prevalent in Asian populations.67 Such a 
database is expected to help researchers to improve drug efficacy as they believe genetic 
variability may have an influence on adverse drug reaction since some diseases are 
reportedly more common among Asians than among Caucasusians.68
In order to achieve this ambitious goal, Vita Genomics plans to first explore genes related 
to diseases common to people in Taiwan and China, such as hepatitis, asthma and some 
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forms of cancers like oral, liver and nasal.69 The CEO and founder of the company, Ellson 
Chen, had commented: “Almost every race you find in China you can find somewhere in 
Taiwan, so I thought this was a good place where it is not that big and difficult to handle 
as China.”70 Ellson Chen, born and educated in Taiwan,71 was a former principal scientist 
at Celera Genomics. Before moving back to Taiwan, he was involved in sequencing the 
human genetic code during his time at Celera and his lab had built Celera the famous 
sequencer, which made this private company able to compete with the publicly-funded 
Human Genome Project in the sequence race.72  
When Ellson Chen worked at Celera Genomics, the company was still part of Perkin-Elmer 
(PE) Corporation, which later changed its name to Applera Corporation. The name 
Applera refers to a combination of the company’s two operating groups and business 
models - the Applied Biosystems Group and the Celera Genomics Group.73 The former 
was responsible for manufacturing machines and therefore it provided tools and 
instruments by developing new sequencers; the latter, Celera Genomics, was formed 
mainly as a way to market the sequencer invented by the former. When the new 
sequencer was successfully invented in 1998, Applera decided that rather than sell this 
new tool to the Human Genome Project, it would be better to use the technology to 
sequence the genetic code by itself. As a result, Applera formed Celera Genomics with an 
investment of USD 300 million that was equivalent to selling 1,000 units of the new 
sequencer at USD 300,000 each and then the company successfully approached its 
balance of investment within a year by selling the new machine to the Human Genome 
Project.74
Although the business strategy was successful it was not sustainable due to the increasing 
criticism of Celera Genomics’ intention to propertise and commercialise the human 
genomic information. The shotgun method applied by Celera led to a rapid acceleration 
of the sequencing efforts used by the HGP, which was officially initiated in 1990 and was 
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originally planning to complete the genome sequence within 15 years with a total budget 
of USD 3 billion.75 Even though the private company Celera Genomics may be able to 
complete genetic code sequencing much earlier than the Human Genome Project and 
cost only a fraction of the HGP, critics claimed that when Celera started its sequencing 
race, a large portion of the human genome had already been sequenced and published 
by the HGP at its freely accessible database - GenBank. Therefore, Celera had benefited 
from the public information with no extra costs. Scientists were also concerned that 
privatizing human genomic data for commercial exploitation would hinder scientific 
progress in the end, and for that reason they urged the US and UK governments to get 
involved in the process of mediation and to persuade Celera to give up its intention to 
privatize the human genome. The initial working draft sequence was finally released by 
both the HGP and Celera in February 2001. It illustrated the triumph of public efforts and 
the prevailing view that the human genome should be treated as a public resource and a 
common good.76
On the other hand, in order to dig for gold on the East side of the world, Celera Genomics 
considered addressing the needs of Asian countries. Its management team initiated a 
project with the code name Celera Asia and thought of the possibilities to make the 
project a fully owned subsidiary of Celera.77 Ellson Chen was then a representative of 
Celera so he travelled extensively in East Asia to seek for the right environment to set up a 
regional company. However, rather than establishing a fully owned subsidiary for Celera, 
Ellson Chen finally split out with an agreement with Celera’s management team to form 
his own company - Vita Genomics - in Taiwan, in which Celera held only 5 % shares but 
was still a strategic partner. In a newspaper interview, Chen emphasised the importance 
to have local people and local officials’ acceptance of a biotech company of this 
magnitude to make it successful. He called it “local input” and viewed this element as 
significant for a biotech company to adopt changes.78 Ellson Chen explained the term 
using a practical case of Celera’s subsidiary in China. He then concluded that seeking 
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partner collaboration in East Asia would be more appropriate for a global biotech 
company like Celera Genomics to expand its business in the East since it may prevent local 
countries from viewing the foreign company as an invader similar to delivering democratic 
values from an “enemy nation.”79
3.2.3 Localisation of Genomics Research
Compared to China, Taiwan’s liberal political milieu and stronger protection of intellectual 
property provides Vita Genomics with a friendlier environment for investment. In addition, 
the company can easily establish local collaborations with other biotech industries as well 
as public academia and research institutes in Taiwan. However, among all of these stated 
advantages, the most helpful one is the enthusiastic attitude from the Taiwanese 
government. Ellson Chen’s idea to form a company to secure Taiwan’s place on the global 
biotech stage echoes the government’s development plan to use biotech industries to 
upgrade its economy and boost Taiwan’s international competitiveness. For that reason, 
fundraising in Taiwan was relatively easier than in other countries of East Asia. Back in 
1996, Taiwan’s Ministry of Economic Affair (MOEA) had established a specific office to 
promote the development of biotech and pharmaceutical industries in Taiwan that aimed 
to promote the country as an “Asia-Pacific bio-manufacturing centre.”80 A year later, a 
five-year investment plan with a budget of NTD 20 billion (about USD 600 million) was 
promulgated from the Executive Yuan’s Development Fund in order to help biotech 
industries carry out R&D research.81 Facing the emerging economic power of China and 
India, Taiwan’s government had planned to use biotech industries to move from a centre 
of manufacturing to an operations centre focusing more on R&D and invention so Taiwan 
may keep its competitive advantage compared with the two emerging powers, both of 
which have surplus population to provide cheaper labour. 
With its management and business centre in Taipei but main lab located in the Tainan 
Scientific Industrial Park in southern Taiwan, Vita Genomics planned to recruit up to 40 
employees in the first year of its operation and then expanded its personnel to 100 a year 
after.82 Its estimated corporate capital is about NTD 3.5 billon (about USD 100 million) 
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and almost half of the amount had been secured when the company was launched in 
March 2001.83 During that time, most Asian countries had not yet completely recovered 
from the Asian Financial Crisis of 1997 so the successful capital recruitment for Vita 
illustrated Taiwan’s optimistic attitudes toward biotech industries, especially about 
genomics research and its related services.84 Many high profile officials attended the 
company’s launching ceremony, including Taiwan’s Minister of Economics and the 
president of the Academia Sinica. It symbolised an anticipated collaboration between 
industries, government and academic institutes in Taiwan. However, on the other hand, it 
preluded a more intricate and complicated entanglement of public and private sectors in 
Taiwan’s biotech development.
Since the company launch, Vita Genomics has been promulgated by the government as a 
successful start-up to attract more overseas Taiwanese experts returning home to bring 
back capital and technology. Many Taiwan-born scientists like Ellson Chen had been 
working overseas for more than two decades. They usually went abroad for a higher 
education after finishing their bachelor degrees in Taiwan and then stayed abroad to work 
until they established their own niches overseas. These professionals have been 
important agents of reconnecting Taiwan to international development trends. However, 
such knowledge and know-how transplants are sometimes at the risk of one-way 
transmission and it can mean that the needs of the local society may not be easily fed 
back. Such a gap usually becomes wider if these agents have been absent from Taiwan
during the period of its most dynamic social transformation. As Taiwan was under martial 
law for a long period from 1947 to 1987 and its presidential direct election had not been 
possible until 1996, Taiwan’s society has experienced a dramatic transition from an 
authoritarian regime to democracy. Without recognising this important context, it would 
not be easy to grasp the civic epistemology behind Taiwan’s biotechnologies and biotech 
policies.
In 2003, the government listed the biotech industry in its Two Trillion and Twin Stars 
programme85 and about a year later, the idea of “Biomedical Technology Island Plan” was 
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born, in which building up a biobank for Taiwan was formally proposed by the 
government. Ellson Chen of Vita Genomics was appointed as a consultant for the Taiwan 
Biobank Preparatory Office. However, the biobank pilot study had experienced an 
unexpected delay since the project commenced. This prolonged delay involving intricate 
ethical review procedures illustrates the situation the biobank study faced in Taiwan. In 
addition, the social resistance to a technocratic scientific plan represents a kind of “local 
input” from Taiwan that may have been out of Ellson Chen’s original consideration when 
he decided to return back to establish his Vita Genomics due to the Taiwanese 
government’s full support. 
In order to put Taiwan on the global biotech map, Vita Genomics was keen to establish 
partnerships with public research institutes and academic R&D centres in Taiwan as Chen 
believed such collaboration would save a great amount of time and capital for his 
company to reach its goal. Both Academia Sinica and the National Health Research 
Institutes (NHRI) were potential partners of interest to Vita Genomics. The NHRI, a 
non-profit foundation, was established by the government in 1995 in order to improve 
health care in Taiwan. It carries out research on basic biomedical science, including 
developing drugs for several of Taiwan’s common diseases. In a print media interview, 
Ellson Chen expressed his interest in collaborating with the NHRI as it had worked on 
some of the diseases that Vita might have a sight on.86 For example, the NHRI had been 
developing a medicine treating Hepatocellular carcinoma, which has a high incidence 
especially in East Asia due to the prevalence of chronic hepatitis B in the region but not 
enough attention had been paid by global pharmaceutical companies to it.87
Since hepatoma is very common in China, it is believed that the potential consumer for 
the drug is nearly 350 million people in Asia.88 In 2001, the drug invented by the NHRI 
was already in the process of clinical trials and it was expected by the institute to finalise 
the medication within 5 years but Ellson Chen believed that if Vita Genomics joined in the 
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finalisation, it would be able to shorten the process.89 It is a similar market logic to the 
one followed when privately-owned Celera Genomics jumped in at a later stage to 
compete with the publicly-funded HGP in the human genome sequence. However, the 
most difficult part of this kind of “collaboration” is not only about how to split up the 
workload but also how to make a fair share arrangement if there are any profits when the 
drug is finally patented and marketed. For a biotech start-up like Vita Genomics, one of its 
goals is to seek to identify biomarkers and new drug targets and obtain intellectual 
property in order to sell it to major pharmaceutical firms for mass production.90 A 
profit-driven logic like this is in conflict with views supporting the common good although 
the boundary between public and private gets blurred when the collaboration between 
industries and public research and academic institutes becomes more and more common 
in Taiwan. 
3.2.4  The Implementation of Neoliberalism
In order to connect upstream R&D with downstream product manufacturing, the 
government has improved Taiwan’s regulatory infrastructure to foster the biotech industry. 
In 1999, the Legislative Yuan passed the Fundamental Science and Technology Act that is 
similar to the Bayh-Dole Act passed by US Congress in 1980 which allows the transfer of 
intellectual property rights from the government to private industries. According to the 
Act, the IP rights derived from a scientific and technological project which is funded, 
subsidised or commissioned by the government may now be retained by implementing 
research institutes. This precludes the application of the National Property Act under 
which the IP rights would be treated as national property.91 As a result, publicly-funded 
research institutes can transfer their technology to industries for commercialisation of 
their research results. In addition, the Act requires the government to formulate 
development plans for science and technology every four years and such plans need to be 
discussed in the National Science and Technology Conference held by the Executive 
Yuan.92 The plans approved through the conference will become national policy for 
implementation. In 2006, the Executive Yuan amended another regulation which clearly 
states that the ownership of publicly-funded research results belongs to the implementing
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institutes although its transfer to a third party needs to be approved by the funding 
agency.93
In June 2007, Taiwan passed the Biotech and New Pharmaceutical Development Act 
aimed at helping to promote biotech and new pharmaceutical industries for the country’s 
economic transition. The Act, effective for 15 years until the end of 2021, provides many 
incentives such as tax benefits for the industries for a total of five years. It plans to 
strengthen Taiwan’s biotech market, which has been growing since 2000 due to the 
government’s full support. According to statistics, from 2002 to 2007, the government’s 
annual investment in the pharmaceutical industry had risen from less than USD 300 
million to almost USD 700 million, and the average growth for the biotech and biomedical 
market was 13%.94 In addition to the tax relief, another major change the Act brings is to 
open another possibility for collaboration of public and private sectors. According to the 
Act, with the permission of the original employer, certain researchers in government 
research institutes, such as the Academia Sinica, are now allowed to help privately-owned 
industries with R&D by serving as founders, executives or acting as consultants to private 
companies.95
In an interview with Nature News, the president of the Academia Sinica, Wong Chi-Huey, 
optimistically predicted that with the help of the Act, Taiwan will have at least 5% of the 
world biotech market within 10 years.96 The Academia Sinica is Taiwan’s top academic 
institution, originally established in mainland China in 1928, and then relocated and 
reestablished in Taipei in 1954. Like Ellson Chen of Vita Genomics, Wong had been 
working in the United States for nearly 30 years before he returned back to take over 
Taiwan’s most eminent research institute in 2006. Wong’s previous experiences as a 
professor of Chemistry at the Scripps Research Institute at San Diego and also a 
co-founder of Optimer Pharmaceuticals made him keen on helping the government 
establish its biotech industry. His message introducing Academia Sinica on its official 
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website shows an increasing commitment by the institution to strengthen the 
cooperation between research and industry by “assuring the protection of intellectual 
property rights, encouraging patent applications, increasing technology transfer, and 
holding joint conferences on research achievements with other domestic research 
institutions.”97
The 1928 established institution, which had been expected to act as an opinion leader in 
the society98 has gradually been transformed to an agency of neoliberalism. The 
Institution was extended rapidly during the term of its former president Lee Yuan-Tseh, 
who is the first Taiwanese Nobel Prise laureate and is also a chemist. Lee served at the 
Academia Sinica for 12 years from 1994 to 2006 during the period when life science and 
genomic research had witnessed a revolutionary development on a global scale. When 
the human genome sequence draft was released, Lee thought that so long as Taiwan 
could take this opportunity to start its life science research and enter the field at the right 
time, it would be able to catch up with this international trend in genomics research.99 At 
the launching event of Vita Genomics, Lee re-emphasised the importance for Taiwan to 
keep up with the international genomics research standard and it would have to be done 
as soon as possible due to insufficient funding up to that point of Taiwan’s R&D.100 In 
order to rapidly integrate resources to improve Taiwan’s life science research platform, 
Lee helped found the Genomic Research Centre at the Academia Sinica in January 2003. 
In addition to emphasis on understanding genomic functions and developing therapeutic
strategies, the centre established a Bio-tech incubator for the purpose of pursuing 
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technology transfer in order to help advance the development of Taiwan’s biotech 
industry.101
A year before the Genomic Research Centre was set up, the National Science Council 
launched a National Research Programme for Genome Medicine (NRPGM). The industry 
and academic collaboration was one of the major parts of this national priority project. 
The Programme was directed by two Academicians and its research division focused on 
disease-oriented topics dedicated to Taiwan’s common diseases, such as lung and liver 
cancers and some highly heritable diseases with a hope to add to Taiwan’s competitive 
edge.102 As Taiwan has a small domestic market compared to China, it is important for it 
to strategically integrate resources among government, industry and academics. Although 
its biotech development had not yet started until the late 90s, the government 
optimistically thought that Taiwan’s previous success in information and computer 
technologies would be able to help with biotech growth. What needed to be done 
immediately is to improve Taiwan’s research capacity, for example to build up 
infrastructure such as a biobank for research and for boosting Taiwan’s biotech and 
pharmaceutical industry. This idea is especially welcomed by a start-up company like Vita 
Genomics as it may save a great amount of capital to establish its own genetic database 
but can still access to crucial data for its research purpose. Also, the company may rely on 
government’s credibility to avoid the difficulties in collecting samples if it had to form its 
own biobank. 
3.3 Governmentality and Biosovereignty
Although the biotech and pharmaceutical industry has a cosmopolitical character, some 
Asian countries have used their sovereign powers to protect their bioresources from being 
consumed by global market forces. An emerging “biosovereignty” seems to have 
challenged the global biotech thinking and practices dominated by Western interests.103
Taking China as an example, it adopts a more rigorous attitude than India toward
international scientific collaborations with global pharmaceutical companies in order to 
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protect Chinese genetic materials from piracy and unauthorised use.104 Moreover, in 
seeking overseas collaborations, China inclines to establish partnerships with overseas 
Chinese experts. It shows “an explicit norm of ethnic trust” which has made genomics 
manifest a deeper layer of meaning of nationalism and its territoriality.105 Similarly, in 
Paul Rabinow’s French DNA, he shows how the civic epistemologies of France as to the 
inseparability of body and personhood caused the failure of scientific collaborative efforts 
with an American biotech start-up in order to prevent French DNA being profited from 
Americans.106 Indeed, through technological intervention, life itself has created a new 
space for exclusive ownership and commercialisation.107 For a nation state, genomics
research reinforces the concept of sovereignty that forms a new kind of identity based on 
biological facts. 
By further extending Rabinow’s notion of biosociality,108 Wen-Chin Sung used the 
concept of “bionation” to examine how China adopts genomic research to recapitulate 
the notion of Chinese ethnicity in order to engage in debates over sovereignty with its 
fifty-six nationalities (“minzu”) and with Taiwan and Tibet.109 The concept of Chinese DNA
shows the “imagined communities”110 have been consolidated through the introduction 
of genomics that contributes to the discourses and practices of China’s ethnopolitical 
narratives as “unity in diversity.”111 It also illustrates how science may help form a new 
identity that makes room for the power of sovereignty to assert its will. China’s story 
demonstrates not only how politics can be scientific but also how science can be political; 
as Bruno Latour argues, science and politics are fully intertwined in the process of 
knowledge production.112 Paradoxically, even though claiming the solidarity of the state, 
China skilfully views its various ethnicities as national treasure and has utilised its 
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abundant genetic resources to build a modern nation in terms of adding its 
competitiveness in the global biotech industry and pharmaceutical markets. 
3.3.1 Taiwanese DNA
Compared to China, Taiwan’s attempt to relate biological identity to national building 
seems to be much trickier. Jennifer Liu argued in her article “Making Taiwanese” that 
some scientists of Taiwan had turned stem cell and genetics research into vehicles to help 
define a “distinctive Taiwanese ethnicity” as opposed to Han Chinese.113 The main 
purpose of doing so is to counterbalance China’s discourse of making sovereign unity out 
of ethnicity. For example, a study suggested that Taiwanese aborigines are genetically 
linked to Maori in New Zealand and over centuries of interbreeding between the 
aborigines and Han immigrants had contributed the Taiwanese genome of aboriginal 
mixture that may further differentiate the people of Taiwan from Han Chinese.114 Even 
though only 2% of the Taiwanese population comes from the group of Taiwanese 
aborigines, this ethnic group has turned into a specific research target in terms of its 
genetic traits, which are relatively unique compared with most of the Han Chinese gene 
pool that covers 98% of the population in Taiwan. The original inclusion of aborigines in 
the population biobank provides an opportunity to form discourses on the uniqueness of 
Taiwanese DNA. A geneticist in Taiwan has even suggested that the genetic variant 
HLA-B46 may have caused susceptibility to the SARS virus and because Taiwanese 
aborigines do not have this kind of genes, no aborigines are reported to have suffered
from the epidemic of SARS when the disease was prevalent in Southeast China.115
The biobank story in Taiwan shows the entanglement of identity configuration, sovereign 
reasons and governmentality within the context of biocapital formation. The biobank 
initiative enhances the formation of identity that makes people of Taiwan a distinct 
category for scientific research. When addressing the importance of setting up a biobank 
with Taiwanese genetic characteristics, the supporting scientists emphasised the project 
will ensure the people of Taiwan not be excluded in the therapeutic promise of 
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personalised medicine. Wu Chen-Wen, the founder of the National Health Research
Institute, had commented Taiwan needs to have its own genetic database to study 
diseases common to people in the region so it will help Taiwan develop suitable medicines 
for the diseases that might have been ignored by Western markets.116 In an Academician
Conference held by the Academia Sinica in 2000, Academician Tsuang Ming-Tseh 
proposed to build up a population-based genetic database for Taiwan to collect genetic
samples from Hoklo, Hakka and Aborigines according to the relative proportion of their 
population in the country.117
These narratives suggested that a category of ethnicity which presupposed a genetic 
distinction has been adopted by scientists and may have existed before any new genetic 
studies were embarked upon. At the same time, it reflects the logic of population genetics 
adopted by the Taiwan Biobank project, namely to infer degrees of relatedness among 
populations by comparing their genetic markers with the hypothesis presupposing that an 
individual within a population is more compatible genetically with other individuals from 
the same population than with individuals from different populations. However, as 
categories may not be ontological, they do not necessarily reflect distinctions among 
groups but are often reflective of power and knowledge for which the categories 
themselves are invented.118 As it has been rightly pointed out, scientific categories used 
by Taiwanese scientists for genetics and stem cell research are determined largely by 
historical and cultural ways of reckoning identity; as a result, the categories themselves 
require examination.119
Since “Taiwanese” is not a stable designator, in order to collect samples which can better 
represent the genetic compositions of all the people in Taiwan, the original research
design for biobank’s population sampling followed the four ethnic categories of Hakka, 
Hoklo, Mainlander and Taiwanese Aborigine. As both Hakka and Hoklo, referring to the 
offspring of the earlier immigrants coming to Taiwan about 400 years ago mainly from 
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Fujian and Guangdong provinces, can be viewed as dialect groups from Southern China
and the category of mainlander which refers to the group who migrated from mainland 
China to Taiwan after the Chinese Civil War in 1949 and their descendants who are born 
and raised in Taiwan, such categories are not completely biological. 
In fact, the slogan of the “four great ethnicities” was first proposed by a legislator 
candidate during one of Taiwan’s electoral campaigns in the early 90s. The primary goal of 
the category was to converge a fragmented society due to the political confrontation 
between local Taiwanese and mainlanders in Taiwan’s ethnopolitics. Since then, the four 
categories have been used as a common description of Taiwan’s ethnicities. Nevertheless, 
the original inclusion of aborigines into the scheme shows that not only different 
languages, social structures, or even migration times may constitute ethnicities in Taiwan, 
but also biological appearance, skin colours and body figure, which are what physical
anthropologists have mainly used to identify the components of ethnicity. Although some 
genetics research may hope to substantiate a scientific basis to claim that there is
Taiwanese DNA which can be distinguished from Chinese genetic composition, a question 
as to whether and how Taiwanese are Chinese depends on which categories have been 
used in differentiation. Are they cultural, biological, national or political? The complicated 
naming practices make Taiwan Biobank a useful prism to observe the entanglement of 
identity formation within the biopolitical and biocapital context of Taiwan.
Interestingly, for the biotech and pharmaceutical industry, Taiwanese DNA may be viewed 
as a concentration of genetic variations of fifty-six ethnicities in China. As the main 
purpose of the biobank plan is for personalised and tailored medicine, if Taiwan can take 
an advanced position in pharmaceutical design for Chinese genes, great potential 
commercial benefits will be expected. As Ellson Chen of Vita Genomics has mentioned, 
because Taiwanese ethnicity comes from various areas of mainland China, Taiwan can 
position itself as the centre for Chinese gene study in the world. In order not to lose this
opportunity and the potential market, setting up a national biobank for Taiwan has been a 
priority for the government that is also promoted, welcomed and greatly supported by 
the industry. Interestingly, even though the biobank was planned to back up personalised 
medicine targeting Chinese and Asian populations, it needed to call for Taiwanese 
people’s participation and support. In addition, under the administration of the
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Democratic Progressive Party (DPP), “localisation” had become a trend for reviving 
Taiwanese identity, which was deemed to have been suppressed for the past 50 years 
under authoritarian rule. Since the transfer of political power in 2000, the term “Taiwan” 
was used much more frequently than its official name the “Republic of China (R.O.C.)” in 
various official and governmental documents. In this milieu, the project was also given 
the name “Taiwan Biobank” to justify its local characteristics. 
While it might be an unconscious choice, a subtle signal of the identity influence appears. 
After the name “Taiwan Biobank” was given, all the advertisements of the project revolve 
around Taiwan and the Taiwanese population only. The concept of the four ethnic groups
was proposed for population sampling but neither the Han Chinese nor the Taiwanese 
aborigines has been singled out in the project as a special gene pool for study. The 
Taiwanese aborigines as a key minority group have played an important role in all of these 
identity debates. They stand out as unique in order to satisfy the requirement of local 
characteristics. However, the aborigines hope to call more attention to their own 
characteristics and the practical issues that are relevant to aboriginal health conditions at 
present.120 What matters for the Taiwanese aborigines is not only whether the biobank 
will bring any promising results in terms of improving their public health environment but 
also whether they are well considered in the whole research design. Paradoxically, even 
though obtaining knowledge of the genetic makeup of Taiwanese aborigines is an 
important component of biopolitics, the biobank plans to act as an ethnic melting pot 
that may form a Taiwanese identity transcending ethnicities, kinship and ethnopolitical 
divisions. According to a scholar in charge of the ELSI group of the biobank project, the 
biobank is expected to create a new form of identity that is not necessarily based on 
scientific facts but also on participants’voluntary actions which contribute to a sense of 
solidarity for citizens’future needs. 
3.3.2 Biosafety
The desire to ensure the Taiwanese population as a whole is included in the therapeutic
promise of personalised medicine calls for a further biopolitical analysis. The biobank 
project funded by the Department of Health aims at identifying Taiwanese genetic 
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Interviews with Taiwanese aborigines in Hualine, Taiwan, 2010. 
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makeup for drug targets of therapeutic purposes, which served a basis for the 
government to form policies of health, bioeconomy and biotech industry for Taiwan. This 
governance of population is a product of scientific governmentality that substantiates 
Foucault’s biopolitics to promote forms of life by noncoercive exercises of power in 
modern states.121 From this angle, the biobank project may be considered as an 
execution of biopower although the mode of the power is distinct due to its connection 
with new genomic knowledge and its entanglement with global pharmaceutical 
biocapitalism. At the same time, the project provides an opportunity to scrutinise how a 
new genomic technology like a biobank is able to be used by sovereign reason to govern 
its population.
On the other hand, even under the significant influence of global biocapitalism, the 
biobank initiative in Taiwan may not be simply reduced to a commercial undertaking. In 
fact, genomics research has been viewed by the government as a way to provide 
biosecurity and reconnect Taiwan to its long absent international health management 
system. Taking the outbreak of severe acute respiratory syndrome (SARS) as an example, 
the spread of the SARS epidemic created a sense of crisis of health in Taiwan. However, 
Taiwan was forbidden to participate in the World Health Organisation (WHO) due to 
Beijing’s insistence. Despite timely reporting of the situation to WHO during the 
prevalence of the SARS epidemic, Taiwan did not receive any official advice and assistance
from the international system. The lack of efficient communication with the WHO caused 
delay in the handling of the disease. Taiwan’s failure to argue for its own seat in the WHO
unfavourably excludes Taiwan from the mechanism of global public health monitor that 
triggers the government’s awareness to safeguard the life of the nation. From this 
viewpoint, life science and the biotech industry have become the solution for Taiwan to
the threat of the rise of China as both an emerging economic power and a military and 
health policy’s deterrence. Becoming a biotech operating centre in East Asia seems to be 
a geopolitical strategy for Taiwan to redefine its distinct identity on the global stage. A 
biobank for Taiwan substantiates the notion of Taiwanese DNA as it echoes the 
government’s enthusiasm to raise Taiwan’s international visibility and it shows that citing 
Taiwanese genetic uniqueness has both scientific and political significance. Furthermore, 
                                                     
121 More information about the notion of biopolitics, See, Michel Foucault, ed. Governmentality, vol. 3 
Power, Essential Works of Foucault, 1954-1984 (New York: New York Press,1994).
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under the Democratic Progressive Party (DPP)’s national building discourses, putting the 
country’s interests in the forefront means exercising name rectification, namely using 
“Taiwan” instead of the “Republic of China” to bring the country necessary international
attention. 
In order to better understand these complicated naming practices, it would be helpful to 
zoom back again to geopolitics in the Asia Pacific. Taiwan has been a “hot” issue even 
during the Cold War period. The Sino-American Mutual Defence Treaty signed in 1954 
between the United States and the Republic of China (R.O.C.) government was a part of 
the US containment policy against the People’s Republic of China (P.R.C.) led by the 
Chinese Communist Party, which won in the Chinese Civil War on mainland China in 1949. 
After the Civil War, the R.O.C. government led by the Chinese Nationalist Party 
(Kuomintang, the KMT) under the rule of Chiang Kai-shek retreated with troops and civil 
officials from mainland China to Taiwan. However, even though the R.O.C. Constitution
went into effect in 1947, it was later suspended by martial law and therefore it had not 
been applied to the region of Taiwan until 1987 when martial law was lifted. For that 
reason, despite being known in the West as a “free China” in contrast to the “Red China”
ruled by the Communist party in the mainland, the Republic of China on Taiwan was 
under martial law and was in fact a single party state from 1947 until 1987. 
Even though retreating to Taiwan, Chiang continued to claim sovereignty over the 
mainland of China according to the constitution and claimed that the R.O.C. government 
was the only legitimate government of the whole of China. This position had been 
recognised by the West and the United Nations until 1971 when the R.O.C. government 
finally withdrew from its U.N. China seat as a result of a gradual loss of international 
support for the R.O.C. statehood. The withdrawal from the United Nations was a historic 
turning point for Taiwan as it led to the country’s subsequent isolation from the 
international system and has had significant impacts on Taiwan’s foreign relations and its 
domestic politics.  
In 1979, the US Congress passed the Taiwan Relations Act by which the US recognised an 
unofficial relationship with Taiwan, namely establishing government-to-government 
interaction (in contrast to state- to- state) as a result of its normalised relations with 
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Beijing. A year later, the Mutual Defence Treaty signed with the United States was 
terminated unilaterally by the Carter administration. Since 1979, the US-Taiwan has 
maintained a de facto diplomatic relationship. Such an unofficial diplomatic model later 
became the major means for Taiwan to establish its relations with other foreign countries 
as a result of Beijing’s insistence on its “One China Principle” and use of it as a diplomatic 
strategy to suppress Taiwan’s international space. The One China principle proposed by 
Beijing asserted that there is only one China and that Taiwan is a part of China. This 
principle is different from the so called “One China Policy” which was formalised in the 
1992 Consensus. The policy refers to the consensus between the R.O.C and the P.R.C. 
governments that there is only one China, one sovereign state called China that 
encompass the territories of both mainland China and Taiwan, even though there are two 
existing governments claiming to be the legitimate representative of the whole of China. 
For the R.O.C. government, for example, the One China refers to the Republic of China, 
which was founded by Dr. Sun Yat-Sen in 1912 after overthrowing the Qing Dynasty in the 
Xinhai Revolution, and it continues to exist on the island of Taiwan. Because the K.M.T 
government has not yet formally recognised the legitimacy of the People’s Republic of 
China established by Mao Zedong in 1949 after the end of the Chinese Civil War, it has 
aroused an increasing identity crisis in Taiwan as the government needs to face domestic 
challenges for its ruling legitimacy, especially after it withdrew from the United Nations.
In 1986, the first opposition party - the Democratic Progressive Party (DPP) - was 
established in Taiwan. It supports Taiwan’s independence as a separate country, a 
sovereign state separate from the territory of China. According to the DPP, claiming 
Taiwan’s official name as the Republic of China has prevented Taiwan from participating in 
the international system and this produces no benefits to the people of Taiwan. As a 
result, the DPP supporters have been demanding name rectification for the country. For 
example, they called for a referendum to use the name of “Taiwan” to apply for 
membership of the United Nations in order to avoid UN General Assembly Resolution 
2758, which was passed in 1971 and recognised the PRC as the sole legitimate 
representative of the China seat in the UN.122 The referendum was held by the DPP 
administration in 2007 under DPP President Chen Shui-bian. Chen won the 10th term’s 
                                                     
122 It includes both the seat in the UN General Assembly and the membership of the United Nationals 
Security Council.
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Presidential election in 2000 because of the split of the KMT party and it was the second 
direct election for the President of the Republic of China on Taiwan since prior to 1996 the 
presidency of the R.O.C. had been elected by the National Assembly. 
The referendum proposed by the DPP administration caused tension across the Taiwan 
Straits as Beijing viewed it as a preliminary action for Taiwan’s independence by planning
to change the state’s name from the “Republic of China” to “Taiwan”. The Chen 
administration explained the necessity of the referendum as only to deepen Taiwan’s 
identity and promote the recognition of Taiwanese statehood by the international 
community. However, the DPP had also been severely criticised for using the referendum
as a way to help its party win domestic elections and to affect political campaigns by 
creating a wave of Taiwanese nationalist sentiment.123 In order to oppose the DPP 
referendum, the KMT proposed another version of referendum emphasising that its 
standing is to make the country “re-join” the United Nations rather than apply for a new 
membership in the UN with the name of “Taiwan.” For the KMT, the “Republic of China on 
Taiwan” has undoubtedly been an independent sovereign state from the P.R.C. regime so 
the main issue for the party turns out to be how to maintain the status quo in the Taiwan 
Straits for the best interests of people in Taiwan. The KMT views the name rectification 
and formulation of a new constitution as impractical and especially not moderate at the 
current stage since it would threaten and destabilise peace in the Western Pacific, breach 
mutual trust in the Taipei-Washington relationship and finally damage Taiwan’s credibility 
in East Asia as a responsible citizen. Nevertheless, the DPP administration considered a 
referendum to be a pragmatic and necessary way to increase Taiwan’s international 
visibility. 
On the other hand, since Beijing never gives up the threat of armed force to solve the 
issue over the Taiwan Straits if Taiwan claims independence, the DPP’s strategy for 
national security is to make Taiwan an international issue and then request support from 
the international community, particularly from Japan and the US, for the latter, based on 
the Taiwan Relations Act passed by the US Congress in 1979. However, even though 
                                                     
123 The text of the DPP referendum reads as follows: “In 1971, the People’s Republic of China replaced the 
Republic of China as a member of the United Nations, thus making Taiwan an international orphan. In order 
to strongly express the will of the Taiwanese people, and to elevate Taiwan’s international status and 
international participation, do you agree with the government to use the name “Taiwan” to enter the 
United Nations?”
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Washington acknowledged its political commitment124 made in the Act that includes
providing Taiwan with arms of a defensive character, it reclaimed its recognition of the 
one China principle in response to Taiwan’s independence claim. Nevertheless, in Taiwan’s 
domestic milieu, the suppression of an international space for the country drives and 
consolidates forces to form an emerging Taiwanese consciousness. Despite the lack of 
consensus with regard to the issue of name rectification, such consciousness has been 
reconfigured as a form of Taiwanese identity through domestic political campaigns. For 
the DPP, such identity is mainly constructed in its nationalism-based discourse to promote 
Taiwan’s independence; for the KMT, on the contrary, identity formation signified its 
endeavours in localisation in order to obtain recognition from Taiwanese society and 
regain its legitimacy in Taiwan’s democratic transition. 
In the 2008 Presidential election, the KMT regained executive power in Taiwan. It 
reclaimed the acceptance of the 1992 Consensus and maintained the status quo by
declaring no reunification and no independence in its cross-strait relations. Later, regular 
direct flights between mainland China and Taiwan resumed for the first time since 1950 
and the Chinese mainland has become the largest market for Taiwan’s exports and 
outward investment. In June 2010, Taipei and Beijing signed the Economic Cooperation 
Framework Agreement (ECFA) which aims to have tariff concessions over 807 products. As 
Taiwan has been prevented from signing free-trade agreements with its neighbouring
economic powers by Beijing, the government hopes that ECFA will benefit Taiwan’s overall 
economic development although the opposition DPP has concerns that ECFA may make 
Taiwan be overly economically dependent on mainland China. 
The historical context illustrates the complexity of how political components and market 
forces may have influenced the constitution of Taiwanese identity and why identity 
formation is not necessarily inherent but fluid and full of flexibility. It also shows that for 
Taiwan, obtaining international recognition has geopolitical significance for its national
security. Taiwanese DNA in these biopolitical discourses has a sense of national 
distinctiveness that represents Taiwan’s anxiety about being excluded from the 
international system and its eagerness to return back to the global stage by using its 
economic power. However, on the other hand, the uniqueness of Taiwanese genes has
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104
also been promoted by the government as a comparative advantage for Taiwan to attract
global investment which targets the potential of the Greater China market. In the public 
imagination, although biobanking in Taiwan causes many ethical concerns among the 
human rights groups, it is recognised by the government as an innovative technology for
the common good and for Taiwan’s future generations. These public interest oriented
discourses constitute ethical configurations in Taiwan that cast the state as both a 
guardian of its population and also an investor in terms of turning the population into a 
resource for the purposes of forming a bioeconomy. 
The paradoxical role the state plays makes biobank governance in Taiwan a challenging 
task and it explains the necessity to deploy the practical governance issues in the context 
of cosmopolitics in order to realise the social and symbolic effects of applying biobanking
as a new form of biotechnologies in Taiwan’s modernity. However, behind the paradox is 
the complicated intertwining of governmentality and the logic of value accumulation that 
shows a kind of biopower has been exercised through the configuration of ethics. In 
addition, the huge Chinese population has turned to be an advantage claimed by Taiwan’s 
government to carry out the development of cures for Chinese-exclusive diseases. It is like 
reliving the territorial boundary cited in the R.O.C. constitution in the realm of genomics 
research that unlocks the potentialities of Chinese populations as values to be harvested. 
In addition, even though the KMT and the DPP have different policies toward the status of 
Taiwan’s statehood, both parties have seriously complied with the logic of neoliberalism 
and taken it as the fundamental principle for Taiwan’s economic development. In contrast 
to other postcolonial countries in East Asia, such as South Korea, for example, the leftist 
influence against capitalism and globalisation is relatively weak in Taiwan. In fact, 
Japanese colonisation not only brought capitalism to Taiwan by creating a system of 
colonial mercantilism but also formed the hierarchical class differentiation in Taiwanese 
society. Even though there was some strong resistance to imperialism from some local 
Taiwanese elites during Japanese colonial rule (1895-1945), these left-wing legacies 
encountered major historic ruptures first by the repression from Japan’s colonial power 
and later from the KMT’s authoritarian rule by using martial law to systematically clean up 
communist ideas and left wing ideas in Taiwan. The influence of these political 
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interferences is not only a long period of White Terror in Taiwan but also a tacit mentality 
of compliance with the logic of capitalism.
3.4 Ethical Configurations in Biocapitalism 
The expectation of biotechnology in improving public health and the treatment of 
diseases enhances the logic for ethicalisation of the biobank practices in Taiwan. Building 
an adequate regulatory infrastructure has become a priority of the government in order 
for Taiwan to be more easily reconnected to the global biotech and pharmaceutical 
market. As Kaushik Sunder Rajan has argued in his ethnographic study of genomics 
research in India, the fundamental structural violence of technoscientific production in 
global capitalism cannot be mitigated by the forms that ethics takes in the region.125 Both 
human rights groups and the actors supporting biobanking in Taiwan are drivers of an 
ethical regulatory environment. However, the national biobanking initiative is more 
complicated than just executing biopower for improving the quality of life for a nation 
state. The biobank project involves analysing the enthusiasm of Taiwan’s government to 
make the state a crucial niche for genomics study in the Asia Pacific. As a result, rather 
than protecting research subjects from possible exploitation, a formal attentiveness to 
ethics, on the contrary, helps turn Taiwan into a site of sample collections for global 
biotech investment and commercialisation.  
In Taiwan, the executing scientists for the national biobank are also concerned with ethics 
as they would like a clearer boundary between what is allowed and what not. For that 
reason, the Human Biobank Management Act passed on 7 January 2010 focuses mainly 
on the issues of good practice such as collecting informed consent and implementing 
confidentiality. Little attention is paid to substantive proprietary issues, for example, the 
ownership of samples and genetic information and the operational and business model of 
the biobank. Consider, for example, Celera’s business strategy in racing for the human 
genome sequence with the HGP. The legally enshrined proper protocol can nonetheless 
lead to consolidating the existing profit-oriented structures of global biocapitalism that 
may risk Taiwan becoming an attractive site of “genetic colonialism” for the global 
pharmaceutical industry. In addition, the distinction between public and private sectors 
has been blurred by mechanisms such as technology transfer and research collaboration
                                                     
125 Kaushik Sunder Rajan, Biocapital (Duke University Press, 2006).
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that further complicate the role of state in the biobanking in Taiwan. Under the influence 
of global capitalism, many publicly-funded research institutes and labs of Taiwan have 
become aggressive market players like biotech companies in seeking patenting of their
research results. However, those participants who decide to voluntarily take part in the 
biobank project because of their trust in the credibility of the government and executive 
agency - the Academia Sinica - may turn out to have a more reserved attitude toward 
biobanking if they know their samples and data collected from the institution would be 
used for profits and marketing in the end.  
Confronting mainland competition in genomics research, Taiwan wants to privilege 
biotechnology as a springboard into the potential market of Sinopathology. In contrast to 
China, Taiwan’s democratic political milieu and its more established regulatory 
infrastructure are competitive advantages. The state can claim it is geographically 
adjacent to the large Chinese populations but is more interested in protecting intellectual
property by complying with the rule of law than the mainland. Interestingly, most of the 
concerns in Taiwan about the establishment of the national biobank had revolved around 
the lack of ethics to regulate this kind of innovative technology. Since the biobank project 
is still in its early development, informed consent and privacy have occupied most of the 
regulatory efforts in the ethical configurations. However, such configurations may have 
sent a hazardous signal to the public in a way that so long as some ethical safeguards are 
in place the biobank can carry on without too many worries left. It also illustrated why the 
critical voices from the human rights groups in Taiwan seem to have been weakened since 
the biobank Act was passed by Taiwan’s Legislative Yuan in early 2010. Ethics and 
regulation have turned out to be an agency to localise global biocapitalism. They 
consolidate the invisible structural violence of commercialisation by internalising 
opposition forces and transforming their concerns into sovereign reasons by configuring 
ethics through a process of legislation.  
According to the proposal for the pilot study for the Taiwan Biobank, the Development 
Centre for Biotechnology (DCB) is responsible for planning the future industrial 
application for the biobank. The DCB, a non-profit organisation established in 1984, is
co-sponsored by both government grants and private donations. The centre’s purpose is 
to serve as a bridge between the upstream R&D and downstream industrial application so 
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publicly funded academic research institutions and private biotech-pharmaceutical
industry can be coordinated in a more efficient way. In addition, the centre positions itself 
as a value-adding partner for the industry that means it adds values to new developed 
drugs by filing Investigational New Drug (IND) Applications to the US Food and Drug 
Administration for approval and then licenses out drug candidates to down-stream 
biotech and pharmaceutical companies for clinical trials and eventually for product 
commercialisation. Even though the possible business models of the biobank, such as
patent licensing, technology transfer or strategic alliance, etc, are still under discussion in 
the DCB, the centre’s objective is for commercialisation and help business expansion into 
the global biotech pharmaceutical market. 
As Sunder Rajan has argued, the global harmonization of ethics and intellectual property 
regimes constitute the structural violence of global capitalism.126 In Taiwan, this violence 
is exacerbated by the fact that a patriarchal state has gradually transformed itself from a 
protector of to an investor in the biotech industry so biopolitical purposes are easily 
intertwined with the underlying logics of neoliberalism. Recently, Taiwan’s Ministry of 
Economic Affairs has launched a Biotechnology Takeoff Action Plan aiming to identify 
opportunities for further commercialisation of biotech and pharmaceutical R&D research
results. According to the plan, a biotech venture capital scheme will be set up so the 
government will work with private capital to invest in some local research projects. In
addition, the Department of Health has planned to establish a Food and Drug 
Administration similar to the FDA in the United States to regulate medical and 
pharmaceutical products in line with international standards. As one of the purposes of 
the Takeoff Action Plan is to promote Taiwan as a R&D partner for the international
biotech community, international alliance has been emphasised through putting extra 
efforts into the harmonisation of regulations. Taiwan’s eagerness to be compatible with 
international standards also represents its geopolitical mentality to act as a springboard
for multinational companies to enter the Chinese market when the global economic 
centre is moving from the West to the East. Taiwan’s recent efforts to link itself with the 
international value chain have opened an opportunity for the country to be integrated
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into the Greater China economic sphere that further shows how Taiwan’s relations with 
China can be competitive as well as cooperative.
However, when the state and public sector act more and more like a profit-driven 
corporation or an investor, the structural violence of biocapitalism, as Sunder Rajan 
argues, turns to be more consolidated and hard to discern. For example, in terms of 
collecting informed consent, the public face of biobanking recruitment suggests the 
project is a public good for realising the causes of diseases common to the people of 
Taiwan. Nevertheless, the project’s underlying link to commercialisation has not yet been 
properly disclosed and as a result it is difficult for individuals to consider whether 
commercial involvement would be a factor to influence their willingness to take part in 
the project. In addition, the biobank’s technocratic purpose such as promoting Taiwan’s 
biotech industry in its international competitiveness has been covered by public health 
related discourses in the biobank’s recruitment of participants. As the government has 
managed well to locate the biobank project inside a narrative of both scientific 
development and Taiwanese genetic distinctiveness, the general public may view the 
biobank simply as a research infrastructure and neglect to challenge its possible 
commercial linkage and ensure if there are any benefits derived from the research results 
in which the public would be entitled to share as voluntary participants. DeCode
Genomics portrayed the Icelandic population as highly educated but “cooperative.”
However, in Taiwan, perhaps the question is not simply to ask whether Taiwanese 
population is cooperative or not. Rather, it is to examine under what narratives and 
context the population of Taiwan may have been viewed as cooperative by the biotech 
industry and government as an ideal population for pharmacogenomics research. 
Conclusion
This chapter discusses the deployment of biotechnologies in Taiwan as a valued 
opportunity for its national building, economic growth and the formation of identity and 
biosecurity. It also examines the social and symbolic effects of biotech innovations, such 
as biobanking in Taiwan’s geopolitical analysis. Biobanking may be viewed here as a useful 
indicator to interpret and reconstruct the notion of biotech modernity in the Taiwanese 
reality. It demonstrates the Taiwanese government’s endeavours to catch up with the 
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international trend in genomics research and pharmaceutical development when 
biobanking articulated not only the scientific imagination but also nationalist aspirations 
to end the exclusion of the country from the international system. Such hope of building a 
modern nation has turned the biobank project into a state-led enterprise that is allied to 
the milieu of neoliberalism in Taiwan in order for the state to restore national identity and 
a competitive niche in the Asia Pacific.
Taiwan’s sovereign reasons to use biotechnologies to revolutionise its industry and 
enhance its international visibility has attracted global pharmaceutical companies to 
establish partnership with Taiwan’s local industry to explore the commercial potentials by 
mining genetic gold in East Asia. Because of this, the influence of the private sector 
significantly increases in Taiwan’s formation of biocapitalism. The story of Vita Genomics 
illustrates the Taiwanese government’s enthusiasm to encourage private start-ups to play 
a leading role to bring capital and transmit innovative technologies in order for the 
country to be reconnected to the global trend of genomics research and biotech 
development. Regulatory infrastructures and capacity building have gradually blurred the 
distinctions between public and private by mechanisms such as technology transfer and 
research collaborations in the hope to integrate resources for Taiwan’s biotech 
development.
Even though for a nation state, genomics research may reinforce the concept of 
sovereignty that forms a new kind of identity based on biological facts, the case of Taiwan
demonstrates the formation of identity is fluid and subject to change. Furthermore, the 
Taiwan Biobank illustrates that ethnic categories may be consequential as the elements 
used in differentiation are not necessarily biologically true. In addition, the chapter argues 
that the Taiwanese government identifies biobanking as a new form of biotech for Taiwan 
and its future citizens’ common good. Relevant ethical configurations have emerged in 
Taiwan’s biopolitical narratives that illustrate the ambiguous and paradoxical role the 
state plays in biobank practices in Taiwan. Since the biobank project is intertwined with 
Taiwan’s governmentality and the formation of Taiwan’s bioeconomy, it is not appropriate
to treat the project as simply a scientific research plan. As a result, the current ethical 
configurations with regard to biobank governance may not be thoroughly responsive to 
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the commercial challenges for the biobank, considering its close association with the 
biotech development but unclear arrangements of proprietary interests.
In addition, this chapter points out that holding a bioethical view to discuss biobank 
governance may ignore the influence of global capitalism on its application to biobanking 
practices in Taiwan. The case of Taiwan shows that how regulation and ethics may be used 
as a helpful way to legitimise sample collections but leave substantial issues such as 
access, ownership and intellectual property unattended. It also demonstrates how the
idea of neoliberalism has prospered in Taiwan’s modernity and seems to keep leading 
Taiwan’s overall development. The Taiwanese biobanking case may act as an important
input to contribute to global assemblages by deploying the country’s development of 
biotechnologies in a cosmopolitical context. It also helps create a space to realise different 
civic epistemologies and their entangled frames in this emerging technoscientific world. 
Finally, the chapter hopes to enliven the current literature with regard to 
commercialisation of biobanks by locating Taiwan’s practical experience in the context of 
cosmopolitical technoscience. In so doing, the force of global capitalism might be easier 
to be recognised and discerned from the covering biopolitical discourses.
111
Chapter 4 Biobanking in Taiwan: the Politics of Science and Technology
Introduction
This chapter introduces the biobanking story in Taiwan by analysing its initiatives, 
agencies, ethical puzzles and governance framework from a perspective of science and 
technology studies. In 2005, the Executive Yuan of Taiwan announced the start of the 
Biomedical Technology Island Plan with the aim of building Taiwan into a centre for 
genomics research and clinical trials in Asia. Several government agencies worked out this 
great scheme in synergy: the Ministry of Economic Affairs (MOEA), the National Science 
Council (NSC), the Department of Health (DOH), the Academia Sinica, and the National 
Health Research Institute (NHRI). The initial agenda for establishing this integrated 
biomedical infrastructure was five years, within which the government was planning to 
call for the investment of NTD 15 billion (equivalent to USD 457 million).1 It is hoped that 
this scheme may greatly improve Taiwan’s environment for biomedical and
pharmaceutical research and attract more overseas investment in local health 
service-related industries. In the future the scheme is expected to generate significant 
resources of biovalue for genomic research and biotechnology development in Taiwan. 
According to the government, the scheme was expected to boost investment of about 
NTD 40 billion from both public and private sectors over the five-year period.2
For the government, Taiwan has many strengths that make it ideal for the development 
of biomedical technology and pharmacogenomics. For instance, during the period of 
2002-04, international medical organizations had conducted 337 clinical studies in 
Taiwan3 and roughly around the same time, the National Science Council launched the 
National Research Programme for Genomic Medicine (NRPGM).4 This collaborative, 
national-level scheme aims to carry out genomics research and capitalise knowledge
acquired through it. In April 2005, the idea of establishing a large-scale population 
biobank as a biomedical research infrastructure was first initiated in the National Science 
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4 More information about the NRPGM can be found in its website: 
http://nrpgm.sinica.edu.tw/en/content.php?cat=agtc (Last visit: 08 March 2012)
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and Technology Conference (NSTC). The NSTC is a national-level meeting held every four 
years under the supervision of the Science and Technology Advisory Group. Unlike usual 
ministerial meetings, the NSTC provides a significant platform for both government 
officials and representatives from industries and academia to express their ideas of how 
to design Taiwan’s science and technology blueprints. After the promulgation of the 
Fundamental Science and Technology Act in 1999, each consensus reached in the NSTC is 
required to be documented and therefore its policies can be integrated into the National 
Science and Technology Development Plan. Proposed under the broader scheme of the 
Biomedical Technology Island Plan, the Taiwan Biobank project aims to provide a 
supportive platform to help promote Taiwan’s biomedical research and biotechnology 
development. With the advantages of well-developed medical centres for clinical trials 
and over 99 % of the population participating in the National Health Insurance Scheme,5
it is acknowledged by the government that establishing a large-scale population biobank 
in Taiwan is beneficial and can help Taiwan secure its niche in the global bioeconomy for 
biomedical and pharmaceutical innovations. 
In addition to this biobanking project, the broad scheme covers two other core facilities -
the National Health Information Infrastructure (NHII) and an integrated system for clinical 
research and trials. The goal of the NHII is to establish an electronic system for rapid 
image transmission of health information among regional medical centres and hospitals. 
This system planned to simplify the complicated data transfer procedures in clinical trials 
that used to rely on a tremendous amount of documents and paperwork for applications. 
After the NHII was founded, the expected time for health information transfer will be 
significantly shortened from a period of two weeks to three working days. The integrated 
clinical trial system aims to support domestic pharmaceutical companies undergoing the 
clinical trial procedure requested by the Department of Health for drug invention and 
production.6 An executive agency - the Clinical Trial and Research Programme Office -
was accordingly established by the Department of Health about four months after the 
announcement of the Biomedical Technology Island Plan. In the future, according to the 
government’s plan, the NHII was expected to support the realisation of the personal 
                                                
5 Founded in 1995, this is a government-run health insurance scheme, financed through a mix of premiums
and taxes. The enrolment is mandatory to ensure the adequate risk pooling.
6 Supra note 1
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health care system and to save about NTD 10 billion annually in national health insurance 
expenses for the state.7
4.1. Biobanking Conditions
4.1.1. Pharmacogenomics
The prospects for the study of pharmacogenomics and genetic epidemiology have made 
biobanking attractive to many scientists in Taiwan. For them, creating a large-scale 
prospective cohort can overcome the shortcomings of a case-control study which is 
frequently shown in their research as a result of ineffective statistics from inadequate 
samples. In fact, collecting large sample sizes for establishing a cohort for medical 
research is not unfamiliar to epidemiologists in Taiwan. Several hospitals, medical centres 
and universities have had their various-sized sample collections for research and
therapeutic uses. For instance, a few decades ago, a famous cohort for the study of 
hepatitis B was established by Dr. Palmer Beasley and his Taiwanese colleagues at the US 
Naval Medical Research Unit No. 2 in Taipei. The cohort consisted of 22,707 Taiwanese 
male government employees who were traced forward for over 15 years.8 The research 
findings demonstrated that carriers of hepatitis B are about 265 times more susceptible 
to liver cancer than average and the use of vaccines may effectively prevent a newborn 
baby whose mother was carrying hepatitis B from becoming infected by it.9 Based on the 
successful experience of using a large-scale cohort in epidemiology research, launching a 
population biobank motivates the supporting scientists in Taiwan to continue exploring 
the scientific unknown.  
In addition, since Taiwan has a relatively small population (23 million), in practice it is 
rather difficult for it to request that every new drug invented outside of the country goes
through the process of local clinical trials before the drug can be permitted to be sold 
openly in the domestic market. Even though some multinational pharmaceutical 
companies have also carried out regional studies, which may take into account different 
racial groups as a factor affecting the efficacy of medications, the results from these 
clinical trials are not necessarily useful for people in Taiwan. According to Chen 
                                                
7 Ibid.
8 RP Beasley et al., "Hepatocellular Carcinoma and Hepatitis B Virus: A Prospective Study of 22,707 Men in 
Taiwan," The Lancet 318, no. 8256 (1981).
9 Ibid.
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Yuan-Tsong, the Director of the Institute of Biomedical Science (IBMS) at the Academia 
Sinica and also a co-principal investigator of the biobank project, Taiwan needs to have its 
own population biobank designed especially for Taiwanese people.
When I returned back (in Taiwan), I had heard from many physicians that the side-effects 
of medications in Taiwan is extremely serious. Even though many countries have started to 
create biobanks, since every different races has different genes, so are environmental 
factors, we couldn’t say that because they have already started doing this, we (Taiwan) 
don’t have to do so. The best example is that we often see many multinational 
pharmaceutical companies inventing pharmaceutics targeting only white people. Although 
the FDA in the United States has mentioned that in clinical trials, it is necessary to profile 
people from different racial groups, the finding results have not yet been sufficient 
because those pharmaceutical companies’ major markets remain in the US or in Europe. 
[T]hen we started to do research on the Stevens-Johnson syndrome and to see why there 
were very few cases with this symptom in Caucasians but so many among people in Taiwan 
and also in South East Asian countries. Later, we found out that there is a genes found in 
people from the South East that cannot be found in Caucasians. Even though the drug
carbamazepine was already out of patent during that time, I have told my students in class 
that if this drug had ever gone though its clinical trials in Taiwan, it would not have been 
able to be passed. (Interview with Chen Yuan-Tsong, Taipei, 2009)
After the publication of this research finding, carbamazepine was requested to be 
relabelled for its possible pharmaceutical side-effects especially for the gene marker of 
HLA-B75 which is frequently seen in East Asian populations (especially Han Chinese and 
Thai).10 Due to the different genotypes of the Taiwanese population, about 5% of 
Taiwanese are severely allergic to carbamazepine which was originally designed for 
Caucasians.11 Another similar example may be found in Iressa, a drug for target therapy 
in lung cancer. According to the study, it shows that the efficacy of Iressa for Europeans 
and Americans is lower than for East Asians.12 The reason is that Iressa has a significant 
                                                
10 Chung WH et al., "Medical Genetics: A Marker for Stevens-Johnson Syndrome," Nature 428, no. 6982 
(2004).
11 Ibid.
12 J. Guillermo Paez et al., "Egfr Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib 
Therapy " Science 304, no. 5676 (2004).
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therapeutic effect on people with the EGFR mutation and, like people in other East Asian 
countries, many people in Taiwan have this kind of genetic mutation. As a result, it has 
been proven that the responding efficacy of Iressa, mainly for tumour regression, works 
much better in Taiwan than in most Western countries.13
According to Shen Chen-Yang, a professorial research fellow at the Institute of Biomedical 
Science and a co-director of the biobank project, setting up a long-term cohort study is in 
the best interests of the next generation because it helps immensely in discovering the 
causes underlying common complex diseases by examining innate genetic composition 
and acquired lifestyle and environmental factors.14 Taking lung cancer as an example, 
according to Shen, even though most people believe that smoking increases the chance 
of developing lung cancer, in Taiwan, only one in every nine women diagnosed with lung 
cancer is a smoker and this shows that one of many unknown variables here may very 
well be genetic.15 Viewed as a platform to support long-term cohort tracking studies, the 
idea of establishing a national-level biobank has been supported by some scientists in 
Taiwan. As establishing a population biobank helps in developing personalised medicine, 
the hope is high that in the future when a doctor prescribes a medicine, she or he will 
take into account patients’ individual genetic makeup in order to manage side effects in
medications. Analogous to biobanking projects launched all over the world, the invention 
of the biobank in Taiwan will have significant implications for Taiwan’s biomedical 
research and public health. In addition, this biobanking project has become an important 
medium for the government to manage the health of its population. 
4.1.2. Genetic Diversity among Taiwanese Populations
In order to push Taiwan’s biomedical research to a new height, some scientists view the 
population biobank project as a powerful infrastructure, especially for genomics research
to take into account Taiwanese unique genetic makeup. Wu Cheng-Wen, the former 
president of the National Health Research Institute, has suggested that Taiwan needs to 
establish its own genetic database for better research on local prevalent diseases, such as 
liver cancer and nasopharyngeal carcinoma because of the genetic variations existing
                                                
13 Interview with Chen Chien-Jen, Taipei, 2010
14 Chang Chiung-fang translated by Phil Newell, "Making a Deposit in Taiwan Biobank: How Safe Are Your 
Secrets?," Taiwan Panorama (2008).
15 Ibid.
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among different ethnic groups.16 In the biobank proposal, genetic diversity is introduced 
as a major strength for the establishment of a population biobank in Taiwan.17 Even 
though the goal of the Human Genome Project was to map the entire human genome, for 
the development of population genomics more attention has been paid to the study of 
genetic variation among different populations and even individuals. Unlike the Icelandic 
Health Sector Database which values the genetic homogeneity of the Icelandic population, 
the genetic diversities among Taiwanese populations encourage geneticists and 
epidemiologists in Taiwan to discover the association between genes and a wide range of 
data relating to human phenotypes and Taiwanese environment. 
Following the significant reduction in the cost of genotyping after sequencing the human 
genome, it is now feasible for scientists to study factors contributing to common diseases 
by discovering genetic polymorphisms. For some scientists, even though many Taiwanese 
may trace their ancestral origins back to Han Chinese, as a migrant society, the 
expression of their genes may have been developing through changes induced by local 
environments, customs and diet habits. In addition, Taiwan’s migrant history enriches its 
genetic diversity. The specific character of Taiwanese migrant history may be illustrated 
by the old saying: “there are Tangshan fathers, no Tangshan mothers.” The term 
Tangshan refers to mainland China and the saying explains that about four hundred years 
ago most people who came to Taiwan from Fujian and Guangdong provinces were male 
immigrants. So the descendants of these immigrants would be through intermarriages 
with Taiwanese aborigines, particularly with the plain aborigines who inhabited the lower 
mountain areas and western plain lands in Taiwan during that time. The intermarriage 
between indigenous and non-indigenous groups enriches the genetic diversity of the 
Taiwanese population. 
Since genetic variation is significant in genomics research, genetic diversity turns to be a 
strength in the establishment of a population biobank in Taiwan. The importance of 
ethnic difference to biobanking lies in the possibility of looking into what combination of 
different genes relates to which diseases. Therefore, setting up a population biobank for 
searching genetic variation among different ethnic groups enables scientists to detect the 
correlation between genetic variation and diseases and carry out a comparison of cross 
                                                
16 Ibid.
17 The Proposal for the Pilot Study of the Taiwan Biobank, (Academia Sinica, October 2005), pp 9-10
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ethnic groups. According to Chen Chien-Jen, a distinguished epidemiologist and an 
Academician at the Academia Sinica, the genetic diversity of the Taiwanese population is 
very vast and that enriches the biobank as a valuable tool to understand the risk factors 
that underlie common complex diseases in Taiwan. 
In Taiwan, one of the strengths for the population biobank is that we have a population 
with a high genetic diversity. The Taiwanese ethnicities are much more complicated than 
we might have ever expected. For instance, in terms of Taiwanese aborigines, there are 
many original traits that make their genetic makeup very diversified. Even for the offspring 
of Han Chinese immigrants, there are many of them through intermarriage related to plain 
aborigines. In addition, the immigrants who came to Taiwan after 1949 may cover 56 
different ethnic groups in mainland China, so generally speaking, the population diversity in 
Taiwanese ethnicities is very vast. If everyone had the same genetic makeup, there would 
be not much of research interest here. (Interview with Chen Chien-Jen, Taipei, 2010)
In the early planning stages of the Taiwan Biobank, scientists used the general term “the 
four great ethnic groups” - Hoklo, Hakka, Mainlanders and Taiwanese Aborigines - as a 
criterion for the project’s research design and population sampling. However, this 
approach of genetic sampling had been criticized in that it failed to recognise that the 
categories themselves are not intrinsically biological. As mentioned in the earlier chapter, 
such ethnic category was socially constructed and initiated by a political figure as a slogan 
during a domestic electoral campaign in the 1990s. The original purpose of constructing 
the term is to diffuse the tension between the local Taiwanese - Hoklo and Hakka 
(referring to the offspring of the earlier immigrants coming to Taiwan about 400 years 
ago from Fujian and Guangdong provinces) - and Mainlander (the later immigrants and 
their offspring who retreated from the Mainland to Taiwan after the end of the Chinese 
civil war in 1949).18 According to population geneticists, both Hoklo (70%) and Hakka 
(15%) may be broadly categorised as subgroups from Southern Han19 and the category of 
Mainlander (13%) may reflect genetic traits of both Han Chinese and the rest of other 
ethnic groups (Minzu) in China. Since, except for Taiwanese aborigines (2%), the other 
three ethnic categories - Hakka, Hoklo and Mainlander - may more or less trace their 
                                                
18 A-Chin Hsiao, Contemporary Taiwanese Cultural Nationalism (London: Routledge Press, 2004).
19 Geographically divided by the Yangzi River in China, Han Chinese can be categorised broadly as Southern 
Han and Northern Han. Interview with a medical geneticist, Taipei, 2009.
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ancestral origins back to the Han Chinese gene pool, the implication of their genetic 
variation on the population sampling for the biobank is not without controversy.
An argument focuses on Taiwanese Austronesian roots emphasising that even though 
only 2% of the population in Taiwan are aborigines, the aboriginal groups have the most 
unique genetic traits compared with the majority Han Chinese gene pool that covers 98% 
of the population in Taiwan.20 However, for some scientists, even among the subgroups 
of Han Chinese, the genetic differences between Hoklo and Hakka would have been 
developed as a result of genetic evolution influenced by different environmental 
exposures. According to Chen Yuan-Tsong, since every specific ethnic group has unique 
characteristics in the gene pool, even though the 1.5 billon Chinese around the globe may 
all trace their genetic roots back to the same source, the genetic makeup of people in 
Taiwan may have been through changes induced by different historical paths and 
circumstances such as local customs and habits that could have impacted on variations in 
gene expression.21 This viewpoint is echoed by Chen Chien-Jen, who has explained the 
reasons why there is a genuine need to establish a biobank devoted to Taiwan and why 
using the category of the four ethic groups for population sampling seems to be 
acceptable. 
We know that even though Hakka and Hoklo speak different dialects and perhaps their 
living habits are quite different as well, in terms of genetic composition, they may be 
broadly categorised into the Southern Han Chinese gene pool. But would it be possible that 
we might find some particular genes which associate with a specific disease among them? 
At least, from the research by far we have found out that the susceptibility to 
nasopharyngeal carcinoma is about two times higher in Hakka than in Hoklo. I would say it 
may still be useful to adopt the category of the four great ethnic groups to sample the 
population as for geneticists, their difference may not be reduced to language and culture. 
Besides, even for people within each group, their ethnic backgrounds might be slightly 
different, not completely the same. (Interview with Chen Chien-Jen, Taipei, 2010)
                                                
20 Peter Bellwood, "Formosan Pre-History and Austronesian Dispersal," in Austronesian Taiwan: Linguistics, 
History, Ethnology and Prehistory, ed. David Blundell (Berkley, CA: University of California Press, 2000).
21 Supra note 14
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In the biobank project, neither the Han Chinese nor the Taiwanese aborigines was singled 
out as a special gene pool for the project’s research design. It demonstrates that the 
biobank in Taiwan plans to address not only the genetic distinction between Han Chinese 
and Taiwanese aborigines but also among the subgroups of Han Chinese gene pool, or 
even within the subgroups, namely to study the genetic variation among individuals 
themselves. Since every ethnic group and even each individual has its own uniqueness in 
its gene pool, a population biobank designed for Taiwan is regarded by the supporting 
scientists as a valuable facility for supporting genomics research for the ultimate goal of 
personalised medicine. 
Nevertheless, even though the population biobank aims to represent the genetic 
composition of the population in Taiwan, throughout history, who the Taiwanese are has 
never been an easy question to answer. The complexity derives not only from the 
ambiguous international political status of Taiwan but also due to fluid self-identification 
criteria influenced by daily Taiwanese social and political experiences.22 For instance, a 
traditionally-categorised Hakka or Hoklo might be willing to be self-identified as not only 
local Taiwanese but also Han Chinese in a broader sense. By the same token, a second or 
third generation Mainlander may choose to identify her or himself as Taiwanese and 
Chinese. Since the “four ethnic groups” is a socially constructed criterion, it is inevitably 
influenced by people’s self-identification that does not necessarily correspond to their 
biological traits. As a result, a question such as whose genes may represent the 
Taiwanese population and its sub-divisions turns out to be an open one as it is 
unavoidably influenced by various factors outside the scientific arena. 
Nevertheless, such an identity configuration inevitably influences the biobank’s research 
design and researchers’ perceptions about the diversity of the Taiwanese population. For 
instance, for sampling recruitment, in order to know if a participant belongs to a specific 
ethnic group, it needs first to rely on that participant’s self-identification about his or her 
ethnicity before any further research on genetics in biobanking can formally start. In 
practice, this self-identification is presented as an ethnic option for box-ticking on the 
questionnaire form which needs to be filled out by participants at sample collection sites. 
                                                
22 More information about this argument, see: Melissa J. Brown, Is Taiwan Chinese? The Impact of Culture, 
Power, and Migration on Changing Identities (Berkeley and Los Angeles, California: University of California 
Press, 2004).
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As a result, a participant’s biological trait is not necessarily being fully reflected as the 
ethnic identity she or he claims or chooses to have. Despite the appeal of the genetic 
diversity of the Taiwanese population to some scientists, to what extent this strength
may be presented effectively through the research design remains a question. At the 
same time, it challenges the feasibility of using the biobank to study the interaction of 
gene and environment among different ethnic groups as the scientists originally planned.
4.1.3 Household Registration and National Health Insurance Databases
4.1.3.1 The Household Registration System
In addition to genetic diversity, the family data and medical history of all the nationals 
provides another favourable condition for establishing a population biobank in Taiwan. A 
pedigree or family tree can be used to trace gene transmission and biological 
characteristics from one generation to another. Unlike rare single gene disorders, 
common chronic disorders such as diabetes, cancers and heart disease are not controlled 
by single genes but by multi-factorial conditions that are often found to run in families.23
Even though genes may not be easily changed, it is easier to impact their expression by 
controlling other factors such as lifestyles and environment. As a result, linking family 
history with data of these common chronic disorders will especially empower a biobank 
and it is also the first step toward preventive medicine. 
In Taiwan, obtaining a national ID card requires proper household registration. However, 
unlike the hukou system in China, the household registration doses not function as a tool 
of government to control and manage residents’ movement within the country. The 
system of household registration (hukou) in Taiwan can be traced back to the Japanese 
colonial period (1895-1945). The system was established in 1906 by categorising 
residents into two broad groups - local residents and temporary residents.24 Even though 
the household survey was the responsibility of the police during that time, the household 
registration was mainly carried out by clerks of local Baojia authorities.25 Invented in the 
Song Dynasty (960-1279) in the Imperial China, Baojia was a community-based system 
                                                
23 More info, see: 
https://www.migeneticsconnection.org/genomics/Family%20History/family%20history.htm (Last visit: 08 
March 2012)
24 The system was introduced by Wang Anshi in his implementation of the seven-year New Policies reform.
25 See, Frederick W. Mote, Imperial China 900-1800 (Harvard University Press, 2003). pp 918-920
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designed for law enforcement and civil control. The system gave “bao”, which was 
composed of several families, authority to maintain local order and organise civil projects 
so it could reduce central government’s financial burden of reliance on mercenaries by 
transferring responsibility of law enforcement from the central government to civil 
societies.26
The Baojia system was in operation in Taiwan even during the period of Japanese 
colonisation. Later, the Household Registration Act was enacted by the government of 
the Republic of China (R.O.C.) in 1931 but it had not been implemented in Taiwan until 
1946 after Taiwan was restored to the R.O.C. government after World War II. According 
to the Act, household registration was governed by the civil administration authority. But 
in reality, since 1973 until 1992, household registration was under the supervision of the 
police authority in Taiwan.27 In 1985 the computerisation of the household registration 
was initiated as a trial and after a decade the household registration data was fully 
computerised and it has been online nationwide since 1997.28 The computerisation 
ensures that the household registration data can be archived in an electronic database 
that makes data sharing and linkage possible, even though it also causes anxieties about 
the infringement of privacy.
4.1.3.2 The National Health Insurance Database
In addition, Taiwan’s well-established national health care system covers about 99% of 
the population.29 The National Health Insurance (NHI) scheme retains complete medical 
records of each registered national. As a single-payer social insurance scheme mainly 
funded by collective premiums, enrolling in the scheme is an obligation for all nationals in 
Taiwan who have household registration. The coverage of the system is broad enough to 
include various forms of medical treatments, from preventive checks, physical 
                                                
26 Ibid. In Song Dynasty, the basic unit of a “bao” consisted of ten families. In the Ming Dynasty (1368-1644), 
the family was relabelled as a “Jia” and a “bao” usually consisted of ten Jia or one hundred families. Even 
though the structure of the system changed over time, the Baojia had been an important way of 
governance in Imperial China to hold the Chinese society altogether.
27 More information about the history of the household registration in Taiwan, see: 
http://www.ris.gov.tw/18;jsessionid=404867C80733D790AE07D6E6CC122FAD (Last visit: 08 March 2012)
28 Ibid.
29 The National Health Insurance Statistics, see: 
http://www.nhi.gov.tw/English/webdata/webdata.aspx?menu=11&menu_id=290&webdata_id=2974&WD_
ID=290 (Last visit: 08 March 2012)
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examinations, laboratory tests to surgeries, medications, nursing and palliative care.30
The health care system was established in 1995 and about 10 years later the Bureau of 
National Health Insurance (BNHI), which is under the supervision of the Department of 
Health, adopted the use of an electronic IC card to replace the previous paper-based 
health insurance card. 
The chip embedded in the IC card stores the card holders’ medical records that include 
data of medical test, treatment and prescription. As the card serves as the authoritative 
record of treatment under the National Health Insurance system, it records medical 
history data of all doctors’ visits. The medical history information can be updated at any 
location where a card reader is available, such as any branches of the Bureau of National 
Health Insurance, city, town, village, or regional administrative office. However, access to 
a card reader is controlled in a way that it can only be operated after installing a security 
authentication module. A mutual recognition system requires doctors to use their health 
professional card to access the data stored in the readers.31 Like the system of 
household registration, the computerisation of the national health insurance scheme 
provides Taiwan with a well-established health sector database that stores a 
comprehensive medical history of each individual national. Associated with genetic 
diversity, the two electronic databases of household and medical history offer a 
competitive condition for Taiwan to establish its population biobank. Because of these 
advantages, some scientists and pharmaceutical industries started to lobby the
government that a population biobank will be a worthwhile investment that can help 
Taiwan improve its scientific research and biotechnology development by mining its 
abundant genetic resources.  
4.1.4 Bioinformatics 
The progress of research on bioinformatics in Taiwan is reflective of Taiwan’s 
biotechnology development. With a hope to make use of biotechnology industries to 
propel Taiwan’s economic growth, the government has systematically supported 
education in bioinformatics since 1990. In addition to setting up the Bioinformatics 
                                                
30 Ibid.
31 More information, see:
http://www.nhi.gov.tw/English/webdata/webdata.aspx?menu=11&menu_id=594&WD_ID=594&webdata_i
d=3173 (Last visit: 08 March 2012)
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Research Centre at Yang-Ming University in 2001 which was then the largest 
bio-computing resource in Taiwan,32 the National Science Council (NSC) founded about 
50 short-term granted programmes to encourage incentives for bioinformatics research 
in the same year. Several undergraduate programmes were established with the funding 
support of the NSC in 2002.33 Furthermore, a coalition research network was established 
together by the National Health Research Institute (NHRI), the National Centre for High 
Performance Computing (NCHC) and three national universities.34 This consortium aims 
mainly to coordinate resources and collaborate to build up a bioinformatics infrastructure 
for Taiwan. Even though the mature IT environment is beneficial for the establishment of 
a biobank, the biobank itself can also stimulate related industry growth. 
For biobanking, it also requires a sophisticated IT system to support its operation. The IT
system in biobanks is generally composed of two major parts. One is the core computing 
system designed for the management of sample collection and storage. It includes an 
information system for data transportation and software programs supporting anonymity 
of data and long-term tracing of coded samples. The other is a peripheral software that 
supports management of documents, standard operating procedures (SOP) and 
systematic automatic operation etc.35 Taiwan’s strength in information technology 
manufacture effectively backs up bioinformatics - the application of statistical knowledge 
and informatics in life sciences. As a biobank produces useful genetic information, the 
government hopes to make the most use of the biobanking project not only for the 
improvement of public health in Taiwan, but also for the advance of the country’s 
competitive edge in the global bio-economies. 
4.2 Building the Biobank
4.2.1 Agencies and Facilities
Taiwan Biobank is designed as a prospective cohort study which plans to collect about 
200,000 blood samples and personal health information from voluntary participants aged 
30-70. Although a consensus was reached in the National Science and Technology 
                                                
32 Sara Harris, "Biotechnology: The Next Engine of Growth for Taiwan's Economy?" (European Molecular 
Biology Organization (EMBO) Reports, 2002).
33 Ibid.
34 Ibid.
35 Supra note 17, P. 17
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Conference that there is a need to build a large-scale population biobank, the term 
“Taiwan Biobank” had never appeared as an official name for the project until the 
Department of Health started to request implementation proposals and to use this term 
on its documents. However, two years before this biobank project was formally proposed 
by the Department of Health in April 2005, the National Science Council, one of the eight 
ministries under the Executive Yuan which is responsible for promoting S&T research, had 
already proposed a feasibility study to establish a genetic database for Taiwanese genes 
and disease. This feasibility study which aimed to collect about 1,000 human samples
during a period from August 2005 to 2007 is a sub-project under the National Research 
Program for Genomic Medicine (NRPGM), a national priority program launched by the 
NSC in 2002. 
The goal of this NRPGM project is to act as an “initiator” for Taiwan’s biomedical research 
and to increase Taiwan’s competitive advantages by capitalizing knowledge acquired
through the studies of genomics and bioinformatics.36 As a result, several core facilities 
have been set up by the project. For example, the National Clinical Core for Genetic 
Medicine (NCC) is an infrastructure for research on pharmacogenetics in Taiwan.37 In 
order to understand the drug responses on the complex diseases, the NCC established a 
Han Chinese Cell and Genome Bank which collected 3,380 samples from voluntary 
non-aboriginal Taiwanese citizens.38 The sample collection for this small-scale database
was completed in 2005. Used as a control group in comparative studies with diseased 
people, this small-scale population database planned to map single-nucleotide 
polymorphism (SNP) markers of Han Chinese in Taiwan for gene-disease association.39
Even though the database sampled only Han Chinese and so was not reflective of the 
entire genetic profile of the Taiwanese population, it commenced a preliminary 
experiment for the establishment of a population biobank for genomics research in 
Taiwan. 
                                                
36 See, http://nrpgm.sinica.edu.tw/en/content.php?cat=agtc (Last visit: 08 March 2012)
37 See, http://db1n.sinica.edu.tw/textdb/nrpgm/webFile/1193392689.pdf (Last visit: 08 May 2012)
38 As the database aims to collect samples from Han Chinese, one of the sampling criteria is that 
participants, aged above 20, need to have “no parents and/or grandparents of aboriginal or foreign 
descent” See, http://ncc.sinica.edu.tw/han-chinese_genomebank/about03_e1.htm (Last visit: 08 March
2012)
39 More information, see: http://ncc.sinica.edu.tw/han-chinese_genomebank/about01_e1.htm (Last visit: 
08 March 2012)
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In 2003 the Institute of Biomedical Sciences (IBMS) at the Academia Sinica was 
commissioned by the National Science Council (NSC) to formally execute the feasibility 
study for the biobank project funded under the NRPGM. Even though no real samples 
had been collected, scientists at the IBMS took this opportunity to plan out the whole 
operating procedures involved in sample collection for the subsequent establishment of 
the Taiwan Biobank. With this earlier experience obtained in participating in the 
feasibility study, when the Department of Health announced this biobanking pilot project 
two years later, the scientists of the IBMS started to organise a preparatory team and 
submitted a joint proposal for bidding for the project. The team won the bid as the sole 
bidder and this preparatory group acted later as the biobank cooperative team 
responsible for designing and executing the whole pilot study. Even though both the 
feasibility and the pilot studies were executed by the same group of scientists at the IBMS, 
Academia Sinica, the two projects appear in different formats. The feasibility study is 
more like a research project funded by the NSC; so strictly speaking, it had not yet 
become a formal plan of the government. In Taiwan, researchers and academics are 
encouraged to propose their plans of study to the NSC for grant application. If a plan is 
approved, the NSC will support the requested funding for research. Compared to the 
feasibility study, the pilot study announced by the Department of Health is a preliminary 
government plan, the budget of which comes from its upper scheme - the Biomedical 
Island Project. As it was a pilot government plan, an open bidding procedure set by the 
Government Procurement Act needed to be followed in order to decide who the 
executors were. 
The original plan held by the IBMS was to implement this biobanking project by making 
the most use of the resources at the Academia Sinica.40 Therefore, in addition to the 
expertise in molecular biology and epistemology that the IBMS already holds, other 
institutes at the Academia Sinica would be expected to provide assistance in the overall 
project design. For example, the Institute of Jurisprudence might help in planning out a 
regulatory framework and the Institute of Information Science could assist in setting up a 
sophisticated information and management technology which is crucial in biobanking. 
However, in the end, the project did not really follow this original plan. On the contrary, 
rather than unified execution by the Academia Sinica, the pilot study of the biobank 
                                                
40 Interview with scientists at the IBMS, Academia Sinica, Taipei, 2009
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project divided itself into four subdivisions - the Medical Genetics, the ELSI (Ethical, Legal, 
and Social Implications), the Information Technology and the Industrial Application. 
Except for the Medical Genetics group which is under the IBMS, the other three divisions 
were in charge of the following organizations and institutes respectively: the Medical 
Professionals Alliance in Taiwan (MPAT) for the ELSI group, the Institute of Information 
Industry (III) for the IT group, and the Development Centre for Biotechnology (DCB) for 
the group of industrial application. A preparatory office is set on the 8th floor of the IBMS 
building in order to coordinate these four groups. 
This fragmented framework design has made the coordination of the project complicated. 
In addition, not every division has equal power in the overall decision making process. 
The Medical Genetics group of the IBMS has been in fact the main unit responsible for 
the major project design and its operation. The Taiwan Biobank Operational Office was 
established in 2005 in order to coordinate these four divisions. Even though the four 
divisions were responsible respectively for setting up operational frameworks involved in 
their own tasks, when different opinions existed, it was up to the Operational Office to 
reach resolutions and made final decisions. Chen Yuan-Tsong is the leading director of the 
Operational Office. Other members in the Office include Shen Chen-Yang, a co-director of 
the biobank project, a PI from the ELSI division, two representatives from IT and biotech 
industries, and two other members with the background of management of information 
technology.
According to the pilot study proposal for the biobank, the Medical Genetics division is 
mainly responsible for planning out the operating procedures concerning recruitment,
sample collection and storage, and questionnaire design. The expectation was that after 
completing this pilot study in four years (2005-2009), approximately 15,000 (out of 
200,000) samples would have been obtained. In addition, in terms of facilities, there are
two laboratories located in the IBMS specially prepared for this biobanking pilot study. 
One is a laboratory for sample storage that includes eight freezers set at -80C and four 
vats of -196C liquid nitrogen, the current lowest temperature equipment for sample 
storage at the IBMS. As to capacity, one freezer can store about 28,800 samples and one 
vat of liquid nitrogen 58,968 samples. As a result, in order to reach the final goal of 
collecting 200,000 samples from Taiwanese people, the biobank will need to have at least 
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86 freezers and 40 vats of liquid nitrogen. Besides the storage equipment, the other lab is 
equipped with a DNA extractor through which DNA can be extracted from blood. 
However, in addition to basic quality check (QC exam), no further DNA analysis is allowed 
to be conducted at the pilot study stage. 
As for the personnel, about 25 to 30 staff members have been recruited to work full-time 
for the project. Most of them are research nurses and medical technologists responsible 
for sample collection. Even though at the current stage, no full-time researchers and 
scientists are recruited specially for the project, the scientists at the IBMS have provided 
a large amount of assistance to the project, especially for questionnaire design and data 
standardisation. Moreover, even though the IBMS has the necessary equipment, it has 
also considered the possibility of transferring the operation of the biobank to other 
research institutes, for instance, the National Health Research Institute (NHRI), after the 
biobank was established. For this reason, the IBMS has tried to keep the pilot study 
project as independent as possible in terms of both its personnel and key facilities. 
Another concern came from the challenge that questioned the initiatives of the biobank 
project. It was said that the project was designed particularly for the scientists at the 
IBMS who need this large-scale biobank to support their own research projects which 
require an adequate amount of samples for analysis.41 In order to ease such worries, 
especially when the two principal investigators of the biobank project are also leading 
scientists at the IBMS, the biobank office guaranteed that this pilot study will be operated 
independently from any other research projects under the IBMS.42 The attitude of the 
IBMS toward the biobank, according to the project directors, is to provide service for the 
government.
We all have our own regular research work to do so that is why I said it is just like providing 
service. It is a task “demanding a great deal of efforts but cannot even please the public.” 
(there is a Chinese proverb: “吃力不討好” Chi Li Bu Tao Hao.) We do this because we truly 
                                                
41 Interview with an anonymous informant, Taipei, 2009
42 For this reason, the pilot study has its own independent set of facilities. A specific operating office was 
set up in particular for the pilot study. The office recruited six full-time staff members working for matters of 
operation preparation - two of them are responsible for laboratory work, two for sample collection and the 
other two for questionnaire design. Each of them has a background in microbiology or epidemiology in 
graduate level.
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think and hope that this project will benefit future generations and will lead to 
improvements in developing preventive medicine. Some social scientists criticize that the 
biobank seems to be a project designed tailoredly for Director Chen43, but just as he (Chen) 
has been saying that one day when the results of this research finally come out, we (refers to 
Shen himself and Chen) even don’t know where we will be then. (Interview with Shen 
Chen-Yang, Taipei, 2009)
Shen had used the term “providing service” to explain the relationship between the IBMS 
and the execution of the biobank project. Even though the Taiwan Biobank was originally 
intended to run for 20 years, the budget and capacity has remained a challenge. The 
budget (about NTD 300 millions) funded by the DOH could only sustain the pilot study for 
four years from 2005 to 2009. After September 2009, whether the budget from the DOH
would continually be granted was still not certain during that time. As the budget needs 
to go through reviews at the Legislative Yuan (Parliament), one condition for continuing 
the budget also depended on whether the pilot study executed by the IBMS had
complied with the ethical norms and standards set up by the Institutional Review Board 
(IRB) of the Academia Sinica. In addition, according to Chen, the IBMS might not be able 
to keep running the biobank in the long run because of the project’s ambitious goal of 
collecting 200,000 samples. One reason for this is due to the spatial capacity. The IBMS 
now has only two buildings (called “Old Building” and “New Building”) at the campus of 
the Academia Sinica but they need to accommodate over 800 personnel, including 56 
full-time and adjunct principal investigators, 61 postdoctoral fellows, 472 administrative 
and technical staff, and 282 graduate students.44
4.2.2 Ethical Puzzles
The Taiwan Biobank is expected to revolutionise Taiwan’s public health system and the 
biomedical research environment. However, rather than being merely a repository of 
bio-specimens and genetic data, this biobank had also provoked anxiety, confrontation 
and even distrust in Taiwanese society. Much criticism of the project was particularly
concerned about issues of inadequate consent, privacy infringement and the lack of 
                                                
43 Director Chen Yuan-Chong is a leading scientist in the area of pharmacogenetics. Chen returned back to 
Taiwan in 2000 from the United States where he obtained his doctorate in Genetics from the Columbia 
University and thereafter had been working for the Duke Medical Centre over 30 years. 
44See, http://www.ibms.sinica.edu.tw/pages/intro/index.php?id=04 (Last visit: 08 March 2012)
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public deliberation. At the beginning of 2006, a few months after the IBMS formulated its 
proposal for implementing the biobank pilot study, an article published in a Taiwanese 
newspaper by a lawyer from the Taiwan Association for Human Rights (TAHR) severely 
challenged the initiatives and purposes of establishing this large-scale biobank in Taiwan
and claimed that the pilot study had severely violated due process in its sample 
collection.45
However, this condemnation was later proved to be a false charge as the writer confused 
the biobank project with another cohort research operated earlier by the IBMS that 
required blood collection from participants as well. Although some clarification was given 
by its two principal investigators, the biobank plan was for the first time exposed under 
the spotlight. For the executing scientists, since the project was still at its very preliminary 
stage that limits the degree of transparency to a certain extent, they thought that this 
article had a negative influence on the public perception of the project. However, for the 
human rights association and some opposing social scientists, this approach toward 
setting up a large-scale population biobank provoked their doubts about the project from 
the very beginning as it had never gone through public debate and serious discussion
among the public. In addition, all the relevant rules and regulation about the biobank 
were still absent in Taiwan. This caused distrust in the project and further deteriorated 
relations between the project and the groups who opposed it. 
The major problems lay in the issue of transparency and the potential commercial 
interests behind this ambitious project. According to the critics, the project should make 
itself more transparent about these issues and initiate public engagement to obtain its 
own legitimacy even if such an attempt would not be an easy task.46 For the human 
rights advocates, the key issue is whether there is a way for the public to be involved in 
every process of decision making.47 According to them, whether this biobank is a 
“must-do” project has never been seriously discussed and debated among society in 
Taiwan. However, as this project is funded completely by the government and has made 
use of a great amount of public resources, it should be viewed as a public issue in society 
                                                
45 Chao-Chun wang, "Taiwan Biobank Project Beat the Gun? Taiwan Association for Human Rights Call for 
the Halt," Yam News, 23 January 2006.
46 Interview with an EGC member, Taipei 2009
47 Interview with human rights lawyers, Taipei 2009
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rather than simply a research plan that can only be understood and discussed among a 
group of scientists in their labs.48
Debates over the issue of transparency and public trust had suspended the pilot study 
project right at the beginning and it was not able to resume until after approval from the 
Institutional Review Board (IRB) of the Academia Sinica. Since the IBMS - the executing 
agency of the biobank - is an institute of the Academia Sinica and the biobank project 
involves research on human subjects, according to the guideline stipulated by the 
Department of Health, this pilot study needed to obtain permission from the Academia 
Sinica’s IRB before commencing its sample collection. The IRB of the Academia Sinica was 
formed in October 2004, comprising 16 members. It is a mechanism planned to review, 
approve, and supervise biomedical and clinical research involving human research 
subjects in order to make sure research does not violate bioethics. 
The pilot study proposal was first proposed by the biobank team to the IRB for review on 
14 May 2007. Nevertheless, an unexpected delay occurred and a decision had not yet 
been made by the IRB until a year later. At its sixth meeting on 19 May 2008, the IRB 
ultimately made an approval decision on the pilot study with a condition that an Ethics 
and Governance Council (EGC)49 needed to be set up.50 On the IRB’s conditional 
approval it stated that in order to seek a greater social legitimacy of the biobank, an EGC 
should be established and be responsible for the supervision of the biobank project. The 
rationale behind this decision is that compared to the EGC, the IRB itself is still a review 
board of the Academia Sinica, so it is not an ethical review mechanism designed mainly 
for the biobank supervision. According to the contents of the conditional approval, the 
EGC has a duty to report back to the IRB about its operation every six months. However, 
whether the pilot study project is allowed to commence and start its sample collection is 
a decision which remains to be decided by the EGC. 
Nevertheless, another issue being raised was regarding how and by which procedures 
this EGC could be set up. An important rationale concerning forming the EGC is based on 
the idea of modern democracy. That is to say, who decides by which standards the rights 
                                                
48 Ibid.
49 This Ethics and Governance Council was also funded by the Department of Health from its original 
budget for the pilot study of the Taiwan Biobank.
50 Interview with an ELSI scholar, Taipei, 2010
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of access of the biobank can be granted is a question that needs to be justified. Unlike the 
IRB which is an institutional supervision mechanism, the EGC is composed of members 
selected from among society with different backgrounds so it may be regarded as a 
representative of “the public” and therefore its decision seems to be more legitimate 
than that be made by the IRB. Even though a consensus was reached that the EGC should 
be set up, its forming process opened another prolonged journey. In fact, it took about 
eight months for the Selecting Committee of the EGC to nominate and vote for the final 
19 members to form this governance council.51 According to the original plan supported 
by the IRB, the members of the EGC should be nominated together by the Academia 
Sinica and the Department of Health. Because the department is the funding agency of 
the biobank project, its responsibility of supervising the execution of the project is a way 
to fulfil the requirement of political accountability. However, this original plan was not 
carried out and it was finally replaced by another selection process of “two-stage 
nomination,” namely it was the IRB who initially nominated a group of people who would
serve as a search committee and from which the final 19 members of the EGC was later 
recommended and selected.52
In fact, after the IRB released its conditional approval in May 2008, in order to meet the 
requirement of setting up the EGC, the ELSI group of the biobank pilot study had 
suggested a list of candidates to be nominated as the members of this EGC. The original 
idea supported by the ELSI group was to invite some principals of universities to set up an 
association called the Principal League and then use this League to act as the EGC to 
supervise the pilot study as well as the biobank’s operation later on.53 In the view of the 
ELSI group, the Principal League which was composed of five university principals and one 
former Minister of Education should have been able to reach a required reputation to call 
for the public’s attention to monitor the project and therefore to assure the check and 
balance function. But this idea was not accepted by the IRB and the Department of 
Health. Wishing to follow the governance framework developed by the UK Biobank, the 
IRB required that the EGC should have at least some kind of independence and only by 
which it could function well on its own responsibility. 
                                                
51 Interview with IBMS scientists, Taipei, 2009
52 Ibid.
53 Interview with an ELSI scholar, Taipei, 2009
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As far as the IRB was concerned, in order to win the public trust, the selection process of 
the EGC should be transparent and open. In addition to supervising the project, the EGC 
is also expected to play a role in communicating with the public in order to bridge the gap 
between science and society. However, the ELSI group of the project have demonstrated 
its concerns that the EGC may become a terrain for human rights groups to accumulate 
social capital by boycotting the project completely.54 Such concern reflects the fact that 
the communication between the biobank and society has not been ideal. For human 
rights advocates, if the biobank has become a project which will be carried out in any 
event, there seems to be not much space for further discussion with scientists.55 As
direct communication seems not to make sense, the human rights groups have turned 
their attention to the media and hope to use public pressure to supervise the project. For 
scientists, this kind of reaction may have made public trust in the project become even 
more vulnerable. Once the feeling of distrust emerges, it will make the project more 
difficult to fulfil in the end.56
In order to set up the EGC, a representative board was initially created. The board 
consisted of three members from the IBMS and four members from the IRB and it 
recommended and appointed the Selecting Committee of 12 members.57 The Committee 
then voted for the 19 members to form the EGC on 21 January 2009. The EGC members 
had their first meeting a month later in March 2009. Since the forming process had been 
slow, the biobank team and the Department of Health requested the IRB of the Academia 
Sinica to temporarily act in place of the EGC to supervise the pilot study until the EGC had 
been established.58 At its meeting in June 2008, the IRB reached a decision agreeing to 
temporarily execute the duty of the EGC. However, the detailed ethical review for the 
biobank project, including whether or not to permit genetic analysis still waited for the 
decision made by the EGC after its formation. Five moths later, at its meeting in 
November 2008, the IRB reviewed and permitted the biobank pilot study to start its 
sample collection of 1,000 participants at its already established two sample collection 
sites - one in Chia-yi city and the other one in Tainan, both of which are in the southern 
part of Taiwan. Before this approval, in order to test the whole design of the process for 
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55 Interview with human rights lawyers, Taipei 2009




sample collection for the project, collection sites had been set up but no blood was 
allowed to be taken.59 These collection sites were located in hospitals even though the 
nature of their work (sample collection) is not really affiliated with these hospitals.
This decision later caused much criticism as during that time the relevant governance 
framework of the biobank was still absent and the EGC was not yet set up. Because of the 
prolonged ethical review procedure, the pilot study originally designed as a four year 
project running from 2005 to 2009 had been forced to delay its execution. The period of 
execution was later extended a year until the end of October 2010. However, the amount 
of the budget allocated by the Department of Health remained the same. Since the 
budget for the four year study now needed to be used for the execution period for five 
years, this hampered the biobank plan from the beginning of its pilot study stage.
After the EGC was established, several meetings were held to review and discuss the 
biobank project.60 A question remained whether any further sample collection could be 
allowed in addition to the 1,000 samples permitted to be collected by the IRB before the 
EGC was formed, taking into account the original goal of collecting 15,000 samples for the 
pilot study. At the meeting on 3 May 2009, the EGC reached a decision to permit sample 
collection in the areas of Yunlin, Chiayi and Tainan by a vote decision of 11-7. This 
decision was criticised heavily by some EGC members as a violation of the 
consensus-based decision-making they agreed on in their earlier meetings.61 In addition, 
some controversies about substantial issues of biobanking were still unsolved. For 
instance, some EGC members criticised that there were still around 30%-50% of the 
participants who misunderstood the project as a health check which demonstrated the 
inadequate endeavours of the biobank team to communicate with the public.62
After the EGC reached this decision, a press conference was organised by an EGC member 
and a legislator in order to call for more public awareness and attention on the biobank 
project. A website was consequently set up as a means of pursuing “the national people’s 
                                                
59 Ibid.
60 The meetings were held on 19 March, 3 May and 28 June in 2009. More info, see: Control Yuan Report 
released on 15 October 2009.
61 Interview with an EGC member, Taipei 2009
62 Supra note 60.
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supervision of the Taiwan Biobank.”63 Influenced by the press meeting, the attitude of 
the Department of Health toward the establishment of the biobank project turned to 
being more cautious and concerned when its minister was questioned at the meeting of 
the general enquiry at the Legislative Yuan. In responding to a legislator’s enquiry about 
the biobank project, the head of the Department of Health made a clear statement that 
so long as the project violated human rights, the department would not continue 
supporting this biobanking project. The biobank plan was therefore put into the public 
spotlight again and it now undoubtedly needed to move out from the laboratory to go 
though scrutiny from society in order to obtain its own legitimacy.
4.2.3 The Complexity of the Governance Framework
The dual-track governance by the IRB and the EGC made the supervision of the biobank in 
Taiwan prolonged and complex. Controversies emerged due to the vague and unclear 
relationship between these two institutions. For example, it was not obvious whether a 
decision made by the EGC was binding for the IRB, or in case the two institutes held 
different opinions on their ethical reviews, which institute should have a final say in terms 
of the biobank governance. Because the EGC was formed solely based on the request of 
the IRB, its position remains ambiguous. Divergent opinions existed even among the 19 
EGC members. For some members, the EGC should act independently to supervise the 
biobank and safeguard participants’ rights. For the others, the EGC should not play a role 
in hindering the project but help the biobank to reach its necessary ethical and legal 
requirements to move forward. A consensus was hard to reach based on these 
fundamentally divergent viewpoints. Since it had never been an issue to be publicly 
debated and discussed whether Taiwan needed a biobank, the debates unavoidably 
revolved around the essential issues of the biobank legitimacy, whenever the EGC 
reviewed and decided whether to commence the pilot study. This caused the project’s 
development to become unpredictable. Furthermore, it postponed the progress of the 
biobank pilot project. 
                                                
63 More info, see the website: http://biobankforum.blogspot.com/ (Last visit: 07 March 2012) However, 
there has been no more updates on the website since the latest article posted in April 2010. In fact, after 
the Human Biobank Management Act was promulgated in February 2010, there have been very few 
discussions about the biobank project in the Taiwanese society. The Taiwan Association for Human Rights 
seems to have switched its attention from the biobank project to other more appealing and important
social issues in Taiwan based on the reason that the biobank project is now being able to be regulated by 
the newly-enacted Act. 
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The unclear relationship between the IRB and the EGC was later clarified in a Control 
Yuan report. Since the pilot study was a governmental plan but it had been delayed 
seriously in its execution, the Control Yuan initiated an investigation in 2009 to check 
whether the biobank team had any administrative defaults in its execution. The report 
released on 15 October 2009 expressed that in terms of the status, the EGC was not 
superior to the IRB because the EGC was requested to be set up to execute the IRB’s own 
duty and it needed to report back to the IRB about its operation every six months. Based 
on this viewpoint, the EGC is not an independent agency but can only be regarded as a 
mini-IRB and therefore whenever there are conflicting opinions between the two 
institutions about the biobank supervision, the IRB still has the final power to decide. For 
some EGC members, this interpretation infringed the independent position of the EGC. 
Three months after the release of the Control Yuan report, the Legislative Yuan passed 
the Human Biobank Management Act on 7 January 2010. 
The Act was enacted to regulate the establishment and operation of all types of biobanks 
in Taiwan. Even though the Act was initially proposed for specifically regulating the 
Taiwan Biobank, it can now be applied to all types of biobanks with a purpose to 
legitimise some already existing small-scale biobanks in research institutes and hospitals 
in Taiwan. Since the passage of the Act, the complex puzzle of the dual-track governance 
has temporarily been solved. According to the Act, the establishment of biobanks should 
be governed by an EGC set up from the biobanks’supervisory authority which needs to 
comply with certain criteria to be set up. For that reason, the EGC formed in January 2009 
will not be expected to continue supervising the biobank project but another EGC needs 
to be established by the Department of Health according to the stipulation of the law. 
However, it also implies another prolonged process in terms of implementing this ethical 
review requirement.   
Since the initiative of the pilot study in 2005, the main issue that has been raised and 
discussed about the biobank project has been how to set up a suitable governance 
framework for the establishment and management of the biobank. Because the biobank 
plan was designed to ultimately collect 200,000 samples from Taiwanese populations, 
this great amount of sample collection and storage requires a well-established 
governance framework for its long-term sustainability. In Taiwan, however, when the 
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idea of the biobank was initiated, relevant rules and regulations were still absent. The 
only rule about sample collection was the Ethical Guidelines for Research on Human 
Subjects released by the Department of Health in 2007. But these guidelines are only an 
administrative order so they have no imposing sanction on the enforcement. In addition, 
since the blood and samples contain genetic information that is not only personally 
identifiable but can also be identifiable to a research subject’s family and ethnicity, the 
requirement of data protection on the biobanking was deemed to be urgent and 
imperative. 
The Human Biobank Management Act was enacted under this background. It is designed 
as a specific regulation on biobanks with the purpose of conducting genetic-related 
biomedical research. Like the biobanking project itself, the Act represents an image of 
power negotiation and compromise among a variety of actors and agencies in order to 
reach a balance between the production of scientific knowledge (and biovalue) and the
protection of research subjects. For example, the scientists of the IBMS, human rights 
advocates of the TAHR, indigenous participants, the IRB of the Academia Sinica, the EGC 
of the pilot study, and ELSI groups both inside and outside of the biobank team all 
participated. These different agencies constitute a governance framework with 
Taiwanese characteristics. It shows that even though self governance such as the 
mechanisms of IRB and peer reviews among scientist groups may be effective in some
countries, in Taiwan, formal legal rules are still placed at a paramount position in terms of 
biomedical governance. How does this respond to Taiwanese culture and milieux? 
Looking in depth into the formation process of the Human Biobank Management Act, it 
illustrates that an emerging social energy from the bottom-up is gradually strong enough
to challenge and transform the formation of a top-down biotech plan. This also explains 
Taiwanese democratic transition to some extent, and therefore, a government policy has 
to go through the scrutiny from the public in society in order to obtain its own legitimacy. 
Even though that whether the biobank project will be successful or not depends on many 
factors, the support from the public should be placed at the foremost. Without a trust 
relationship, a biobank is threatened to fail as several cases around the globe have 
illustrated. In Taiwan, as the biobank is a solely government funded project, the 
Department of Health needs to face seriously all the challenging voices from society. In 
the four year pilot study, however, who should be responsible for the biobank plan has 
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been a mystery. The government holds itself back based on the position that the plan is 
still in its pilot stage. For that reason, most of the time, the executing scientists are 
pushed to respond to critical enquiries from the society. However, for the scientists, they 
seemed to have held a view that the requirement for public communication is also 
beyond their remit. Since no agency was willing to stand up and tell the public in a 
responsible way why Taiwan needed a biobank and why now; then openly call for the 
public’s discussion about the plan, the biobank pilot study has staggered along the way in 
its early four year development.
4.3 A Co-Productive Perspective on Biobanking
As Sheila Jasanoff argues in her book Designs on Nature, the notions of modern 
democracy, such as deliberation, citizenship and accountability can only be better 
understood in a broader context of the politics of science and technology.64 She uses the 
notion of “co-production” to describe the mutual interaction between science and 
society. Although the development of science may bring significant implications to society, 
the existing political and cultural structures in the society will feedback to science in a 
process of policy formation and by political narratives. For Jasanoff, the notion of 
co-production provides a perspective which may be used to comprehend the dynamic
interface of scientific knowledge and social order. In so doing, a new discourse of the 
politics of science and technology may be produced that will provide an opportunity to 
represent identities and institutions which are embedded in the narratives of the science 
and technology policies.   
Jasanoff adopts this co-production perspective to explain in detail how the US, British and 
German governments and their people are coping with several biotechnology innovations, 
such as embryonic cell research and genetically modified food, etc.65 Although the 
governments in these three countries are in favour of promoting biotechnology advances, 
the perceptions of the public in these three nations toward the S&T policies have been 
very different because the historical and cultural contexts vary. In the United States, 
based on its constitutional tradition and Congress’ support of scientific and technological 
development, biotechnology has been reframed as a “product” which is regulated mainly 
                                                
64 Sheila Jasanoff, Designs on Nature: Science and Democracy in Europe and the United States (Princeton, NJ: 
Princeton University Press, 2005). pp 7-9 
65 Ibid., pp 152-155
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by scientists’ self-governance and technocrats’ risk assessment. The result of this is the 
privatization of the decision making process and the narratives concerning S&T policies 
are easily framed by interest groups. On the contrary, biotechnology in the United 
Kingdom has been regarded as a “process” of public concerns. In order to promote public 
communication, the British government has been trying to make institutional innovations. 
However, due to the background of respecting British elite culture, the real practice of 
public participation in S&T decision making remains to be seen. Finally, Jasanoff argues 
that in Germany, biotechnology has been deemed to be a “program” by which the 
government and scientists work together in order to avoid the danger that the 
development of science will be used as a way to infringe human rights. It reflects 
Germany’s deliberate and cautious attitude toward scientific research based on the 
successful strategy used by Germany’s Green Party and the historical context of the 
lessons of the Nazi era. In order to ensure rational decision making, the German 
government adopts expert committees drawing up specific laws to regulate biomedical 
research. However, the government’s conservative attitude toward scientific and 
technological development reflects the public’s silence about the S&T policies in 
Germany. 
For Jasanoff, even though the three governments have different attitudes toward 
biotechnology development, they all fail to propose a new discourse by which the 
opportunity of public involvement into the S&T policy formation can be reinforced. She 
further develops the term of “civic epistemology” to argue that in the process of 
knowledge formation, in particular of scientific knowledge, the public should not only be 
acceptors. 66 In addition, neither is scientific knowledge absolute and definite. To 
conclude, the public’s perception toward new scientific and technological policies is 
influenced by various factors and elements which are embedded deeply in a broader 
historical and cultural context. Following this discussion, it may be worthwhile to ask: 
what are the politics of science and technology in Taiwan? Or the question may be 
further formulated in this way: what political and socio-economic contexts may be 
outlined in a theoretical way that provides a broader network of meanings where the 
observation of public attitudes toward the biobank project in Taiwan can be anchored? In 
the language of Paul Rabinow, it is to ask: what national characteristics can be delineated 
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to show “a reflection on the forms” of important events?67 To answer these questions, 
technocrat governance seems to be a proper prism by which the deeper relationships 
among politics, S&T policy formation, and the Taiwanese society may be observed. Even 
though deliberative democracy and public engagement have been proposed by the ELSI 
group of the biobank project, these notions have not yet been fully materialised in the 
biobanking practices in Taiwan. The major obstacle to involving the public into the 
process of policy making lies in that Taiwan still lacks a strong tradition for public 
consultation in its development of science and technology policies. In addition, it is also 
worth exploring the role of the emerging society in Taiwan. 
4.4 The Politics of Trust
4.4.1 Pubic Engagement
Public engagement is an essential ingredient in the process of biobanking. The rationale 
for public involvement in S&T policy formation is usually in two parts. One is for achieving 
ideal outcomes in rules and policy implementation; the other is for expression of rights of 
individuals and groups participating in the policy-making process.68 Even though the 
establishment of the biobank in Taiwan may be viewed as a way to meet the common 
good, in this pluralist-values modern society it seems more and more difficult to keep an 
objective standard to decide what the common good of the society would be. For that 
reason, some mechanisms have to be deployed for making sure that different viewpoints 
on any matter can be fully expressed. A mechanism of public engagement is expected to 
be an ideal option to guarantee public trust and make sure that different voices may be 
taken into account. Participatory democracy has been proposed by the ELSI group of the 
biobank project as an important principle for the engagement of the public. Contrary to 
the traditional representative democracies that tend to rely on decisions made by 
politicians and limit citizens’ participation to voting, participatory democracy creates an 
opportunity for a bottom-up decision-making model as it creates the legitimacy of 
decision making coming from the participation of the citizenry. In Hannah Arendt’s words, 
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such participation is significant because this is not only a way for men to be heard and be 
seen, but also to excel and be remembered.69
The antiquity, especially the Greek polis, is the model for Arendt. She uses Greek 
experience as both the exemplar of her political dream and a standard by which 
postclassical experiences are judged. For ancient Greek citizens, citizenship meant first of 
all to be present at the citizen assembly (courts or clubs) since in these occasions they 
could talk, discuss, and make decisions.70 The ultimate source of the Greeks’ enthusiasm 
for the public came from their agony of death and their pursuit of immortality.71 As 
argued by Arendt, the ability to act is the “exclusive prerogative” left by God to men that 
makes immortality somewhat possible.72 Actions - or one can say “participation” in the 
current context - are very basic in the sense that they not only make men immortal, but 
“insert men into the human world” and make men be reborn.73 Arendt’s views of the 
political depict her ideal of participatory democracy. That provides us a profound 
platform for a review of public engagement in biobanking nowadays. 
However, before further analysis, there is a need to clarify the notion of “public 
engagement” itself. As Sue Weldon has mentioned in her report for the UK North-West 
Genetics Knowledge Park (NOWGEN), the term “engagement” is often used 
interchangeably with such other terms as “dialogue” and “consultation.”74 However, she 
fails to argue that these three terms actually bear very different purposes. Like the 
practical guidelines that the Research Councils UK suggests, “public engagement” in the 
context of genomics research is stimulating interest in, and raising awareness of, science 
among the public. Under this definition, “engagement” is more like an informal, two-way 
interaction while the “dialogue” is being portrayed as an informal but multi-way one, and 
the “consultation” implies being formally instigated for a policy outcome.75 These 
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definitions help us to understand that there are at least three different approaches to 
perform the interactions between the public and professional experts, who are often 
decision makers in law or related policies. 
However, once the requirement of “public engagement” has been lifted to a higher 
standard, such as “participatory democracy” as the ELSI group of the biobank puts it, 
public engagement here seems to imply the possibility of creating something new. In this 
sense, public engagement is more like a formal process of policy creation rather than an 
informal mutual understanding between the experts and the public in its narrowest 
literary interpretation. This reminds us again of Arendt’s “second-born” reference and 
where her aspiration of freedom comes from.76 For Arendt, the polis is an abstract 
concept that depicts a sphere wherein the people are acting and speaking together.77 So, 
what matters for men who live in a polis is their “speech and act.” Participatory 
democracy presupposes the capability of the public and people’s willingness to take part 
in public matters. In John Dryzek’s words, participatory models of engagement imply that 
there is an opportunity for all parties to negotiate and revaluate their position in the 
society.78 Therefore, the fulfilment of participatory democracy is mainly based on 
people’s voluntary involvement, people’s speech and acts.
Another important aspect in public engagement involves the term “the public.” As 
addressed by Weldon, the public is no longer one homogenous entity.79 The public 
constitutes a range of “publics,” which may share different interests and may not be 
mutually exclusive. For that reason, it may be worthy to discuss which “publics” in what 
capacity one needs to consider in evaluating engagement. In the case of Taiwan, however, 
individuals have been addressed as unitary users in the whole biobanking process rather 
than being addressed as members of wider social groups. For example, while talking 
about the basis of public engagement in the biobank, “local community” had been
proposed as the basic unit in the process of enhancement of public trust. But even 
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though the idea recognizes the need to engage with representatives of local residential 
communities, it fails to justify such awareness while the target local community is 
particularly described as the “model community.” In fact, by doing so, an outcome of 
preference might have been “framing” the interactions with the public in particular ways 
while emphasizing the importance of joining the biobank project.80 Such participatory 
design has kept itself away from appreciation of the freedom Arendt claims. While the 
“speech and act” are reframed, the freedom is limited — at most it could be the freedom 
of choice (yes/no option for the biobank), rather than the freedom of creation one 
pursues. 
4.4.2 Public Sphere and Civil Society
The major obstacle to public engagement in the biobank case in Taiwan lies in the fact 
that Taiwan lacks a long tradition of community consultation in its development of laws 
and policies. In addition, it has been arguable whether a mature public sphere or civil 
society has been developed and functions well in Taiwan. Even though “public sphere” 
and “civil society” have been used interchangeably in a great amount of literature, strictly 
speaking, these two terms are not equivalent. To some extent, “civil society” is connected 
to the discourses of modern liberal democracy, but various meanings of this term are still 
deeply embedded in the historical context. But what is meant by civil society today? In 
general, modern discourses of civil society can be understood by three crucial 
components. The first perspective pays attention to the cultural dimension of civil society 
by which civil society is seen as a site of social contestation wherein collective identities, 
ethical values, and alliances are forged.81 Under this perspective, the meaning of civil 
society is to form various values and identifications rather than repeating the established 
beliefs.82
The second view of civil society, however, arises from the observation of the radical part 
of social movements and informal networks. Initiative social movements respond to 
social concerns by generating new values and identities. The ultimate goal of this radical 
approach is not to seek reform within the polity but to reform “the institutions of civil 
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society itself.”83 The last, but also the most influential perspective of civil society, comes 
from the discourse theory of Habermas. For him, the institutional core of civil society 
comprises those “nongovernmental and non-economic connections and voluntary 
associations that anchor the communication structure of the public sphere in the society 
of the lifeworld.”84 Here, Habermas distinguishes between the concepts of “civil society” 
and “public sphere.”  According to him, the public sphere is located in civil society and is 
where people can openly discuss matters of mutual concern with a status of equality.85
Following this discussion, one may further ask: is there a civil society in Taiwan? Or we 
may put the question in this way: to what extent can this western-born notion be applied 
to Taiwan to explain its state and society relationship? Is there any limit of such adaption? 
What is the real implication when connecting discourses of civil society to the public 
engagement requirement of the biobank project in Taiwan? If civil society can be 
described as a confrontation of the power of the state that derives from the desire of 
individual protection, a civil society seems to have been emerging in Taiwan along with 
Taiwan’s democratic transition since the 1990s. However, this society has its own 
characteristics, one of which is its relationship with the concept of “public sphere.” For 
Habermas, public sphere refers to a public space that constitutes “a network for 
communicating information and points of view,” which finally transforms themselves into 
a public opinion.86 Under this definition, public sphere presupposes an ideal speech 
situation in which consensus is possible and each individual is recognized as an equal and 
rational participant whose “communicative action” forms public discourse.   
However, in Taiwan, which witnesses its democratic transition in an early stage, public 
opinion, in fact, still relies heavily on a formal legislative procedure in order to constitute 
a power of communication. The very difference lies in that, in the ongoing process of 
democratic transition, the existence of public sphere cannot guarantee that its outcome 
of consensus (if any) can necessarily become the basis of public policy or legislation. 
Therefore, the bottom-up voice may not be strong enough to legitimately transform itself 
to the status of a given right or entitlement which constitutes the core of the individual 
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protection. A similar dilemma appears in the biobank case in Taiwan. Even though the 
concept of “public engagement” or even “participatory democracy” has been introduced 
to supplement the possible challenges of the technocrat-decision model, there is still a 
lack of formal mechanism that is capable of presenting the function of public sphere 
within the policy and legal regime. If the existing gap between rules formation and public 
opinion is an outcome not only of institutional design but also of a historical heritage, 
what does civil society really mean in Taiwan’s future implementation of its biobank 
project? 
4.4.3 Technocrat-Decision Model and Its Challenges
The requirement of public engagement in the establishment of the biobank seems to 
have projected an important signal that the traditional technocrat-decision model may 
not be appropriate in today’s biotech era. In order to achieve public trust in biobanking, 
scientific experts are expected to tear down an invisible wall built between the public 
understanding of science and the scientific rationality held by experts. Public engagement 
presupposes the possibility of rational communication through which different opinions 
may be discussed and finally a consensus (if any) may be formed.87 However, in reality, 
rational communication does not necessarily lead to a consensus formation. At most, 
rational communication refers to only a process but nothing beyond. Such process, in 
Arendt’s words, is a process trying to get rid of violence. But under what conditions can 
rational communication really relate itself to a consensus formation? For Habermas, 
consensus will be possible if and only if an ideal communicative situation exists. Several 
principles underpin this ideal situation, one of which is that each individual is entitled to 
an equal right to participate in dialogue. In addition, each participant should be able to 
sincerely express her or his opinions and be willing to rationally accept the “better 
argument” presented by others.88
However, this ideal situation ignores the existence of “information asymmetry” among 
communicators while the emphasis is focused on the “rationality”. Rationality itself may 
include “mutual understanding” that makes an objective evaluation of arguments 
become possible. Nevertheless, mutual understanding may not mitigate the problems of 
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information asymmetry because, although open attitudes might be helpful to alleviate 
institutional infringement, it is eventually helpless in changing the underlying structure 
that contributes such infringement. Unfortunately, information asymmetry in terms of 
biobanks arises directly from the knowledge gap that is the core obstacle in public 
engagement. Knowledge itself, especially professional scientific knowledge, has its own 
power and authority. Such authority is by no means unchallengeable, but it may be easily 
legitimatized by the modern technocrat-decision model. Public engagement will be 
possible if scientific experts and the public speak the same language in describing the 
unknown biotech future. However, one may find the limits of language under this 
scenario. Technocrat governance is not new to the modern era since the bureaucracy 
emerged in which one-man rule has transformed into no-man rule. In the case of 
biobanking in Taiwan, scientific rationality has been lifted to a somewhat irrational height 
wherein scientific experts are responsible for all the governance, including the initial 
decision of establishing the biobank. Public engagement has never played a crucial role in 
the biobank project even though it was proposed and discussed by the ELSI group of the 
project. 
This policy reminds us to rethink Taiwan’s technocrat governance. Since martial law was 
lifted in 1987, Taiwan’s public sphere has been growing rapidly. Since 1949, when the 
KMT government came to Taiwan from mainland China, the major national policy in 
Taiwan has been evolving the core principle of “development.” In the early years, the 
main purpose of such development was aiming to fight for an opportunity to return to 
the Mainland. However, since 1972, the year when the government of the Republic of 
China (R.O.C.) formally withdrew itself from the United Nations, the KMT government has 
not been able to legitimately claim its sovereignty over the Mainland. Since then, the 
purpose of the development plan switched its interests to local construction. Generally 
speaking, this development principle contains almost every aspect of the process of 
modernization, but the main focuses are in three interdependent schemes: infrastructure 
establishment, economic (land) reforms, and industrialization.89 With a limited support 
of inner market and natural resources, the KMT government pays its major attention to 
the promotion of human resources.  
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Obtaining higher education allows professional experts the opportunity to perform civil 
service in the governmental administration. To a certain extent, Taiwan’s economic and 
industrial development has greatly benefited from this technocrat-governance model 
that covers from the beginning of policy formation to the later supervision of policy 
implementation. The Taiwanese government also enjoys the general advantages this
technocrat-governance brings. The most obvious one is that the technocrat-decision 
model can form a national scheme in a very efficient way. Nevertheless, even though 
Taiwanese society had been used to this kind of governance, along with democratic 
transition in Taiwan since the early 90s, technocrat-governance has increasingly been 
challenged by scrutiny from society. Hopefully, public engagement for the biobank will be 
able to mark its significance in Taiwan’s participatory democracy, even though the 
engagement scheme has not yet ripened during the current stage. After all, public 
engagement is valued not only for its instrumental effect in formation of the public good, 
but also for building a trust relationship between the state and society.
Conclusion
For scientists, building a biobank seems to be a straightforward idea; nevertheless, along 
with the criticism that has grown among society, the scientific rationale has been forced 
to confront challenges coming from society. The puzzle at the heart of the biobanking 
story in Taiwan, as this chapter has argued, lies in how to find a way to transform the 
invectives into an acceptable mechanism which can fulfil democracy and not hamper 
scientific development. Here, a co-productive perspective of biobanking might support 
this way of reflection. As co-production implies the importance of inter-subjectivity,
science and the social are expected to move forward at the same pace as they are rowing
the same boat. In addition, public opinions formed through the engagement of the public 
may ease social distrust as it forms the bond on which the social relies to live. Biobanking 
in Taiwan could therefore be an opportunity for the government and Taiwanese society 
to re-imagine together what the nation stands for, what the core value of the society 





Many discussions of governance of biobanks focus on the issue of informed consent. 
Since the conclusion of the Nuremberg trials after the World War II, informed consent has 
been developed by ethicists and lawyers as a mechanism to protect human subjects in 
medical research and human experimentation. However, the emergence of biobanks 
challenges the practice of fully informed consent because the details of specific future 
research are still unforeseen at the time of consent. Manson and O’Neill recognise that 
there is a need to rethink classical informed consent requirements as the scope of consent 
has been extended from clinical treatment and medical research to the secondary use of 
specimens and personal data over time.1 Bartha Knoppers also suggests that the rigorous 
standards which require explicit and written informed consent as recommended by the 
Declaration of Helsinki have caused many difficulties to biobanking in the post-genomic 
era. 2 In order to facilitate biomedical research and make possible international 
networking and cooperation, the principles of informed consent need to be refocussed
away from its rationalities of autonomy and individualism towards an emphasis on
reciprocity, mutuality and citizenship.3
This chapter aims to examine critically the role of consent in biobanking in Taiwan. Rather 
than engaging in a philosophical discussion that focuses on the principles of consent in 
Western liberal political theories, the chapter looks at how informed consent have been 
conceptualised and positioned in the forefront of Taiwanese biobank governance. Various 
standards and modalities have been developed to deal with the mechanisms of informed 
consent in biobanking. They vary from self-governance to external legally binding 
instruments. In Taiwan, ethical configuration introduces a framing process through which 
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consent was constructed not only as a matter of ethics4 but also as a legal and judicial 
endeavour for the establishment of the Taiwan Biobank. By inserting the consent 
requirement into the national legislation, the mechanism of consent was instrumentalised 
by the state to legitimise various agendas in the politics of life.5
This chapter analyses the dynamic relations among individual and collective, state and 
society, culture and identity that are involved in the practice of consent in biobanking in 
Taiwan. As biobanks generate issues concerning intervention into an individual’s private 
sphere, the governance of biobanks opens up an arena of power rearrangement between 
the individual and the collective. At the same time, the commercial potential of 
biobanking has influenced the consent requirement. When consent is mainly constructed 
as an ethical discourse, it leaves other essential issues such as access and property aside 
since obtaining consent provides biobanks with a justification for turning human 
specimens into the property of a biobank whose ownership is not yet clear.6 In addition, 
this chapter argues that an overemphasis on consent has meant that biobank governance 
in Taiwan has failed to challenge the neoliberal rationality that focuses on individual 
choices but leaves the underprivileged on an unequal footing in the development of 
modern life sciences. 
Moreover, the inclusion of Taiwanese aborigines in the biobank project in Taiwan 
questions the rationale of the individual consent model which overlooks the significance 
of collective involvement in the process of decision making in aboriginal cultures. As a 
result, how to respect aboriginal groups’ interests needs to be seriously considered in the 
practice of informed consent for biobanking in Taiwan. This chapter further argues that 
the configuration of consent depicts a contradiction in the Taiwanese reality. Even though 
the national legislation attempts to consolidate the protection of human subjects in 
biobank research, the consent mechanism risks being “demoralized” in its practice as a 
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way to feed the process of “turning populations into resources”7 under the global 
biocapital trend of commodification of human tissue samples. 
5.1. A Technique of Governance
Policies may be viewed as instruments of governance or even social institutions as some 
anthropologists have suggested in the sense that they shape people’s ways of thinking 
and acting and form relations between the different agencies involved.8 Even though 
such processes of formation are not static, so that the policies themselves may also be 
challenged and modified by the relevant actors, what needs to be noticed is how the 
construction of policies represents existing power structures that may be further 
consolidated by legal instruments to endorse political agendas. The strategic legislation 
for the governance of the biobank in Taiwan illustrates how law may operate through 
various governmental agencies as an instrument to serve underlying agendas even though 
it is apparently neutral. In this context, consent is instrumentalised as a technology of 
power that serves the state’s policies in the name of individual autonomy.9
5.1.1 Embedding Consent in the National Legislation
The recently enacted Human Biobank Management Act in Taiwan provides the general 
legal basis for the construction, management and operation of biobanks. Before the Act 
entered into force on 3 February 2010, there had been no legislative initiative in Taiwan to 
regulate the procurement and storage of human specimens for research use. However, 
the increasing demand for human samples for biomedical research encouraged the 
Department of Health to amend its administrative rules - the Guidelines for Collection 
and Use of Human Specimens for Research - in August 2006 in order to ensure that the 
procedures of sample collection were ethically adequate. The Guidelines set concrete 
contours for the process of sample collection by adopting a model of explicit and written 
informed consent.10 Even though the Guidelines regulate human subject research in 
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general and may therefore apply to the case of biobanking, they do not deal with issues 
concerning the use of human genetic information for the purposes of biomedical study. In 
addition, whether a traditional doctrine of informed consent is suitable for the case of 
biobanking had been a main issue considered among the biobankers in Taiwan.
The Department of Health - the funding body of the Taiwan Biobank - was the 
governmental agency in charge of drafting the Human Biobank Management Act. 
However, in reality, it was the experts of the ELSI group at the biobank team who were 
responsible for initiating the first few drafts of the Act that were subsequently submitted 
to the Department of Health for reviews and revisions.11 Since the drafting process 
started in early 2007, the space for public engagement was fairly limited. Even though the 
Legal Office of the Department of Health had organised several meetings for reviewing 
the drafts of the Act, most of the discussions were carried out among a few selected 
groups of experts. Only one “public hearing” was held by the Department of Health in 
2008 to gather responses about the drafts from the interested biobank stakeholders. As a 
result, in reality, there have been few opportunities for the public to be involved in the 
formation of the biobank legislation and not enough government research was carried out 
to gather adequate information about the public’s concerns on the Taiwan Biobank.12
The final draft of the Human Biobank Management Act was proposed to the Legislative 
Yuan (the Parliament) for approval on 21 July 2009 after it went through the process of 
internal reviews in the Department of Health and in the Executive Yuan (the Cabinet) 
respectively. The Act subsequently moved through a fairly smooth voting process in the 
Legislative review— it took only about a week from sending the draft from the Committee 
of Social Welfare and Environmental Hygiene to the General Meeting for a vote, and it 
was passed on 7 January 2010. The passage of the Act in such a speedy way was not very 
common in Taiwan. Normally the process of legislation is expected to be delayed if the 
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legislation is politically controversial.13 The Human Biobank Management Act was listed 
as one of the urgent laws for review and voting in the Legislative Yuan even though it was 
not politically sensitive.
Several reasons may explain this particular phenomenon. First, informed consent raised 
most difficulties since recruitment for the pilot study of the biobank started. In fact, right 
after the idea of the Taiwan Biobank was initiated, there had been a few scandals 
reported in the news media about researchers’ collection of samples from Taiwanese 
aborigines without proper informed consent.14 In order to rebuild trust from the general 
public, the government had planned to use the Taiwan Biobank as a special niche to 
trigger a unification of regulations on human subject research. This attempt was
supported by the human rights groups even though they had taken a rather conservative 
attitude towards the biobank project in Taiwan. For the human rights advocates, enacting
national legislation for biobanking in Taiwan is necessary. As the groups had planned to 
call for the public’s supervision of the Taiwan Biobank, they pushed hard for the 
enactment of the Human Biobank Management Act in the expectation that Taiwan might
prevent itself from becoming a target of sample collection for global pharmaceutical
companies to carry out drug invention and clinical trials.15
Besides, the unclear relationship between the Institutional Review Board (IRB) of the 
Academia Sinica and the later, elected, Ethics and Governance Council (EGC) had made 
the supervision of the Taiwan Biobank prolonged and complicated. The enactment of law 
is thus expected to be a more suitable way for the management of the Taiwan Biobank. In 
terms of the governance of a biobank, an external supervision model such as the 
enactment of national legislation is not a universal model. In some jurisdictions, for 
example in the United Kingdom, governing biobanks is mainly based on self-governance 
or an independent supervision mechanism, such as relying on research ethics committees 
or an Ethics and Governance Council. In Taiwan, the authority of the EGC had been 
challenged by the biobank team on the grounds that the formation of the EGC was only a 
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decision made by the IRB of the Academia Sinica. For that reason, the EGC was regarded 
by the executing scientists of the biobank team and the Department of Health - the 
biobank sponsor - as a mini-IRB which was set up to function as a model of internal 
supervision. This point of view had not yet been accepted by some EGC members who 
viewed the EGC as an independent institute. For these members, the IRB had no capacity 
to supervise the Taiwan Biobank because the biobank project in their views was no longer 
a research plan. Rather, the project is more like a public policy that will have a significant
impact on society. 
Nevertheless, even among the 19 selected members of the EGC, their opinions were very 
diverse. Some members highly valued the independence of the institute and held the 
view that the decision made by the EGC should prevail against the contrary decision made 
earlier by the IRB. These members challenged the social legitimacy of the Taiwan Biobank. 
They claimed that due to the lack of legitimacy, the sample collection should not have 
been permitted. The decision to permit sample collection was made by the IRB on 19 May 
2008, about eight months before the EGC was formally set up. For this reason, opponents 
in the EGC insisted that the sample collection should be halted until the relevant 
legislation was enacted. As for the samples which were already collected, they could only 
be stored for DNA extraction, and no further DNA analysis should be allowed. Later, the 
function of the EGC was further clarified by the Control Yuan in Taiwan.16 In its
investigatory report on 15 October 2009, the Control Yuan echoed the viewpoint taken by 
the biobank team, viewing the role of the EGC as a mini-IRB. For that reason, the samples 
which had been collected could continue to be used for research; however, the report 
also recommended that a specific law should be enacted as soon as possible in order to 
help clarify the supervisory mechanism for the biobank and to make the relevant
regulations on sample collections clearer. Ironically, even though the desirability of the 
biobank project remained questionable in Taiwan, a consensus had been formed about 
the enactment of a specific law for governance of the biobank.
On the other hand, as the biobank project had raised many concerns, the Legislative Yuan 
made a decision in December 2008 to freeze half of the budget allocated for the biobank 
                                                     
16 The Control Yuan, set by the Constitution, is a central-level governmental agency in charge of 
impeachment and audit for all government officials and government branches in Taiwan. 
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until the passage of the required legislation. This decision slowed down the process of
recruitment for the pilot study that was originally planned to reach the goal of collecting 
15,000 samples from Taiwanese people by September 2009. According to the 
administrative contract, the delay in the collection of samples imposed a penalty on the 
biobank executive team. The penalty was charged according to the total shortage of 
samples calculated on a daily basis. As a result, both the Department of Health and the 
scientists involved expected that the passage of the Human Biobank Management Act 
would allow the Taiwan Biobank project to keep moving on. 
In addition, in order to ease the ethical controversies caused by the Taiwan Biobank, the 
Department of Health made an administrative order to impose a halt on sample collection 
for all biobanks in Taiwan, right after the draft of the Human Biobank Management Act 
was proposed to the Legislative Yuan in July 2009. In the administrative order, the term 
“biobanks” was given a broad definition, so it included the archive collections of human 
specimens in hospitals and laboratories if the collections had been used to link with the 
donors’ phenotypic data for the purpose of biomedical study. Due to this broad definition, 
several biomedical research projects were forced to be interrupted. This led to great 
pressure from scientists and pathologists on the government to speed up the legislation,
so the lack of regulation would not continue impeding their research.
When the draft was in the final review process in the Legislative Yuan, the Head of the 
Department of Health made a presentation to the legislators emphasizing the importance 
of the biobank project for Taiwan and pleaded for support from the legislators to approve 
the draft. The presentation introduced the current international trend of biobanking and 
recognised that the government had tried to improve ethical mechanisms such as
informed consent and data protection in order to fulfil the requirement of good ethics for 
biobanking. The Taiwan Biobank was presented as a key infrastructure for Taiwan to 
develop research on personalised medicine in order to catch up with the international 
trend and to improve public health by discovering the causes of local common diseases. In 
the end, the Act was passed by the Legislative Yuan as a way to ease all the controversies 
regarding biobanking in Taiwan. The Human Biobank Management Act is expected by the 
biobankers to play a role in helping to position Taiwan’s biobank initiative in the context of 
the global health economy. In addition, it has transformed the mechanism of consent 
from a notion of ethics to a technology of power for serving various policy agendas.
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5.1.2 Compromise Legislation
Unlike formal regulation in some other jurisdictions such as the Norwegian law that 
defines a biobank as sample storage without reference to data,17 or the governance 
framework of the UK Biobank which relies on separate legislation - the Human Tissue Act 
2004 and the Data Protection Act 1998 - to regulate samples and data respectively, the 
Human Biobank Management Act serves as specific legislation for biobanks in Taiwan by 
prescribing rules on human biological samples and associated data together. 18 A 
respondent from the biobank sponsor indicated that such a legal strategy is deliberate as 
it aims to avoid a prolonged law-making process. In addition, it makes the legislation 
successfully escape from a sophisticated yet unsolved puzzle with regard to the 
application of a data protection law to human samples. In the current literature, it is still 
unsettled whether a specific law regulating data and information may apply to tangible 
biological samples which contain DNA information.19
Even though in the drafting process, there had been several discussions about the 
need for the enactment of two separate laws for regulating human biological 
samples and associated data respectively, we later decided to have a specific law to 
regulate biobanks so that it would save us a great deal of time in dealing with all the 
details of the rules with regard to complicated issues on samples and databases. As a 
result, we can have a law to be used immediately for the Taiwan Biobank project and 
all other biobanking activities can keep moving on. (G1, Governmental official, Taipei, 
2010)
However, as compromise legislation, the newly enacted Human Biobank Management Act 
raises more questions than it can probably answer. The main difficulty lies in the unclear 
scope of the Act that turns consent into a loaded notion waiting to be further interpreted. 
Even though there are great variations in the definitions of biobanks, what is included in 
                                                     
17 Act on Biobank No 12, February 21, 2003 (Norway); see 
http://www.europa.eu.int/comm/research/biosociety/pdf/norwegian_act_biobanks.pdf
18 Before the latest revisions of the Personal Data Protection Act approved by the Legislative Yuan on 27 
April 2010, the Data Protection Act in Taiwan applied only to eight specific industries. After revisions, the 
revised Act applies to all industries and every individual. In addition, and genetic information is enumerated 
in the revised Act as personal information to be protected.
19 Relevant arguments may be found, for example, in Heather Widdows and Caroline Mullen, eds., The 
Governance of Genetic Information: Who Decides? (Cambridge University Press, 2009). P. 8
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regulations defining the term has ethical consequences. 20 Originally, the Act was 
specifically enacted for the Taiwan Biobank; however, it later carried another functional 
task assigned by the Department of Health to unify regulations of sample collection and 
to provide a general rule for governing all existing biobanks in Taiwan. As a result, the 
draft was revised extensively in the internal review process in the Department of Health. 
By expanding its scope of application, the Act was finally expanded from a specific law 
designed for the Taiwan Biobank to a general regulation applying to all types of biobanks 
in Taiwan. However, since how to interpret consent remains ambiguous, the Act raises a 
great deal of difficulties for its practical application. 
For instance, Article 7 of the Act adopts a specific consent model that requires biobankers 
to inform participants of the objectives and duration of research, the manner in which 
tissues will be collected, the mechanisms for data protection, the expected associated 
health data to be linked in the future, etc.21 However, it has been generally recognised 
that a classical model of informed consent which requires consent to be “informed and 
explicit” may cause difficulties for population biobanks as researchers cannot identify 
future research uses at the time of consent. So, how the Taiwan Biobank could fit itself 
into this consent requirement remains to be seen. Unfortunately, even though the scope 
of the Act was expanded, the basic definition of the terms in the legislation remained the 
same. According to Article 3, the term “biobanks” was defined as “the collection of 
human biological samples which are stored for the linkage of associated data and 
                                                     
20 A. Cambon-Thomsen, E. Rial-Sebbag, and B.M. Knoppers, "Trends in Ethical and Legal Frameworks for 
the Use of Human Biobanks," EUROPEAN RESPIRATORY JOURNAL 30, no. 2 (2007).
21 Article 7 of the Human Biobank Management Act: As set forth in the preceding Article, a participant 
shall be informed of the following matters: 1. The legal authorities and their contents governing the
establishment of the biobank. 2. The identity of the biobank operator. 3. Information regarding the identity 
and the service unit of the biological specimen collectors. 4. The reasons why a particular participant was 
selected 5. The rights and direct benefits the participant is entitled to pursuant to this Act. 6. The purposes 
of collection and the range and duration of the use of the collected biological specimens; collection 
methods; types and quantities of specimens to be collected; and regions where specimens are collected. 7. 
Any complications and hazards that might possibly occur during and as a result of a collection(s). 8. Any 
possible impacts of the genetic information derived from the biological specimens on the participant, and 
his/her relatives or an ethnic group. 9. Any reasonable risks or inconvenience which the participant may 
anticipate. 10. The rights which are excluded by this Act. 11. The mechanism designed to safeguard 
personal privacy and other rights and benefits of the participant. 12. The Operator’s organizational 
structure and operating principles. 13. Specific type of health information of the participant that is
expected to be linked in the future. 14. Relevant regulations governing the applications of the biobank. 15. 
Anticipated commercial applications. 16. The participant may choose whether upon his/her death or
incapacity, his/her biological specimens and related data and information will continue to be stored and 
used. 17. Other important matters related to the biobank.
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information based on population or specific groups for the purpose of biomedical 
research.”22 Due to the lack of a clear definition of “population” and “specific groups” 
which constitute the fundamental elements for defining a population biobank, the 
application of the Act turns out to be complicated and problematical. 
The Act neglects the fact that the Taiwan Biobank uses a prospective population-based 
long-term cohort, and as a result, it requires not only collecting a massive amount of 
samples and linking them with associated personal health databases for follow-up 
application, but also re-contacting participants again and again for updating their health 
data and additional information over a long period of time. These features make the 
Taiwan Biobank different from other types of biobanks, such as biobanks for diagnosis or 
therapy of specific diseases which generally do not have a longitudinal nature and 
therefore are easier to define in terms of their research purposes. In addition, even 
though Article 7 enumerates the matters participants need to be informed of, it is not yet 
clear whether re-consent is required for future research uses of samples and data, and 
whether the consent requirement could be waived when certain safeguards are ensured, 
such as anonymisation of samples and data or the approval for future use from research 
ethics committees, etc. Due to the unclear definitions, the Act fails to respond 
appropriately to the distinction between various types of biobanks considering their 
different functions and purposes. Such uncertainty makes the interpretation of the Act 
exceptionally difficult in the biobank practice in Taiwan that includes finding an
appropriate interpretation of the consent requirements.
5.2. Framing Consent
5.2.1 Consent Models
Numerous discussions in the literature revolve around the applicability of informed 
consent to biobanking.23 The general argument points out that it seems to be inadequate
to apply a classical doctrine of informed consent to biobanks, especially to a population 
                                                     
22 Article 3, the Human Biobank Management Act (Taiwan)
23 In the recent literature about biobanks, consent has been a major issue to be touched upon. See, for 
example, Principles and Practice in Biobank Governance, ed. Jane Kaye and Mark Stranger (Surrey, England: 
Ashgate Publishing Limited, 2009).; Bernice Elger et al., eds., Ethical Issues in Governing Biobanks: Global 
Perspectives (Hampshire: Ashgate,2008).
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research biobank of a longitudinal nature. Since research questions for such a biobank 
evolve over time, it is difficult to anticipate future projects when a sample is taken at a 
certain moment. Given that the contents of future research are unforeseen for both 
researchers and participants, in reality, it is impractical to obtain participants’ specific and 
explicit consent, even though in bioethics, such consent is normally required for human 
subject research. Besides, among current international guidelines, there is a lack of 
consensus on what types of consent are suitable for biobanking. A variety of modified 
consent requirements emerge between the two extremes of strict consent and broad 
consent. For instance, a multi-layered consent was proposed as a compromise between 
the two. Introduced by the Medical Research Council of Canada, this consent 
arrangement requires a comprehensive consent form, which allows participants to choose 
among the listed options they would like to be kept informed about for secondary use of 
their donated samples.24
In addition, a hybrid consent model has also been projected. In this model, specific 
consent needs to be obtained for the collection and storage of samples but broad consent 
for presently unspecified research. 25 The model emphasises respect for the core 
rationalities of consent even though all future research projects cannot be specified at the 
time when consent is obtained. As a result, in order to obtain broad consent for presently 
unspecified research, researchers need to inform participants sufficiently for them to 
understand what the research is generally about.26 New legislation in Spain on biobanks 
adopts another consent model that requires individuals to give explicit consent for one 
kind of research use and then broad consent to further unspecified uses so long as the 
new research projects are related to the original uses.27 Under this model, a Research 
Ethics Committee, on the donor’s behalf, has the power to make the decision on the 
unspecified research.28
                                                     
24 There are some options on the consent form for participants to choose, for example, whether they
permit biobanks to reuse samples under certain conditions of irreversible anonymization, or if they permit 
coded use for identified study, etc. See Medical Research Council of Canada 1998, Art 8.7. 
25 Margaret Otlowski, "Developing an Appropriate Consent Model for Biobanks: In Defence of 'Broad' 
Consent," in Principles and Practice in Biobank Governance ed. Jane Kaye and Mark Stranger (Ashgate, 
2009).
26 Ibid.
27 Antonio Casado da Rocha and Ismael Etxeberria Agiriano, "Consent by Research Ethics Committees: The 
New Law on Biomedical Research in Spain," in Principles and Practice in Biobank Governance, ed. Jane Kaye 
and Mark Stranger (Ashgate, 2009).
28 Ibid.
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Aiming to avoid a costly process of re-contact and re-consent, broad consent has been 
supported by several international institutions, such as the World Health Organisation 
(WHO),29 the Human Genome Organisation (HUGO),30 and the European Society of 
Human Genetics (ESHG),31 etc., provided certain considerations are met. The UK Human 
Genetics Commission and UK Biobank also favour a broad consent model in order to 
prevent impediments to scientific research from the application of a strict informed 
consent.32 A broad consent (or so-called “general consent”) allows investigators to use 
samples and data for the future research without the need to re-contact original 
participants for obtaining their re-consent. Inspired by the consent model taken from the 
experience of the UK Biobank, the pilot study of the Taiwan Biobank adopts similar broad 
consent requirements. It is worth noting, however, that even though the later enacted 
Human Biobank Management Act in Taiwan adopts a specific consent model, broad 
consent has been used for the pilot study since the project started its recruitment in 2008. 
Therefore, it still remains to be seen how the Taiwan Biobank, if it is enacted successfully 
in the future, would be able to cope with the new legislation that requests a stricter 
requirement of obtaining consent.   
It has also been argued that consent should not be treated as the sole basis of 
safeguarding participants’ autonomy and broad consent generally operates best in an 
environment of a strong governance regime.33 On the consent form of the Taiwan 
Biobank, it states that samples and associated data are permitted to be used for future 
medical research, which needs to be approved by the project’s ethics committee and 
relevant institutional review board. However, unlike the UK Human Tissue Act 2004 that 
permits the secondary use of identifiable samples whenever reasonable efforts have been 
made to re-contact donors, the consent requirements for the Taiwan Biobank do not 
specify that non-identifiability of samples and data are also a necessary condition for the 
waiver of consent. The rationale of broad consent in biobanking reflects the need to 
                                                     
29 "Genetic Databases: Assessing the Benefits and the Impact on Human & Patient Rights,"  (World Health 
Organization (WHO), 2003).
30 "Hugo Ethics Committee:Statement on Human Genomic Databases," (Human Genome Organisation 
(HUGO), 2002).
31 "Data Storage and DNA Banking for Biomedical Research: Technical, Social and Ethical Issues," According 
to the guidelines, consent may be waived if samples are annonymised. (rec.9) (European Society of Human 
Genetics (ESHG), 2003).
32 "Inside Information Balancing Interests in the Use of Personal Genetic Information," (London: UK Human 
Genetics Commission, 2002). P. 94
33 Supra note 25
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balance the freedom of research and participants’ rights. For that reason, it is important 
to consider if the waiver of consent involves no more than minimal risk for the interests of 
the participants and if research may be impeded by the extra effort and cost of obtaining 
re-consent. 
In Taiwan, this kind of independent evaluation is completely left to ethics committees to 
decide. Even if participants still have the right to withdraw from the biobank project at 
any time without liability, it raises questions such as whether the broad consent 
requirements may be justified in the Taiwanese context and for what reasons the decision 
made by ethics committees may legitimately replace the individual’s decision. In the 
recent literature, a “co-determination” structure has been introduced to supplement 
broad consent in order to uplift participant autonomy in the consent arrangement.34
Inspired by German labour law on co-determination, the idea requires researchers to 
keep participants updated on present and prospective future use of samples and data. As 
the framework asks for a greater degree of transparency, it allows participants to be 
perceived as partners of biobanks rather than simply sample suppliers. In addition, the 
model makes possible transferring decision-making from biobankers to participants who 
will then have more opportunities to decide how they would like their samples and data 
to be used in a biobank, especially a population biobank which requires a long-term 
follow-up of participants’health data.35
Nikolas Rose had used the term “ethico-politics”36 to introduce a field of “technologies of 
responsibilization”37, arguing that an increased freedom of choice has turned out to be a 
politics of enrolling citizens in government whose choice will have to be influenced by 
experts. This perspective offers a useful angle to analyse the broad consent practice in 
Taiwan. Any arguments made to support broad consent seem to concede that even if 
individual autonomy needs to be respected, other values such as communitarianism and 
reciprocity are also significant in modern society, so they have to be equally weighted in 
the process of evaluation of the knowledge production of the causes of diseases. The 
                                                     
34 Lukas Gundermann and Ulrich Stockter, "Co-Determination of Donors in Biobanks," in Principles and 
Practice in Biobank Governance, ed. Jane Kaye and Mark Stranger (Ashgate, 2009).
35 Ibid.
36 Nikolas Rose, Powers of Freedom: Reframing Political Thought (Cambridge: Cambridge University Press, 
1999). P. 188
37 Ibid. pp 74-83
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project itself might thus be regarded as a social asset so long as its research promotes 
certain values which most citizens in the society would like to support.38 As Graeme 
Laurie, the former Chair of the UK Biobank Ethics and Governance Council, has argued,
adopting broad consent does not necessarily make the UK Biobank ethically deficient if 
other adequate governing mechanisms exist.39 However, the public engagement process 
which the UK Biobank relies upon to build its own legitimacy has been omitted from the 
practice of biobanking in Taiwan. For the case of the Taiwan Biobank, a fundamental 
prerequisite to adopting a broad consent model is perhaps to enable the public to join a 
wider discussion and debate concerning the necessity, the research design and 
governance framework of the biobank in order to ensure that participants’ opinions have 
been properly represented. As a result, the legitimacy of the ethics committee will have to 
be recognised by the public in order to distinguish the institute from other possible 
instruments of policy legitimatisation. 
Salter and Jones point out that biobanks are not innovative in terms of the collection of 
samples and data for the purposes of research, diagnosis or medical treatment. 
Nevertheless, what is new in this technology is the political sensitivity of linking genetic 
data with health information for the study of whole populations.40 In Taiwan, such 
sensitivity makes the creation of the population biobank a socio-political activity. At the 
same time, it constructs the consent process as a discourse of political utility. In order to 
call for the public’s support, “creating a biobank for the health of our next generation” has 
been deployed by policy makers as a policy discourse. The rationale behind this appeal is 
the doctrine of altruism, under which participation in the biobank has been formulated by 
the biobank team as an act of donation. Such a rationale provides a distinct perspective of 
further observation on the role of informed consent in biobanking. Even though consent 
has been viewed by bioethicists and lawyers as a mechanism to secure individual 
self-autonomy, when examining its embedding context, what seems to be ignored is the 
possibility that the informed consent may have been used unintentionally as a political
                                                     
38 Erik Christensen, "Biobanks and Our Common Good " in The Ethics of Research Biobanking ed. Jan Helge 
Solbakk, Soren Holm, and Bjorn Hofmann (London: Springer, 2009). P. 2
39 Grame Laurie, "The UK Biobank Ethics and Governance Council: How Valuable Is an 'Ethics+' Approach to 
Governance?," in New Challenges for Biobanks: Ethics, Law and Governance, ed. Kris Dierickx and Pascal 
Borry (Intersentia, 2009). P. 242 
40 Brian Salter and Mavis Jones, "Biobanks and Bioethics: The Politics of Legitimation," Journal of European 
Public Policy 12, no. 4 (2005).
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technology whenever ethics becomes another terrain for power negotiation between 
actors who are on an unequal footing. Therefore, it is worth noting that how easily the 
practice of informed consent procedures in Taiwan may encourage and then transform
participation in the biobank from a voluntary action to an ethical conduct. For instance, as 
an interviewee in Taiwan pointed out, what matters to her was not what types of consent 
were used for the biobank project. Rather, it was whether she had been convinced from 
the information given that the biobank is the kind of research she would like to support. 
I would be glad to participate as it seems to me this (referring to Taiwan Biobank) is 
research that can help many people... I am not really worried about if there is a fully 
informed consent so long as I think it is a project through which I can help others and 
the research itself is good for society, I would be willing to support. Other issues 
would not really matter and won’t bother me that much.  (P1, Taiwanese Aborigine,
Focus Group, Taiwan, 2010)
However, the procedure of consent should not be regarded as requiring communication 
or conviction. Rather, it is a process of comprehension for which trust needs to be 
embedded to prevent the consent requirement from being a merely formal endorsement. 
Corrigan and Tutton have argued that for sample collection more attention should be paid 
to research participants since interpretation of consent in a broader sense has to 
re-entangle individuals within their communities, under which the notion of solidarity can 
replace individualism.41 Waldby has also used the term “imagined communities” to 
describe how discourses of reciprocation may be established from sample donations in 
which trust is framed.42 According to Waldby and Mitchell, informed consent represents 
a form of social relationship by which biological samples formally enter into a process of
tissue economies.43 Such economies are associated with not only actions and decisions 
relating to scientific progress but also great commercial potentials arising from genetic 
research on personalised medicine. As a result, it is worthwhile examining critically not 
only what kind of information is created for the process of consent, but also how such 
                                                     
41 Oonagh Corrigan and Richard Tutton, eds., Introduction: Public Participation in Genetic Databases, 
Genetic Databases: Socio-Ethical Issues in the Collection and Use of DNA (Routledge,2004). pp 1-19
42 Cathy Waldby and Robert Mitchell, Tissue Economies: Blood, Organs, and Cell Lines in Late Capitalism 
(Duke: Duke University Press, 2006). P. 76
43 Ibid., P. 33
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information is constructed as well as in which ways it has been delivered, acknowledged, 
understood and interpreted by the consenters. 
In terms of broad consent requirements for biobanks, since participants are not expected 
to be re-contacted for each new research project in the future, biobanks’ purposes and 
aims are regarded as essential information to be communicated when consent is sought. 
In practice, how such information is formed and delivered normally has a direct impact on 
participants’ willingness to take part. Nevertheless, a statement about the purposes of 
biobanks is of a normative nature. Rather than a scientific truth waiting to be proven, the 
statement essentially is a discourse of anticipation of the future. Since such entanglement 
may be difficult for a consenter to discern, the information delivered for the informed 
consent is easily entangled with the underlying policy agenda set for the biobanks. For 
instance, an inner document of the Taiwan Biobank indicates that it normally takes about 
23 minutes for each participant to complete the required consent procedure at a sample 
collection site.44 Even though participants are encouraged to ask questions when consent 
is sought, in practice, there are usually no more significant questions to be raised during 
the consent procedure. Among the participants, about 45.7% had attended the recruiting 
events organised by the biobank team before they visited the collection sites where they 
gave their consent.45 Therefore it could be inferred that quite a few participants who had 
joined the recruiting activities made their decisions to take part in the biobank project 
thereafter. For these participants, their knowledge about the biobank primarily came 
from the information provided by the biobank team. 
For the pilot study of the Taiwan Biobank, research nurses are mainly responsible for 
organising the recruiting events. The nurses are staff recruited particularly for the biobank 
project so they are full-time employees on a contract basis with the Institute of 
Biomedical Science (IBMS) of the Academia Sinica. They usually have nursing or related 
degrees and need to pass the exams on their training for sample collection. Such training 
is provided by the biobank team and includes necessary techniques of carrying out 
sample collection, obtaining consent and some basic knowledge about ethical issues 
associated with biobanking. The purpose of the training is to equip the nurses with 
                                                     
44 An unpublished document, released by the biobank team, IBMS, Academia Sinica, Taipei, 2009
45 Ibid.
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needed knowledge for answering questions raised by participants in the recruitment and 
in the consent procedures. 
Currently, there are six collection sites operating in Taiwan— three in Chiayi and three in 
Tainan— all of them are in the Southern part of the country. Generally, about seven to 
nine research nurses are assigned to a collection site where they are divided into two 
groups responsible for sample collection and recruitment respectively. The recruiting 
activities are normally task-oriented, namely the venue for recruitment is not completely 
chosen by chance. In contrast, the recruiting venue needs to be adjusted according to the 
research need. For instance, when the samples collected in a particular area are donated 
mostly by women, the research nurses will arrange to have their recruiting events aimed 
at male audiences, for example, holding events for staff working in fire stations or police 
stations, etc. In a recruiting event, research nurses mainly introduce the audiences to 
what the biobank is - its functions and purposes. 
Usually, a recruiting event lasts for about half an hour depending on the time allocated 
and the reaction from the audience. Though the contents introduced include the possible 
risks and harms associated with the biobank, the main focus is on how much effort the 
biobanking had made and will continue to make to ensure that the biobank is ethical. 
Issues such as informed consent, the right of withdrawal, coding, anonymity, and the 
ethics committee are all mentioned briefly to emphasize that a high standard of ethical 
governance is a central consideration to the biobank operator. Nevertheless, the 
recruiting process itself is in a lecture style, so it is mainly a one-side information delivery, 
not a discussion or consultation in which the information may be further examined, 
challenged or reformulated by the audience. Certainly, there is not much space for the 
creation of new knowledge about biobanking that may be fed back in to the biobank 
governance framework from this type of recruitment. 
In Taiwan, according to the Medical Law, sample collection for medical purposes needs to 
be carried out in a hospital or health clinic. Even though it is arguable whether this rule 
may apply to sample collection for a research biobank, in order to avoid controversies, the 
biobank team separates recruitment from the formal sample collection procedure. 
Currently, all six collection sites are set in hospitals. They are either a converted patient 
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chamber or a similar size rented office to make it more accessible to the interested 
participants. At the end of the recruiting activities, the audiences who showed interest in 
taking part in the biobank project are invited to leave their contact information with the 
research nurses. Then, the nurses will contact them by phone to further check on their 
willingness and arrange appointments to visit a collection site nearby. 
The formal consent procedure starts at the collection sites. Before any samples are taken, 
participants will be given a consent form with a 13-page introductory booklet that covers 
all the needed information about the biobank project: its functions, purposes, aims, 
operators, research scope and duration, the methods of recruitment, the use of samples 
and data, privacy protection, potential risks and harms it may entail, potential benefits 
(none of pecuniary benefits, but there is reimbursement of a coupon of 300 NT dollars for 
the transportation expenses), the right of withdrawal, the consent procedure, the 
governance framework, the supervision institute, waiver of any rights for any commercial 
benefits derived from the research, the accessible data from the participation and the 
circumstances for re-contact etc. In the form, there is a separate statement for the 
participants to decide whether they permit their samples and data to continue to be used 
when they become diseased or lack the ability to consent.  
The participants are expected to read thoroughly the booklet together with research 
nurses, who sit beside them. After ensuring all the information is understood, the 
participants are asked to tick beside each statement in the consent form to indicate that 
they now have a preliminary understanding about the project and they permit the 
biobank to use their samples and data for medical research purposes, which need to be 
approved by the project’s ethic committee or relevant institutional review board. In 
addition, the participants need to specify if they permit the biobank to keep in contact 
with them (every two to four years) for follow-up purposes. A separate statement on the 
consent form requests participants to indicate that they understand that their samples 
and data will be transferred to the Taiwan Biobank if it is set up successfully in the future. 
If the Taiwan Biobank is not established, their samples and data will be destroyed under
the supervision of relevant institutes, provided that there is no contrary agreement from 
the participants to allow their samples and data to be used for other purposes.46
                                                     
46 See, the Taiwan Biobank Pilot Study Introductory Booklet and Informed Consent From, released by the 
IBMS, Academia Sinica. The booklet was approved by the IRB of the Academia Sinica on 19 May 2008.
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5.2.2. Framing Consent for the Taiwan Biobank
In Taiwan, the creation of the biobank is regarded by policy makers as a project for the 
common good. For instance, on the cover of the consent booklet, there is a cartoon 
drawing showing several characters of different ages in various costumes making a circle 
standing hand in hand on the island of Taiwan. Below the drawing is the statement— “To 
build the new healthy Age, it requires you and me.” In order to have the public’s support 
for the project, common good and altruism are the two themes for justifying the biobank. 
Though what the term common good refers to needs to be further defined, it is largely 
deemed to be a utilitarian appeal for the achievement of the greatest possible benefits 
for the maximum number of people. Nevertheless, a very key issue is who decides what 
the common good is so that the rationale may be used appropriately to support the 
creation of the biobank in the Taiwanese context. A specific good that is regarded as 
something common and important by policy makers may be at the expense of citizens of 
the state. Even though in civil society, it is ordinarily problematic to reach consensus in 
the formation of public opinion, what is essential here is whether a decision concerning 
public policy is able to be fully discussed before it is made.
Certainly, improving health for the coming generation is a valid public interest. It is also a 
significant purpose for the creation of the population biobank for Taiwan. However, what 
has not yet been disclosed properly to the public is the project’s potential for 
commercialisation. According to the biobank proposal and the structure of the biobank’s 
executive preparatory team, industrial application has been anticipated by the project. 
Even though the biobank is still in its pilot study phase, in the proposal, the project is 
expected to rely on its own earnings for continuous operation if it is successfully set up in 
the future. Since the project’s current funding is solely from the Department of Health 
and its executive agency is the IBMS of the Academia Sinica, when participants are 
informed about the project, they are easily convinced that the biobank is a government 
related public asset and their participation is a meaningful action that can do something 
good for society. 
Discussion of the current governance framework of the Taiwan Biobank focuses mainly on 
the issues of consent and data protection. Controversies with regard to the potential for 
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commercialisation have not yet been fully touched upon. This partial framework has 
influenced the recently enacted Human Biobank Management Act. According to this 
legislation, the establishment of biobanks in Taiwan needs to be approved by the 
Department of Health. 47 In addition, biobank operators are restricted to certain 
organisations, such as governmental agencies, medical or academic institutions and 
research institutes.48 Therefore, who is allowed to set up biobanks in Taiwan has become 
a matter of administrative discretion. Relevant rules with regard to the review standard 
and qualifications for such applications are for the Department of Health to further 
prescribe. For that reason, whether a pharmaceutical company or any other commercial 
entity would be allowed to establish biobanks in Taiwan remains ambiguous. Even though 
Article 21 of the Human Biobank Management Act concedes the principle of benefit 
sharing for profits derived from commercial uses49, other related issues with regard to 
commercialisation remained untouched by the Act. For instance, it is still unclear who has
access rights to biobanks, whether the Taiwan Biobank is permitted to be jointly operated 
by commercial partners after it is set up, or if it is allowed to be transferred to a private 
entity for its future management, and if so, whether a re-consent needs to be obtained 
from participants, etc. In addition, if the biobank is forced to cease operation in the future, 
how to deal with the existing samples and data remains an important but unsettled issue. 
According to the Human Biobank Management Act, when the participants are deceased 
or become incapable, so long as there are no other contrary instructions, Article 9 permits 
biobank operators to continue using their donated samples and data based on the original 
scope of the consent.50 Nonetheless, under the unclear definition of biobanks and 
                                                     
47 Article 4 of the Human Biobank Management Act: A biobank operator must be a governmental agency, 
medical or academic institution, research institution, or legal person (hereinafter collectively referred to as 
“organization”) and shall apply to the Competent Authority for a permit. The Competent Authority shall 
stipulate rules and regulations to govern matters related to the permit applications mentioned in the
preceding paragraph, such as applicant qualifications, application procedures, and conditions for the 
establishment approval, review standards, regular inspections, relevant managerial matters, and other
matters of compliance.
48 Ibid.
49 Article 21 of the Human Biobank Management Act: Any profits derived from the commercial use and 
received by an operator and biobanks shall be given back to the human population groups or specific 
population groups to which the respective participants belong. The Competent Authority shall stipulate 
regulations governing the distribution of profits mentioned in the preceding Paragraph.
50 Article 9 of the Human Biobank Management Act: In the event of a participant’s death or incapacity, 
except as otherwise agreed herein, the biobank may, in accordance with the original agreement, continue 
the storage and use of the biological specimens and related data and information.
167
biomedical research prescribed by the legislation, what the scope of consent refers to 
would be difficult to interpret in its application. In addition, whether the deceased 
person’s offspring is able to request withdrawal of biobank samples considering the 
shared nature of genetic information remains unsolved. Even though Article 17 indicates 
the principle of fairness and equality to be applied for a third party’s access rights to 
biobanks if the biobanks are publicly-funded or established in the public interest,51 there 
are no more regulations in the Act to clarify proprietary interests in biobank samples and 
genetic information produced from them. As a result, how to apply the principle fairly 
remains questionable. If a third party is a pharmaceutical company, under what criteria 
would it be considered fair and equal for the company to access biobank samples, data 
and information? To what extent does the current trend of international data sharing 
need to be taken into account in interpreting third party access rights? Undoubtedly, 
these issues will have to be discussed in a much more sophisticated way that is beyond 
the research scope of this chapter. Nevertheless, such discussion needs to be grounded in 
the Taiwanese social context to consider how biobanking has been reconfigured as a 
bio-economic and bio-political activity in Taiwan. 
Since the biobank project bears various economic and political agendas, in Taiwan, it has 
become a special enterprise. As a result, the major issue that needs to be clarified is not 
whether any “good ethics” exist for sample collection and storage in terms of the 
governance of the enterprise. On the contrary, more awareness needs to be invested in 
examining cautiously how ethics was formally embodied in national legislation and how it 
is used to legitimise the underlying agenda. For a longitudinal research biobank, the 
practice of consent is doomed to be difficult since the information about future research 
is yet unknown even to researchers and biobank operators themselves. As Onoagh 
Corrigan has observed, the term ‘informed consent’ is tautological because it creates the 
misleading impression that there is explicit and specific information with which to 
inform.52 In order not to make the practice of consent turn into an “empty ethics,”53 it is 
                                                     
51 Article 17 of the Human Biobank Management Act: In the event that a Biobank that is established for the 
purpose of public interests or subsidized by the government should provide its biological specimens and 
relevant data and information to a third party, the principle of fairness and equality shall apply.
52 Oonagh Corrigan, "Empty Ethics: The Problem with Informed Consent," Sociology of Health & Illness 25, 
no. 7 (2003). pp 768-92
53 Ibid.
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necessary to bring the consent procedure back to its social and cultural context. At the 
same time, it is essential to scrutinise the possible implications when informed consent, 
introduced as an ethical principle, becomes a legal and judicial criterion of regulation in 
the governance of biobanks in Taiwan.
5.3 Group Consent 
5.3.1 Aboriginal Participation in Biobanking 
The current informed consent mechanism is based mainly on the rationale of 
individualism, considering its emphasis on autonomy and self-determination. According to 
the ethical guidelines released from the Council for International Organisations of Medical 
Sciences (CIOMS), consent can only be made by the individual even though a group can 
authorise research involving human subjects by permitting its implementation. 54
However, in genetic research, such as biobanking, the potential risks carried out from 
research results are normally of a collective nature. Taking stigmatisation as an example,
consent obtained from individuals of a specific group is regarded as inadequate to 
safeguard the interests of the entire group on which the detrimental social impact occurs. 
Under this circumstance, an individual consent needs to be supplemented by other 
mechanisms, such as group consent made from the related group or community. 
However, group consent still receives little attention in the current international 
guidelines on biobanks. The HUGO statement recognises that the choice of communities 
regarding the use of their data should be respected but leaves open the possibilities of 
implementation of such principle. The European Society for Human Genetics (ESHG) 
points out that additional group consent may be required for population studies, but it 
does not further specify the criteria for applying group consent.55 In terms of group 
involvement in consent procedures, the main issues are how to identify a group, by whom 
and by which criteria, and who may legitimately represent the group in order to give 
consent. Since “group” and “community” are open-loaded notions, the meaning of these 
                                                     
54 "International Ethical Guidelines for Biomedical Research Involving Human Subjects," ed. the Council for 
International Organizations of Medical Sciences (CIOMS) (Geneva2002). See, 
http://www.cioms.ch/publications/layout_guide2002.pdf
55 See, the European Society of Human Genetics, "Data Storage and DNA Banking for Biomedical Research: 
Technical, Social and Ethical Issues: Recommendations of the European Society of Human Genetics," 
European Journal of Human Genetics 11, Suppl 2, S8–S10 (2003).
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terms needs to return back again to its embedding context. In Taiwan, even though the 
recently passed Human Biobank Management Act intends to safeguard the welfare of 
human research subjects, several bewildering contrasts remain between the concerns of 
law makers and potential participants. The most controversial one is about how to protect 
Taiwanese aboriginal group interests when the aborigines are recruited in the Taiwan 
Biobank. 
5.3.1.1 Taiwanese Aborigines 
Recently, genetic research on Taiwanese aborigines had caused many disputes. Even 
though only 2% of the Taiwanese population comes from the aboriginal groups, this 
ethnic group has turned into a specific research target for genetic-related studies in terms 
of its genetic traits, which are relatively unique compared with most of the Han Chinese 
gene pool that covers 98% of the population in Taiwan. In addition, studies of Taiwanese 
aboriginal genetic origins are regarded as politically sensitive due to the special role the 
aborigines play in Taiwanese ethnic politics. Although it is still arguable whether the 
ancestors of the aborigines originated in Taiwan or migrated from southern China or from 
the Malay archipelago 6,000 years ago, it is generally believed that they belong to the 
Austronesian race and were once the majority of the inhabitants in Taiwan before a 
massive Han Chinese migration from mainland China in the 17th Century.56 As a result, 
the aborigines have become an expressive symbol under the trend of localisation to 
present a distinct identity for Taiwan that enables it to be distinguished from mainland 
China.
However, within Taiwanese society, the aborigines have been culturally and economically 
marginalised and also politically and socially underrepresented. In fact, obtaining 
aboriginal status in Taiwan requires government recognition. According to the Basic Law 
of Indigenous People promulgated in 2005, a group which regards itself as aboriginal 
needs to apply for approval from the central authority - the Council of Indigenous Peoples 
in the Executive Yuan. Although the Basic Law is regarded as of the same status as the 
Constitution and it was enacted for the purpose of protecting the fundamental rights of 
                                                     
56 More arguments about the creation story of the Taiwanese aborigines, See, Robert Blust, "Subgrouping, 
Circularity and Extinction: Some Issues in Austronesian Comparative Linguistics," in Selected Papers from 
the Eighth International Conference on Austronesian Linguistics ed. E. Zeitoun and P.J.K Li (Taipei: Academia 
Sinica., 1999). pp 31-94
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the aborigines, it has been criticized by aboriginal rights advocates as a violation of their 
self-determination and self-governance.57 Viewing themselves as the descendants of 
Taiwan’s original inhabitants, the aborigines hold a distinct identity from Han Chinese. 
They usually use their group to self-identify who they are. For instance, rather than using 
the term Taiwanese, they prefer calling themselves Amis, Atayal, Paiwan, Taroko, etc by 
direct referring to their groups’ names. In some cases, they also use the term Taiwanese 
aborigines to self-identify, when they have to be distinguished from Han Chinese. 
Currently, there are 14 ethnic groups that have been recognised by the Executive Yuan. 
Each of the groups has its own distinct language, customs, social structure and cultural 
features.58  
Nevertheless, it is also worth noting that the Taiwanese aboriginal groups have not been 
categorised according to their biological traits. In the Qing Dynasty of the mid-eighteenth 
century, the aborigines were broadly categorised into two groups - cooked savages and 
raw savages - according to their degree of civilisation,59 namely acculturation to the 
Chinese settlers’ culture and their relationship to the state.60 This cultural-political 
classification was followed by the Japanese colonial regime (1895-1945) and since then 
the two groups have come to form a larger subdivision - the aborigines of Taiwan.61
During the Japanese colonial period, the cooked savages were given the name plain 
aborigines as they practiced agriculture and lived on the western plains of Taiwan. The 
raw savages were called mountain aborigines who inhabited the hills and mountains. The 
ethnic categories in Taiwan were changed again after World War II by the KMT regime. In 
1956, the category of plain aborigines was dropped. The aborigines belonging to this 
category was merged into the larger subdivisions of Hoklo and Hakka based on the belief 
                                                     
57 Tsai Wen-ting, "From the Streets to the Villages - the Indigenous Peoples' Movement Turns 20," Taiwan 
Panorama (March 2006).
58 See the website of the Council of Indigenous Peoples, Executive Yuan, R.O.C. 
http://www.apc.gov.tw/main/ (Last visit: 10 March 2012)
59 It is interesting to see how the evaluation of cooking techniques has been used as a symbol to 
distinguish culture and nature in the interpretation of the degree of “civilisation.” For example, French 
anthropologist Claude Lévi-Strauss used a similar pair in his book The Raw and the Cooked published first in 
1964. He analysed the myths of certain South American Indians by exploring the evaluation of cooking rules, 
namely to see cooking as a language that can be structured as a cultural agent and transformed into a 
cultural process. More information see, Claude Levi-Strauss, The Raw and the Cooked (New York: Octagon 
Books, 1979).
60 Antonio C. Tavares, "The Japanese Colonial State and the Dissolution of the Late Imperial Frontier 
Economy in Taiwan, 1886-1909," The Journal of Asian Studies, 64, no. 2 (2005). P. 364
61 Ibid.
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that they had been acculturated into Han society.62 At the same time, mountain 
aborigines were recognised by their groups’ names. From 1956-1980, the central 
government recognised 9 aboriginal groups. Since then, the numbers of groups have been 
gradually increasing as a result of the aboriginal renaming movements. In 1990, the 
notion of the “four great ethnic groups” was invented by a politician of the Democratic 
Political Party during an electoral campaign.63 The notion broadly divided the Taiwanese 
people into four ethnic groups and the Taiwanese aborigine is one of them with the other 
three subdivisions of Hoklo, Hakka, and Mainlanders. 
5.3.1.2 Concerns about Stigmatisation
In terms of potential risks associated with biobanking, stigmatisation of aboriginal people 
concerns most human rights advocates, social scientists and lawyers in Taiwan. For 
instance, due to the emergence of genetic technology, some scientific papers regarding 
genetics research on Taiwanese aboriginal alcoholism have been published in 
international medical journals since the 90s.64 Nevertheless, this kind of research has also 
encountered serious criticism for violation of aboriginal rights. Several commentators 
claimed that the interpretation of the research findings has formed a state discourse of 
alcoholism that helps reproduce the imbalance in power relations between the aborigines 
and Han Chinese.65 The critics further pointed out that such discourse involves a 
repetition of negative stereotypes that creates a public perception of social pathology for 
the Taiwanese aborigines but not enough attention had been paid to the social and 
political conditions contributing to the phenomenon or the cultural meaning of alcohol 
for some aboriginal groups.66 This viewpoint is shared by an aboriginal interviewee who 
mentioned his concerns about the impact of the research results: 
For scientists, ethnicity is a valued label in research, but I am concerned about the 
impact of the research results… Just like a few earlier scientific studies have published 
                                                     
62 Fu Chang Wang, Dang Dai Taiwan She Hui De Zu Qun Xiang Xiang 當代台灣社會的族群想像 Ethnic 
Imagination in Contemporary Taiwan (Taipei Qun xue 2003).
63 Ibid.
64 See, Mark Munsterhjelm, "Alcoholism Related Genetics Research Involving Taiwan Aborigines as a New 
Terrain of Settler Colonialism," in Canadian Sociology and Anthropology Association Conference (2005).
65 Liu Shao-hua, "Genes, Ethics and Aborigines," Taipei Taimes, 29 August 2000.
66 Ibid.
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that aboriginal people seem to have a genetic predisposition to the illness of gout or 
to alcohol drinking. It seems to me that a research result presented in a way like this 
has made society think that aborigines are more vulnerable to have a particular kind 
of illness or inclined to have drinking problems due to our genetic markers. Of course, 
it is an unfair judgement to us. (A1, Taiwanese Aborigine, Taiwan, 2010)
In fact, informed consent procedures had been poorly enforced for most genetics 
research on Taiwanese aborigines. In some cases, obtaining consent was under the name 
of a free health check with the help of local health authorities.67 However, once consent 
was obtained, blood samples were completely detached from the living aborigines. Even 
though blood is regarded as sacred for some aboriginal cultures, the informed consent 
procedure has “secularised” the samples so they can be easily transported without 
boundaries, be processed in labs and then transformed into data and information for 
scientific analysis. Such a process of secularisation echoes the western concept of dualism 
that separates an individual into mind and body and treats the body as a morally neutral 
item so it may be objectified and even commoditised.68 Current informed consent 
discourse reinforces this kind of separation as it legitimates the detachment of blood from 
personhood and further transforms human samples into valuable resources of biocapital 
under the name of autonomous and self-determined donation. Arguing further from this 
perspective, informed consent acts ironically as a “waiver” of true autonomy as it is 
normally based on choices but often ignores how limited the space of negotiation could 
be for individuals to make their own “choices.” The situation usually deteriorates when 
research subjects come from a minority population. As was often pointed out during the 
interviews, uncertainty about how research results will be published worried most 
aboriginal interviewees. 
What concerns us here is that we do not really understand how researchers will 
present their research results. In the past, some researchers just took our blood to 
do analysis and published their research findings in international journals in English 
but we have no idea at all what the content is…  (A1, Taiwanese Aborigine, Taiwan, 
2010)
                                                     
67 Ibid
68 Kerry Bowman and Maxwell Smith, "Culture, Identity and Consent for Genomic Research," in New 
Challenges for Biobanks. Ethics, Law and Governance, ed. Kris Dierickx and Pascal Borry (Intersentia, 2009).
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An aboriginal respondent indicated that she would consider her consent to be valid only 
when some preconditions exist. One of them is the necessity to obtain group consent 
from her tribal group before any research findings were published in order to 
appropriately redress the detrimental impacts from genetics studies. 
We all know that there are so many ways in terms of interpreting research results. 
Even if I already gave my consent, it should not be inferred that I had agreed with 
you to carry out research that would eventually bring harm to my group. If I had 
known that your research findings would bring us this kind of harm, I would not 
have agreed to sign the form and give my samples. (A3, Taiwanese Aborigine, 
Taiwan, 2010)
Due to such concern, whether individual informed consent is able to safeguard aboriginal 
groups from the risks of stigmatisation is highly arguable. Taking genetics research on 
aboriginal alcoholism as an example, the critics have challenged that the increase in 
alcoholism reflects Taiwan’s rapid modernisation. Due to the rapid social transformation, 
it has disrupted aboriginal social structures fundamentally by converting their territories 
and land into resources for Taiwan’s economic development.69  However, this basic 
historical and social context was generally disproportionally evaluated in the 
interpretation of research findings. As a result, it is worth noting whether genetics 
research has in fact reproduced a hegemonic narrative regarding health and welfare for 
the Taiwanese aborigines as some critics claim.70 If so, some interpretation of genetic 
research findings may reinforce the social impact of stigmatisation that cannot be easily 
justified by legal instruments such as individual consent before the research started. 
Additionally, even if the Biobank Act stipulates the right of withdrawal, such rights 
concentrating on individuals still fail to address risks associated with biobanks as genetic 
data. Information in biobanks is of a collective nature and is usually analysed statistically. 
Although a population-based biobank relies on the use of individual samples and data for 
                                                     
69 Supra note 56
70 More arguments can be found in Mark Munsterhjelm’s doctoral thesis, "Living Dead in the Pacific: 
Racism, Sovereignty, and Biopolitics in Genetics Research Involving Taiwan Aborigines and Maori " 
(University of Windsor 2010).
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genetics analysis, it is essentially a kind of research on the group itself, so the risks and 
harms associated with such biobanks may be imposed on the entire group not on 
individuals only.71 Consequently, it is worth discussing whether a collective form of 
decision-making is required to supplement traditional individual consent especially when 
the research subject group is a minority population such as the Taiwanese aborigines for 
the biobank project in Taiwan. Some respondents suggested the necessity to have not 
only prior group consent for research but also further group agreement before any 
research findings were published in order to better safeguard aboriginal group interests.
I think that it is irrelevant whether or not I have given my consent earlier because if 
research results are detrimental, I would not have been willing to let researchers do 
a project like that, so if researchers say that I cannot say anything at this stage 
because a consent has been given, I would feel that I have been used (by 
them)… Besides, once research results have been manipulated, it will take at least 
another ten or twenty years to overcome the wrong impression from the whole 
society so even if an interpretation about genetics is proven later to be wrong, it has 
caused a disaster for the generation that is affected.  (A3, Taiwanese Aborigine, 
Taiwan, 2010) 
Because we are an ethnic minority, even if scientists already have our group consent 
(before research starts), if they are going to publish something in the future that is 
relevant to our group, it is still possible to cause the risk of stigmatisation for us, so 
they need to request another consent from our whole group before the publication. 
(P2, Taiwanese Aborigine, Focus Group, Taiwan 2010)
5.3.1.3 Economic and Political Rights of Taiwanese Aborigines
In addition to the issue of stigmatisation, genetics research may bring tangible harms to 
aboriginal groups’ economic and political rights. In Taiwan, since the status of aboriginal 
people and its associated rights’ protection are embedded in law, genetic information 
could be used to challenge an existing aboriginal status or preventing a group from 
asserting its legal claims to be recognised as aborigine based on research findings.72 For 
                                                     
71 Agomoni Ganguli-Mitra, "Collective Consent," in Ethical Issues in Governing Biobanks: Global 
Perspectives ed. Bernice Elger, Nikola Biller-Andorno, and Alexander M. Capron (Ashgate, 2008). P. 121
72 Supra note 64
175
example, the Kavalan dispute in Taiwan demonstrated that what most worried the 
Kavalan aborigines was not only the lack of adequate informed consent for genetics 
studies, but also the concerns about recasting Kavalan’s historical identity that had been 
shared by the entire group members. Kavalan is a recently recognised aboriginal group 
which had been categorised in a larger group of plain aborigines before its new name 
Kavalan was approved by the Executive Yuan in 2004. The dispute arose in April 2007 
when a geneticist was requested by the Kavalan Development Association73 to openly 
destroy the 29 saliva samples she collected for interdisciplinary research studying the 
migratory routes and the origins of Taiwanese aborigines. According to the claims 
asserted by the Association, since the sample collection was carried out in one of the 
Kavalan villages, it had violated Article 21 of the Indigenous Peoples’ Basic Law that 
requires consultation and consent from aboriginal people when academic research is 
conducted in the aboriginal regions. 
Although the implementation rules still remain to be developed, Article 21 of the Basic 
Law of Indigenous People was recognised as a legal ground for Taiwanese aboriginal group
consent. After the samples were collected, the Association found out that some of the 
geneticists’ earlier publications had implied that the origins of Taiwanese plain aborigines 
were not distinctive enough to be indigenous so this group was in danger of being 
declassified. Such research interpretations threated the Kavalan as most of its population 
(about 3000 or so) are descendants of the plain aborigines. After complaining to the 
National Science Council, the funding body of the interdisciplinary research, on the 
grounds of violation of research ethics, the Association reached an agreement with the 
geneticist to withdraw completely from the research. The 29 saliva samples were 
returned to the village and later destroyed in public in a traditional Kavalan ceremony. 
       
The Kavalan dispute and the ceremony made the headline in China Times next day and 
have made Taiwanese aborigines more cautious about participating in genetics studies 
and giving their blood or samples for academic and research uses. What often concerns 
them is the impact of genetics research on their historical identities based on which their 
sense of belonging and memories are grounded. As some respondents mentioned during 
                                                     
73 The association itself is a non-government organisation set up for promoting Kavalan’s community works 
and rights movements.
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the interviews, they do not need scientific research to tell them their own history and for 
them identities are not formed completely by biological traits. However, publication of 
genetic findings that contradict existing historical identities will bring more harm than 
benefit for aboriginal groups, especially when the aborigines have little power and limited 
abilities to argue against such claims made by research. 
In genetics studies, you may define whether he or she is aboriginal by genetic 
markers, but for indigenous ourselves, ancestry or lineage is only one factor in 
forming our identities, it is however, not an absolute one... (A2, Taiwanese Aborigine, 
Taiwan, 2010)
       
As long as you don’t have such feeling of belonging, there is not much sense to say 
which genes you have.. Aborigines put heavy emphasis on interrelationship and 
partnership.. So kinship is important but there are also many other factors we use to 
build up our historical identities.. I would say it is more like a cultural image, because 
of the collective memories we have been sharing together, we are families. Because 
we have lived together in this specific region for such a long time in which we 
establish our belongings so we feel that we belong to this group. (A1, Taiwanese 
Aborigine, Taiwan, 2010)
Even though the purpose of the biobank in Taiwan is not for defining ethnicity, what 
needs to be noticed is how to avoid the data and findings resulting from the biobanking 
initiative being used to form historical narratives that may contradict the aborigines’ 
beliefs. As a result, a prior individual consent should not be interpreted as a contractual 
relationship from a pure legal perspective. Rather, it has to be a process of reciprocal 
exchange so research subjects, especially when they belong to minority populations, can 
have a certain amount of bargaining power to decide how the data will be processed, 
interpreted, and presented. A respondent recognised that even if he had been informed 
about the research purposes and given his consent, a potential threat to his group’s 
identity and culture may still exist if he cannot be informed again how research findings 
will be published. 
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As for their scientific findings, you know, many of us just cannot accept their 
conclusions. We do not know exactly if what they are saying is correct or not. But if 
they didn’t tell us what their research purposes are or even if they have said so but 
didn’t inform us again about their research findings before publishing their research 
results, it could cause a big catastrophe for us and for our culture. (A1, Taiwanese 
Aborigine, Taiwan, 2010)
The concerns of the respondents indicate the limits of prior individual consent when it is 
applied to the aborigines in the Taiwanese context. As the aboriginal people are an ethnic 
group to be included in the Taiwan Biobank’s sampling design, it is indispensible to 
re-evaluate the current consent mechanism in order to protect aboriginal groups’ 
interests in the biobanking process in Taiwan. 
5.3.2. Aboriginal View’s on Informed Consent 
Before further discussing the mechanism of group consent, it is necessary to first explore 
Taiwanese aborigines’ views on informed consent so their concerns with biobanking may
be analysed more appropriately from a culturally specific perspective. Since culture 
provides an epistemological system for communication and understanding, it is a crucial 
factor to be considered in examining the practice of consent.74 For example, the results of 
the interviews show that some Taiwanese aboriginal groups may hold different 
explanatory models of genes and illness based on their cultures and cosmological
outlook.75 In order to have an adequate comprehension of the informed consent 
requirements, these cultural aspects need to be taken into account. In addition, even 
though an important goal for the Taiwan Biobank is to find the causes of illness and to 
improve health, health and illness are both experience- loaded notions and therefore in 
terms of evaluations of and beliefs about these concepts, they may not be always 
universal. Culture provides a fundamental setting to comprehend values and beliefs 
shared by members of a particular social group.76 It can also form a sense of belonging 
and identity that may redefine the boundaries of groups and communities. 
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Sometimes, culture influences the way in which health information is configured, 
transmitted and comprehended by the Taiwanese aborigines. As an aboriginal 
interviewee indicated, due to different cultures, aboriginal groups have developed 
different configurations of health knowledge from the ones established for modern 
Western medicine. However, he took “taboo” as an example to show how similar this 
traditional aboriginal value is to modern knowledge of preventive medicine. 
Each (aboriginal) group has its own explanation about health. In some cultures, we 
develop the notion of taboo. Namely, from elders we know what to do and what not 
to do. These taboos prevent us from being ill in our daily lives. They are   developed 
as a way for us to maintain our health and safety in our specific environments. Now 
this kind of knowledge can be transferred to modern medicine to operate. The main 
difference is about the terminology. In fact, we already have this kind of notion 
(referring to health-related notions in Western medicine). But when staff from local 
health authorities came to our villages to teach us these things, we felt that we did
not really understand what they said (referring to the terms they use). But if you 
knew our cultures, you could express these ideas in a different way, for example, 
talking to aborigines about taboos, then we can easily follow up because these are 
something we already have in our own cultures.  (A3, Taiwanese Aborigine, Taiwan, 
2010)
A similar example may be found in aboriginal views of genes and genetic research. As 
another aboriginal respondent suggested, in consent transactions, what needs to be 
avoided is use of scientific or biomedical terms to explain research purposes, its 
applications and goals. Rather, these ideas should be delivered in a way corresponding to 
the aboriginal health knowledge configuration. 
Many indigenous people have a different perception about genetic-related diseases 
from modern western medical knowledge. They might not understand what genes 
are but they would connect their inherited illness to a moral or value judgement. If 
one suffers from a kind of genetic disease, they frequently think that it is because in 
their families there is someone who had violated an ancestral taboo. (A1, 
Taiwanese Aborigine, Taiwan, 2010)
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These examples help to recognise that the practice of informed consent should be able to 
reflect these kinds of cultural differences in order to achieve real respect and autonomy. 
In the process of informing and comprehending, sample collectors and research subjects 
need to be able to communicate with the same language. The language here refers not 
only to the literal meaning of aboriginal dialects but also the underlying backdrop of 
aboriginal epistemology in which a culturally specific knowledge configuration may be 
identified. For instance, in terms of obtaining consent from Taiwanese aborigines, local 
people associated with aboriginal groups might be the agency to carry out recruitment 
and sample collection. As an aboriginal medical doctor pointed out during the interview, 
informed consent should be regarded as a process or, borrowing his own words, - “an 
encounter of the traditional and the modern” embedded in the aboriginal context in 
order to make the consent requirement morally justifiable. He used a twisted ankle as an 
instance to illustrate how the aboriginal knowledge configuration put more emphasis on 
the process rather than on the results. 
A non-aboriginal, modern trained physician usually ignores that in aboriginal 
cultures we form health knowledge in a very different way. We put more emphasis 
on the process rather than on the result. So when an aboriginal patient comes to 
seek your medical advice, she might spend much time in explaining what happened 
to her. She puts emphasis on the process.. For informed consent, we should also 
treat it as a process, rather than a single event. But are sample collectors aware of 
this? Or they may think it is just a routine procedure they have to follow? (A3, 
Taiwanese Aborigine, Taiwan, 2010)
Finally, the interviewee pointed out that in consent transactions, it is necessary to identify 
the connotations and emotional coloration used in aboriginal communication in order to 
trace their feelings and implied value judgements. Due to different modes of expression 
and linguistic reasoning, for some aboriginal groups, even an apparently positive sentence 
may imply a conservative attitude that is sometimes hard to be discerned from someone 
not familiar with this kind of communication. It also demonstrates why it is important to 
cooperate with local aboriginal communities when consent is sought.
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You have to get used to the way we speak... Sometimes it may sound like we agree 
with something as we express something in a positive way, but in reality, we have 
negative feelings about it. That’s because we translate the sentence from our 
mother language to mandarin in our mind before we speak. So for informed consent 
you got to take into account our feelings, attitudes at that specific moment.  (A3, 
Taiwanese Aborigine, Taiwan, 2010)
5.3.3 The Notion of “Group” and Its Representatives
Even though collective consent has been little discussed in the international guidelines 
with regard to the storage and use of human samples and data, it has been associated 
with the protection of indigenous rights by the Convention on Biological Diversity (CBD). 
Entering into force on 29 December 1993, the CBD was the first international treaty to 
recognise that biological diversity is a global asset and to commit to its conservation and 
sustainable use.77 The initiative of the CBD was relevant to the international debate on 
extending intellectual property protection to genetic resources.78 The quick expanding IP 
scope on genetic resources which has mostly occurred in developed countries 
consolidates the Northern countries’ economic power and increases their political and 
economic influence. 79 It also changes the status of genetic resources that were 
traditionally regarded as a common heritage. However, as Stenson and Gray argued, since 
most biodiversity is distributed in the Southern countries, patent protection has resulted 
in commercialisation of genetic resources that create more value for pharmaceutical 
industries in the developed countries than benefits returning back to developing ones.80  
In order to redress this disparity, the CBD was proposed to recognise several fair and 
equal principles such as benefit sharing and group consent obtained from indigenous 
communities, etc. 
                                                     
77 More info, See, the CBD website: http://www.cbd.int/history/ (Last visit: 10 March 2012)
78 See, Susan Bragdon, Kathryn Garforth, and John E. Haapala Jr, "Safeguarding Biodiversity: The 
Convention on Biological Diversity (CBD)" in The Future Control of Food: A Guide to International 
Negotiations and Rules on Intellectual Property, Biodiversity and Food Security, ed. Geoff Tansey and 
Tasmin Rajotte (Earthscan, 2008).
79 Anthony J. Stenson & Tim S. Gray, "An Autonomy-Based Justification for Intellectual Property Rights of 
Indigenous Communities," Environmental Ethics 21, no. 2 (1999). P. 15
80 Ibid.
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In Taiwan, even if Article 21 of the Basic Law of Indigenous Peoples81 is regarded by some 
aboriginal rights advocates as a legal basis for aboriginal group consent, how to 
implement it remains questionable. The current debates about group consent revolve 
mainly around its implementation rather than its principle. Even though there is 
recognition in the literature82 of the limits of individual informed consent for biobanks, 
how to adequately protect group interests is still unresolved. The greatest difficulty lies in 
the equivocal definition of the term “group.” In terms of aboriginal group consent, does 
“group” refer to the whole aboriginal population or their specific tribal groups or 
communities? Where are the boundaries drawn for a group and by which criteria are 
these boundaries being made? Are the criteria based on biological traits, such as blood 
and kinship, or on cultural ideas such as identity and memories? In addition, who may
represent aboriginal groups to decide if group consent will be given or not -
representative elders or chiefs of their groups or other significant figures based on their 
administrative tasks assigned by their groups? Certainly, all of these important questions 
will influence how group consent is to be implemented. 
In Taiwan, aboriginal group consent has been embedded in a broader narrative of 
Taiwanese aboriginal autonomy. However, more concrete rules regarding how to 
implement this higher principle remain to be discussed. On 23 September 2010, the 
Executive Yuan proposed a draft of the Aboriginal Autonomy Act to the Legislative Yuan 
for review and approval. Nevertheless, this draft was criticised heavily by aboriginal 
commentators for its violation of the Basic Law’s principles and failure to fulfil real 
aboriginal self-autonomy.83 According to the draft, the creation of aboriginal autonomous 
regions needs to be approved not only by aboriginal group leaders but also city and 
                                                     
81 It stipulates as follows: I. The government or private party shall consult indigenous peoples and obtain 
their consent or participation, and share with indigenous peoples benefits generated from land 
development, resource utilization, ecology conservation and academic researches in indigenous people’s 
regions. II. In the event that the government, laws or regulations impose restrictions on indigenous 
peoples’ utilization of their land and natural resources, the government shall first consult with indigenous 
peoples or indigenous persons and obtain their consent. III. A fixed proportion of revenues generated in 
accordance with the preceding two paragraphs shall be allocated to the indigenous peoples’ development 
fund to serve as returns or compensations.
82 See, for example, Jane Kaye, "Abandoning Informed Consent: The Case of Genetic Research in 
Population Collections " in Genetic Databases: Socio-Ethical Issues in the Collection and Use of DNA, ed. 
Oonagh Corrigan and Richard Tutton (Routledge, 2004).
83 See, Chiou Kuo-rong and Lydia Ma, "Aborigines Protest against Illusive Aboriginal Autonomy Act," 
Taiwan Church News October 2010.; Loa Iok-sin, "Aborigines Fight for Autonomy," Taipei Times 20 
November 2010.
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township councils.84 Since many aboriginal groups still inhabit regions where Han 
Chinese are the majority, the designed mechanism would make the setting up of 
aboriginal autonomous regions extremely difficult.
The challenge of seeking group permission lies in the fact that the traditional social 
structure in Taiwanese aboriginal cultures for group consent has gradually disappeared. It 
makes the concept of group and community in the Taiwanese aboriginal context “fluid 
and porous.”85 In fact, group and community are both meaning-loaded notions though 
they may refer to different kinds of human associations.86 When asking aboriginal 
respondents what ‘group’ means to them during the interviews, many of them pointed 
out that for the case of biobanking, they think their tribal groups or the aborigines as a 
whole should be able to give consent. In addition, such consent should prevail over 
individual consent since the group may be exposed to harms and risks such as 
stigmatisation associated with genetic research. At the same time, some respondents also 
mentioned that they do not see there is a specific person, entity or organisation that may
speak for all aboriginal people in Taiwan. Although they offered their opinions from 
aboriginal perspectives, many respondents recognised that their viewpoints may not be 
regarded as representative of their groups or Taiwanese aborigines as a whole. 
          
I think group consent is necessary, but the point is how do we implement it? I 
doubt that we can find an organisation or entity to be representative of all 
aboriginal people in Taiwan. To this point, we still have no consensus about the 
issue of representation. If it is individual consent, there is no such problem. But for 
group consent, there is always an issue like that. (A4, Taiwanese Aborigine, Taiwan, 
2010)
Since it remains arguable who can legitimately represent aboriginal group interests to give 
their consent for taking part in the biobank project, the Taiwan Biobank team had reached 
a decision to halt the sample collection from the Taiwanese aborigines until relevant rules 
are enacted. However, according to the ELSI group of the biobank team, in their original 
                                                     
84 Ibid. 
85 Here, I borrow this term to illustrate how difficult a boundary can be made to describe ‘group’ and 
‘community’. See, Marshalla, Patricia, and Jessica Bergb. "Protecting Communities in Biomedical Research."
The American Journal of Bioethics 6, no. 3 (2006). P. 25
86 Ibid.
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design, they would have liked to use the notion of “community” to carry out the required 
group consent. In this sense, community is mainly based on location and place that 
transcends ethnic relationships of kinship and ancestry. The proposed idea was to use the 
biobank project to build communities so a partnership may be established between 
communities and the Taiwan Biobank. It is the communities which will be responsible for 
recruiting individual aboriginal participants in the biobank project. These communities are 
located in aboriginal regions and their boundaries may have been defined as a result of a 
series of community development or community name rectification movements. Since 
several kinds of group consent mechanisms have already been developed at the 
community level, the biobank team hopes to use the existing collective decision 
structures to implement the obscure group consent requirement for recruiting Taiwanese 
aborigines. For instance, group consent may be obtained based on decisions made in 
elders’ or cadres’ meetings. Even in modern society where the traditional social structures 
have gradually disappeared, elders still play important symbolic roles for some aboriginal 
groups, especially in the groups’ ceremonies and traditional rituals. On the other hand, in 
some aboriginal groups, decisions with regard to ordinary administrative matters are 
generally made by cadres, who are usually school teachers or secretaries of local 
administrative officials. 
Even though the biobank team would like to use the notion of community to replace the 
sub-divisions of the aboriginal groups, in order to create a collective entity that 
transcends the notion of ancestry, it ignores the fact that the biobanking data is of a 
collective nature so the aboriginal groups will be analysed as the Taiwanese aborigines as 
a whole. For that reason, even though the proposed community consent is based on the 
principle of group consent made by aboriginal people, it cannot be equivalent to a 
mechanism representing the Taiwanese aborigines when they are aggregated as an ethnic 
entity compared with other ethnic groups in Taiwan. It also demonstrates the current 
complicated situation with regard to defining the boundaries of “group” for the Taiwanese 
aborigines. Since most Taiwanese aboriginal people have their collective identities based 
on their own tribal groups, the existing collective decision mechanisms have not yet been
developed to go beyond their groups’ level. However, in terms of the representation of 
the Taiwanese aborigines as a whole, currently there is not yet any organisation or 
individual that may be entrusted to fulfil this role. For instance, for some aborigines, the 
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Council for Indigenous Affairs is an organ of government so it is regarded as a 
representative of the governing class rather than a legitimate representative of the 
aboriginal people. As for group consent of the Taiwanese aborigines, a respondent 
suggested that it should be for aboriginal self-determination to decide. 
The issue of representation finally needs to be solved by aboriginal 
self-determination. As it is not only about consent for biomedical research but also 
regards our collective permission and decision for land rights and name rectification, 
etc.. I don’t see the Council for Indigenous Affairs can represent us legitimately. It is a 
government branch but what we ask is real autonomy that is to say let aborigines 
decide what we want by means of our own mechanisms…   (A5, Taiwanese 
Aborigine, Taiwan, 2010)
Even though the issue remains unsolved in terms of how to decide who can be suitable 
representatives of the Taiwanese aborigines, most respondents recognise that such 
decisions should only be made by the aboriginal people. This viewpoint echoes the 
opinions of the respondents that there has to be a member of aboriginal status in ethics 
committees of biobanks to safeguard aboriginal rights, especially when broad consent is 
adopted as the consent mechanism for biobanks in Taiwan. However, this viewpoint has 
not yet been well reflected in the recently enacted legislation. Although Article 5 of the 
Human Biobank Management Act stipulates the required types of professions such as 
legal experts and social workers to act as members of the ethics committee, it fails to 
enumerate that at least aboriginal status has to be a selection criterion for satisfying the 
requirement of legitimate representative if the aborigines are recruited in biobanks. 
Conclusion
Even though informed consent has been a major issue to be discussed in biobank 
governance, its implementation varies across different jurisdictions. In Taiwan, consent 
has been positioned in the forefront among all other ethical and legal issues posed by 
biobanks. By analysing the process of the enactment of the Human Biobank Management 
Act in Taiwan, this chapter argues that the introduction of informed consent in national 
legislation has transformed the consent mechanism from ethics to regulation, from 
morality to power. Such a transformation opens up an opportunity to legitimise sample 
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collection when informed consent is framed as a due process for the conduct of 
biobanking in the Taiwanese reality. In addition, a broad consent mechanism adopted by 
the Taiwan Biobank consolidates the leeway of framing consent whenever the given 
information is entangled with the biobank’s underlying policy agendas. Even though 
adopting a broad consent model for population biobanks is not necessarily detrimental to 
individual autonomy if the consent operates in a strong governance regime, the chapter 
suggests that there has to be a prerequisite for using an ethics committee to replace 
specific consent and the prerequisite lies in the establishment of the social legitimacy of 
the biobank project in Taiwan. This requires the public to be granted an opportunity to 
debate the necessity of the project as well as its research design so the voices from the 
public can be well reflected along with the development of the biobank project.
Furthermore, the chapter argues that by setting aside other essential issues of biobanking 
such as access and ownership, consent has been instrumentalised as an ethical and 
legitimate way to justify sample collection. The consent mechanism satisfies the general 
expectation of good ethics for biobanks at the expense of substantive deliberation of the 
important arrangement of rights and benefits associated with biobanking. By so doing, 
the practice of consent in biobanking in the Taiwanese context has difficulty fulfilling its 
original purpose although informed consent has been articulated as the major narrative in 
the bioethical discourse and in Taiwan’s legislation. Besides, the current consent 
mechanism emphasizing individualism has failed to safeguard Taiwanese aboriginal group 
interests when they are recruited for the Taiwan Biobank. By analysing aboriginal 
viewpoints on informed consent, the chapter hopes to provide a culturally specific 
perspective that may contribute to the current discussions of consent requirements for
biobanks, which focus only on the types of information to be delivered rather than the 
modes of delivery and the comprehension of such information. Since the aborigines have 
been in the margin of Taiwanese society, in order to avoid the potential risks and harms of 
stigmatisation, group consent is necessary in addition to individual consent whenever the 
aborigines become a target of sampling in biobanks in Taiwan.  
Finally, for better respect of aboriginal group interests in biobanks, this chapter argues 
that consent needs to be regarded as a process rather than an event so the aborigines 
should be entitled to be consulted before any related research findings are to be 
186
published. Although there is still no consensus among Taiwanese aborigines with regard 
to how to implement group consent, the issues of representation and the boundaries of 
groups should be decided by the aborigines themselves. Because Taiwanese aborigines 
are minority populations in the Taiwan Biobank project, the practice of informed consent 
in Taiwan has its own special characteristics. In such practice, individual consent needs to 
be supplemented by aboriginal group consent whenever the research design plans to 
recruit aborigines in the conduct of biobanking. In addition, in terms of qualification for 
the selection of members of ethics committees, aboriginal status needs to be stipulated in 
order to better represent Taiwanese ethnicities. 
Even though informed consent has been introduced in national legislation in Taiwan, 
many issues remain in its practice in terms of achieving “good ethics” and the protection 
of participants’ interests in biobanks. Since the biobank project in Taiwan has gradually 
transformed from a research platform to a social and political enterprise, the Taiwanese 
experience may provide a distinct opportunity to reflect on the current principle and 
discussion of informed consent on biobanks. In the end, the chapter argues that informed 
consent should not be regarded as only a contractual relationship but as a relationship of 
trust. 
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Chapter 6 Property, Privacy and Commodification
Introduction 
In the politics of the life sciences, biobanks are regarded not only as modern assemblages 
of human tissue and genetic information but also as unsettling relations between persons 
and things.1 Viewing property relations as a culturally specific form of power, various 
social entitlements have been invented in order to meet the interests of different groups 
involved in the process of biobanking.2 Access and ownership are two crucial but 
contested issues often raised and discussed in biobank governance. Even though 
collection and storage of human biological materials for treatment and research purposes 
is not a novel phenomenon, biobanks are distinguishable from the old collection by their 
open-ended nature and by containing biospecimens and genetic information that may be 
linked with phenotypic data and genealogical records. In addition, human tissue and
health information have increasingly become useful resources of biovalue along with the 
development of biomedical innovations. As a result, biobanks bring new challenges to 
ownership with regard to property entitlements in stored tissue samples, personal health
information and databases themselves. 
A question worth further discussion is whether recognising property rights in human 
tissue and genetic information derived from it would be more appropriate to protect the 
sources of the tissue in terms of retaining control over its use once the tissue has been 
removed from the body. In addition, when human tissue samples are processed and 
transformed from gifts to commodities, whether the sources are entitled to claim for any 
share of benefits on the ground that they are the “owners” of their tissues? The 
well-documented Moore case opens up profound debates about ownership of the human 
body and body parts.3 It also makes a legal distinction between property and personhood.
                                                     
1 David E. Winickoff, "Partnership In. U.K. Biobank: A Third Way. For Genomic. Property? ," Journal of Law, 
Medicine and Ethics 35, no. 3 (2007). P. 440
2 Klaus Hoeyer, "The Emergence of an Entitlement Framework for Stored Tissue - Elements and 
Implications of an Escalating Conflict in Sweden," Science Studies 17, no. 2 (2004). pp 63-64
3 After the Moore case, subsequent Greenberg and Catalona cases also upheld the principle that the 
sources of the human bodily material hold no property rights when the material was voluntarily handed 
over. More discussions about the cases, see, Rao, Radhika. "Genes and Spleens: Property, Contract, or 
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The patenting of the cell line, Mo, transformed Moore’s excised tissues through invention 
from “biological substances in their natural state” to the enhancement made by “added 
human labour.”4 Such enhancement is deemed to be distinct from Moore’s personhood 
according to the legal dichotomy of nature and invention.5 The decision upholds the 
inalienability of the human body by personifying tissue, which is treated as the essence of 
the person rather than as a commodity for exchange.6 Even though the case tends to 
prevent human tissue from being commodified by refusing to recognise self-ownership of 
human body parts, the presumed gift model implied from using consent to replace 
property renders patients and research subjects powerless in a capitalist market system in 
which biotechnological commodification has turned human tissue from waste to 
resources of biovalue. 
In Taiwan, the issue of property has been relatively ignored in discussions of biobank 
governance. Bioethical concerns have, instead, focused heavily on consent and privacy. 
On the one hand, this demonstrates that property in the body has not yet been formally
recognised in the Taiwanese jurisdiction.7 On the other hand, however, it illustrates that 
the role of capital and markets may have been insufficiently represented in the ethical 
configuration of biobanking practice in Taiwan. Gift relationship and solidarity constitute 
the main discourses of sample collection for the biobank, which has been purveyed to the 
public as an altruistic enterprise that will benefit public health and facilitate the 
production of scientific knowledge. In addition, technical safeguards have been 
introduced into legal frameworks in order to protect the privacy of individuals which is 
considered to be an indispensable fundamental right advocated by local human rights 
groups. Since privacy rather than property dominates the ethical concerns surrounding 
                                                                                                                                                               
Privacy Rights in the Human Body?" The Journal of Law, Medicine & Ethics 35, no. 3 (2007).
4 Klaus Hoeyer, "Person, Patent and Property: A Critique of the Commodification Hypothesis," BioSocieties
2, no. 3 (2007). P. 338
5 Ibid.
6 Supra note 4. P. 339
7 In Taiwan, the legal status of removed human tissue is not yet clear. In civil law tradition, once human 
tissue is separated or removed from the human body, it is considered to be abandoned as “waste” and 
therefore the source of the tissue has no further property rights on it. In Taiwan, there have been no rules 
or adjudication to demonstrate legislative and judicial opinions about the legal status of human tissues 
even though the recognition of property rights on human body parts has been supported by some legal 
scholars in Taiwan. For instance, according to Wang Tez-Chien, there are proprietary interests on removed 
human body parts so the source is entitled to ownership although whether the removed tissue or body 
parts may become consideration of contract still depends on the principle of ordre public and boni mores. 
See, Wang Tez-Chien, General Rinciple of Civil Law (2000). (in Chinese) pp 233-234
189
biobank governance, issues such as commodification of human biological samples and the 
penetration of market forces into human tissue and personal health data seem to have 
not yet been seriously reflected upon in Taiwanese society. 
This chapter discusses property and privacy concerns with regard to biobanking. It first 
analyses the Moore case and its relevant theoretical issues about the commodification of 
human body parts. It then studies the case of Taiwan in order to examine whether the 
existing legal framework is sufficient to protect research subjects and if the recognition of 
property interests in human tissue and health information may be an alternative 
supplement to bioethical practice in the Taiwanese context. 
6.1 Property in Human Biological Materials
6.1.1 Fictitious Commodities
According to John Locke’s labour theory of property, an appropriator may claim the “fruits
of labour” over a resource by mixing his or her labour with it in the course of production. 
Locke’s epistemology presupposes the distinction of subject and object and the object 
may become property of the subject who works on it. For Locke, ownership is a natural 
right which implies exclusive possession for particular individuals as a form of social 
control of the arrangement of resources. The justification for an exclusive right is through 
the individual’s labour on things as that can be viewed as an expression of the self. 
Nevertheless, applying Locke’s theory to the human body and genetic information in the 
post genomic era remains complex. Even though new technology has brought with it 
various innovative forms of potential property, such as cell lines, DNA, genome and 
genealogies, concerns are raised when the increasing association of market and science 
gradually transforms human tissue and DNA into commercial property that blurs the 
distinction of persons and things and makes the new creature possible to be exchanged in 
the marketplace in the form of commodities.8
Throughout history, the human body and its parts has been a target for commodification 
that can be traced through various forms such as slavery and female reproduction.9
                                                     
8 Gisli Palsson, Anthropology and the New Genetics (Cambridge University Press, 2007). P. 173
9 More info about the history of human body commodification may be found in Lesley A. Sharp, "The 
Commodification of the Body and Its Parts," Annual Review of Anthropology 29(2000). pp 287-328
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Although commodification remains a controversial notion when it applies to bodies for 
the purpose of medical technology, issues about commodifying bodies involve the 
formation of a new social relationship that is increasingly challenged and governed by 
market rules. Anthropologist Arjun Appadurai argues that it is politics that focuses on the 
things exchanged rather than simply on the forms or functions of exchange and creates 
the link between exchange and value, which is embodied in commodities.10 Because
commodities may be defined as objects of economic value which can be created by 
exchange,11 when objects are put into circulation in a monetary economy, they gradually 
lose their “social lives”, as Appadurai puts it, in the process of being commoditised.12 For 
Appadurai, the omission of the trajectories of things is a kind of methodological fetishism
since it ignores apparently that things-in-motion may illuminate their human and social 
settings.13 By extending Marxian commodity fetishism, which denotes the mystification 
of commodities as if they attain independent power that are separable from social 
relations in which they were produced and exchanged, Appadurai argues that social life of 
an object may be understood by situating it within a culturally constructed context. By 
pushing Appadurai’s argument further, it may be worth expanding attention and analysis 
from things and their exchange to the politics itself in which social setting is embedded. In 
the context of commodifying bodies, this shift refers to exploring the circumstances and 
conditions by which human tissue may be deemed to be an economic object that can be 
detached from personhood and commodified for free circulation in a modern market 
system.
In arenas of bioethics and law, informed consent has come to play a significant role for 
instituting a procedural scheme in which persons may be distinguished from things by 
withdrawing their subjectivities from tissue samples. Moreover, by being granted the 
                                                     
10 Arjun Appadurai, "Introduction: Commodities and the Politics of Value," in The Social Life of Things : 
Commodities in Cultural Perspective, ed. Arjun Appadurai (Cambridge: Cambridge University Press, 1986). P. 
3
11 For instance, For Karl Marx, a product needs to be transferred to another to serve its social use values in 
order to be considered as a commodity. More info, see, Karl Marx, Capital, Vol. I: A Critical Analysis of 
Capitalist Production (International Publishers Co, 1967).
12 In order to argue what constitutes commodity exchange, Appadurai contrasts this form of exchange with 
two other different kinds of exchange modes - barter (direct exchange) and the exchange of gifts. For 
Appadurai, barter may be regarded as one form of commodity exchange in which money plays an indirect 
role and gifts represent the spirit of reciprocity that link things to persons and also embed a drive mediated
by sociality.
13 Supra note 10
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authority to give consent, persons are qualified as subjects of biotechnology; as Alain 
Pottage argues, it illustrates how the replication of contemporary bio-power is different 
from the traditional sovereign power which emphasizes the power over the extinction of 
a subject’s life.14 Even though the classical sovereign power is characterised by the power 
to ‘take life or let live’, in the modern biopower, according to Michel Foucault, individual 
autonomy has become a technique of self-governance for modern states to govern its 
subjects. However, due to the limits of consent, this broadly applied bioethical 
mechanism may only ensure a conditional autonomous decision when consent is given 
and no further control of the use of tissue samples for consenters may be expected 
without appropriately recognizing property rights in human bodies and body parts. 
Modern technology and molecular biology have given rise to serious debates concerning 
ownership in bodies as they have opened up lucrative opportunities for marketing of 
body parts and their derived DNA information. Even though whether somatic 
commodification is acceptable depends on the particular historical and social context, the 
influence of markets and capital on the trend of biotechnological commodification is 
worth further analysis. 
When life becomes an object of manipulation, it turns to be a new fetish in the history of 
modernity. For Ivan Illich, such focus on the extension of life at any cost by the invention
of medications has made life into the ultimate fetish that transforms a person into a 
life-as-such that may be saved and prolonged by the intervention of modern medical 
technologies.15 By extending Illich’s notion of the fetishisation of life, Scheper-Hughes 
argues that modern biotechnology such as organ transplants has introduced an 
“artificially created need”, in the words of Illich, that erases the possibility of a social ethic 
by disguising bioethical choice as individual autonomy.16 In addition, such fetishisation 
creates new relations between the market, technologies and human body parts that have
reconceptualised the meaning of property in human bodies and at the same time, have
driven the alienation of human body parts for biomedical research. In the global economy, 
as Margaret Lock points out, the escalation of procurement of human tissue to make 
                                                     
14 Alain Pottage, "Persons and Things. An Ethnographic Analogy," Economy & Society 30, no. 1 (2001). pp 
122-3
15 Ivan Illich, "The Institutional Construction of a New Fetish: Human Life," in Ivan Illich: In the Mirror of the 
Past, Lectures and Addresses (New York: Marion Boyars, 1992).
16 Nancy Scheper-Hughes, "Bodies for Sale- Whole or in Parts," in Commodifying Bodies, ed. Nancy 
Scheper-Hughes and Loïc J. D. Wacquant (SAGE, 2002). P. 3
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patenting of tissue samples and cells has constituted a sign of “globalised commodity 
fetishism.”17 Such fetishism illustrates how human tissue may have been transformed 
into technological artifacts in the process of patenting and how patent as a legal 
technique may keep transgressing the boundaries between nature and artifacts. In the 
current age of genomics, human tissue, cells and genetic materials have been deemed to 
be a part of a “commodity fiction,” in the words of Karl Polanyi, while considering the 
exposure of nature to a market economy. The commodification of bodies now forms a 
new discourse in scientific and biotech advances by creating a space for the speedy flow 
of technologies and capital across the globe.18
By analysing social and economic changes brought about by the great transformation of 
the Industrial Revolution in the nineteenth century, Polanyi argues that the self-
regulating market system which has emerged since then has made society separate into 
an economic and a political sphere.19 In ancient civilisations, the market was not an 
institutional pattern as it later evolved but a meeting place for trade and exchange of 
goods. Therefore, before the industrial revolution, the economy was mainly embedded in 
social relationships and was operated through reciprocity and redistribution guaranteed
by an environment for continued exchange of resources, either due to a symmetrical
relationship between trading partners or a centricity for the rearrangement.20 The 
market itself was a part of society, and it was subject to social relations and governed by 
other mechanisms such as community arrangements, moral considerations and religious
beliefs.21
A new market pattern emerged when the great transformation occurred that made 
markets be regarded as autonomous forces separating from society. In this self-regulating 
market economy, as Polanyi argues, production was no longer for household use or for 
exchange but for gain, and the crucial elements of industrial life - labour, land and money 
- were treated as commodities for selling and buying. In this market system, the order of 
production and distribution of goods was ensured by prices alone as everyone was 
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assumed to act for the purpose of seeking maximum gains.22 For Polanyi, such a market 
economy could only function in a market society, which means that all elements of 
industry, including the substance of society itself, needed to be included into the market 
mechanism and subordinated to the laws of the market. The so-called self-regulating 
market implied that all production was for sale and was regulated by prices. In this 
system, labour and land were no longer human beings and natural surroundings but also 
commodities for sale and purchase. Polanyi recognises that the deficiency of the market 
system is based on this “commodity fiction”, as a true commodity needs to be produced
for sale, and as a result, labour, land and money are only “fictitious commodities” as they 
are not produced for sale but regarded as commodities in order to organize the market 
system.23
Modern critiques of the commodification of bodies are commonly manifested as a 
resistance to this self-regulating market system in which the ideal society embedded in 
sociability and morality is now challenged by a profit-orientation. In order to respond to 
the increasing desire for the enhancement of life driven by both global capitalism and
biotechnology, body materials and fluids are allowed to transform into fungible 
commodities by removal, extraction, processing and perhaps patenting in the end as a 
way to create commercial value. The process of transformation constitutes a part of 
circulation that commodifies body samples in economic exchange which is associated 
with the capitalist mode of production and consumption. As Appadurai points out, in 
modern capitalist societies more contexts are likely to become legitimate commodity 
contexts, within which the standards and criteria that define the exchangeability of things 
may embrace a larger part of the world of things than in non-capitalist societies.24 It 
shows that the extent to which a thing may be regarded as a commodity depends not 
only on its social status of exchangeability but also on the political and cultural contexts in 
which the thing belongs. 
In anthropological writing, the contrast between primitive and modern societies is often 
presented as an embedded social and cultural setting for the distinction between gifts
and commodities. Putting such a contrast in a very simplified way, gifts linking things to 
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persons and relations usually represent the spirit of reciprocity that is contrasted to the 
nature of commodities which are relatively impersonal and are largely deemed to be free 
of cultural constraints.25 Even though it is a very rough distinction that has been criticized
for ignoring the common spirit found in gift and commodity circulation, such a mutually 
exclusive distinction has added a critical dimension to reflect the invisible association of 
politics and value in the process of commoditization. In other words, it is worth thinking 
over who has been benefited in terms of creating a commodity flow in a self-regulating 
market system or, as Appadurai enquires, - “who is permitted to exercise what kind of 
effective demand in what circumstances”26 so that a thing may be commoditized for 
circulation and exchange.
The new genetics and genome research has redefined and expanded the notions of 
property in response to the increasing monopolies exercised by pharmaceutical industries. 
Since a DNA sequence is allowed to be patentable, the idea of UNESCO which proposes to 
treat the human genome as the common heritage of humankind in order to avoid abuse 
by private interests only remains a symbolic meaning. Furthermore, in the arena of law, 
ownership and property rights in the human body and body parts are still unsettled. Even 
though invention, such as cell lines, may be the subject of property by recognising Locke’s 
labour theory, its rights of control derive mainly from added values rather than from the 
sources. As a result, whether a proprietary interest may be recognised in the sources 
themselves remains legally complex. In some jurisdictions, privacy and informed consent 
have been proposed to replace property as a regulatory mode to govern the control and 
use of human tissue in medical research. Nevertheless, without an appropriate 
recognition of property rights in human body parts, it has disempowered patients and 
sample donors by treating their removed tissue as either waste or gift. 
6.1.2 The John Moore Case
The famous but contentious John Moore case demonstrates that in the common law 
tradition, property of excised tissue may be granted by patent through invention; however, 
such ownership has not yet been extended to the subject of the tissue by simply alleging 
that the subject is entitled to share the financial benefits derived from patent because she 
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or he is the “owner” of the biological materials.27 In the case, Moore, the plaintiff, was
diagnosed with and under treatment for hairy-cell leukemia by Dr. Golde at the UCLA
Medical Centre. In October 1976, Moore underwent a splenectomy operation. Although 
Moore had signed a written consent form for the operation based on Golde’s 
representations, he was not informed of Golde’s plan to establish a cell line from his 
excised tissues; neither had his permission been requested to carry out this kind of
research. From November 1976 to September 1983, Moore traveled several times from 
his home in Seattle to the UCLA Medical Centre in Los Angeles for the follow up 
treatment because of the suggestions of Golde, who then took additional samples from 
Moore without his consent. In 1979, Golde established an immortal cell line from 
Moore’s T-lymphocytes that was later issued a patent in 1984, naming Golde and his 
assistant Quan as the inventors and the Regents of University of California as the assignee. 
Later, Golde made an agreement with the Genetics Institute for commercial development 
of the cell line. In the agreement, the Genetics Institute had exclusive access to the cell 
line and it agreed to pay Golde 75,000 shares of common stock and Golde and the 
Regents at least USD 330,000 over three years in exchange for the use of the cell line. 
Moore discovered the deal thereafter. He sued for a share of the financial benefits based 
on 13 causes of action including conversion.28
The majority of the California Supreme Court rejected the argument that Moore’s excised 
tissue should be protected by conversion of property in order to protect Moore’s interest
in his bodily integrity and privacy. Viewing conversion as a strict liability tort and 
considering extending it might sacrifice the protection of innocent parties in society. The 
court pointed out that patients’ rights of privacy and autonomy would be better 
protected by existing disclosure obligations in the fiduciary duty and informed consent 
theories without hindering research by restricting access to or exchange of the raw 
materials.29 In his concurring opinion, Justice Arabian identified the moral issue of the 
case as the plaintiff’s request for the court to recognise and enforce a right to “sell one’s 
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own body tissue for profit.”30 He argued that recognizing Moore’s claim for conversion of 
his body tissue was like regarding the most venerated subject in any civilized society as a 
“commercial commodity” and therefore commingled “the sacred with the profane.”31
According to the court, Moore did not retain a sufficient interest of possession in his 
excised cells to support a cause of action for conversion although under traditional 
common law principles, a plaintiff may recover the economic value of the right to control 
the use of his body parts. When considering whether to “extend” the liability of the tort 
of conversion to the case, the court held as a matter of policy that a patient’s continuing 
interest in the use of excised cells should be limited because imposing tortious liability to
the use of human samples in research meant imposing on scientists a duty to investigate 
the pedigree of each sample they used and would have a negative influence on medical 
research in society.32 In addition, by citing Diamond v. Chakrabarty33, the famous 
intellectual property case in the United States in 1980, the court recognised that the 
patented cell line in the Moore case was the product of invention since what patent law 
rewards was inventive efforts rather than the discovery of “naturally occurring raw 
materials.”34 As a result, the cell line was considered by the court both “factually and 
legally”35 distinct from the cells taken from Moore’s body that made Moore’s allegations 
that he “owned” the cell line because he was the subject of the cells inconsistent with the 
rationale of patent law.
Even though the court stated that it did not purport to hold that property can never be 
granted in excised tissue without considering any purposes, it claimed that in the Moore 
case relevant policy considerations were taken into account in order to decide if the 
extension of liability of conversion would be necessary. However, such policy 
considerations were not based only on an apparent reason to avoid judicial uncertainty 
as the reasoning of the adjudication explained. On the contrary, they also aimed to 
facilitate the market economy because uncertainty about the legal title of human 




33 In the case, the Supreme Court of the United States held that a genetically engineered bacterium was 
patentable as a “new and useful manufacture.” More info, see, Diamond v. Chakrabarty (1980) 447 U.S. 
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samples might affect commercial use of medical research and companies’ willingness to 
invest in developing a patented product, which mainly relied on samples provided by 
human sources.36 The Moore case has made the legal status of human body parts elusive 
and ambiguous. After all, it was legally untenable, as Justice Mosk remarked in his 
dissenting opinion, that the defendants could own Moore’s tissues but Moore himself
could not. Despite the worries of commodification of human body parts implied by the 
decision, for research resulting in significant financial benefits for the researchers but 
almost no gain for sample donors, it was equivalent to treating the human body as a 
commodity, namely a means to an end.37
In addition, the court rejected a proposal to expand the notion of “joint inventor” to 
include the human source of biological materials used in research, so that sample donors 
were completely excluded from the property model.38 The difficulty of the case, perhaps 
as Justice Arabian commented, lay in requiring a choice to be made between competing 
social and economic policies, namely the court was asked to decide whether treating 
human tissue as fungible articles of commerce would uplift or degrade the human 
condition in both spiritual and scientific senses.39 As the implications of the decision on 
research and industrial development would be profound, recognizing a property interest
in human tissue seemed to have involved engaging with conflicting moral and 
philosophical values. 
The Moore case demonstrates that market and economic impact has been acting as a 
crucial policy reason, which, however, ignores other equally important factors such as 
notions of equity and distributive justice. Since the parties in the case did not have equal 
bargaining power, in order to prevent unjust enrichment, recognizing that the plaintiff 
had a property interest in his excised tissues may entitle him to an equitable share as a 
morally acceptable result of fairness.40 Besides, the nondisclosure cause of action such as 
informed consent was in reality inadequate to protect Moore’s interests as it gave him 
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only a right to veto rather than entitling him to an affirmative right to consent to the 
commercialisation of his tissues and to request sharing in its proceeds. Moreover, by 
exercising consent, as the dissenting opinion already points out, it is not possible to reach 
potential defendants outside of the formal physician-patient relationship, such as 
research institutes or pharmaceutical companies, which are often major parties involved 
in the control and use of patients’tissues. Since the nondisclosure cause of action fails to 
protect Moore’s affirmative rights to share in the proceeds and it may make the true 
exploiters escape from their liabilities, it should not be deemed to be an adequate 
substitute for conversion as the Court held.41
6.2 Gift Relationship, Reciprocity and Benefit Sharing
Like the Moore case, the consent mechanism proposed by the pilot study of the Taiwan 
Biobank claims that participants retain no property rights in their donated tissue samples 
and therefore they are not entitled to claim any interests of intellectual property if 
granted in the future based on the use of the tissues in question.42 Since Moore did not 
really consent to removal of the cells from his spleen for the purposes of research and
commercialisation, whether his consent to treatment for his hairy-cell leukemia would 
suggest abandonment of his excised cells was not yet clear and is certainly worth 
discussion. However, had Moore indeed been well informed of the potential commercial 
use of his cells and had he also given his consent to his doctor for patenting of the cell line, 
the formulations of consent would have granted Moore only an illusory power in terms of 
exercising continuing control of his body materials. In biomedical research, in order to 
ensure the participation is on a voluntary basis without any undue influence, consent has 
been deemed to be the most important, or in some circumstances, the only appropriate
ethical and legal approach to procure samples. However, once consent is obtained, the 
continued relationship with donors and their samples has ceased with the result that it 
precludes research subjects from being considered as stakeholders in the overall research
project. 
A recent case with regard to gene hunting in the Solomon Islands illustrates the limits on 
consent in terms of empowering and providing real respect for the research subjects in 
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the context of commercialisation of collected samples. On 1 April 2011, a Taiwanese 
medical researcher, Dr. Ko Ying-Chin, filed an express abandonment of his patent 
application entitled “Method and Kit for Assessing Risk of Gout and Hyperuricemia” to 
the United States Patent and Trademark Office.43 The patent application was reported to 
use genetic samples from 192 Solomon Islanders collected in the Islands’local hospitals 
during a research trip led by Ko in 2006. The withdrawal of the patent application was in 
response to the public challenge of serious ethical breaches raised by the Network of the 
Indigenous Peoples- Solomons (NIPS). The NIPS’claim was supported by other local NGOs 
and the government of the Solomon Islands. The basis of the challenge lay in the 
inappropriateness of the informed consent obtained from blood donors in 2006 which 
stated that blood was limited to medical research uses and contained no mention of 
using the collected samples for patenting and commercial purposes.44 According to the 
NIPS, even though the process of patent application was now stopped and Ko stated that 
he did not immortalize cell lines based on the samples and he would be willing to 
repatriate the samples back to the Solomon Islands, it was still not clear whether the 
collected samples had been shared with other researchers in Taiwan or abroad.45 A 
similar scenario happened about a year ago when Ko and his colleague were forced to 
withdraw another US patent application that involved using samples from 1500 Taiwan 
Atayal Aboriginal donors with informed consent only for health research rather than for 
commercialization.46
Both cases involved biopiracy and raise serious questions about consent. Even though 
obtaining consent has been deemed to be a part of the official process that a researcher 
in Taiwan needs to go through in order to have permission to carry out medical research
in Taiwan and abroad, it is far from a sufficient mechanism in terms of continued
monitoring of the use of samples by research subjects. The Moore case seems to suggest 
that consent may sufficiently empower the plaintiff so that the recognition of proprietary
rights in bodies is not necessary. Such a point of view putting consent and property in a 
position of mutual exclusivity has been questioned by some legal scholars.47 For instance, 
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Beyleveld and Brownsword argue that the informed consent strategy presupposes that 
there is property in our own bodies and body parts so that, rather than denying it, the 
rights lying behind consent regimes are “most plausibly explained as proprietary.”48
Graeme Laurie also suggests that a property model may serve as a major supplement to 
privacy and autonomy in protection of the personality if it can empower research
subjects by providing them with continuing control over their samples or information.49
Laurie further points out that the language of ‘gift’ used frequently in bioethical 
discourses implies ownership and property but it has been used in a way associated with 
altruistic behavior, so rather than being deemed to be exercises of self-ownership, in the 
context of donation, the concept of gift presumes the surrender of an individual’s 
residual interests in donated samples.50  
6.2.1 Reassessing the Gift Relationship
In his work The Gift Relationship, Richard Titmuss studied the role of altruism in modern 
society by comparing blood donation systems on both sides of the Atlantic in the 1960s.51
He argues that the commercially oriented approach of blood procurement in the United 
States not only led to the exploitation of socially disadvantaged groups and the 
production of contaminated blood but was also degrading for society as a whole by 
diminishing social solidarity and altruism.52 Giving, for Titmuss, was the human capacity 
that demonstrates the individual’s conception of the needs of others and their views of 
external world, and to donate is to give with an altruistic motive.53 Recognising that men 
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are not born to give, Titmuss argued that it is the government’s responsibility to set up 
instruments and institutions of public policy in order to foster the individual expression of 
altruism because eventually this kind of moral behaviour contributes to holding a society 
together.54 As a proponent of the welfare state, Titmuss’s idea of altruism was for 
utilitarian purposes. For him, preserving the freedom of the individual is the potential
role that social policy should play. According to Titmuss, the voluntary blood donation
system operated in Britain was an important way to form a sense of community and 
solidarity because it mainly relied on donors’altruism to give blood to unknown strangers 
on whom no obligations were imposed to make a corresponding gift in return.   
Titmuss’s notion of gift relationship has been commonly used as a policy model to govern 
the relationship of researchers and research subjects. For instance, the ethical guidelines 
published by the Medical Research Council (MRC) of the UK in 2001 made a clear 
statement that “samples of human biological materials obtained for use in research
should be treated as gifts.” 55 The rationale behind the guidelines reflects the 
undesirability of the commodification of human body parts, so rather than viewing 
biological materials as commodities for sale, such materials are deemed to be altruistic 
gifts. Gift-giving is therefore being categorised in the context of medical research. On the 
one hand, it has been viewed as a legitimate way for the transfer of samples in 
accordance with the distinction between personhood and property so even though body 
parts cannot be sold, they may be given. On the other hand, the language of gift reflects 
an altruistic nature that is conceived as expressing the quality of human values, as 
Titmuss puts it, in order to benefit the greater common good. Nevertheless, as Richard 
Tutton rightly recognises, such a gift model may have been used as a boundary maker 
around the commercialisation of tissue samples that implies a tendency to avoid the 
rearrangement of entitlements for a share of profits and for the exercise of control over 
the samples.56
In order to make the provision of human biological materials for research being treated 
as a non-commercial transaction, the gift model precludes donors from any further claims 
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to their samples after donation and from entitlements for a share of benefit made from 
its commercial development. However, the increasing entanglement of science and 
markets has constituted a very different political and social setting from the time of the 
1960s when Titmuss proposed his altruistic ideal to underpin the British blood donation 
system. Even though it may be true, as Titmuss argues, that the essential altruism 
fostered by the British National Health Service was vital to the moral health of the 
welfare state, there remain crucial differences between blood donation and biobanking 
itself. Compared to blood donation, which is more like a random one-off event except for 
some regular donors, biobanking relies on participants’ long-term involvement for 
discovery research by establishing the correlations of genotype and phenotype through 
linking DNA information with health data.57 In addition, for Titmuss, it is anonymity that 
makes pure gifts possible as donating blood to unknown strangers frees recipients from 
social obligatory returns of gifts. However, the anonymous gifts Titmuss relied on to 
depart from Marcel Mauss’s anthropological account of gift exchange may not fit well in 
the context of biobanking in which recipients are no longer disinterested strangers but 
specific biobankers. 
For Mauss, gifts are not given for free. By observing gift exchange in Polynesian culture 
where the exchange is governed by the notion of mana - a spiritual quality of 
supernatural origin existing in the universe - , Mauss argued that in archaic societies, gifts 
are deemed to be a mode of exchange that helps establish the bonds of reciprocity 
between givers and recipients.58 Because having mana is to have prestige and authority, 
gift-giving represents a way for the givers to maintain and increase such glory, wealth and 
honour, and to reciprocate gifts shows the willingness of the recipients to accept the bond 
of alliance and commonality.59 To refuse the gifts means to reject the social bond which 
values communal identity and may even be tantamount to the declaration of war.60 In 
this mode of exchange, the gift is no longer a mere object but may be deemed to be a 
spiritual article that constitutes a part of the giver who has been indissoluble from it. 
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Since the gift has never been separated from the giver, there is no real distinction 
between persons and things comparable to that which emerges in a commodity economy 
in which objects can be completely alienated and sold to new owners through the notion 
of private property.
6.2.2 Reciprocal Altruism and Redistributive Exchange
Mauss’s gift relationship emphasises the obligation to reciprocate.61 Rather than being 
given for free, each gift is part of a system of reciprocity in which the subjectivities and 
power relations of givers and recipients are formed. The grand cycles of exchanges 
constitutes the whole society which can be viewed as a total system of gift or be 
described by “the catalogue of transfers,” as Mary Douglas puts it, that map all the 
obligations between its members whose permanent commitments articulate the 
dominant institutions.62 However, the challenging issue here is how to apply Mauss’s 
theory in a different social and temporal setting, namely in a modern, industrial society in 
which institutions and laws of exchanges are governed by the rule of markets. The same 
question seemed to be not unfamiliar to Mauss when he tried to use his own 
ethnographic observations of primitive societies to support social democracy’s 
redistributions and the idea of solidarity in contemporary societies. As Mauss recognized,
these kinds of anthropological facts should not be taken as curiosities or serving only for 
the purpose of comparison. In fact, they have general sociological value and can be used 
to explain modern societies from a historical perspective that would allow us to 
understand where we are and how far we have traveled in the process of social 
evolution.63
Indeed, by extending Mauss’s recognition, ethnographic knowledge may provide a 
meaningfully alternative way to reflect on how the notion of the free gift may be taken 
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for granted when it is used in the context of biomedical research especially in a modern 
capitalist society. In addition, even though modern legal systems have created many 
categories by making distinctions, such as a general distinction made between persons 
and things, new developments in genetic research and biotechnology have urged us to 
think over the appropriateness of continuing with such distinctions. Even though 
ownership rights over removed human biological materials are still controversial in the 
arena of law, a complete refusal of the recognition of property rights in the human body 
and body parts is far from the only solution to respond to the dilemma. Instead, when 
commercial interests are involved, the unbalanced arrangement of benefits and risks 
between donors and researchers triggers a deeper reflection on issues of equality and 
distributive justice that have been relatively ignored in the traditional moral debates on 
the commodification of bodies.  
Mauss’s moral economy of redistribution based on gift circles which focuses mainly on the 
larger collective benefits may be viewed as an alternative supplement to the current 
unsettling debates about the recognition of individual proprietary interest in human body 
materials. Like consent, granting property in human tissues and the information derived 
from them is mainly concerned with individual rights even though genetic information is 
of a group nature. The shared nature of genetic information means that an individual’s 
choice and action will have an impact on those who share genetic similarities with them. 
As a result, modern biotechnologies and their application of genetic information have 
challenged bioethics and law which put more emphasis on individual autonomy than on 
collective benefits. Biobanking, like health care initiatives, is an activity with an ethic 
beyond individual rights. On the one hand, it involves the use of genetic information of a 
shared nature, on the other hand, however, it relates to larger groups of participation so it 
needs to be further justified by values of a community of rights, such as citizen
responsibilities in the emerging biosociality, in the words of Paul Rabinow,64 or the 
stewardship responsibilities of the state. 
Mauss’s theory on the totality of society provides a justification to mitigate the tension 
between an ethic of individual rights and utilitarianism which prioritises the public good 
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and the interests of the community at large. For Mauss, considering the total social facts 
and the whole entity of society in which individuals become aware of their own positions 
and their situation in relation to others is a way to the so-called ‘civilized world.’65 In the 
total social phenomenon constituted by the gift-exchange, a new form of ethic may be 
created when individuals are organized as collective subjects to produce mutual interests 
based on their positive obligations to the greater community. In the case of biobanking, 
even though individual agents do not have a positive duty to participate in biobanks, the 
state’s stewardship responsibility for the general wellbeing of the community may have 
extended the obligation of citizens who are expected to act as responsible agents to 
improve conditions of public health for the common good of the community. 
Rose and Novas have used the term ‘biological citizenship’to explore how conceptions of 
citizenship have been linked with the biological existence of human beings by states’
citizenship projects that encompass practical techniques to make individuals as potential 
citizens.66 Developments in bioscience and biomedicine have reconfigured notions of 
citizenship by norms and practices of health. On the one hand, the biologisation of politics 
produces biological citizens who understand their entitlements and responsibilities in 
terms of their rights to health services and social welfare. Life, therefore, creates a new 
type of value concerning regulation and compensation which may be negotiated by 
citizens for their economic and social inclusion.67 On the other hand, however, biological 
citizens may be viewed by states as potential generator to provide a valuable resource for 
genomics research and biotech innovation. 68 Such biovalue concerning the moral 
economy of health and national imperatives has redefined notions of what it means to be 
a citizen. 
Since the adjudication of the Moore case in the early 90s, the biovalue of human tissue 
has increased on a dramatic scale along with the development of genomics studies. 
Participants’ growing awareness of potential commercial entanglement with their 
donated samples and the derived information challenges the distinction between gifts 
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and commodities because their tissue samples and personal information may now be 
transformed from a pure gift to a circulating commodity as a form of product with 
exchange value.69 In the context of biobanking, the potential for commercialisation has a 
significant impact on participants’willingness to take part in projects. Taking Iceland as an 
example, even though the Icelandic Parliament endorsed the biobanking project by 
passing national legislation to give exclusive commercial rights to a company - deCODE 
genetics - for the establishment of the Icelandic Health Service Database (HSD), the lack 
of public support due to concerns about commercialisation finally led to deCODE filing for 
bankruptcy in 2009. As a cohort study monitors follow-ups on participants’ health 
condition for succeeding years, the sustainability of a biobank requires establishing a 
long-term partnership between biobankers and participants. In order to obtain trust from 
the general public, such a partnership needs to be reciprocal by recognizing the return of 
“gift” as a social obligation of biobanks so that a reciprocal relationship may be expected 
to be established among all actors in the process of biobanking. 
Even though the calculation of research benefits may not be easy for biobanks because 
future research results are still unknown even to researchers themselves, governing 
mechanisms based on the principle of reciprocity need to be proposed by biobankers at 
the initial stage when they procure consent from participants. In Mauss’s gift relationship, 
in primitive societies, the chief may give proof of his mana by redistributing what he 
received to his relations so that he may sustain his own rank among the chiefs.70 In 
biobanking, the recognition of the share of benefits by treating participants and their 
communities as stakeholders may eventually consolidate the legitimacy of biobanks. 
Furthermore, according to Mauss, the system of ‘total services’is the system in which the 
exchange of everything among individuals and groups become possible so that the 
system can provide a basis on which the morality of the exchange has flowed.71 By 
analogy, in order to form a trust relationship, it will be the biobankers’responsibility to 
make an initial step to construct the room of morality in which public interests may be 
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fostered and the contents of a common good be debated and shaped. In fact, a free gift 
model used in blood donation is not ideal to be transplanted into the circumstances of 
biobanking. Rather than empowering participants, the discourse of a pure gift-giving 
creates ambiguities and difficulties in the arena of law in which the status of removed 
human tissue is contestable and a donation has been treated as the surrender of 
participants’rights of further control over their samples. 
For Mauss, gift-giving not only forms the basis of social relations in primitive societies but 
also lays the foundation for justifying a broader scheme of redistributive exchange in 
modern industrial economies. In his concluding remarks to The Gift, Mauss extended the 
idea of gift-exchange to enhance solidarity in modern societies based on market exchange 
by referring approvingly to proposals on welfare and social support such as health and 
unemployment insurance. By so doing, the gift cycle which was presented as a theoretical
counterpart to Adam Smith’s invisible hand may operate in a way of ‘being visible’so the 
redistribution of accumulated goods and service based on political innovations of 
alliances may avoid the failure of market exchange by subjecting it to judgments of 
fairness.72 Mauss’s theories on the gift cycle provide an alternative response to Polanyi’s 
analysis of the great transformation brought by the industrial revolution. Rather than 
being alienated, redistribution of wealth and power in the moral economy reunifies the 
entire social systems as the greater totality in which institutions such as law, religion and 
economy are not segmented but entities of the total social facts.
It is by considering the whole entity, according to Mauss, that individuals could be 
sentimentally aware of who they are and of their relations with others.73 The ultimate 
goal of reciprocal altruism which suggests stable relationships and giving in return 
between individuals involves a new form of ethics that concerns a wider politics of 
organization and decision-making by which consensus about mutual interests may 
consequently be formed. In the case of biobanking in Taiwan, such ethics further involves 
accountability of commerce to biological citizenship when the citizens are constructed not 
only as political subjects of entitlements but also generators of biovalue for health and 
wealth of the state. In other words, the moral ideal of an alliance of participants and the
biobank (and its commercial extensions) needs to be acknowledged with reference to
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their joint interest and their co-dependent relations in a greater totality in which they are 
parts of a division of labour. 
In order to protect the individual’s autonomy from undue inducement and to appeal for 
altruism, the introductory booklet for the pilot study of the Taiwan Biobank states that no 
financial rewards may be given to participants; neither any property rights in donated 
samples or in the information derived from the samples may be claimed from the 
participants.74 If a participant agrees to take part in the biobank project, any research
results relying on his or her samples will be published as collective data and be used as a 
common resource for global medical research. In the future, if there is any commercial 
product, for example, intellectual property derived from the invention based on samples 
and data of the biobank, according to the booklet and the consent form, such property 
belongs to the inventing institutes rather than to the participants. These arrangements 
clearly demonstrate that in the biobanking case in Taiwan, participants have been treated 
as donors or free-gift providers rather than being included as stakeholders of the project 
who are entitled to decide how the samples and health data may be used in the future. 
However, the unreciprocated gift will eventually make the person who has accepted it 
inferior, as Mauss emphasizes, particularly when the receiver has no thoughts of 
returning it.75 Applying the analogy of Mauss’s gift model to the creation of the Taiwan 
Biobank, without a proper mechanism for the project to implement the principle of 
reciprocity, the biobank will be threatened by gradually losing its own credibility in social 
relations it has endeavoured to establish.  
6.2.3 From Profit-Sharing to Power-Sharing
In fact, the ongoing biobanking project in Taiwan may not be easily fitted into any broad 
categories of its international counterparts. It is not like the cases of Iceland and Tonga in 
which the biobanks are mainly operated by commercial companies or pharmaceutical 
industries but backed up by national governments through legislation for exclusive 
licensing.76 Nor is it similar to the projects in Sweden and Estonia, both of which were
initially funded by governments but later operated in cooperation with commercial 
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enterprises even though the genetic databases are mainly based in academic and 
research departments.77 In Norway, Singapore and Quebec, the biobanks are set up for 
research purposes so they are government-funded projects with no commercial 
involvement.78 According to its purposes and the initial framework, the Taiwan Biobank 
may be viewed as a research platform that is wholly funded by the Taiwanese 
government in order to improve the health of the next generation in Taiwan and to 
become a common resource for medical research on the global stage. However, in the 
proposal for the establishment of the biobank, the potential commercialisation is hardly 
invisible. The idea of commercialisation has been proposed as a potential business model 
for the biobank’s future operation so that the project can have its own niche for 
long-term development without continued reliance on government funding. Even though 
how such a commercial idea may be executed remains to be discussed - whether it will 
rely on cooperation with pharmaceutical or like-minded commercial companies, or
whether the biobank’s ownership may be allowed to be transferred to private entities for 
continued operation, collaboration between public and private seems to dominate the 
future sustainability of the biobank in Taiwan. 
In September 2010, the Department of Health79 in Taiwan published the implementing 
rules for the Human Biobank Management Act on the sharing of benefit.80 Even though it 
is still to be seen how the rules may be implemented in practice, they may be viewed as a 
significant step for biobankers’ recognition of the importance of reciprocity. These 
implementing rules echo current international guidelines which address the issue of 
benefit-sharing in human genetic research. For instance, in UNESCO’s International 
Declaration on Human Genetic Data, Article 19 recommends the forms that benefits may 
take. In addition to provision of facilities for new treatments or drugs that directly stem 
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from the research, the forms of benefits may also include capacity building, access to 
medical care or support for health services, etc. As a result, the recipient of the benefits, 
according to the article, may not be limited to the persons and groups that have taken 
part in the research. It may also be broadened to a population, the society as a whole or 
even the international community as the article recommends.81  
In addition, the Human Genome Organisation (HUGO) - the international organisation
involved in the Human Genome Project - released its Ethics Committee Statement on 
Benefit Sharing in 2000. In the statement, a benefit is described as “a good that 
contributes to the well-being of an individual and/or a given community.”82 Even though 
how to define a community reflects practical difficulties in applying the principle of 
benefit-sharing, the statement recognises that since a benefit is not identical with profit 
in the monetary sense, determining a benefit depends not only on needs and values but 
also priorities and cultural expectations. 83 In Taiwan, according to the rules, the 
obligation for biobankers to share benefits arises only when the commercial use is 
involved.84 As a result, although there is a power disparity between biobankers and 
participants, benefit-sharing may not always take place if there is no involvement of 
commercial gains. The measure stipulates that biobankers and users should reach an 
agreement by contract to decide the percentage of profits to feed back when the profits 
at issue are estimable.85 In the circumstances when the potential profits are inestimable, 
biobankers may charge a set fee depending on the nature and quantity of the use when 
the users apply for access to biobanks. If the users and biobankers are identical, the rate 
of feed-back or the set fee needs to be decided by biobanks’ethics committees.86
By observing what constitutes a fair benefit in the regulation, benefit-sharing in the 
context of biobanking in Taiwan may have been reduced to “profit-sharing.” As 
anthropologist Cori Hayden rightly points out, although intellectual property may serve 
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either as an enabling device for or as an idiom of benefit-sharing, the right itself is rarely 
considered “part of the package of goods” to be redistributed to benefit-recipients.87 As 
a result, benefits are “posed as not-rights.”88 When assessing who is entitled to benefits, 
a new boundary may be created in order to form a community acting as a 
benefit-recipient to satisfy the collective nature of biobanks. When intellectual property 
is used as a metaphor in defining who should be included or excluded in a benefit-sharing 
scheme, John Locke’s labour theory of property which emphasizes the necessity of mixing 
one’s labour with an object seems to have reclaimed its own title in the discussion. For 
instance, as Hayden illustrates, the Lockean notion has set the stage for indigenous rights 
activists who claimed property rights by arguing that much biodiversity was already 
suffused with labour that has been produced and reproduced by indigenous people over 
a long period of time.89 On the other hand, when considering the relationship between 
intellectual property and benefit-sharing, it is procedurally complicated to trace back to 
identify who has contributed to adding value to the collected materials.90 For that reason, 
the indigenous group as a whole may be entitled to rights of ownership or compensation 
as they have collectively put labour into the product.
The mechanism of benefit-sharing in Taiwan may also be viewed as an institutional 
response to the mobilization of local human rights groups and their criticism of the 
Taiwan Biobank due to a lack of consensus and of an appropriate governance framework 
to deal with related ethical and legal issues. In Taiwan, according to the regulation, if the 
profits of the use of biobanks may be attributed to the contribution of a specific 
population, they shall be shared with the population. Where it is difficult to ascertain the 
attribution, the profits shall be fed back to the population as a whole.91 In order to 
reward participants’contributions, the principle of benefit-sharing is mainly based on the 
values of redistributive justice. To some extent, such an endeavour is worth encouraging
as it recognises the necessity of “giving-back” that may help complete the total system of 
exchange, in Mauss’s words, and forms social relations among biobankers and 
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participants. However, benefit-sharing cannot address the fundamental problem with 
regard to property rights in human body parts if property is not to be recognised as a 
form of benefit. The very difference lies in that such form of benefit-sharing grants 
“profits” rather than “power” to recipients so the power asymmetry between biobankers
and participants may not be abridged by merely redistributing profits derived from the 
use of biobanks. Ownership and property relate to the interest in control over things. 
Therefore, the core issue in biobanking in general and in the Taiwan Biobank in particular
is whether participants may attain some degree of control over their samples after they 
have been given to biobankers in research through the mechanism of informed consent. 
In the terms of Mauss’s gift relationship, the benefit-sharing arrangement in Taiwan may 
serve as gesture of reciprocity but not the spirit of it because true reciprocity emphasizes
forming power relations in which the subjectivities of givers and recipients are able to be 
restructured. When such a power relationship is formed, no one would be deemed to be 
inferior as even though the society itself may be archaic and hierarchical, givers and
recipients are constructed as inter-subjectivities in the whole system of exchange of gifts. 
By viewing biobanks as assemblages of human biological materials, genealogies and
personal health information, it has been argued that the assemblages have unfolded the 
new distributive politics of life science.92 However, within the politics, the normative 
unsettlement for property relations between biobankers and participants has made
solutions to the governance of biobanks elusive and impractical. In the Moore case,
Justice Mosk favoured a policy permitting Moore’s cause of action for conversion by 
claiming that property is a complex bundle of rights. According to him, a proprietary
interest in the human body should be granted as such rights did not attach to all forms of 
property, and as a result, the limitation on or prohibition of the exercise of certain rights 
over certain forms of property did not entirely destroy the title.93 To understand 
property as a bundle of rights meant to treat property as an abstract notion rather than 
viewing it directly as a concrete material object and therefore it referred to the rights 
being exercised with respect to the object, for example, the right to possess, to use or to 
refrain others from using it, etc.94 When the same rule applies to the case, as Justice 
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Mosk pointed out, Moore still retained property rights in his excised tissues so he should 
be entitled to the rights to do with his tissues as the defendants did with them, such as 
contracting with pharmaceutical companies to develop the tissues’ commercial 
potentials.95
Although the majority opinions in the Moore case seem to think that granting a 
proprietary interest would make the human body a commodity, this perception is itself 
ambiguous and not completely true. Not granting property rights in human tissues and 
their derived information ignores the power asymmetry between sample subjects and 
researchers and also it may make sample providers lose their control in samples after 
they are excised. Although it is still unsettled in law in many jurisdictions, including 
Taiwan, with regard to the recognition of property in human samples in medical research,
participants’interests in a better control over the use of their samples in research and 
the information derived from them should be prioritised. By so doing, a true reciprocity 
as Mauss had wished to apply in a modern industrial society, may be expected and in the 
context of biobanking, a long-term trust relationship may be reshaped and consolidated. 
6.3 Privacy, Confidentiality and Public Interest
The emergence of new technologies for collecting, processing and storing personal data 
has gradually reconfigured the relationships between citizens and states. As David Lyon 
has argued, the rapid expansion of technologies along with the development of 
computerization in modern bureaucracies has not only reshaped personal experiences of 
daily life but also influenced large-scale social processes by constituting novel social 
formations.96 In addition, collecting detailed personal information in a systematic and 
comprehensive way by the mediation of new computing and digital technologies features 
administration in modern societies in which rational institutions and a hierarchical 
management order can now be formed more easily than in the past.97 According to Max 
Weber, modern societies may be characterized by observing the growth in capitalism and 
bureaucracies that has transformed old types of social actions established in feudal 
systems based on lineage and religious relationship to systems based on rational 
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calculation, impersonality and efficiency.98 In order to effectively operate the huge 
bureaucratic apparatus, states have managed to develop ways to handle their detailed 
modes of governance involving large amounts of data connecting the daily life of citizens 
such as routine record keeping for the purposes of identification, tax collection, welfare 
and policing, etc. However, the introduction of computer technology into the processing 
of personal data provides modern states not only with more efficient techniques to run 
their bureaucracies but also with an effective mode of governance of their citizens.99
When modern information societies came into being, George Orwell’s concerns about the 
augmented power of states by pervasive government surveillance does not only exist in 
his dystopian novel Nineteen Eighty-Four or in his imagination of the geopolitical analysis 
of the Oceania province of Airstrip one,100 but also in people’s social relations and real 
daily life. For instance, a report published by Big Brother Watch, a campaign group set up 
for defending civil liberties in the United Kingdom points out that the operation of closed 
circuit television (CCTV) camera on Britain’s street had increased from a figure of 21,000 
to at least 59,753 in 2009 in about ten years’ time.101 In addition to using the camera as a 
technique of governance, population biobanks collecting and storing human biological 
materials and genetic information bring the issue of privacy in the forefront. As the 
biobanks generally require the linkage of different databases of massive population 
registries and personal health information in order to know the causal interaction among 
diseases, environmental and genetic factors, concerns about the misappropriation of 
personal data and its social impact renders protection of privacy a significant issue to be 
discussed. 
In April 2001, the Bureau of National Health Insurance (BNHI) in Taiwan introduced a 
health care smart card scheme in order to replace the original paper-based patient card 
system. The smart card is an integrated circuit (IC) card with 32 kilobytes (KB) of memory 
which allows it to store a cardholder’s status such as personal information, health 
insurance related information, medical service information and the information of public 
health administration. As the smart card contains personal and medical data such as a 
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cardholder’s name, national ID number, last six medical visits and treatments,
prescriptions, history of immunisation, drug allergy and remarks for catastrophic diseases, 
it functions like a carryable medical record accessible to all participating health provider 
institutions by setting up the required interface and card readers. Furthermore, as the 
card includes health care related information such as accumulated medical expenditure 
records and the amount of cost-sharing, it has proprietary interest not only to the card 
holder him/herself but also to the state’s health care agency - the BNHI. 
The implementation of the smart card scheme has become compulsory in Taiwan since 1 
January 2004. The overall electronic system requires registered hospitals and clinics102 to 
upload their medical records to the BNHI on a daily basis so that the bureau is able to 
access patients’ information and then to reimburse medical service providers in a more 
efficient way. Although compared to the paper-based patient card system, the smart card 
scheme helps reduce waste of resources for the BNHI by identifying fraud and excess false 
insurance payments claimed from registered health providers, it has caused human rights 
concerns that a centralised medical data storage could turn Taiwan into a police state due 
to mass “datavelliance”, in the language of David Lyon.103 In addition, who is entitled to 
claim ownership of the medical data stored in the smart card is still a pending question. 
Like human biological materials, even though personal and medical data has significant 
proprietary interests in a modern information society, its ambiguous legal status has 
challenged the notion of property in the arena of law. However, rather than clarifying
titles of proprietary interest, legal mechanisms focusing on personal data protection have 
switched the issue of property to a concern with privacy.
6.3.1 Confidentiality: A Narrow View of Privacy
In the Source Informatics case the England appellate court suggested that patients do not 
have proprietary interests in their information in prescription forms, so that they are not 
entitled to claim for the misappropriate use of their prescription information for 
commercial purposes even though the use was without obtaining the patients’ consent. In 
the case, the appellant (Source) was a company engaged in obtaining information about 
doctors’ prescribing habits which then could be sold to pharmaceutical companies for 
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marketing their products. Concerned that the practice of target marketing would increase 
prescriptions made by doctors and add the burden for the British National Health Service 
(NHS) to pay the bill, the Department of Health in the United Kingdom issued a policy 
document claiming that the disclosure of prescription information to third parties 
without patients’ consent was a breach of patients’ confidentiality even though the 
patients’ identities were not revealed. Source appealed against an English High Court 
decision which refused to grant a declaration that the Department of Health’s policy 
document was made in error. According to the High Court, it was a breach of confidence 
to use prescription information given by patients for treatment for any other purposes 
without their consent. However, the Court of Appeal overturned the High Court’s 
decision on the grounds that patients’ privacy was not being infringed in this 
circumstance because their personal information was not identifiable. For the Court of 
Appeal, as the patient had no proprietary claim to the prescription form and the 
information the form contains, he was deemed to have no right to control the use of his 
information as the protection of his privacy seemed to be intact.104
Clearly, what the Court of Appeal recognised is a narrow view of privacy that suggests the 
patient’s privacy would be infringed only if the patient’s prescription information was
identifiable and was used unfairly against the patient. A weakness of the legal reasoning 
shown in Source Informatics lies in the fact that it treats confidentiality and privacy as 
identical notions. However, in terms of respecting self-control of personal information, 
privacy is a much broader concept since it requires no relationship characterised in 
confidentiality as a duty owned by confidants to confiders in order to maintain the 
security of confidential information.105 In addition, in the ruling, the English Court of 
Appeal has suggested that it is a fair use of information to disclose anonymised data to a 
firm for commercial uses even without consent from patients. Such a ruling has 
challenged the traditional defence of public interest to the breach of confidence by 
obviating the competing public interest to the reassessment of the notion of fairness of 
use.106 As a result, what the court in fact suggested seems to be that so long as there is 
no unfairness in the use of information to the confider, there may be no breach of 
confidence even though a proposed use of information is unauthorised and the use is not 
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within the public interest defence as the duty of confidence.107 Following this legal 
reasoning, the Court of Appeal imposed an onus on the confider to demonstrate that the 
proposed use is unfair even though what is supposed to be protected should be 
confiders’own information as confidentiality is one of patients’rights in their relationship 
with health care professionals.  
This minimalist view of privacy taken in the judgment of Source Informatics ignores the 
argument that individual’s autonomy may not be simply reduced to anonymisation of 
personal information. By the same token, discussions of access and management of 
participants’health and genetic information in the context of biobanking should not be 
limited to the rules relating to confidentiality such as forms of the coding and 
anonymisation of samples and data stored in biobanks.108 On the contrary, a broader 
conception of privacy needs to be taken into account. By so doing, the focus may be 
shifted from the sensitivity of genetic information and how to maintain stricter control of 
its use to more fundamental aspects about the notion of privacy itself and how to 
balance collective and individual rights in the circumstances especially when a relevant 
public interest is identified. 
By analyzing different approaches biobank governance adopts to deal with legal and 
ethical issues of consent, property and privacy, Brownsword argues that the UK Biobank 
has adopted a compromise model as its governance framework design mixes a regime of 
weak provisions on property but strong provisions on consent and privacy.109 In terms of 
strong privacy, the UK Biobank Ethics and Governance Framework addresses the 
importance of protection of confidentiality of data and samples by ensuring that samples 
are reversibly anonymised and are linked and stored by strict measures and to high 
standards.110 Following the UK Biobank’s governance principles, a similar governance 
model of strong privacy can also be detected in Taiwan. For instance, Article 18 of the 
Human Biobank Management Act provides particulars about anonymisation to ensure 
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that participants could not be identified through their samples and related personal data 
and information in the process of biobanking. 111 In addition, in July 2010, the 
Department of Health released the implementing rules on Article 13 of the Human 
Biobank Management Act that stipulates electronic security measures about the 
management of information technology. These mechanisms demonstrate that anonymity 
and confidentiality are prioritised in the biobanking case in Taiwan and the biobankers 
have made a great deal of effort in order to ensure that the storage and processing of 
information would not violate participants’data protection.  
However, it demonstrates that what the Taiwan Biobank adopts is also a narrow and thin 
conception of privacy as the biobankers take the view that so long as participants’
samples and personal data have been anonymised, the protection of privacy is sufficient 
and there is a low realistic possibility that confidentiality could be breached or 
participants’ identities could be revealed. For instance, the interview contents below 
illustrate that the scientists who are in charge of the pilot study of the Taiwan Biobank 
project have taken the minimalist view of privacy that reflects their beliefs in that if a 
person’s identity is protected, the person’s privacy is not put at risk.
We understand critics’concerns, so we have set the highest standards to ourselves in terms 
of protection of participants’ privacy. We would like to be the model in bioethics for 
biomedical research in Taiwan. These years we have developed strict standard operating 
procedures for the collection, management and the storage of samples and data. For 
instance, samples and lifestyle information collected in every sample collection sites will be 
coded at the sites and the data transmitted from the collection sites to our main lab will be 
encrypted. Identifiable personal information such as participants’ names, birth, and 
addresses, etc will be stored separately with their samples. Only the holder of the key may 
link participants’samples to their identities. Therefore, in the future, even when we need 
to use samples and data stored in the biobank, we are required to apply to access to the 
biobank through a user committee.112
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In science, when we talk about risk management, we would like to evaluate the possibility, 
namely the chance of the risk happening. Even though the public may concerned about the 
sensitivity of their personal and genetic information, scientifically speaking, I would say that 
the chance of data leakage is very low in the current IT security system of double coding 
and encryption. (Interview with scientists at the IBMS, the Academia Sinica, Taipei, Taiwan, 
2010)
6.3.2 Informational Conception of Privacy
Nevertheless, this narrowly conceived privacy ignores another valid claim that the right to 
privacy, to some extent, is also to respect individual autonomy and such autonomy 
includes a decision with regard to how individuals would like their own information to be 
used.113 Even though privacy is a fluid idea as its content changes constantly depending 
on context and circumstance, the protean character of privacy, as some legal scholars 
suggest, may be broadly reflected in its two conceptions - spatial and informational 
conceptions.114 The spatial conceptions of privacy refer to the state of separateness to 
an individual’s self in a physical or psychological sense and the informational conceptions 
of privacy may be viewed as inaccessibility to an individual’s personal information from 
others.115 Although “the right to be let alone”116 makes the right to privacy be conceived 
as a passive right, the notions of privacy has gradually changed along with the advent of 
the information age in which the right to control the use of personal information 
reconfigures the right to privacy from a passive right to a positive one. 
In Taiwan, privacy117 has not been enumerated as a fundamental right in the R.O.C. 
Constitution. However, it has been recognized through judicial interpretations based on 
Article 22 of the Constitution, a catchall provision guaranteeing the protection of people’s 
freedoms and rights that are not detrimental to social order and public welfare.118 The 
Council of Grand Justices composed of 15 members is the Constitutional Court in Taiwan 
responsible for interpreting the Constitution. In its Interpretation No. 585, the Council
                                                     
113 Supra note 47, P. 225 
114 More info, see, supra note 46, P. 6; Supra note 106, P. 18 
115 Supra note 47, P. 6 
116 Warren and Brandeis, "The Right to Privacy," Havard Law Review IV no. 5 (1890).
117 Here, the meaning of “privacy” is limited to the discussions of rights to privacy in the Taiwanese reality, 
although the notion of privacy itself, as it has been mentioned in the chapter, is a much broader concept 
than being viewed as a fundamental right.
118 For instance, Interpretations No. 509, 535 and 603 of the Council of Grand Justices, Taiwan, R.O.C.
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formally recognised spatial and informational conceptions of privacy as a way to preserve 
the value of the constitutional structure of free democracy.119 However, the concrete 
contents of the rights of informational privacy have not yet been elaborated until the 
release of the Interpretation No. 603 in which it is claimed to be unconstitutional to make 
fingerprinting a compulsory condition for the issuance of an ROC national identity card.120
In summer 2005, the Council of Grand Justices in Taiwan announced a preliminary 
injunction on the fingerprint policy which requires all Taiwanese nationals over 14 years 
of age to provide their fingerprints when applying for a new national identity card. 
According to an amendment to the Household Registration Act, no new ID cards will be 
issued unless the applicant is fingerprinted. Even though the Ministry of Interior made a 
statement in a press conference claiming that the collected fingerprints would be used 
for identification purposes only and no law enforcement agencies may use the data to 
investigate criminal cases, local human rights groups had launched a series of public 
campaigns with the concerns that the establishment of a fingerprint database would 
infringe people’s privacy and could bring Taiwan back to a police state after the lifting of
martial law in 1987.121 A few months later, the Council of Grand Justices issued its 
Interpretation No.603 in which the relevant provisions of the Household Registration Act 
were deemed to be unconstitutional by conditioning the issuance of an identity card 
upon compulsory fingerprinting. In the Interpretation, the Council recognized that the 
right of informational privacy includes the rights for individuals to decide whether or not 
to disclose their personal information, and if so, to what extent and in what manners 
such information may be disclosed. 122 The self-control of personal information 
constitutes part of the right to privacy which was viewed by the Council as an 
indispensable right for the free development of personality and for the preservation of 
human dignity.123 As fingerprints are a form of abstract personality characterized by 
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biological uniqueness and lifetime unchangeability, they are deemed to be sensitive 
personal data by the Council to be protected under the right of informational privacy. 
6.3.3 Public Interest: the Individual and the Collective
However, as the right to privacy is not an absolute right, the mass collection of people’s 
fingerprints by the state still needs to be justified by the compelling public interest and by 
enacting unambiguous laws in order to satisfy the principles of legal reservation. As the 
legislative purposes of collecting fingerprints were mainly to enhance personal identity 
verification in household administration, they were viewed by the Grand Justices as 
overly generous, broad and not compelling for the defence of the public interest in 
Taiwan. Furthermore, since compulsory fingerprinting and record keeping were not the 
least intrusive means to effectively serve the purpose of identification, it was deemed to 
be in violation of the principle of proportionality.124 In order to protect people’s right of 
informational privacy, the Grand Justices also required that the state shall make sure all 
legitimately collected personal data is reasonably used and properly secured and 
maintained. 
In considering whether the right to privacy may have been infringed, the defence of public 
interest is generally viewed as a way to evaluate the balances within the tension between 
individual and collective. Under the tradition of Western liberal democracy, in order to 
encourage debates and communication of public matters and to foster the development 
of trust relationships in society, individuals’ personal privacy is expected to be guaranteed 
so that not every aspect of an individual’s private life could be infringed as a result of 
serving greater social purposes.125 In the context of biobanking, the tension between the 
individual and the collective is much more apparent as genetic information which relates
not only to its sample source but also to the group of people who share the same genetic 
lineage is involved. Moreover, since the purposes of the establishment of population 
biobanks aim to enhance understanding of the causes of diseases in order to improve 
preventive medicine for future generations, these expectations are mainly collective 
interests rather than individual ones. 
                                                     
124 Ibid.
125 Supra note 47, pp 10-11 
222
Biomedical development on human genetics challenges mainstream modern bioethics 
which puts more emphasis on the protection of individual rights than on community 
benefits. Even though the right to self-control of personal information is recognised in 
Taiwan, considering giving the individual more control over his or her personal 
information illustrates how the legal analysis may have been influenced by the rationale 
to prioritise the autonomy of individuals.126 Moreover, when considering what kinds of 
benefits biobank research seeks to bring, such as the advancement of scientific 
knowledge and the improvement of public health, the boundary between public and 
private turns out to be negotiable. The scope of privacy becomes floating as an individual 
agent whose self-governance of her or his health condition may no longer be viewed as 
simply a personal decision made in the private sphere. The intervention of the state turns 
out to be much more delicate compared to the past that empowers the individuals to look 
after themselves by introducing health care rather than by using police to exercise the 
power of traditional sovereignty in order to fulfill the functions of control and discipline. 
According to Michel Foucault, biopower involves a set of mechanisms and procedures 
through which human beings became the object of political strategy.127 In eighteenth 
century Western Europe, governmentality changed from taking life to maintaining the 
sustainability of the population as a result of the threats of scarcity and the outbursts of 
epidemic diseases such as smallpox. As both of these phenomena could lead to a very 
high mortality rate, several techniques and mechanisms of security such as statistics, 
inoculation and vaccination were adopted by the states to safeguard population growth. 
In addition, the emergence of the town, which was deemed to be an exception to the 
power of feudalism, posed new problems of government technique. How to integrate this 
kind of autonomous zone that was able to govern itself within the central mechanism of 
power concerned the legitimacy of the sovereign.128 In other words, how the power of 
the sovereignty could be executed effectively over the population challenged not only the 
validity of the governance but also the sustainability of the modern state. 
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127 Michel Foucault, Security, Territory, Population : Lectures at the Collège De France, 1977-78 (New York 
Palgrave Macmillan, 2007). pp 1-2
128 Ibid., pp 64-65
223
In fact, such a mechanism of security did not function in the form of the prohibition or a 
way to ensure the totality by sacrificing the individuals. On the contrary, it governed the 
individual by allowing the natural processes, namely by recognising the naturalness of the 
population, which was not deemed to be the simple sum of individuals, but a “datum” 
depending on a series of variables, such as customs, religious values, laws, material 
surroundings, or the intensity of commerce in the circulation of wealth, etc.129 The datum, 
according to Foucault, could not be transparent to the sovereign as the variables on which 
the population depended might easily escape the sovereign’s direct action in the form of 
the law.130 As a result, the relation between the sovereign and the population was 
dynamic rather than simply be “one of obedience or revolt.”131 Because the population 
appeared as a “thick natural phenomenon” which was constantly accessible to agents and 
techniques of transformation, a new technique of governance emerged whose purpose 
was not getting the population to obey the sovereign’s will but governed far away from 
the population’s immediate behaviour by having a hold on a range of factors and 
elements through calculation and analysis and knew that an effect on the population 
would be expected.132  
Besides, even though the population was made up of individuals with different opinions 
and behaviours, for Foucault, the commonality of each individual was that everyone acted 
out of desire - out of the pursuit of the individual’s interests - and when each individual 
acted following his or her spontaneous play of desire, it would allow the production of the 
favourable interest of the population.133 As a result, the new technique for the sovereign 
to govern the population was simply to recognize the naturalness of the desires of the 
individuals and then to follow, to encourage or even to stimulate this desire, so that it 
would produce necessary beneficial effects on the population. By introducing “nature”
into the field of governance, an effective technique of power turned to be something that 
may demonstrate the reflected procedures of the sovereign’s governance within this 
nature. From this point of view, on the one hand, the population was characterised as 
“the human species” in the form of the integration within biology and, on the other hand, 
however, it was “the public” when viewing the appearance of the population from the 
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aspects of its opinions and requirements.134 A space was therefore created from the 
biological rootedness to the surface of the public and it was within this space, according 
to Foucault, that the pertinent elements for mechanisms of power became possible.135
6.3.4 Advanced Liberalism
The traditional distinction between public and private spheres of life is blurred in 
Foucault’s discourses of biopower and governmentality, as recognising the space for the 
individuals’self-governance has become a new technique of power for the state to govern 
its subject population. In contemporary political economy, such a technique of 
governance is manifested by the practice of neo-liberalism, which proposes the view that 
the utilisation of the individuals’freedom of choice is to govern in an advanced liberal 
way.136 The individual is conceived by neo-liberalism as an active social agent who can be 
cultivated to be responsible for his or her own wellbeing and by so doing, a space of 
governance may be created in which the relations between citizens and the state is 
reconfigured from obedience and coercion to acts of choice exercised by responsible 
individuals. The dominant logic underpinning this new strategy of governance is the logic 
of a free market which introduces new relations of power by treating autonomous 
individuals as consumers who can evaluate and manage risks and to make a decision to 
fulfill their maximum interests.137 For that reason, the most effective strategies of 
governance are in fact those that may transplant the goals of authorities into the choices 
of the individuals who can govern themselves by their autonomy and by their freedom to 
choose. 
Even though the discourses of biopower Foucault used to analyse the relations between 
the sovereignty and the population in Eighteenth century Western Europe were 
embedded in a temporal and social setting very different from contemporary Taiwan, it 
provides a useful theoretical perspective to observe the intermingling phenomenon of 
public and private in the Taiwanese reality. In fact, the privacy-related problems in Taiwan 
are embedded in a much broader political and economic context. The increase in the 
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elderly population combined with a declining birthrate has changed the profile of 
Taiwanese demographic development, and therefore, how to improve public health in 
order to support the aging society gradually dominates the government’s welfare policy. 
Health and disease may no longer be treated as merely a scientific or medical concern 
under this broader perspective. Rather, they are closely connected to the sustainability of 
the state and as a result, the improvement of health for the population turns to be a 
crucial issue in Taiwanese governmentality. Investing in preventive medicine not only 
allows the state opportunities to build up its domestic biotech industries, it is also a 
strategy to reduce health care costs that have risen due to the increase in longevity. 
This illustrates that the role of the state has changed from the threat of death to taking 
charge of life. According to Foucault, such intervention of modern state governmentality 
is no longer to control populations through rules or regulations but to manage, to
recognise and to work with the population in its naturalness, namely that the population 
is no longer conceived as simply a collection of subjects but a set of natural phenomena 
for which the state needs to take responsibility.138 However, when the population 
appears as a reality, it forms like a social body and its relation with each individual who 
comprises it becomes dynamic when the state’s intervention has extended to the 
wellbeing and health of the individual. The ethical tension between considering individual 
rights as paramount and pursuing the common good based on maximising aggregate
utility seems not to be uncommon in the formation of modern welfare states. How to 
balance the dilemma challenges not only the role of the state but also the individuals’ 
self-reflections in terms of the formation of their social identity. In other words,
individuals are expected to play a role as responsible citizens in a larger community as 
their individual autonomous choices will inevitably have impacts on the other members of 
the greater social to which the individual belongs. 
However, scientific advances in genomics have allowed a new way for individuals to view 
health and diseases. For instance, the purpose of studies on pharmacogenomics is to find 
out new strategies for optimising drug therapy based on the correlations between the 
variation in drug responses and each individual’s genetic make-up. This purported 
objective echoes the scientific goal of the establishment of the Taiwan Biobank that plans 
                                                     
138 Supra note 127, pp 352-353
226
to discover and to capitalise new therapeutic targets for the improvement of preventive 
medicine in Taiwan. In order to obtain the public’s support for the project, one effective 
strategy is therefore to translate the purported goal and the possible benefits of 
biobanking into the Taiwanese citizens’ perceptions of self and of health. This kind of 
indirect governance has been reflected through the discourses of altruism and solidarity 
proposed by the biobank project. By so doing, the relationship between the collective and 
the individual is more elusive and ambiguous as the intervention of the state into the 
private sphere of individual health management turns to be more subtle and invisible. 
As a result, important questions for the privacy-related issues in Taiwan may no longer be 
limited to the legal and judicial ones such as whether the mechanisms of confidentiality 
and data protection exist, or whether an individual’s self-control of personal information 
has been respected. On the contrary, it has turned out to be a more profound question 
challenging the trust relationship between the state and its citizens, namely to what 
extent an individual would be willing to act as a responsible social agent and to accept the 
neo-liberal strategy proposed by the government. Such ethical complexity between the 
individual and the collective highlights the issue of privacy especially in the context of
biobanking as participating in the biobank project, to some extent, also means to entrust 
certain risks of privacy infringement to the biobankers. Even though samples and data 
stored in the biobank may have been encoded and made anonymous, due to the nature 
of the biobank research, individuals are supposed to be followed up for their health 
conditions and life styles throughout a certain periods of their lives. As a result, in reality, 
it is still questionable whether the privacy of individuals would remain intact without 
decoding data for tracing identified participants. 
As the Taiwan Biobank is a government-funded project, citizens’ attitudes towards the 
project are heavily influenced by their perceptions of the state. In Taiwan, the role of the 
state has been transformed dramatically since the lift of martial law in 1987. The old 
authoritarian apparatus gradually faces the challenges proposed by the burgeoning 
society which has increased its own autonomy and is no longer docile in its interaction 
with the state. Even though Taiwan has moved slowly into a welfare state since the early 
90s as a result of its successful economic development and its democratic transition, the 
role of the state remains ambiguous in terms of its relationship with society, which keeps 
itself distant and skeptical from the apparatus due to the influence of a long-term
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governance under the martial law. Under this context, in Taiwan, the stewardship 
responsibilities of the state are more complicated than the common debates between 
Right and Left in modern Western welfare states. On the one hand, the state has learned 
how to adopt the techniques of power to govern its population; on the other hand, 
however, the state’s reactions with a free market remains unsettled as market and capital 
are no longer easily to be controlled and managed by the will of the state. Even though 
Taiwan is also generally recognised as a society influenced by Confucian philosophy which 
prioritizes community interests over individual ones, the influence of modernity along 
with the transitional role the state plays has rendered Taiwan a more vivid case reflecting 
on the distinction of public and private in the discussions of privacy-related issue in the 
context of biobanking. 
Conclusion
The purpose of this chapter has been to provide an alternative perspective to reflect on 
issues of property and privacy raised by the emergence of biobanks as a modern 
technology. This chapter examined the way the mechanism of consent and the legal 
rationality of intellectual property that recognises proprietary interests on added values 
rather than in the sources of human biological materials may have facilitated the 
commodification of human body and body parts. It argues that the Moore case fabricated 
the distinction of property and personhood that renders the legal status of human tissue 
samples much more ambiguous. In addition, the presumed gift model implied by using 
the mechanism of consent to replace property has put research subjects in a relatively 
powerless position especially in a capitalist market system where the innovation of 
biotechnologies has transformed human biological materials from waste to valuable 
resources. The major difference between the models of consent and property, as the 
chapter argued, lay in the fact that the mechanism of property grants an affirmative right 
for the sample sources to continuously control their removed samples after giving 
consent and it allows a legal standing to request a share of benefits from the related 
proceeds as a result of the research.  
Even though the Moore case raised the issue of treating human biological materials as 
gifts, it is mainly the case of individual interest; whereas Mauss’ perceptions of moral 
economy with greater societies based on gift-exchange provides insights into the 
228
justification of reciprocal altruism and redistribution. This chapter questioned the ethical 
guidelines adopting the gift model from Titmuss’ work to govern the relationship of 
researchers and research subjects. It suggested that it is not appropriate to treat biobank 
participants as simply donors who are expected to have no entitlements to a share of 
profits derived from research based on the differences between blood donation and 
participation in biobanking. In addition, Mauss’theories on viewing society as ‘a greater 
totality’illustrates why the giving-back needs to be extended to the larger collective even 
though they are not participants in the biobank and the reasons why a profit-sharing may 
fail to satisfy the requirement of redistributive justice if it does not address the distinction 
between “power” and “profits” by ignoring the fundamental problem with regard to the 
recognition of property interest of human biological materials.  
In the end, this chapter discussed the issues of privacy and confidentiality in the context 
of Taiwan. Rather than redefining the notion of privacy, the chapter challenged the 
narrow conception of privacy adopted by the biobankers in Taiwan that has 
inappropriately treated privacy and confidentiality as the same and has mistakenly 
suggested that so long as the samples and data are encoded, privacy would no longer be 
an issue in the practice of biobanking in Taiwan. The chapter argued that the unsettling 
property interests of human genetic information have rendered the legal status of the 
ownership of medical records and the personal information stored in the biobank 
ambiguous. Such ambiguity became more apparent when the legal mechanism of 
personal data protection smoothly switched the issue of property to the concerns of 
privacy. 
Finally, by introducing Foucault’s theories on surveillance and governmentality, the 
chapter argued that the boundary between the private and public spheres of life is no 
longer firm and stable; rather, it may be subject to negotiation especially when the 
individuals are viewed as autonomous agents whose choices and freedom have real 
effects on the greater interests of community. The role of the state has changed in this 
neoliberal way of governance that blurs the traditional distinction between individual 
rights and community benefits. As biobanking is a project involving groups, the discussion 
of privacy and its public interest defence needs to consider how this technique of 
governance may have influenced the scope of privacy in the Taiwanese biobanking reality. 
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Conclusion
Even though the co-production of life sciences and capitalism is in itself not new, 
biobanking introduces a new form of global assemblages of capital and vital politics that 
leads to innovative institutions and arrangements in fields of technoscience and ethics. In 
current literatures, there has been much discussion about the implications and regulatory 
frameworks of biobanks in order to ensure that this epistemic and biotechnological 
innovation may proceed in the post-genomic age without compromising rights and 
creating new ethical problems. However, a focus on the ethical and regulatory aspect of 
biobanks often neglects the larger social and political-economic contexts that shape the 
initiatives and trajectories of these newly formed global assemblages. This thesis has 
tried to investigate in depth the biobank project in Taiwan by exploring issues related not 
only to its governance framework but also to the political and economic aspects of the 
biobank. This emphasis, focusing on the way in which biovalue is produced, 
politico-scientific decisions are made and ethical configurations are framed, allows an 
opportunity to reassess law and ethics, capital and politics, as well as the role of the state 
and its population in this new form of biotechnology.
Since Iceland initiated its population biobank in the late 90s, a number of countries have 
joined in this globally technoscientific trend to establish their own national biobanks in 
response to the rapid development of genomics and its associated demands of health 
and wealth. These biobanks across the globe retain their own heterogeneous and 
situated characteristics that make possible the global phenomenon in which biobanking 
conditions vary significantly according to their local settings. The case of Taiwan, as this 
thesis has demonstrated, contributes to this global phenomenon by presenting distinctive 
features in its biobanking endeavours. It reflects the formation of Taiwan’s biocapital and 
the state’s aspirations to make use of this biotech innovation to increase Taiwan’s 
competitiveness and visibilities on the global stage. Developments in life sciences are 
deemed by the government of Taiwan to be a way to promote the wellbeing of its 
populations and materialise its sense of modernity. These sovereign incentives attract 
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biotech and pharmaceutical industries to form public-private collaborations through 
innovative arrangements for technology transfer between the government, academia 
and industry. Law (regulations) and the system it operates, as this thesis has argued, not 
only are affected by their social context but also affect in turn the broad context in which
they are embedded. 
This thesis has presented research findings which combine empirical and theoretical
viewpoints in a modest attempt to demonstrate that theory (concept) and method 
(observed phenomenon) are mutual so they may connect with each other in the study of 
law and its related phenomenon. The case of Taiwan contributes the so-called “local 
inputs” to the bigger image of the developing cosmopolitical technoscience, so what this 
image is able to reflect is no longer a broadly encompassing and conventional 
phenomenon, as the terms ‘global’and ‘cosmopolitical’tend to suggest. Rather, as these 
inputs pay detailed attention to heterogeneous, contingent and situated conditions 
which highlight the distinctive civic epistemologies and politics of technoscience in 
Taiwan, they enrich an understanding of the evolution of this rapidly emerging 
cosmopolitical technoscientific world. Biobanking fits itself well into this particular 
perspective as the development of genomics and life sciences have been closely
entangled with capital, technology and science, all of which are deemed to be elements 
of global forms given their universal and mobile nature. However, as every state’s 
approach to the formation and development of its technoscientific policies are varied 
(based on its own national politics and civic epistemologies), the manifestation and 
operation of biobanks in these different localities are diversified. It is because of these 
variations that the Taiwanese experience provides its own value in terms of enriching 
current literatures on the development and governance of biobanks. 
I. Reassessing Bioethics from the Perspective of Biopolitics
In addition to empirical contributions, as the biobanking case in Taiwan illustrates, 
however, this thesis has also opened up several theoretical points which are summarised
and addressed in these concluding remarks. The first theme concerns the re-evaluation of 
bioethics in biobank governance from a perspective of biopolitics and governmentality. 
As this thesis has argued that while informed consent and privacy have been placed in 
the forefront of biobank governance in Taiwan, such an ethical configuration has,
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however, failed to challenge the influence of global capitalism. Rather, it has further 
consolidated a neoliberal rationality which echoes the state’s transformation from its role 
of steward to an investor in global bioeconomic competition. Bioethics, if positioned in 
the context of Taiwan’s biocapital formation (and its entanglement with the global flow
of capital), may easily be reduced to procedures and framed as a governing mechanism to 
help the state turn its population into resources through discourses of citizenship in the 
name of individual autonomy. Even though bioethics is one of the key elements in 
legitimating modern biomedical research involving human subjects, they are equally
useful tools to act as a procedural safeguard that in reality consolidates invisible power 
structures associated with capital and politics, especially when the ethics are introduced 
into law as a formal technique of the technology of governance. 
Nevertheless, the purpose of this thesis is not to blindly question the necessity of 
bioethics in Taiwan’s biomedical research. Certainly, in a country whose bioethical 
arrangements and regulation are still in the early developing stage, bioethics is an 
appropriate point to reflect the importance of human value and conditions in the 
production of scientific knowledge. However, this thesis has emphasized that bioethics 
should not be viewed as a neutral and sufficient mechanism, and as its configuration 
implies the compromise of various competing interests, the ethics itself also needs to be 
scrutinised for its underlying agendas through tracing its process of formation and the 
possible entanglement with capital and politics. As a result, Michel Foucault’s notions of 
biopower and governmentality provide a useful angle in this thesis to detach bioethics 
from its moral-loaded appearance, especially when these ethical configurations are 
connected to a neo-liberal logic which focuses on individual autonomy as a way to justify 
liberal democracies. A modern governing technique can extend its liberal governance in 
the name of individual autonomy to the wellbeing of the population and the individuals 
who compose it in the interests of the state. This advanced liberal rule, as Nikolas Rose 
suggests, seeks to govern through the regulated choices of individual citizens, who are to 
be governed through their freedom as they are constructed as subjects of choices.1
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Such a technique of governance, as argued by Rose, may not be understood thoroughly 
without taking into account the emergence of modern welfare states in which the state’s 
intervention to redress social problems for national wellbeing becomes a legitimate 
technique of governance “at a distance.”2 In other words, governing through individuals’
self-governance becomes a more effectual way than traditional authoritarian rule using
laws and bureaucracies for political purposes to seek to produce desired effects.3 As a 
result, the state of welfare becomes a specific terrain to observe the relations between 
the political sphere and other domains of economy and society as the state may now take 
its stewardship responsibility for generating technologies of government by rearranging 
its resources in the name of collective security and the public good.4 Social insurance and 
national healthcare are both exemplary of this welfare formula by addressing social 
solidarity and individuals’responsibilities as dutiful citizens to share the common good 
for the management of both individual and collective risks. 
Discourses of citizenship in biobanks, as this thesis has argued, re-conceptualise national 
populations from biovalue generators to political subjects who are entitled to their rights 
and entitlements for social protection in exchange for their duties of social 
responsibilities, for example, their will to be healthy and to contribute to public health. 
This neo-liberal method of governance which guarantees individual autonomy and acts of 
choice has become an advanced liberal strategy for the state. National biobanks 
exemplify this governing technique by forming active citizens as voluntary participants of 
the biobanks for the public good. Rather than governing through society, this advanced 
liberal strategy seeks to govern through the choices of individual citizens by creating a 
space to recognise their freedom to pursue maximum benefits for themselves and for 
others. Nevertheless, this modern technique disguises the economic role of biobanks 
which focuses on the production of biovalue by forming biobanks for the application of 
genomics research. In other words, as these population biobanks have been deemed to 
be valuable resources in the global bioeconomy, the advanced liberal governance relying 
on the discourses of citizenship may effectively help states in turning their populations 
into resources of biovalue.5
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Bioethics, such as informed consent and the protection of confidentiality, constitutes a 
crucial part of this global biocapital structure but its entanglements with relations of 
power and capital have not yet been fully presented in the establishment and operation 
of population biobanks. Even though the Iceland controversy regarding the application of 
presumed consent on the establishment of its Health Sector Database has been 
frequently discussed in the current literature, these discussions focus more on the 
dimension of bioethical issues associated with governance frameworks than on reflecting
the political and economic roles of biobanks. Following the Icelandic project are similar 
biobanking plans across the globe with different scales, approaches and different forms 
of collaboration between the public and private sectors but all of them seem to pose 
similar fundamental ethical concerns from bioethical vantage point addressing consent 
and privacy as key issues in biobank governance.6
In addition, bioethics in the Icelandic case, as Gisli Palsson and Paul Rabinow argue, 
provides a fertile ground for the Association of Icelanders for Ethics in Science and 
Medicine to accumulate symbolic capital in the transnational market of civic virtue.7
Taiwan provides an excellent case study, as this thesis has illustrated, to observe how 
biomedical issues have become bioethical problems and how the ethical gaze in Taiwan is 
focused on some themes (consent and privacy) and blind to others (property and access 
rights). Like the association in Iceland, the Taiwan Association for Human Rights is also a 
strong ethical and political body which acts as the main platform for ethical criticism for 
the biobank project in Taiwan. Given the association’s earlier success to put on hold a 
governmental plan to establish a national fingerprint database, the biobank project 
concerns human rights advocates in relation to the infringement of individual privacy and 
the lack of transparency and trust. These ethical concerns had led to the biobank 
project’s sample collection being temporarily suspended until its Ethics and Governance 
Council was formed. 
                                                
6 Gísli Pálsson and Paul Rabinow, "The Iceland Controversy: Reflections on the Transnational Market of 
Civic Virtue," in Global Assemblages: Technology, Politics, and Ethics as Anthropological Problems, ed. 
Aihwa Ong and Stephen Collier (Oxford: Blackwell Publishing, 2005). P. 92 
7 Ibid. 
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Moreover, the biobanking case in Taiwan has demonstrated that in terms of the public 
engagement, the public is no longer one homogenous entity. Rather, it constitutes a 
range of “publics”, which may share different interests and may not be mutually exclusive. 
For that reason, this thesis has suggested that it is worthy to discuss which “publics” in 
what capacity one needs to consider in evaluating the engagement of the public in the 
production of scientific knowledge and biovalue. The major obstacle to public 
engagement in the biobank case in Taiwan lies in the fact that Taiwan lacks a long 
tradition of community consultation in the formation and implementation of S&T policies.
However, the subsequent democratic transition in Taiwan has challenged the traditional 
technocrat decision model, so a technocrat-based policy now needs to go through the 
scrutiny from society in order to obtain its own legitimacy. It also illustrates why Taiwan 
relies on formal legal rules rather than self-governance, such as institutional review 
boards and peer reviews among scientific groups, to govern biobanks and how this 
newly-enacted Human Biobank Management Act has become a special terrain to reflect
power negotiation and social mobilisation in its forming process. 
Furthermore, this thesis has suggested that public engagement should not be valued only 
for its instrumental effect in formation of the public good. Rather, it needs to be viewed 
as a way to build a trust relationship between state and society as opinions formed 
through the engagement of the public may ease social distrust that forms the bond that 
society relies to live on. In so doing, the allocation of resources may be better justified as 
what constitutes the common good has become a decision made by “the publics”. This 
thesis has also illustrated that the ethics involved in the biobank project in Taiwan entails 
a wider politics of organisation, decision-making and accountability in democratic
societies to political subjects self-organised as citizens. As a result, the ethics involved 
here is not only limited to the narrow bioethics and codified norms for biomedical 
practices on which most lawyers and ethicists focus. Rather, the thesis argues that these
ethics involve wider political innovation and joint decision-making of potential research
subjects. As a result, the analysis of ethics presented by this thesis hopes to connect with 
empirical reality entailing the impact of politics and capital, which have been relatively 
neglected in current discussion of the ethical and legal issues posed by biobanks. 
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II. Individual and Collective 
Concerns about Taiwanese aboriginal participation in the biobank project challenge the 
current informed consent mechanism, which is mainly based on the rationale of 
individualism. In the context of biobanking, as the potential risks posed by research 
results are normally of a collective nature, individual consent by members of a specific 
ethnic group is often regarded as inadequate to safeguard the interests of the entire 
group on which the detrimental social impact occurs. The original plan to include 
Taiwanese aborigines in the biobank project in Taiwan highlights this inner tension 
between the interests of the individual and the collective. This thesis has demonstrated 
how such a contrast may have been extended from a general discussion on the conflicting 
interests of individual rights and common good to a more specific consideration of the 
inclusion of minority populations in the biobank project in Taiwan. 
As aborigines constitute only 2% of the entirety of the population in Taiwan, their 
potential to be included in the biobank triggers a more specific question about 
stigmatisation and the implementation of consent at a collective level. Moreover, as this
thesis has mentioned, human rights advocates challenged the process of sample 
collection for the biobank based on Article 21 of the Basic Law of Indigenous People
(Taiwan), which requires collective consent obtained from aboriginal groups in addition 
to the consent of the individual when academic research is conducted in the aboriginal 
regions. As a satisfactory mechanism for obtaining group consent from Taiwanese 
aborigines is still under debate, the biobank project has decided to temporarily postpone 
its sample collection from aboriginal groups until a proper mechanism of group consent is 
devised.
This thesis has linked the relation between bioethics and accountabilities in a democratic 
society by placing ethical governance frameworks and group consent in the broader 
political and social context of Taiwan. In so doing, the issue of bioethics may be 
connected with core questions in politics such as who decides on the question to whom a 
collective decision through the mechanism of ethical governance council or group 
consent is accountable. This thesis attempts  to deepen the analysis of biobank 
governance frameworks and consent by moving beyond defining instances of moral 
certainties when new contexts of decision making arise due to the emergence of new 
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biotechnology such as biobanks. In addition, this thesis seeks to demonstrate that ethics 
involves a set of tactics which play a significant role in shaping contexts in which ethical 
norms may be subject to change as well.8 The Taiwanese experience further shows that 
even though group consent is necessary to safeguard the interests of minority 
populations in biobanking, its implementation concerns group identification, 
representation, and how to reach consensus by joint decision making, all of which involve 
deeper political implications with regard to the recognition of aboriginal status and its 
related economic and social inclusion.
Furthermore, this thesis has suggested that it is necessary to take into account Taiwanese 
aboriginal views on genetic research and informed consent so their concerns with 
biobanks may be analysed from a culturally specific perspective. However, this 
culturally-oriented approach does not mean to evoke the notion of cultural relativism, 
which tends to argue that cultural differences are unbridgeable divides.9 In health and 
medical related ethnographic research, this culturally relative view has been criticised as
making research subjects more susceptible and dependent as it entrenches inequality by 
blindly defending local cultural traditions without thinking about their implications.10
Being aware of these concerns, this thesis has sought to move beyond an emphasis on 
difference and demonstrated that the inclusion of the element of cultural difference can 
help design a more suitable consent mechanism for the best interests of Taiwanese 
aborigines in their practice of collective decision-making.
In fact, in the context of biobanks, the inner tension between the individual and the 
collective is particularly apparent as genetic information relates not only to its sample 
source but also to the group of people who share the same genetic lineage. As a result, 
biobanks have challenged bioethics and law which put more emphasis on individual 
autonomy than on collective benefits. Biobanking not only involves the use of genetic 
information of a shared nature but also relates to larger groups of participation, so it 
needs to be further justified by values of a community of rights. This thesis has argued 
that when considering what kinds of benefits biobank research seeks to bring, the 
boundary between public and private turns out to be negotiable. The scope of privacy 
                                                
8 Adriana Petryna, "Globalizing Human Subjects Research " in Global Pharmaceuticals: Ethics, Markets, 
Practices, ed. Adriana Petryna, Andrew Lakoff, and Arthur Kleinman (Duke University Press, 2006). P. 34 
9 Ibid., P. 35
10 Ibid.
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becomes floating as an individual agent’s self-governance of her or his health condition is 
no longer viewed as simply a personal decision made in the private sphere from the 
perspective of biopolitics. 
In addition, this thesis has argued that important questions for privacy-related issues in 
Taiwan may no longer be limited to the legal and judicial spheres. Rather, there is a more 
profound question challenging the trust relationship between the state and its citizens. 
This thesis has further illustrated that in Taiwan, the stewardship responsibilities of the 
state are more complicated than those of modern Western welfare states. On the one 
hand, the government of Taiwan has learned how to adopt the techniques of power to 
govern its population; on the other hand, however, the state’s relations with a free 
market remain unsettled as market and capital are no longer easily controlled by the will 
of the state. The influence of modernity along with the transitional role the state plays, as 
this thesis has recognised, make Taiwan a distinctive case for reflecting on the distinction 
between public and private in the context of biobanks.
III. The Moral Economy of Biobanks
In the end, this thesis argues that the inner tension between the interests in biobanks 
between the individual rights and the benefits of the collective may be mitigated by the 
principle of the moral economy of Marcel Mauss. Compared to the free gift model 
proposed by Richard Titmuss, Mauss’s perceptions of the morality of exchange based on 
the gift relationship in a total society provides insights into the justification of 
redistributive exchange and reciprocal altruism. Even though collection and storage of 
human biological materials for medical use is not a new phenomenon, the possible 
combination of genealogical history and health information with genetic data has made 
biobanks useful resources along with the development of biomedical innovations. As 
intellectual property protects the interests arising from enhancement made by added 
human labour rather than the sources of tissue samples, in order to prevent human 
tissues from being commodified, human body materials have been treated as either gift 
or waste in medical research, rather than as a commodity for exchange. However, this 
thesis has argued that this presumed gift model implied by using consent to replace 
property renders research subjects powerless in a capitalist market system in which 
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biotech commodification has turned human biological materials from waste to resources 
of biovalue. 
In Taiwan, as consent and privacy rather than property dominate the ethical concerns 
surrounding biobank governance, issues such as commodification of human biological 
materials and the penetration of market forces into human tissue and personal health 
data have not yet been seriously reflected upon. On the contrary, altruism and solidarity 
constitute the main discourses of sample collections for the biobank, so proprietary
control of human tissue and personal health data remains in the hands of medical 
researchers and it also means that the economic role played by participants in the 
co-production of biovalue has not been fully recognised in the operation of the biobank. 
This thesis has pointed out that the increasing association of capital and life sciences 
gradually transforms human tissue and genetic data into commodities whose value can 
be created by exchange. In this process of transformation, informed consent plays a 
significant role in instituting a procedure in which persons may be detached from their 
tissue samples by withdrawing their subjectivities and personhood. So being granted the 
authority to give consent, biobank participants are qualified as subjects of modern 
biotechnologies. In addition, this thesis has argued that without an adequate recognition 
of property in human biological materials, the formulations of consent grant research
subjects only an illusory power in terms of exercising continuing control over their tissue 
samples and personal data. 
By analysing the John Moore case, this thesis demonstrated that putting consent and 
property in a position of mutual exclusivity ignores the notions of equity and distributive 
justice and fails to recognise that the patient in the case did not have equal bargaining
power in biomedical research. Similarly, in biobanks, once consent is obtained, the 
continued relationship with participants and their samples has ceased with the result that 
it precludes the participants from being considered as stakeholders in the project. Even 
though the language of ‘gift’ is used frequently in bioethical discourses, it has been 
interpreted in a way associated with altruistic behavior. So rather than being deemed to 
be exercises of self-ownership implied by property, the free gift model presumes the 
surrender of participants’ residual interests in their donated samples.11 By further 
                                                
11 Graeme Laurie, Genetic Privacy: A Challenge to Medico-Legal Norms (Cambridge: Cambridge University 
Press, 2002). P. 317 
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analysing the notion of gift relationship proposed by Richard Titmuss, this thesis 
distinguished the differences between blood donation and biobanking and argued that an 
altruistic gift model may be used in biomedical research to suggest that it may avoid the 
rearrangement of entitlements for the exercise of control over the samples and for a 
share of benefits derived from the application of research results.12
On the contrary, for Mauss, gifts are deemed to be a mode of exchange that helps 
establish the bonds of reciprocity between givers and recipients. To reciprocate gifts 
shows the willingness of the recipients to accept the bond of alliance and commonality. In 
addition, in this mode of exchange, the gift is no longer a mere object but a spiritual 
article that constitutes a part of the giver who has been indissoluble from it. As the gift 
has never been separated from the giver, there is no real distinction between persons 
and things as emerges in a commodity economy in which objects can be completely 
alienated and sold to new owners through the notion of property. According to Mauss, 
the grand cycles of exchanges constitute the whole society that maps all the obligations 
between its members whose permanent commitments articulate the dominant 
institutions. As this thesis has observed, the main purpose behind Mauss’s concept of 
gift-exchange was to support social democratic redistribution and the idea of solidarity in 
modern industrial economies in which the institutions and laws of exchange are governed 
by the rule of markets. 
By extending Mauss’s gift relationship to a discussion of biobanks, this thesis has argued 
that the morality of exchange proposed by Mauss for redistribution may be viewed as an 
alternative supplement to the current unsettling debates about the recognition of 
individual proprietary interests in human body materials. For Mauss, in the total social 
phenomenon constituted by the gift-exchange, a new form of ethic may be created when 
individuals are organized as collective subjects to produce mutual interests based on their 
positive obligations to the greater totality. As a result, even though individual agents do 
not have a positive duty to participate in biobanks, the state’s stewardship responsibility 
for the general wellbeing of the community may have extended the obligation of citizens, 
who are expected to act as responsible agents to improve conditions of public health. 
                                                
12 Richard Tutton, "Person, Property and Gift: Exploring Languages of Tissue Donation to Biomedical 
Research," in Genetic Databases : Socio-Ethical Issues in the Collection and Use of DNA, ed. Richard Tutton 
and Oonagh Corrigan (London and New York Routledge, 2004). P. 20
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However, as such biological citizens may also be viewed by states as a valuable resource 
for biomedical research, this production of biovalue concerning the moral economy of 
health and national imperatives has redefined notions of what it means to be a citizen. 
This thesis has further argued that participants’ growing awareness of potential 
commercial entanglement with their donated samples challenges the distinction between 
gifts and commodities in a market economy because their tissue samples and the derived 
personal information may now be transformed from pure gifts to circulating commodities
as a form of product with exchange value. As the potential for commercialisation has a 
significant impact on participants’ willingness to take part in biobanks, in order to obtain 
trust from the general public, this thesis has suggested that governing mechanisms based 
on the principle of reciprocity need to be proposed by biobanks at the initial stage when 
they procure consent from participants. In addition, as the sustainability of a biobank 
requires establishing a long-term partnership between biobanks and participants, in 
order to obtain trust from the general public, such a partnership needs to be reciprocal 
by recognizing the return of “gift” as a social obligation of biobanks. Furthermore, 
according to Mauss, the system of ‘total services’ is the system in which the exchange of 
everything among individuals and groups become possible. Such a recognition of the 
share of benefits, by treating participants and the whole society as stakeholders, may 
eventually consolidate the legitimacy of biobanks.
Mauss extended the idea of gift-exchange to enhance solidarity in modern societies 
based on market exchange by referring approvingly to proposals on welfare such as 
health and unemployment insurance. In so doing, the redistribution of accumulated 
goods and services based on political innovations of alliances may avoid the failure of 
market exchange by subjecting it to judgments of fairness. As this thesis has argued, 
Mauss’s theories on the gift cycle provide an alternative response to Polanyi’s analysis of 
the great transformation brought by the industrial revolution. Rather than being 
alienated, redistribution of wealth and power in the moral economy reunifies the entire 
social system as the greater totality in which institutions such as law, religion and 
economy are not segmented but entities of the total social facts. This thesis has further 
illustrated that the ultimate goal of reciprocal altruism which suggests stable 
relationships and giving in return between individuals involves a new form of ethics which 
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entails the accountability of commerce to biological citizenship when citizens are 
constructed not only as political subjects of entitlements but also as generators of 
biovalue for the health and wealth of the state. As a result, the moral ideal of an alliance 
of participants, the biobank and its commercial extensions needs to be fully 




Appendix I. Interview Subjects
A. Aboriginal doctors and public health officials
1. A1, Thao group, University
2. A2, Taroko group, University
3. A3, Ami group, Indigenous Medical Association
4. A4, Kavalan group, Kavalan Development Association
5. A5, Taroko group, University
B. Scientists within the biobank team
6. Chen Yuan-Tsong, Institute of Biomedical Sciences, Academia Sinica
7. Shen Chen Yang, Institute of Biomedical Sciences, Academia Sinica 
C. Geneticists and Genomicists
8. Wu Cheng-Wen, Member, Academia Sinica; Founding President of the National 
Health Research Institutes (NHRI)
9. Chen Chien-Jen, Member & Distinguished Research Fellow, Genomics Research 
Centre, Academia Sinica
10. S1, Scientist, Division of Molecular and Genomic Medicine, NHRI        
11. S2, Scientist, Division of Biostatics and Bioinformatics, NHRI
12. S3, Medical Doctor & Professor, National Taiwan University Hospital
13. S4, Scientist, Division of Molecular and  Genomic Medicine, NHRI
D. Government Officials 
14. L1, legislator, Legislative Yuan   
15. G1, Staff, Department of Health
  
E. ELSI People
16. EL1, ELSI scholar
17. EL2, ELSI scholar
18. E1, EGC member
19. I1, IRB member
F. Human Rights Lawyers
20. H1, Human Rights Lawyer
21. H2, Human Rights Lawyer
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Appendix II. Interview Question Outlines
A. For Aboriginal Doctors
-- What do you think of the idea of building up a national biobank for Taiwan? Do you 
have any concerns about it? If so, what are they? What do you think about the 
informed consent requirement in the biobank? What do you think of the “group 
consent”? How do you define your “group”? What do you think of benefit sharing? 
What does the benefit mean to you? How do you identify yourself? Is your self-
identity biological? 
B. For Scientists, Geneticists and Genomicists 
1. Questions about the Taiwan Biobank:
-- What do you think of the idea of building up a national biobank for Taiwan? 
What kinds of implication do you expect? What are the advantages and 
disadvantages for Taiwan to set up this biobank? What do you think about 
grouping the population in Taiwan by the four great ethnicities? What is the 
uniqueness of Taiwanese genes?
2. Questions about biobank governance in general:
-- Before the Human Biobank Management Act is enacted, what kind of 
mechanisms do you use to govern your research biobanks? Would different 
biobank purposes influence your answers? What do you think of the new Human 
Biobank Management Act? Will it do any good or bad to your biobanks? How does 
your lab deal with remaining samples? Can other labs apply to use your samples? 
If so, who decides with what criterion about the access rights? How does your lab 
deal with international cooperation in terms of sharing samples and data?
C. For legislators and government officials:
-- What is the background of the enactment of the Human Biobank Management Act? 
What are the difference between the draft and the legislative version of the Act? How
does Department of Health see the biobank plan? What is Department of Health’s 
attitude toward the biobank? Who is responsible for the biobank and its future 
development? 
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Appendix III. A Brief Description of the Focus Group Research
In January 2010, I did a focus group research with 6 Taroko youths discussing their 
concerns about the biobanking project. The purpose of doing this research is in order to 
spot issues that might worry aboriginal people about biobanking. Because the purpose 
is for “issue spotting” only, the research results should not be further interpreted as the 
general perception of the Taroko group or the Taiwanese aborigines in general. Nor can 
the results represent as the general public’s perception in Taiwan about the biobank 
plan.
A. Participants: 6 Taroko youth, with ages of 23-30; 2 of them are females; 5 of them 
have college degrees; their backgrounds are varied; 1 person with law background; 1 
person with pharmaceutical background; the other 4 people have backgrounds in art, 
engineering, and business management. 
B. Time: about 2 hours
C. Procedure: Before the discussion started, each of the participants was given a test 
about their knowledge of what a biobank is. The Test lists 5 questions. Every question 
contains on item of information about the description of the Taiwan Biobank. All the 
5 descriptions are true. All the information comes from the IBMS website of the 
biobank plan. The answer proposes 5 responses that refer to the different knowledge 
degrees about these sentences in questions. The choices of answers are as follows: 1. 
don’t know; 2. know it but not clear. 3. know it and somewhat clear, 4, know it and 
quite clear, 4. know it clearly.
       The question sentences are follows:
(1) The biobank collects and stores participants’ samples for biomedical research
(2) In addition to collecting samples, the biobank keeps tracing back participants’ 
personal and medical information in a certain period of time
(3) The biobank collects samples from different ethnicities in the hope of finding 
out the causes of diseases among different populations.
(4) The biobank collects participants’ personal and medical data in order to know 
the correlation with these data and the diseases.
(5) The biobank is a long-term research project, for at least 20 years or even 
longer.
(6) To participate in the biobank is not like participating in a health check so 
participants will not receive a formal report about their health condition. 
      
245
          The responses of this knowledge test are as follows: (P refers to participant)
              P1:  2, 2, 2, 2, 2, 2
              P2:  5, 1, 5, 4, 5, 2
              P3:  1, 1, 1, 1, 1, 1 
              P4:  1, 2, 2, 2, 2, 1
              P5:  2, 1, 2, 2, 3, 1
              P6:  2, 3, 3, 3, 1, 2
        
After the knowledge test, the formal discussion began. At that time, the 6 
participants more or less had an idea what we were going to discuss. I introduced to 
them again what the biobank is, according to the information released by the IBMS 
team. Then I asked them to write down a positive and a negative thing about the 
biobank. Then I asked each of them to briefly explain what they think of the positive/ 
negative parts. In sum, the positive things are: to know why people got sick; to 
improve health condition, to improve biomedical research, etc. The negative things 
are: the reliability of the research results; too long to know the results; privacy 
concerns; the result could be manipulated, like eugenic things; if the results are 
useless, it wastes a great amount of resources. 
After everyone gave their explanations, the main discussion started. The discussion 
covered 4 big topics about biobank dilemmas— privacy & data exchange, informed 
consent, commercialisation & benefit sharing, and laws. Each dilemma was briefly 
explained and then it was followed by several detailed questions for further 
discussion. Each participant was given a red and a green card for them to answer 
some of the detailed questions. Raising the red card means they think it is a negative 
thing (or they don’t agree), and the green card means they think it is positive (or they 
agree). After they showed their cards to some yes/ no questions, they were asked to 
explain the reasons to their answers. 
The question outlines for each topic:  
(1) Privacy & Data sharing:
What do you think about linking biobank with personal medical and household 
data? When would you be willing for your information to be traced down to you? 
When wouldn’t you? What do you think of the coding system; would you trust the 
coding? Why, and under what circumstance would you trust the coding? What do 
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you think of international data sharing among biobanks? Would biobanks in 
different regimes be a consideration for you?
(2) Informed consent: 
What do you think of general consent (for research now and in the future)? What 
kinds of information are the most important for you to know before you give such 
consent? What do you think of group consent? What does the group mean to you? 
What do you think of the re-contact? Would you like to have a right to withdraw 
from your consent? 
           (3) Commercialisation and Benefit sharing 
What do you think of voluntary participation of the biobank (see participants as 
donors)? If the biobank is funded by some private companies, would that 
influence your answers? E.g, the government cooperates with private companies? 
What do you think about benefit sharing? What does benefit mean to you? How 
to share and who to share, by individual or group as whole?
(4) Laws:
If relevant laws were absent, would that concern you? What do you think is the 
best way to govern biobank? E.g, by government, or by an independent institute, 
by scientists’ self-governance, etc.
After the discussion was completed and before the meeting was dismissed, each 
participant was asked whether they would be willing to take part in the Taiwan 
Biobank project. Six of them gave red cards for this question. Then I asked further 
under what circumstances, would they change their minds? Several answers were 
given: For example, the biobank purpose needs to be clearer; they need to be given 
more information about the biobank; their privacy and their groups’ reputation 
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